97. Al-​Sawaf O, Bazeos A, Rob­recht S, Bahlo J, Gower C, Fink AM, Tre­sc­kow JV, Cra­mer P, Lan­ger­beins P, Kutsch N, Hum­ph­rey K, Fingerle-​Rowson G, Stil­gen­bauer S, Wendt­ner CM, Fischer K, Eich­horst B, Hal­lek M, Goede V. Mode of pro­gres­sion after first line treat­ment cor­re­la­tes with out­come of chro­nic lym­pho­cy­tic leuke­mia (CLL). Am J Hema­tol. 2019 Sep;94(9):1002-1006.

96. Eng­ler A, Shi R, Beer M, Schmid­ber­ger J, Krat­zer W, Barth TFE, Grimm J, Hil­len­brand A, Henne-​Bruns D, Grue­ner B, Beer AJ, Grae­ter T. Simple liver cysts and cystoid lesi­ons in hepa­tic alveo­lar echi­no­coc­co­sis: a retro­spec­tive cohort study with Houns­field ana­ly­sis. Para­site. 2019;26:54.

95. Poe­schel V, Held G, Zie­pert M, Witzens-​Harig M, Holte H, Thur­ner L, Borch­mann P, Viar­dot A, Soe­k­ler M, Kel­ler U, Schmidt C, Tru­em­per L, Mahl­berg R, Marks R, Hoeff­kes HG, Metz­ner B, Dier­lamm J, Frick­hofen N, Hae­nel M, Neu­bauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Feder­ico M, Leng­fel­der E, di Rocco A, Trappe R, Rosen­wald A, Ber­del C, Maisen­hoel­der M, Shpil­berg O, Amam J, Chris­tofyl­la­kis K, Hart­mann F, Muraw­ski N, Stil­gen­bauer S, Nickel­sen M, Wulf G, Glass B, Schmitz N, Alt­mann B, Loeff­ler M, Pfreund­schuh M; FLYER Trial Inves­ti­ga­tors; Ger­man Lym­phoma Alli­ance. Four ver­sus six cycles of CHOP che­mo­the­rapy in com­bi­na­tion with six appli­ca­ti­ons of ritu­xi­mab in pati­ents with aggres­sive B-​cell lym­phoma with favoura­ble pro­gno­sis (FLYER): a ran­do­mi­sed, phase 3, non-​inferiority trial. Lan­cet. 2019 Dec 21;394(10216):2271-2281.

94. Grei­ner J.The Important Role of Immu­n­o­the­ra­pies in Acute Mye­loid Leuke­mia.  J Clin Med. 2019 Nov 22;8(12).

93.Thoene S, Man­dal T, Vegi NM, Quintanilla-​Martinez L, Rös­ler R, Wiese S, Met­ze­ler KH, Herold T, Hafer­lach T, Döh­ner K, Döh­ner H, Schwarz­mül­ler L, Kling­mül­ler U, Buske C, Rawat VPS, Feuring-​Buske M. The ParaHox gene Cdx4 indu­ces acute ery­throid leuke­mia in mice. Blood Adv. 2019 Nov 26;3(22):3729-3739.

92. Her­ling CD, Coom­bes KR, Ben­ner A, Blo­eh­dorn J, Bar­ron LL, Abrams ZB, Majew­ski T, Bon­daruk JE, Bahlo J, Fischer K, Hal­lek M, Stil­gen­bauer S, Czer­niak BA, Oakes CC, Fer­ra­joli A, Kea­ting MJ, Abruzzo LV. Time-​to-progression after front-​line fludar­a­bine, cyclo­phos­pha­mide, and ritu­xi­mab che­mo­im­mu­n­o­the­rapy for chro­nic lym­pho­cy­tic leu­ka­e­mia: a retro­spec­tive, mul­ti­co­hort study. Lan­cet Oncol. 2019 Nov;20(11):1576-1586.

91. Fuchs M, Goer­gen H, Kobe C, Kuh­nert G, Lohri A, Greil R, Sasse S, Topp MS, Schä­fer E, Her­ten­stein B, Soe­k­ler M, Vogel­hu­ber M, Zijl­s­tra JM, Kel­ler UB, Krause SW, Wil­helm M, Masch­meyer G, Thie­mer J, Dühr­sen U, Meiss­ner J, Viar­dot A, Eich H, Baues C, Diehl V, Rosen­wald A, von Tre­sc­kow B, Diet­lein M, Borch­mann P, Engert A. Posi­tron Emis­sion Tomography-​Guided Treat­ment in Early-​Stage Favorable Hodg­kin Lym­phoma: Final Results of the Inter­na­tio­nal, Ran­do­mi­zed Phase III HD16 Trial by the Ger­man Hodg­kin Study Group.  J Clin Oncol. 2019 Nov 1;37(31):2835-2845.

90. Hei­del FH,  Doh­ner K, Risk-​adapted treat­ment of chro­nic BCR-​ABL1 nega­tive mye­lo­pro­li­fe­ra­tive neo­plasms. ONKO­LOGE. 2019 Nov; 25 (11): 985-993

89. Knop S, Engel­hardt M, Lie­bisch P, Meis­ner C, Hol­ler E, Metz­ner B, Peest D, Kauf­mann M, Bun­jes D, Straka C, Fischer T, Sezer O, Hen­trich M, Oster­mann H, Bas­ser­mann F, Hess G, Her­ten­stein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frick­hofen N, Mielke S, Bar­gou RC, Masch­meyer G, Svaldi M, Lan­ger CH, Gra­matzki M, Hebart H, Kanz L, Ein­sele H; Deut­sche Stu­di­en­gruppe Mul­ti­ples Mye­lom. Allo­gen­eic trans­plan­ta­tion in mul­ti­ple mye­loma: long-​term follow-​up and cyto­ge­ne­tic sub­group ana­ly­sis. Leuke­mia. 2019 Nov;33(11):2710-2719.

88. Fischer K, Rit­gen M, Al-​Sawaf O, Rob­recht S, Tan­don M, Fink AM, Schil­ha­bel A, Stü­big T, Brüg­ge­mann M, Jiang Y, Schary W, Eich­horst BF, Wendt­ner CM, Tausch E, Kreu­zer KA, Lan­ge­rak AW, Goede V, Bött­cher S, Stil­gen­bauer S, Kneba M, Hal­lek M. Quan­ti­ta­tive Ana­ly­sis of Mini­mal Resi­dual Disease (MRD) Shows High Rates of Unde­tec­ta­ble MRD after Fixed-​Duration Chemotherapy-​Free Treat­ment and Ser­ves As Sur­ro­gate Mar­ker for Progression-​Free Sur­vi­val: A Pro­spec­tive Ana­ly­sis of the Ran­do­mi­zed CLL14 Trial. Blood. 2019 Nov 13;134(Sup­ple­ment_1):36.

87. Rücker FG,Agra­wal M, Cor­ba­cio­glu A, Weber D, Kapp-​Schwoerer S, Gaid­zik VI, Jahn N, Schroe­der T, Wat­tad M, Lüb­bert M, Kol­ler E, Kind­ler T, Götze K, Ring­hof­fer M, Wes­ter­mann J, Fied­ler W, Horst HA, Greil R, Schro­ers R, Mayer K, Hei­ni­cke T, Krau­ter J, Schlenk RF, Thol F, Heu­ser M, Gan­ser A, Bul­lin­ger L, Paschka P, Döh­ner H, Döh­ner K. Mea­sura­ble Resi­dual Disease Moni­to­ring in Acute Mye­loid Leuke­mia with t(8;21)(q22;q22.1): Results of the AML Study Group. Blood. 2019 Nov 7;134(19):1608-1618.

86. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barri­entos JC, Barr PM, Byrd JC, O'Brien SM, Dil­huydy MS, Hill­men P, Jae­ger U, Moreno C, Cra­mer P, Stil­gen­bauer S, Chanan-​Khan AA, Mah­ler M, Sal­man M, Eckert K, Sol­man IG, Bala­subra­ma­nian S, Cheng M, Londhe A, Nino­moto J, Howes A, James DF, Hal­lek M. Long-​Term Stu­dies Asses­sing Out­co­mes of Ibru­ti­nib The­rapy in Pati­ents With Del(11q) Chro­nic Lym­pho­cy­tic Leuke­mia. Clin Lym­phoma Mye­loma Leuk. 2019 Nov;19(11)

85. Tausch E., Stil­gen­bauer S. Response to Com­ment by Jona­than Weiss <i>et al.</i>  Hae­ma­to­lo­gica. 2019 Nov;104(11):e542.

84. Bau­mann S, Shi R, Liu W, Bao H, Schmid­ber­ger J, Krat­zer W, Li W; Col­la­bo­ra­tors: Barth TFE, Bau­mann S, Blo­eh­dorn J, Fischer I, Grae­ter T, Graf N, Grue­ner B, Henne-​Bruns D, Hil­len­brand A, Kal­ten­bach T, Kern P, Kern P, Klein K, Krat­zer W, Ehtes­hami N, Schlin­geloff P, Schmid­ber­ger J, Shi R, Staehe­lin Y, Theis F, Ver­bits­kiy D, Zarour G. inter­di­sci­pli­nary Echi­no­coc­co­sis Work­ing Group Ulm. World­wide lite­ra­ture on epi­de­mio­logy of human alveo­lar echi­no­coc­co­sis: a sys­te­ma­tic review of rese­arch published in the twenty-​first cen­tury. Infec­tion. 2019 Oct;47(5):703-727.

83. Jurczak W, Długosz Dane­cka M, Buske C. Ritu­xi­mab bio­si­mi­lars for lym­phoma in Europe. Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056.

82. Wel­ler J, Tza­ri­dis T, Mack F, Stein­bach JP, Schle­gel U, Hau P, Krex D, Grauer O, Gold­brun­ner R, Bähr O, Uhl M, Sei­del C, Taba­ta­bai G, Breh­mer S, Bul­lin­ger L, Gall­diks N, Schaub C, Kebir S, Stum­mer W, Simon M, Fim­mers R, Coch C, Glas M, Herr­lin­ger U, Schä­fer N. Health-​related qua­lity of life and neu­ro­co­gni­tive func­tio­ning with lomustine-​temozolomide ver­sus temo­zo­lo­mide in pati­ents with newly dia­gno­sed, MGMT-​methylated glio­blas­toma (CeTeG/NOA-09): a ran­do­mi­sed, mul­ti­centre, open-​label, phase 3 trial. Lan­cet Oncol. 2019 Oct;20(10):1444-1453.

81. Doe­scher J, Weis­sin­ger SE, Schön­stei­ner SS, Lis­son C, Bul­lin­ger L, Barth TF, Leit­häu­ser F, Mueller-​Richter U, Laban S, Hoff­mann TK, Möl­ler P, Len­n­erz JK, Schuler PJ. Cli­ni­cal uti­lity of a protein-​based onco­pa­nel in pati­ents with end-​stage head and neck can­cer. Immu­n­o­the­rapy. 2019 Oct;11(14):1193-1203.

80. Blätte TJ, Schmal­b­rock LK, Skam­braks S, Lux S, Coc­ci­ardi S, Dol­nik A, Döh­ner H, Döh­ner K, Bul­lin­ger L. getITD for FLT3-​ITD-based MRD moni­to­ring in AML. Leuke­mia. 2019 Oct;33(10):2535-2539. No abs­tract availa­ble.

79. Stil­gen­bauer S, Aur­ran Schlei­nitz T, Eich­horst B, Lang F, Off­ner F, Rossi JF, Schroy­ens W, Van Den Neste E, Yse­baert L, von Wan­gen­heim U, Ursula Kress U, Blum P, Zenz T. Phase 1 first-​in-human trial of the anti-​CD37 anti­body BI 836826 in relap­sed/refrac­tory chro­nic lym­pho­cy­tic leuke­mia. Leuke­mia. 2019 Oct;33(10):2531-2535. No abs­tract availa­ble.

78. Saus­sele S, Haver­kamp W, Lang F, Koschmie­der S, Kiani A, Jentsch-​Ullrich K, Ste­gel­mann F, Pfei­fer H, La Rosée P, Goek­bu­get N, Rie­ger C, Wal­ler CF, Franke GN, le Coutre P, Kirch­mair R, Jung­hanss C. Pona­ti­nib in the Treat­ment of Chro­nic Mye­loid Leuke­mia and Phil­adel­phia Chromosome-​Positive Acute Leuke­mia: Recom­men­da­ti­ons of a Ger­man Expert Con­sen­sus Panel with Focus on Car­dio­va­s­cu­lar Manage­ment. Acta Hae­ma­tol. 2019 Oct 7:1-15. Review.

77. Nguyen TM, Scholl K, Idler I, Wais V, Kör­per S, Lotfi R, Bom­mer M, Wies­neth M, Schre­zen­meier H, Döh­ner H, Bohl SR, Hars­dorf SV, Rein­hardt P, Bun­jes D, Ring­hof­fer M, Kuchen­bauer F. Gra­nu­lo­cyte trans­fu­si­ons - bridging to allo­gen­eic hema­to­poie­tic stem cell trans­plan­ta­tion. Leuk Lym­phoma. 2019 Sep 24:1-4. No abs­tract availa­ble.

76. Wiktor-​Jedrzejczak W, Drozd-​Sokolowska J, Eikema DJ, Hoek J, Pot­ter M, Wulf G, Sell­ner L, Ljung­man P, Che­val­lier P, Volin L, Koc Y, Mar­tin S, Bun­jes D, Rovira M, Itälä-​Remes M, Foá R, Deco­ninck E, Gedde-​Dahl T, Cor­ne­lis­sen J, Col­lin M, Brecht A, Patel A, de Groot M, Reményi P, Nag­ler A, Finke J, Tur­lure P, Iaco­belli S, van Bie­zen A, Sche­te­lig J, Krö­ger N, Dre­ger P. EBMT pro­spec­tive obser­va­tio­nal study on allo­gen­eic hema­to­poie­tic stem cell trans­plan­ta­tion in T-​prolymphocytic leuke­mia (T-PLL). Bone Mar­row Trans­plant. 2019 Sep;54(9):1391-1398.

75. Jeba­raj BMC, Tausch E, Landau DA, Bahlo J, Rob­recht S, Taylor-​Weiner AN, Blo­eh­dorn J, Schef­fold A, Mer­tens D, Bött­cher S, Kneba M, Jäger U, Zenz T, Wen­ger MK, Fingerle-​Rowson G, Wendt­ner C, Fink AM, Wu CJ, Eich­horst B, Fischer K, Hal­lek M, Döh­ner H, Stil­gen­bauer S. Short telo­me­res are asso­cia­ted with infe­rior out­come, geno­mic com­ple­xity, and clo­nal evo­lu­tion in chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2019 Sep;33(9):2183-2194.

74. Yor­da­nova K, Stil­gen­bauer S, Bohle RM, Lesan V, Thur­ner L, Kaddu-​Mulindwa D, Bit­ten­bring JT, Schar­ber­ger M, Aßmann G, Bewar­der M. Spon­ta­neous regres­sion of a plas­ma­blastic lym­phoma with MYC rear­ran­ge­ment. Br J Hae­ma­tol. 2019 Sep;186(6):e203-e207. No abs­tract availa­ble.

73. Lorenz I, Bod­schwinna D, Hal­len­s­le­ben N, Döh­ner H, Nie­der­wie­ser D, Zim­mer­mann T, Meh­nert A, Gün­del H, Ernst J, Hoe­nig K. INPART - a psycho-​oncological inter­ven­tion for part­ners of pati­ents with haemato-​oncological disease - study pro­to­col. BMC Can­cer. 2019 Sep 5;19(1):885.

72. Owat­tana­pa­nich W, Ung­pra­sert P, Wais V, Kungwan­kiat­tic­hai S, Bun­jes D, Kuchen­bauer F.FLAMSA-​RIC for Stem Cell Trans­plan­ta­tion in Pati­ents with Acute Mye­loid Leuke­mia and Mye­lo­dys­plastic Syn­dro­mes: A Sys­te­ma­tic Review and Meta-​Analysis. J Clin Med. 2019 Sep 11;8(9). Review.

71. Straka C, Knop S, Vogel M, Mül­ler J, Kropff M, Metz­ner B, Lan­ger C, Sayer H, Jung W, Dürk HA, Sal­wen­der H, Wandt H, Bas­ser­mann F, Gra­matzki M, Rös­ler W, Wolf HH, Brug­ger W, Fischer T, Lie­bisch P, Engel­hardt M, Ein­sele H. Bor­te­zo­mib con­so­li­da­tion fol­lo­wing auto­lo­gous trans­plant in youn­ger and older pati­ents with newly dia­gno­sed mul­ti­ple mye­loma in two phase III tri­als. Eur J Hae­ma­tol. 2019 Sep;103(3):255-267.

70. Tausch E, Close W, Dol­nik A, Blo­eh­dorn J, Chyla B, Bul­lin­ger L, Döh­ner H, Mer­tens D, Stil­gen­bauer S. Vene­toclax resis­tance and acqui­red BCL2 muta­ti­ons in chro­nic lym­pho­cy­tic leuke­mia. Hae­ma­to­lo­gica. 2019 Sep;104(9):e434-e437.

69. König L, Drey­ling M, Dürig J, Engel­hard M, Hoh­loch K, Viar­dot A, Witzens-​Harig M, Kie­ser M, Klap­per W, Pott C, Herfarth K. The­rapy of nodal Fol­li­cu­lar Lym­phoma (WHO grade 1/2) in cli­ni­cal stage I/II using response adap­ted Invol­ved Site Radio­the­rapy in com­bi­na­tion with Obi­nu­tu­zu­mab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adap­ted Involved-​site Radio­the­rapy): a study pro­to­col for a single-​arm, non-​randomized, open, natio­nal, multi-​center phase II trial. Tri­als. 2019 Aug 30;20(1):544.

68. Boett­cher S, Mil­ler PG, Sharma R, McCon­key M, Leven­thal M, Krivt­sov AV, Gia­co­melli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milen­ko­wic K, Pic­cioni F, Root DE, Rücker FG, Fla­mand Y, Neu­berg D, Linds­ley RC, Jänne PA, Hahn WC, Jacks T, Döh­ner H, Arm­strong SA, Ebert BL. A dominant-​negative effect dri­ves sel­ec­tion of TP53 mis­sense muta­ti­ons in mye­loid mali­gnan­cies. Sci­ence. 2019 Aug 9;365(6453):599-604.

67. Schef­fold A, Jeba­raj BMC, Tausch E, Blo­eh­dorn J, Ghia P, Yahiaoui A, Dol­nik A, Blätte TJ, Bul­lin­ger L, Dhee­n­a­daya­lan RP, Li L, Schnei­der C, Chen SS, Chio­razzi N, Diet­rich S, Seif­fert M, Tann­hei­mer S, Döh­ner H, Mer­tens D, Stil­gen­bauer S. IGF1R as drug­gable tar­get media­ting PI3K-δ inhi­bi­tor resis­tance in a murine model of chro­nic lym­pho­cy­tic leuke­mia. Blood. 2019 Aug 8;134(6):534-547.

66. Bame­zai S, Buske C. Cut­ting Off Leu­ke­mo­ge­ne­sis: Hydra-​like Plasti­city of Mature Leuke­mic Cells. Cell Stem Cell. 2019 Aug 1;25(2):167-168.

65. Jones J, Mato A, Coutre S, Byrd JC, Fur­man RR, Hill­men P, Oster­borg A, Tam C, Stil­gen­bauer S, Wierda WG, Hee­rema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM. Eva­lua­tion of 230 pati­ents with relap­sed/refrac­tory dele­tion 17p chro­nic lym­pho­cy­tic leu­ka­e­mia trea­ted with ibru­ti­nib from 3 cli­ni­cal tri­als. Br J Hae­ma­tol. 2018 Aug;182(4):504-512.

64. Gru­nen­berg A, Buske C.Ritu­xi­mab and ibru­ti­nib in the treat­ment of Wal­den­ström's macro­glo­bu­li­ne­mia. Future Oncol. 2019 Aug;15(23):2687-2697.

63. Jyots­ana N, Sharma A, Cha­tur­vedi A, Budida R, Scherr M, Kuchen­bauer F, Lind­ner R, Noyan F, Sühs KW, Stan­gel M, Grote-​Koska D, Brand K, Vorn­lo­cher HP, Eder M, Thol F, Gan­ser A, Hum­phries RK, Ram­say E, Cul­lis P, Heu­ser M. Lipid nanoparticle-​mediated siRNA deli­very for safe tar­ge­ting of human CML in vivo. Ann Hema­tol. 2019 Aug;98(8):1905-1918.

62. Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuend­gen A, Ring­hof­fer M, Her­ten­stein B, Mar­tens UM, Grieß­ham­mer M, Bern­hard H, Krau­ter J, Gir­schi­kof­sky M, Wolf D, Lange E, Wes­ter­mann J, Kol­ler E, Kre­mers S, Wat­tad M, Heu­ser M, Thol F, Göh­ring G, Haase D, Teleanu V, Gaid­zik V, Ben­ner A, Döh­ner K, Gan­ser A, Paschka P, Döh­ner H. Ran­do­mi­zed phase-​II trial eva­lua­ting induc­tion the­rapy with idaru­bi­cin and eto­po­side plus sequen­tial or con­cur­rent aza­ci­ti­dine and main­ten­ance the­rapy with aza­ci­ti­dine. Leuke­mia. 2019 Aug;33(8):1923-1933.

61. Sey­fried F, Demir S, Hörl RL, Stirn­weiß FU, Ryan J, Schef­fold A, Villalobos-​Ortiz M, Bold­rin E, Zinn­grebe J, Enzen­mül­ler S, Jenni S, Tsai YC, Born­hau­ser B, Fürst­ber­ger A, Kraus JM, Kest­ler HA, Bour­quin JP, Stil­gen­bauer S, Letai A, Deba­tin KM, Meyer LH. Pre­dic­tion of vene­toclax acti­vity in pre­cur­sor B-ALL by func­tio­nal assess­ment of apo­pto­sis signa­ling. Cell Death Dis. 2019 Jul 29;10(8):571.

60. Rudorf A, Mül­ler TA, Klin­ge­berg C, Kreut­mair S, Pog­gio T, Gorantla SP, Rück­ert T, Schmitt-​Graeff A, Gen­gen­ba­cher A, Paschka P, Bal­dus C, Zei­ser R, Vas­si­liou GS, Brad­ley A, Duys­ter J, Illert AL. NPM1c alters FLT3-D835Y loca­liza­tion and signa­ling in acute mye­loid leuke­mia. Blood. 2019 Jul 25;134(4):383-388.

59. Jak­ob­sen JS, Laur­sen LG, Schus­ter MB, Pund­hir S, Schoof E, Ge Y, d'Altri T, Vitting-​Seerup K, Rapin N, Gen­til C, Jend­holm J, Theilgaard-​Mönch K, Reck­zeh K, Bul­lin­ger L, Döh­ner K, Hok­land P, Fitz­gib­bon J, Porse BT. Mutant CEBPA directly dri­ves the expres­sion of the tar­ge­ta­ble tumor-​promoting fac­tor CD73 in AML. Sci Adv. 2019 Jul 10;5(7):eaaw4304. eColl­ec­tion 2019 Jul.

58. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eich­horst B, Hal­lek M, Byrd JC, Hum­ph­rey K, Zhou L, Chyla B, Niel­sen J, Pot­luri J, Kim SY, Ver­dugo M, Stil­gen­bauer S, Wierda WG, Sey­mour JF. Effi­cacy of vene­toclax in relap­sed chro­nic lym­pho­cy­tic leuke­mia is influ­en­ced by disease and response varia­bles. Blood. 2019 Jul 11;134(2):111-122.

57. Thom­sen H, Chat­topad­hyay S, Wein­hold N, Vodi­cka P, Vodick­ova L, Hoff­mann P, Nöthen MM, Jöckel KH, Lan­ger C, Hajek R, Hall­mans G, Pettersson-​Kymmer U, Ohls­son C, Späth F, Houl­s­ton R, Gold­schmidt H, Hem­minki K, Försti A. Genome-​wide asso­cia­tion study of mono­clo­nal gam­mo­pa­thy of unk­nown signi­ficance (MGUS): com­pa­ri­son with mul­ti­ple mye­loma. Leuke­mia. 2019 Jul;33(7):1817-1821.

56. Schnei­der C, Stein­bre­cher D, Stil­gen­bauer S. Tar­ge­ted the­rapy in CLL: chan­ging the treat­ment para­digm. Onco­tar­get. 2019 Jun 18;10(40):4002-4003. eColl­ec­tion 2019 Jun 18. No abs­tract availa­ble.

55. Fischer K, Al-​Sawaf O, Bahlo J, Fink AM, Tan­don M, Dixon M, Rob­recht S, War­bur­ton S, Hum­ph­rey K, Samoy­lova O, Libe­rati AM, Pinilla-​Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Nie­mann CU, Wein­kove R, Robin­son S, Kipps TJ, Boett­cher S, Tausch E, Hume­rick­house R, Eich­horst B, Wendt­ner CM, Lan­ge­rak AW, Kreu­zer KA, Rit­gen M, Goede V, Stil­gen­bauer S, Mobas­her M, Hal­lek M. Vene­toclax and Obi­nu­tu­zu­mab in Pati­ents with CLL and Coexis­ting Con­di­ti­ons. N Engl J Med. 2019 Jun 6;380(23):2225-2236.

54. Schulze-​Edinghausen L, Dürr C, Öztürk S, Zuck­nick M, Ben­ner A, Kal­ter V, Ohl S, Close V, Wuch­ter P, Stil­gen­bauer S, Lich­ter P, Seif­fert M. Dis­sec­ting the Pro­gno­stic Signi­ficance and Func­tio­nal Role of Pro­gra­nu­lin in Chro­nic Lym­pho­cy­tic Leuke­mia. Can­cers (Basel). 2019 Jun 13;11(6).

53. Shar­man JP, Coutre SE, Fur­man RR, Che­son BD, Pagel JM, Hill­men P, Barri­entos JC, Zel­e­netz AD, Kipps TJ, Flinn IW, Ghia P, Era­dat H, Ervin T, Lamanna N, Coif­fier B, Pet­titt AR, Ma S, Tausch E, Cra­mer P, Huang J, Mitra S, Hal­lek M, O'Brien SM, Stil­gen­bauer S. Final Results of a Ran­do­mi­zed, Phase III Study of Ritu­xi­mab With or Wit­hout Ide­la­li­sib Fol­lo­wed by Open-​Label Ide­la­li­sib in Pati­ents With Relap­sed Chro­nic Lym­pho­cy­tic Leuke­mia. J Clin Oncol. 2019 Jun 1;37(16):1391-1402.

52. Hüllein J, Słabicki M, Roso­low­ski M, Jethwa A, Habrin­ger S, Tom­ska K, Kuri­lov R, Lu J, Schein­ost S, Wagener R, Huang Z, Lukas M, Yavor­ska O, Hel­f­rich H, Schol­ty­sik R, Bon­neau K, Tedesco D, Küp­pers R, Klap­per W, Pott C, Stil­gen­bauer S, Burk­hardt B, Löff­ler M, Trüm­per LH, Hum­mel M, Brors B, Zapatka M, Sie­bert R, Kreuz M, Kel­ler U, Huber W, Zenz T. MDM4 is tar­ge­ted by 1q gain and dri­ves disease in Bur­kitt lym­phoma. Can­cer Res. 2019 Jun 15;79(12):3125-3138.

51. Stei­ne­bach C, Sosič I, Lind­ner S, Bricelj A, Kohl F, Ng YLD, Mons­chke M, Wag­ner KG, Krönke J, Güt­schow M. A Med­Chem tool­box for cereblon-​directed PROT­ACs. Med­chem­comm. 2019 May 28;10(6):1037-1041. eColl­ec­tion 2019 Jun 1.

50. Hanna BS, Roess­ner PM, Schef­fold A, Jeba­raj BMC, Demer­dash Y, Öztürk S, Lich­ter P, Stil­gen­bauer S, Seif­fert M. PI3Kδ inhi­bi­tion modu­la­tes regu­la­tory and effec­tor T-​cell dif­fe­ren­tia­tion and func­tion in chro­nic lym­pho­cy­tic leuke­mia. Leuke­mia. 2019 Jun;33(6):1427-1438.

49. Lind­ner S, Stei­ne­bach C, Kehm H, Man­gold M, Güt­schow M, Krönke J. Che­mi­cal Inac­ti­va­tion of the E3 Ubi­qui­tin Ligase Cereb­lon by Pomalidomide-​based Homo-​PROTACs. J Vis Exp. 2019 May 15;(147).

48. Mallm JP, Iskar M, Ishaque N, Klett LC, Kug­ler SJ, Muino JM, Teif VB, Poos AM, Groß­mann S, Erdel F, Tavern­ari D, Koser SD, Schu­ma­cher S, Brors B, König R, Remon­dini D, Vin­g­ron M, Stil­gen­bauer S, Lich­ter P, Zapatka M, Mer­tens D, Rippe K. Lin­king aberrant chro­ma­tin fea­tures in chro­nic lym­pho­cy­tic leuke­mia to tran­scrip­tion fac­tor net­works. Mol Syst Biol. 2019 May 22;15(5):e8339.

47. Sasca D, Szy­bin­ski J, Schü­ler A, Shah V, Hei­del­ber­ger J, Haehnel PS, Dol­nik A, Kriege O, Fehr EM, Geb­hardt WH, Reid G, Scholl C, Theo­bald M, Bul­lin­ger L, Beli P, Kind­ler T. Neu­ral cell adhe­sion mole­cule 1 (NCAM1; CD56) pro­mo­tes leu­ke­mo­ge­ne­sis and con­fers drug resis­tance in AML. Blood. 2019 May 23;133(21):2305-2319.

46. Jawhar M, Döh­ner K, Kreil S, Schwaab J, Shou­ma­riyeh K, Meg­gen­dor­fer M, Span LLF, Fuhr­mann S, Nau­mann N, Horny HP, Sot­lar K, Kubuschok B, von Bubnoff N, Spie­ker­mann K, Heu­ser M, Metz­ge­roth G, Faba­rius A, Klein S, Hof­mann WK, Kluin-​Nelemans HC, Hafer­lach T, Döh­ner H, Cross NCP, Sperr WR, Valent P, Rei­ter A. KIT D816 muta­ted/CBF-​negative acute mye­loid leuke­mia: a poor-​risk sub­type asso­cia­ted with sys­temic masto­cy­to­sis. Leuke­mia. 2019 May;33(5):1124-1134.

45. Coc­ci­ardi S, Dol­nik A, Kapp-​Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skam­braks S, Krönke J, Hei­del FH, Schnö­der TM, Cor­ba­cio­glu A, Gaid­zik VI, Paschka P, Teleanu V, Göh­ring G, Thol F, Heu­ser M, Gan­ser A, Weber D, Sträng E, Kest­ler HA, Döh­ner H, Bul­lin­ger L, Döh­ner K. Clo­nal evo­lu­tion pat­terns in acute mye­loid leuke­mia with NPM1 muta­tion. Nat Com­mun. 2019 May 2;10(1):2031.

44. von Tre­sc­kow J, Cra­mer P, Bahlo J, Rob­recht S, Lan­ger­beins P, Fink AM, Al-​Sawaf O, Ill­mer T, Kla­proth H, Esten­fel­der S, Rit­gen M, Fischer K, Wendt­ner CM, Kreu­zer KA, Stil­gen­bauer S, Bött­cher S, Eich­horst BF, Hal­lek M. CLL2-BIG: sequen­tial treat­ment with ben­da­mus­tine, ibru­ti­nib and obi­nu­tu­zu­mab (GA101) in chro­nic lym­pho­cy­tic leuke­mia. Leuke­mia. 2019 May;33(5):1161-1172.

43. Michel C, Burchert A, Hoch­haus A, Saus­sele S, Neu­bauer A, Laus­eker M, Krause SW, Kolb HJ, Hoss­feld DK, Nerl C, Baer­lo­cher GM, Heim D, Brüm­men­dorf TH, Faba­rius A, Hafer­lach C, Schle­gel­ber­ger B, Ball­ei­sen L, Goebeler ME, Hänel M, Ho A, Deng­ler J, Falge C, Möhle R, Kre­mers S, Kneba M, Ste­gel­mann F, Köhne CH, Lin­de­mann HW, Wal­ler CF, Spie­ker­mann K, Ber­del WE, Mül­ler L, Edin­ger M, Mayer J, Bee­len DW, Bentz M, Link H, Her­ten­stein B, Fuchs R, Wernli M, Schle­gel F, Schlag R, de Wit M, Trüm­per L, Hebart H, Hahn M, Tho­malla J, Scheid C, Schaf­hau­sen P, Ver­beek W, Eckart MJ, Gas­smann W, Schenk M, Bross­art P, Wün­disch T, Geer T, Bildat S, Schä­fer E, Has­ford J, Hehl­mann R, Pfirr­mann M. Ima­ti­nib dose reduc­tion in major mole­cu­lar response of chro­nic mye­loid leuke­mia: results from the Ger­man Chro­nic Mye­loid Leukemia-​Study IV. Hae­ma­to­lo­gica. 2019 May;104(5):955-962.

42. Van Roos­bro­eck K, Bay­rak­tar R, Calin S, Blo­eh­dorn J, Dra­go­mir MP, Okubo K, Ber­til­ac­cio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chio­razzi N, Thomp­son P, Fer­ra­joli A, Ber­toni F, Stil­gen­bauer S, Kea­ting MJ, Calin GA. The invol­vement of microRNA in the patho­ge­nesis of Rich­ter syn­drome. Hae­ma­to­lo­gica. 2019 May;104(5):1004-1015.

41. Döh­ner H, Müller-​Tidow C, Lüb­bert M, Fied­ler W, Krä­mer A, Wes­ter­mann J, Bug G, Schlenk RF, Krug U, Goeld­ner RG, Hil­bert J, Taube T, Ott­mann OG. A phase I trial inves­ti­ga­ting the Aurora B kinase inhi­bi­tor BI 811283 in com­bi­na­tion with cyt­ara­bine in pati­ents with acute mye­loid leu­ka­e­mia. Br J Hae­ma­tol. 2019 May;185(3):583-587.

40. Yosi­fov DY, Wolf C, Stil­gen­bauer S, Mer­tens D. From Bio­logy to The­rapy: The CLL Suc­cess Story. Hemas­phere. 2019 Feb 9;3(2):e175. eColl­ec­tion 2019 Apr. Review.

39. Bas­heer F, Gio­to­pou­los G, Meduri E, Yun H, Mazan M, Sasca D, Gal­li­poli P, Marando L, Goz­de­cka M, Asby R, Shepp­ard O, Dudek M, Bul­lin­ger L, Döh­ner H, Dil­lon R, Free­man S, Ott­mann O, Bur­nett A, Rus­sell N, Papaem­ma­nuil E, Hills R, Camp­bell P, Vas­si­liou GS, Huntly BJP. Con­tras­ting requi­re­ments during disease evo­lu­tion iden­tify EZH2 as a the­ra­peu­tic tar­get in AML. J Exp Med. 2019 Apr 1;216(4):966-981.

38. Fürst D, Hau­ber D, Rein­hardt P, Schau­we­cker P, Bun­jes D, Schulz A, Myti­li­neos J, Wies­neth M, Schre­zen­meier H, Kör­per S. Gen­der, cho­li­nes­ter­ase, pla­te­let count and red cell count are main pre­dic­tors of peri­phe­ral blood stem cell mobi­liza­tion in healthy donors. Vox Sang. 2019 Apr;114(3):275-282.

37. Gra­se­dieck S, Mulaw M, Sperb N, Wes­sin­ger K, Rouhi A, Bom­mer M, Brom­berg JEC, Otto M, Tumani H, von Arnim CAF, Mer­tens D, Kuchen­bauer F. Com­pre­hen­sive microRNA expres­sion pro­fi­ling in cere­bro­s­pi­nal fluid distin­guis­hes bet­ween neu­ro­lo­gi­cal disease clas­ses. Neu­ro­pa­thol Appl Neu­ro­biol. 2019 Apr;45(3):318-323.

36. Böll B, Plüt­schow A, Bürkle C, Atta J, Pfreund­schuh M, Feuring-​Buske M, Vogel­hu­ber M, Sök­ler M, Eiche­nauer DA, Thie­len I, von Tre­sc­kow B, Fuchs M, Engert A, Borch­mann P; Ger­man Hodg­kin Study Group (GHSG). Doxo­ru­bi­cin, vin­blas­tine, dac­ar­ba­zine and lenali­do­mide for older Hodg­kin lym­phoma pati­ents: final results of a Ger­man Hodg­kin Study Group (GHSG) phase-​I trial. Br J Hae­ma­tol. 2019 Apr;185(1):42-52.

35. Jutzi JS, Basu T, Pell­mann M, Kai­ser S, Stei­ne­mann D, San­ders MA, Hinai ASA, Zei­lema­ker A, Kovacs SB, Koel­le­rer C, Osten­dorp J, Aumann K, Wang W, Raf­foux E, Cas­si­nat B, Bul­lin­ger L, Schle­gel­ber­ger B, Valk PJM, Pahl HL. Alte­red NFE2 acti­vity pre­dis­po­ses to leuke­mic trans­for­ma­tion and mye­los­ar­coma with AML-​specific aberra­ti­ons. Blood. 2019 Apr 18;133(16):1766-1777.

34. Sanz MA, Fen­aux P, Tall­man MS, Estey EH, Löwen­berg B, Naoe T, Leng­fel­der E, Döh­ner H, Bur­nett AK, Chen SJ, Mathews V, Iland H, Rego E, Kan­ta­jian H, Adès L, Avvi­sati G, Mon­te­si­nos P, Platz­be­cker U, Ravandi F, Rus­sell NH, Lo-​Coco F. Manage­ment of acute pro­mye­lo­cy­tic leuke­mia: updated recom­men­da­ti­ons from an expert panel of the European Leuke­mia­Net. Blood. 2019 Apr 11;133(15):1630-1643.

33. Saraceni F, Labo­pin M, Brecht A, Krö­ger N, Eder M, Tischer J, Labussière-​Wallet H, Ein­sele H, Bee­len D, Bun­jes D, Nie­der­wie­ser D, Bocht­ler T, Savani BN, Mohty M, Nag­ler A. Fludarabine-​treosulfan com­pa­red to thiotepa-​busulfan-fludarabine or FLAMSA as con­di­tio­ning regi­men for pati­ents with pri­mary refrac­tory or relap­sed acute mye­loid leuke­mia: a study from the Acute Leuke­mia Work­ing Party of the European Society for Blood and Mar­row Trans­plan­ta­tion (EBMT). J Hema­tol Oncol. 2019 Apr 25;12(1):44.

32. Bohl SR, Bul­lin­ger L, Rücker FG. New Tar­ge­ted Agents in Acute Mye­loid Leuke­mia: New Hope on the Rise. Int J Mol Sci. 2019 Apr 23;20(8).

31. Viar­dot A, Wais V, Sala E, Koer­per S. Chi­me­ric anti­gen recep­tor (CAR) T-​cell the­rapy as a treat­ment option for pati­ents with B-​cell lym­pho­mas: per­spec­ti­ves on the the­ra­peu­tic poten­tial of Axi­cab­ta­gene cilo­leucel. Can­cer Manag Res. 2019 Mar 25;11:2393-2404. eColl­ec­tion 2019.

30. López C, Kleinheinz K, Aukema SM, Rohde M, Bern­hart SH, Hüb­sch­mann D, Wagener R, Toprak UH, Rai­mondi F, Kreuz M, Was­zak SM, Huang Z, Sie­ver­ling L, Para­ma­sivam N, Seufert J, Sun­ga­lee S, Rus­sell RB, Baus­in­ger J, Kretz­mer H, Ammer­pohl O, Berg­mann AK, Bin­der H, Bork­hardt A, Brors B, Cla­viez A, Doose G, Feu­er­bach L, Haake A, Hans­mann ML, Hoell J, Hum­mel M, Kor­bel JO, Lawe­renz C, Lenze D, Radl­wim­mer B, Rich­ter J, Rosen­stiel P, Rosen­wald A, Schil­ha­bel MB, Stein H, Stil­gen­bauer S, Stad­ler PF, Szc­ze­panow­ski M, Weni­ger MA, Zapatka M, Eils R, Lich­ter P, Loeff­ler M, Möl­ler P, Trüm­per L, Klap­per W; ICGC MMML-​Seq Con­sor­tium, Hoff­mann S, Küp­pers R, Burk­hardt B, Schles­ner M, Sie­bert R. Geno­mic and tran­scripto­mic chan­ges com­ple­ment each other in the patho­ge­nesis of spo­ra­dic Bur­kitt lym­phoma. Nat Com­mun. 2019 Mar 29;10(1):1459.

29. Heitz L, Krat­zer W, Grä­ter T, Schmid­ber­ger J; EMIL study group; Col­la­bo­ra­tors: Adler G,  Arm­sen A, Banz­haf HM, Bau­er­dick M, Bern­hardt P, Bert­ling U, Boehm BO, Brand­ner BO, Brock­mann SO, Deckert M, Ding­ler C, Eggink S, Fuchs M, Gaus W, Gous­sis H, Grue­ner B, Gru­e­nert A, Haenle MM, Hampl W, Haug C, Hay B, Heitz L, Huet­ter ML, Iftik­har N, Imhof A, Kal­ten­bach T, Kern P, Kim­mig P, Kirch A, Klass D, Koenig W, Krat­zer W, Kron M, Man­fras B, Mei­tin­ger K, Mer­tens T, Oehme R, Pfaff G, Piecho­tow­ski I, Reu­ter S, Romig T, von Schmie­sing AFA, Sta­nosek S, Stein­bach G, Tour­bier M, Voegtle A, Wal­cher T, Wolff S, Schlin­geloff P. Gall­blad­der­po­lyps - a follow-​up study after 11 years. BMC Gas­tro­en­te­rol. 2019 Mar 18;19(1):42. doi: 10.1186/s12876-019-0959-3.

28. Sme­land S, Bielack SS, Whelan J, Bern­stein M, Hogen­doorn P, Krailo MD, Gorlick R, Jane­way KA, Ing­leby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-​Bahloul T, Cala­mi­nus G, Capra M, Dhooge C, Eriks­son M, Fla­na­gan AM, Frie­del G, Geb­hardt MC, Geld­erblom H, Goldsby R, Grier HE, Gri­mer R, Hawkins DS, Hecker-​Nolting S, Sundby Hall K, Isa­koff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabick­ova E, Lang S, Lau CC, Lea­vey PJ, Less­nick SL, Mas­ca­ren­has L, Mayer-​Steinacker R, Mey­ers PA, Naga­ra­jan R, Randall RL, Rei­chardt P, Renard M, Rech­nit­zer C, Schwartz CL, Strauss S, Teot L, Tim­mermann B, Sydes MR, Marina N. Sur­vi­val and pro­gno­sis with osteo­s­ar­coma: out­co­mes in more than 2000 pati­ents in the EURAMOS-​1 (European and Ame­ri­can Osteo­s­ar­coma Study) cohort. Eur J Can­cer. 2019 Mar;109:36-50.

27. Gru­nen­berg A, Möl­ler P, Viar­dot A, Teleanu V, Eier­mann D, Buske C, Barth TF. Unusual trans­for­ma­tion of pri­mary ext­r­ano­dal mar­gi­nal zone B cell lym­phoma of the ute­rus into a nodal fol­li­cu­lar lym­phoma grade IIIB. Ann Hema­tol. 2019 Mar;98(3):797-799. No abs­tract availa­ble.

26. Fried­richs B, Nickel­sen M, Zie­pert M, Alt­mann B, Hae­nel M, Viar­dot A, Schmidt C, Ruebe C, Loeff­ler M, Pfreund­schuh M, Rosen­wald A, Glass B, Lenz G, Schmitz N; Ger­man high-​grade lym­phoma Study Group. Doubling ritu­xi­mab in high-​risk pati­ents with aggres­sive B-​cell lym­phoma -​results of the DENSE-​R-MegaCHOEP trial. Br J Hae­ma­tol. 2019 Mar;184(5):760-768.

25. Chris­ten F, Hoyer K, Yoshida K, Hou HA, Wald­hue­ter N, Heu­ser M, Hills RK, Chan W, Hables­rei­ter R, Blau O, Ochi Y, Kle­ment P, Chou WC, Blau IW, Tang JL, Zemoj­tel T, Shirai­shi Y, Shio­zawa Y, Thol F, Gan­ser A, Löwen­berg B, Linch DC, Bul­lin­ger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F. Geno­mic land­s­cape and clo­nal evo­lu­tion of acute mye­loid leuke­mia with t(8;21): an inter­na­tio­nal study on 331 pati­ents. Blood. 2019 Mar 7;133(10):1140-1151.

24. Ste­pen­sky P, Grisa­riu S, Avni B, Zaid­man I, Sha­dur B, Elpe­leg O, Sirin M, Hoe­nig M, Schuetz C, Fur­lan I, Beer M, von Hars­dorf S, Bun­jes D, Deba­tin KM, Schulz AS. Stem cell trans­plan­ta­tion for osteo­pe­tro­sis in pati­ents beyond the age of 5 years. Blood Adv. 2019 Mar 26;3(6):862-868.

23. Simo­netti G, Padella A, do Valle IF, Fon­tana MC, Fonzi E, Bruno S, Bal­dazzi C, Gua­da­gnuolo V, Man­f­rini M, Fer­rari A, Pao­lini S, Papa­yan­nidis C, Mar­coni G, Fran­chini E, Zuffa E, Lagi­nes­tra MA, Zanotti F, Astolfi A, Iaco­bucci I, Ber­nardi S, Sazzini M, Ficarra E, Her­nan­dez JM, Van­den­berghe P, Cools J, Bul­lin­ger L, Otta­viani E, Tes­toni N, Cavo M, Hafer­lach T, Cas­tel­lani G, Remon­dini D, Mar­ti­nelli G. Aneu­ploid acute mye­loid leuke­mia exhi­bits a signa­ture of geno­mic alte­ra­ti­ons in the cell cycle and pro­tein degra­dation machi­nery. Can­cer. 2019 Mar 1;125(5):712-725.

22. Hei­mann SM, Veh­re­s­child MJGT, Cor­nely OA, Heinz WJ, Grü­ner B, Sil­ling G, Kes­sel J, Sei­del D, Veh­re­s­child JJ. Heal­th­care bur­den of pro­ba­ble and pro­ven inva­sive mucor­my­co­sis: a multi-​centre cost-​of-illness ana­ly­sis of pati­ents trea­ted in ter­ti­ary care hos­pi­tals bet­ween 2003 and 2016. J Hosp Infect. 2019 Mar;101(3):339-346.

21. Ott­mann OG, Müller-​Tidow C, Krä­mer A, Schlenk RF, Lüb­bert M, Bug G, Krug U, Bocht­ler T, Voss F, Taube T, Liu D, Garin-​Chesa P, Döh­ner H. Phase I dose-​escalation trial inves­ti­ga­ting vola­ser­tib as mono­the­rapy or in com­bi­na­tion with cyt­ara­bine in pati­ents with relap­sed/refrac­tory acute mye­loid leu­ka­e­mia. Br J Hae­ma­tol. 2019 Mar;184(6):1018-1021. No abs­tract availa­ble.

20. Sche­te­lig J, Link CS, Stuh­ler G, Wag­ner EM, Hänel M, Kobbe G, Bött­cher S, Kreu­zer KA, Mid­deke JM, Sockel K, Tei­pel R, von Bonin M, Stöl­zel F, Kra­mer M, Stil­gen­bauer S, Hal­lek M, Born­häu­ser M; Deut­sche CLL Stu­di­en­gruppe and the Ger­man Coope­ra­tive Trans­plant Study Group. Anti-​CD20 immu­n­o­the­rapy as a bridge to tole­rance, after allo­gen­eic stem cell trans­plan­ta­tion for pati­ents with chro­nic lym­pho­cy­tic leu­ka­e­mia: results of the CLLX4 trial. Br J Hae­ma­tol. 2019 Mar;184(5):833-836. No abs­tract availa­ble.

19. Hof­mann S, Schmitt M, Götz M, Döh­ner H, Wies­neth M, Bun­jes D, Grei­ner J. Donor lym­pho­cyte infu­sion leads to diver­sity of spe­ci­fic T cell respon­ses and redu­ces regu­la­tory T cell fre­quency in cli­ni­cal respon­ders. Int J Can­cer. 2019 Mar 1;144(5):1135-1146.

18. Pflug N, Cra­mer P, Rob­recht S, Bahlo J, Wes­ter­mann A, Fink AM, Schra­der A,
Mayer P, Ober­beck S, Sei­ler T, Zenz T, Dürig J, Kreu­zer KA, Stil­gen­bauer S,
Eich­horst B, Hal­lek M, Her­ling M, Hopfin­ger G. New les­sons lear­ned in T-PLL: results from a pro­spec­tive phase-​II trial with fludarabine-​mitoxantrone-cyclophosphamide-alemtuzumab induc­tion fol­lo­wed by alem­tu­zu­mab main­ten­ance. Leuk Lym­phoma. 2019 Mar;60(3):649-657.

17. Pro­chazka KT, Pre­gart­ner G, Rücker FG, Heit­zer E, Pabst G, Wöl­f­ler A, Zebisch A, Berg­hold A, Döh­ner K, Sill H. Cli­ni­cal impli­ca­ti­ons of sub­clo­nal TP53 muta­ti­ons in acute mye­loid leuke­mia. Hae­ma­to­lo­gica. 2019 Mar;104(3):516-523.

16. Hanna BS, Roess­ner PM, Yaz­danpa­rast H, Colo­mer D, Campo E, Kug­ler S, Yosi­fov D, Stil­gen­bauer S, Schmidt M, Gabriel R, Lich­ter P, Seif­fert M. Con­trol of chro­nic lym­pho­cy­tic leuke­mia deve­lo­p­ment by clonally-​expanded CD8⁺ T-​cells that undergo func­tio­nal exhaus­tion in secon­dary lym­phoid tis­sues. Leuke­mia. 2019 Mar;33(3):625-637.

15. Mulinge E, Njenga SM, Odongo D, Magambo J, Zeyhle E, Mbae C, Kagendo D, Kanyi
H, Traub RJ, Was­ser­mann M, Kern P, Romig T. Mole­cu­lar iden­ti­fi­ca­tion of zoo­no­tic hook­worms in dogs from four coun­ties of Kenya. J Hel­m­in­thol. 2019 Feb 28;94:e43.

14. Schlenk RF, Weber D, Fied­ler W, Salih HR, Wulf G, Sal­wen­der H, Schroe­der T, Kind­ler T, Lüb­bert M, Wolf D, Wes­ter­mann J, Krae­mer D, Götze KS, Horst HA, Krau­ter J, Gir­schi­kof­sky M, Ring­hof­fer M, Süd­hoff T, Held G, Derigs HG, Schro­ers R, Greil R, Grieß­ham­mer M, Lange E, Bur­chardt A, Mar­tens U, Her­ten­stein B, Mar­retta L, Heu­ser M, Thol F, Gaid­zik VI, Herr W, Krzy­kalla J, Ben­ner A, Döh­ner K, Gan­ser A, Paschka P, Döh­ner H; German-​Austrian AML Study Group. Mido­stau­rin added to che­mo­the­rapy and con­ti­nued single-​agent main­ten­ance the­rapy in acute mye­loid leuke­mia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-851.

13. Herr­lin­ger U, Tza­ri­dis T, Mack F, Stein­bach JP, Schle­gel U, Sabel M, Hau P, Kort­mann RD, Krex D, Grauer O, Gold­brun­ner R, Schnell O, Bähr O, Uhl M, Sei­del C, Taba­ta­bai G, Kowal­ski T, Rin­gel F, Schmidt-​Graf F, Suchor­ska B, Breh­mer S, Weyer­b­rock A, Reno­vanz M, Bul­lin­ger L, Gall­diks N, Vaj­koczy P, Misch M, Vat­ter H, Stu­plich M, Schä­fer N, Kebir S, Wel­ler J, Schaub C, Stum­mer W, Tonn JC, Simon M, Keil VC, Nel­les M, Urbach H, Coe­nen M, Wick W, Wel­ler M, Fim­mers R, Schmid M, Hat­tin­gen E, Pietsch T, Coch C, Glas M; Neu­roon­co­logy Work­ing Group of the Ger­man Can­cer Society. Lomustine-​temozolomide com­bi­na­tion the­rapy ver­sus stan­dard temo­zo­lo­mide the­rapy in pati­ents with newly dia­gno­sed glio­blas­toma with methy­la­ted MGMT pro­mo­ter (CeTeG/NOA-09): a ran­do­mi­sed, open-​label, phase 3 trial. Lan­cet. 2019 Feb 16;393(10172):678-688.

12. Stei­ne­bach C, Kehm H, Lind­ner S, Vu LP, Köpff S, López Mármol Á, Wei­ler C, Wag­ner KG, Rei­chen­zel­ler M, Krönke J, Güt­schow M. PROTAC-​mediated cross­talk bet­ween E3 liga­ses. Chem Com­mun (Camb). 2019 Feb 5;55(12):1821-1824.

11. Close V, Close W, Kug­ler SJ, Rei­chen­zel­ler M, Yosi­fov DY, Blo­eh­dorn J, Pan L, Tausch E, West­hoff MA, Döh­ner H, Stil­gen­bauer S, Oswald F, Mer­tens D. FBXW7 muta­ti­ons reduce bin­ding of NOTCH1, lea­ding to clea­ved NOTCH1 accu­mu­la­tion and tar­get gene acti­va­tion in CLL. Blood. 2019 Feb 21;133(8):830-839.

10. Hütter-​Krönke ML, Fied­ler W, Künd­gen A, Krau­ter J, von Lilienfeld-​Toal M, Döh­ner H, Schlenk R. Con­ti­nuous high dosing of lenali­do­mide in relap­sed, refrac­tory or older newly dia­gno­sed acute mye­loid leuke­mia pati­ents not sui­ta­ble for other treat­ment opti­ons - results from a phase I study. Hae­ma­to­lo­gica. 2019 Feb;104(2):e63-e64. No abs­tract availa­ble.

9. Schlenk RF, Weber D, Fied­ler W, Salih HR, Wulf G, Sal­wen­der H, Schroe­der T, Kind­ler T, Lüb­bert M, Wolf D, Wes­ter­mann J, Krae­mer D, Götze KS, Horst HA, Krau­ter J, Gir­schi­kof­sky M, Ring­hof­fer M, Süd­hoff T, Held G, Derigs HG, Schro­ers R, Greil R, Grieß­ham­mer M, Lange E, Bur­chardt A, Mar­tens U, Her­ten­stein B, Mar­retta L, Heu­ser M, Thol F, Gaid­zik VI, Herr W, Krzy­kalla J, Ben­ner A, Döh­ner K, Gan­ser A, Paschka P, Döh­ner H. Mido­stau­rin added to che­mo­the­rapy and con­ti­nued sin­gle agent main­ten­ance the­rapy in acute mye­loid leuke­mia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-851.

8. Bul­lin­ger L. IDH2 inhi­bi­tion: ano­ther piece to the puz­zle. Blood. 2019 Feb 14;133(7):625-626. No abs­tract availa­ble.

7. Frick M, Chan W, Arends CM, Hables­rei­ter R, Halik A, Heu­ser M, Michon­neau D, Blau O, Hoyer K, Chris­ten F, Galan-​Sousa J, Noe­ren­berg D, Wais V, Stad­ler M, Yoshida K, Sche­te­lig J, Schuler E, Thol F, Clap­pier E, Chris­to­peit M, Ayuk F, Born­häu­ser M, Blau IW, Ogawa S, Zemoj­tel T, Ger­bitz A, Wag­ner EM, Sprie­wald BM, Schre­zen­meier H, Kuchen­bauer F, Kobbe G, Wies­neth M, Kol­de­hoff M, Socié G, Kro­e­ger N, Bul­lin­ger L, Thiede C, Damm F. Role of Donor Clo­nal Hema­to­poie­sis in Allo­gen­eic Hema­to­poie­tic Stem-​Cell Trans­plan­ta­tion. J Clin Oncol. 2019 Feb 10;37(5):375-385.

6. Schmid­ber­ger J, Wei­mer H, Schlin­geloff P, Krat­zer W, Grü­ner B; Echi­no­coc­co­sis Work­ing Group, Ulm. Health-​related qua­lity of life in pati­ents with alveo­lar echi­no­coc­co­sis: across-​sectional study. Infec­tion. 2019 Feb;47(1):67-75.

5. Böhm MJ, Mari­en­feld R, Jäger D, Mel­lert K, von Witz­le­ben A, Brü­der­lein S, Wit­tau M, von Baer A, Schult­heiss M, Mayer-​Steinacker R, Rücker FG, Möl­ler P, Bul­lin­ger L, Barth TFE. Ana­ly­sis of the CDK4/6 Cell Cycle Pathway in Lei­o­myo­s­ar­co­mas as a Poten­tial Tar­get for Inhi­bi­tion by Pal­bo­ci­c­lib. Sar­coma. 2019 Jan 21;2019:3914232. eColl­ec­tion 2019.

4. Lan­ge­rak AW, Rit­gen M, Goede V, Rob­recht S, Bahlo J, Fischer K, Steu­rer M, Trněný M, Mul­ligan SP, Mey UJM, Trun­zer K, Fingerle-​Rowson G, Hum­ph­rey K, Stil­gen­bauer S, Bött­cher S, Brüg­ge­mann M, Hal­lek M, Kneba M, van Don­gen JJM. Pro­gno­stic value of MRD in CLL pati­ents with comor­bi­di­ties recei­ving chlor­am­bu­cil plus obi­nu­tu­zu­mab or ritu­xi­mab. Blood. 2019 Jan 31;133(5):494-497.

3. Cas­tillo JJ, Itchaki G, Paludo J, Varet­toni M, Buske C, Eyre TA, Cha­vez JC, Shain KH, Issa S, Palomba ML, Pas­vol­sky O, Simpson D, Tal­au­likar D, Tam CS, Tede­schi A, Ansell SM, Nayak L, Treon SP. Ibru­ti­nib for the treat­ment of Bing-​Neel syn­drome: A mul­ti­cen­ter study. Blood. 2019 Jan 24;133(4):299-305.

2. Went M, Sud A, Försti A, Hal­vars­son BM, Wein­hold N, Kim­ber S, van Duin M, Thor­leifs­son G, Hol­royd A, John­son DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mit­chell JS, Gudb­jarts­son DF, Kui­per R, Ste­phens OW, Bertsch U, Bro­de­rick P, Campo C, Ban­d­a­palli OR, Ein­sele H, Gre­gory WA, Gull­berg U, Hil­len­gass J, Hoff­mann P, Jack­son GH, Jöckel KH, Johns­son E, Kris­tins­son SY, Mell­qvist UH, Nahi H, Eas­ton D, Pha­roah P, Dun­ning A, Peto J, Can­zian F, Swerd­low A, Eeles RA, Kote-​Jarai Z, Muir K, Pas­hayan N; PRAC­TI­CAL con­sor­tium, Nickel J, Nöthen MM, Raf­nar T, Ross FM, da Silva Filho MI, Thom­sen H, Tures­son I, Vangs­ted A, Ander­sen NF, Waage A, Wal­ker BA, Wihl­borg AK, Broyl A, Davies FE, Thor­steins­dot­tir U, Lan­ger C, Hans­son M, Gold­schmidt H, Kai­ser M, Son­ne­veld P, Ste­fans­son K, Mor­gan GJ, Hem­minki K, Nils­son B, Houl­s­ton RS. Author Cor­rec­tion: Iden­ti­fi­ca­tion of mul­ti­ple risk loci and regu­la­tory mecha­nisms influ­en­cing suscep­ti­bi­lity to mul­ti­ple mye­loma. Nat Com­mun. 2019 Jan 10;10(1):213.

1. Dre­ger P, Michal­let M, Bos­man P, Diet­rich S, Sobh M, Bou­men­dil A, Nag­ler A, Scheid C, Cor­ne­lis­sen J, Nie­der­wie­ser D, Mül­ler L, Van­den­berghe E, Scor­te­chini I, Scho­e­mans H, Ander­sen NS, Finke J, Russo D, Ljung­man P, Pass­weg J, van Gel­der M, Dura­ko­vic N, Labussiere-​Wallet H, Berg T, Wulf G, Bethge W, Bun­jes D, Stil­gen­bauer S, Cane­pari ME, Schaap M, Fox CP, Krö­ger N, Mon­toto S, Sche­te­lig J. Ibru­ti­nib for bridging to allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion in pati­ents with chro­nic lym­pho­cy­tic leuke­mia or man­tle cell lym­phoma: a study by the EBMT Chro­nic Mali­gnan­cies and Lym­phoma Work­ing Par­ties. Bone Mar­row Trans­plant. 2019 Jan;54(1):44-52.

97. Campo E, Cym­ba­lista F, Ghia P, Jäger U, Pos­pi­si­lova S, Rosen­quist R, Schuh A, Stil­gen­bauer S. TP53 aberra­ti­ons in chro­nic lym­pho­cy­tic leuke­mia: an over­view of the cli­ni­cal impli­ca­ti­ons of impro­ved dia­gno­stics. Hae­ma­to­lo­gica. 2018 Dec;103(12):1956-1968.

96. Jac­que­lin S, Straube J, Cooper L, Vu T, Song A, Bywa­ter M, Bax­ter E, Hei­de­cker M, Wack­row B, Por­ter A, Ling V, Green J, Aus­tin R, Kaza­koff S, Wad­dell N, Hes­son LB, Pimanda JE, Ste­gel­mann F, Bul­lin­ger L, Döh­ner K, Ram­pal RK, Heckl D, Hill GR, Lane SW. Jak2V617F and Dnmt3a loss coope­rate to induce mye­lo­fi­bro­sis through acti­va­ted enhancer-​driven inflam­ma­tion. Blood. 2018 Dec 27;132(26):2707-2721.

95. Thur­ner L, Preuss KD, Bewar­der M, Kemele M, Fadle N, Regitz E, Alt­meyer S, Schor­mann C, Poe­schel V, Zie­pert M, Wal­ter S, Roth P, Wel­ler M, Szc­ze­panow­ski M, Klap­per W, Mono­ranu C, Rosen­wald A, Möl­ler P, Hart­mann S, Hans­mann ML, Macken­sen A, Schä­fer H, Schorb E, Iller­haus G, Bus­lei R, Bohle RM, Stil­gen­bauer S, Kim YJ, Pfreund­schuh M. Hyper N-​glycosylated SAMD14 and neurabin-​I as dri­ver CNS auto­an­ti­gens of PCNSL. Blood. 2018 Dec 27;132(26):2744-2753.

94. Flinn IW, Hill­men P, Mon­tillo M, Nagy Z, Illés Á, Eti­enne G, Del­gado J, Kuss BJ, Tam CS, Gaszt­onyi Z, Off­ner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jae­ger U, Ghia P, Cym­ba­lista F, Por­tell CA, Skarb­nik AP, Cashen AF, Wea­ver DT, Kelly VM, Turn­bull B, Stil­gen­bauer S. The phase 3 DUO trial: duve­li­sib ver­sus ofa­tu­mu­mab in relap­sed and refrac­tory CLL/SLL. Blood. 2018 Dec 6;132(23):2446-2455.

93. Al-​Sawaf O, Bahlo J, Rob­recht S, Fischer K, Her­ling CD, Hoech­stet­ter M, Fink AM, von Tre­sc­kow J, Lan­ger­beins P, Cra­mer P, Stil­gen­bauer S, Wendt­ner CM, Eich­horst B, Hal­lek M, Goede V. Out­come of pati­ents aged 80 years or older trea­ted for chro­nic lym­pho­cy­tic leu­ka­e­mia. Br J Hae­ma­tol. 2018 Dec;183(5):727-735.

92. Döh­ner H, Dol­nik A, Tang L, Sey­mour JF, Min­den MD, Stone RM, Del Cas­tillo TB, Al-​Ali HK, San­tini V, Vyas P, Beach CL, Mac­Beth KJ, Ski­kne BS, Son­ger S, Tu N, Bul­lin­ger L, Dom­bret H. Cyto­ge­ne­tics and gene muta­ti­ons influ­ence sur­vi­val in older pati­ents with acute mye­loid leuke­mia trea­ted with aza­ci­ti­dine or con­ven­tio­nal care. Leuke­mia. 2018 Dec;32(12):2546-2557.

91. Braess J, Amler S, Kreu­zer KA, Spie­ker­mann K, Lin­de­mann HW, Leng­fel­der E, Grae­ven U, Staib P, Lud­wig WD, Bier­sack H, Ko YD, Uppen­kamp MJ, De Wit M, Kors­ten S, Peceny R, Gaska T, Schiel X, Beh­rin­ger DM, Kiehl MG, Zinn­grebe B, Mecken­stock G, Roe­mer E, Med­gen­berg D, Spaeth-​Schwalbe E, Mas­sen­keil G, Hin­dahl H, Schwerdt­fe­ger R, Trenn G, Sauer­land C, Koch R, Lablans M, Fal­dum A, Gör­lich D, Boh­l­an­der SK, Schnei­der S, Dufour A, Buske C, Fiegl M, Sub­klewe M, Braess B, Unter­halt M, Baum­gart­ner A, Wör­mann B, Bee­len D, Hid­de­mann W; AML-​CG. Sequen­tial high-​dose cyt­ara­bine and mit­ox­an­trone (S-HAM) ver­sus stan­dard dou­ble induc­tion in acute mye­loid leukemia-​a phase 3 study. Leuke­mia. 2018 Dec;32(12):2558-2571.

90. Zajac M, Zale­ska J, Dol­nik A, Bul­lin­ger L, Gianno­pou­los K. Expres­sion of CD274 (PD-L1) is asso­cia­ted with unfa­voura­ble recur­rent muta­ti­ons in AML.Br J Hae­ma­tol. 2018 Dec;183(5):822-825.

89. Wagener R, López C, Kleinheinz K, Baus­in­ger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Alt­mül­ler J, Thiele H, Schnei­der C, Kola­rova J, Park J, Hüb­sch­mann D, Murga Penas EM, Drex­ler HG, Attar­ba­schi A, Hov­land R, Kjeld­sen E, Kneba M, Kontny U, de Leval L, Nürn­berg P, Oschlies I, Oscier D, Schle­gel­ber­ger B, Stil­gen­bauer S, Wöss­mann W, Schles­ner M, Burk­hardt B, Klap­per W, Jaffe ES, Küp­pers R, Sie­bert R. IG-​MYC-positive neo­plasms with pre­cur­sor B-​cell phe­no­type are mole­cu­larly dis­tinct from Bur­kitt lym­pho­mas.Blood. 2018 Nov 22;132(21):2280-2285.

88. Dimo­pou­los MA, Sal­man Z, Buske C. Ibru­ti­nib and Ritu­xi­mab in Wal­den­ström's Macro­glo­bu­li­ne­mia. N Engl J Med. 2018 Nov 15;379(20):1975-1976. Com­ment.

87. Ebert BL, Krönke J. Inhi­bi­tion of Casein Kinase 1 Alpha in Acute Mye­loid Leuke­mia. N Engl J Med. 2018 Nov 8;379(19):1873-1874.

86. Gri­go­ryan A, Guidi N, Sen­ger K, Liehr T, Sol­ler K, Marka G, Voll­mer A, Mar­kaki Y, Leon­hardt H, Buske C, Lipka DB, Plass C, Zheng Y, Mulaw MA, Gei­ger H, Flo­rian MC. LaminA/C regu­la­tes epi­ge­ne­tic and chro­ma­tin archi­tec­ture chan­ges upon aging of hema­to­poie­tic stem cells. Genome Biol. 2018 Nov 7;19(1):189.

85. Trot­man J, Bar­ring­ton SF, Belada D, Meig­nan M, MacE­wan R, Owen C, Ptáčník V, Rosta A, Fingerle-​Rowson GR, Zhu J, Niel­sen T, Sahin D, Hid­de­mann W, Mar­cus RE, Davies A, Buske C as Col­la­bo­ra­tor; PET inves­ti­ga­tors from the GAL­LIUM study.Pro­gno­stic value of end-​of-induction PET response after first-​line immu­n­o­chemo­the­rapy for fol­li­cu­lar lym­phoma (GAL­LIUM): secon­dary ana­ly­sis of a ran­do­mi­sed, phase 3 trial.Lan­cet Oncol. 2018 Nov;19(11):1530-1542.

84. Ogura M, San­cho JM, Cho SG, Naka­zawa H, Suzu­miya J, Tumyan G, Kim JS, Len­nard A, Mariz J, Ilyin N, Jurczak W, Lopez Mar­ti­nez A, Samoi­lova O, Zhav­rid E, Yañez Ruiz E, Trneny M, Popp­le­well L, Coif­fier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Effi­cacy, phar­ma­co­ki­ne­tics, and safety of the bio­si­mi­lar CT-P10 in com­pa­ri­son with ritu­xi­mab in pati­ents with pre­viously untrea­ted low-​tumour-burden fol­li­cu­lar lym­phoma: a ran­do­mi­sed, double-​blind, parallel-​group, phase 3 trial. Lan­cet Hae­ma­tol. 2018 Nov;5(11):e543-e553.

83. Leblond V, Aktan M, Ferra Coll CM, Dar­ti­geas C, Kisro J, Mon­tillo M, Raposo J, Merot JL, Rob­son S, Gresko E, Bosch F, Stil­gen­bauer S, Foà R. Safety of obi­nu­tu­zu­mab alone or com­bi­ned with che­mo­the­rapy for pre­viously untrea­ted or relap­sed/refrac­tory chro­nic lym­pho­cy­tic leuke­mia in the Phase 3b GREEN study.Hae­ma­to­lo­gica. 2018 Nov;103(11):1889-1898.

82. Thol F, Gab­doul­line R, Lie­bich A, Kle­ment P, Schil­ler J, Kand­ziora C, Ham­bach L, Stad­ler M, Koenecke C, Flin­trop M, Pan­kratz M, Wich­mann M, Neziri B, Bütt­ner K, Heida B, Klesse S, Cha­tur­vedi A, Kloos A, Göh­ring G, Schle­gel­ber­ger B, Gaid­zik VI, Bul­lin­ger L, Fied­ler W, Heim A, Hamwi I, Eder M, Krau­ter J, Schlenk RF, Paschka P, Döh­ner K, Döh­ner H, Gan­ser A, Heu­ser M. Mea­sura­ble resi­dual disease (MRD) moni­to­ring by NGS before allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion in AML. Blood. 2018 Oct 18;132(16):1703-1713.

81. Wais V, Bun­jes D, Kuchen­bauer F, Sor­ror ML. Comor­bi­di­ties, age, and other patient-​related pre­dic­tors of allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion out­co­mes. Expert Rev Hema­tol. 2018 Oct;11(10):805-816.

80. L Abbate A, Tolo­meo D, Cifola I, Severg­nini M, Tur­chiano A, Augello B, Squeo G, D Add­abbo P, Tra­versa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dol­nik A, Mueh­le­mat­ter D, Schou­mans J, Van Roy N, De Bel­lis G, Mar­ti­nelli G, Merla G, Bul­lin­ger L, Hafer­lach C, Stor­lazzi CT. MYC-​containing ampli­cons in acute mye­loid leuke­mia: geno­mic struc­tu­res, evo­lu­tion, and tran­scrip­tio­nal con­se­quen­ces. Leuke­mia. 2018 Oct;32(10):2152-2166.

79. Dre­ger P, Ghia P, Sche­te­lig J, van Gel­der M, Kimby E, Michal­let M, Moreno C, Robak T, Stil­gen­bauer S, Monts­er­rat E. High-​risk chro­nic lym­pho­cy­tic leuke­mia in the era of pathway inhi­bi­tors: Inte­gra­ting mole­cu­lar and cel­lu­lar the­ra­pies. Blood. 2018 Aug 30;132(9):892-902.

78. Buske C. Alky­la­ting Agents in the Treat­ment of Wal­den­ström Macro­glo­bu­li­ne­mia. Hema­tol Oncol Clin North Am. 2018 Oct;32(5):821-827. Epub 2018 Jul 25. Review.

77. Krau­ter J, Fied­ler W, Schlenk RF, Paschka P, Thol F, Lüb­bert M, Wat­tad M, Ver­beek M, Köne­cke C, Neu­haus B, Pap­kalla A, Kebenko M, Jan­ning M, Döh­ner K, Gaid­zik VI, Becker H, Greil C, Rei­mer P, Götze KS, Döh­ner H, Gan­ser A, Heu­ser M. Phase I/II study on cyt­ara­bine and idaru­bi­cin com­bi­ned with escala­ting doses of clo­f­a­ra­bine in newly dia­gno­sed pati­ents with acute mye­loid leu­ka­e­mia and high risk for induc­tion failure (AMLSG 17-10 CIARA trial). Br J Hae­ma­tol. 2018 Oct;183(2):235-241.

76. Wal­li­ser C, Wist M, Herm­kes E, Zhou Y, Schade A, Haas J, Dein­zer J, Désiré L, Li SSC, Stil­gen­bauer S, Mil­ner JD, Gier­schik P. Func­tio­nal cha­rac­te­riza­tion of phos­pho­li­pase C-γ₂ mutant pro­tein caus­ing both soma­tic ibru­ti­nib resis­tance and a germ­line mono­ge­nic auto­in­flam­ma­tory dis­or­der. Onco­tar­get. 2018 Sep 28;9(76):34357-34378. eColl­ec­tion 2018 Sep 28.

75. Stei­ne­bach C, Lind­ner S, Ude­shi ND, Mani DC, Kehm H,Köpff S, Carr SA, Güt­schow M, Kronke J.Homo-​PROTACs for the Che­mi­cal Kno­ck­down of Cereb­lon. ACS Chem Biol. 2018 Sep 21;13(9):2771-2782.

74. Pflug N, Cra­mer P, Rob­recht S, Bahlo J, Wes­ter­mann A, Fink AM, Schra­der A, Mayer P, Ober­beck S, Sei­ler T, Zenz T, Dürig J, Kreu­zer KA, Stil­gen­bauer S, Eich­horst B, Hal­lek M, Her­ling M, Hopfin­ger G. New les­sons lear­ned in T-PLL: results from a pro­spec­tive phase-​II trial with fludarabine-​mitoxantrone-cyclophosphamide-alemtuzumab induc­tion fol­lo­wed by alem­tu­zu­mab main­ten­ance.Leuk Lym­phoma. 2018 Sep 20:1-9.

73. Lux S, Bul­lin­ger L. Cir­cu­lar RNAs in Can­cer. Adv Exp Med Biol. 2018;1087:215-230.

72. Schef­fold A, Jeba­raj BMC,Stil­gen­bauer S.Vene­toclax: Tar­ge­ting BCL2 in Hema­to­lo­gi­cal Can­cers. Recent Results Can­cer Res. 2018;212:215-242.

71. Davids MS, Hal­lek M, Wierda W, Roberts AW, Stil­gen­bauer S, Jones JA, Gere­ci­tano JF, Kim SY, Pot­luri J, Bus­man T, Best A, Ver­dugo ME, Cerri E, Desai M, Hill­men P, Sey­mour JF. Com­pre­hen­sive Safety Ana­ly­sis of Vene­toclax Mono­the­rapy for Pati­ents with Relap­sed/Refrac­tory Chro­nic Lym­pho­cy­tic Leuke­mia. Clin Can­cer Res. 2018 Sep 15;24(18):4371-4379.

70. Went M, Sud A, Försti A, Hal­vars­son BM, Wein­hold N, Kim­ber S, van Duin M, Thor­leifs­son G, Hol­royd A, John­son DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mit­chell JS, Gudb­jarts­son DF, Kui­per R, Ste­phens OW, Bertsch U, Bro­de­rick P, Campo C, Ban­d­a­palli OR, Ein­sele H, Gre­gory WA, Gull­berg U, Hil­len­gass J, Hoff­mann P, Jack­son GH, Jöckel KH, Johns­son E, Kris­tins­son SY, Mell­qvist UH, Nahi H, Eas­ton D, Pha­roah P, Dun­ning A, Peto J, Can­zian F, Swerd­low A, Eeles RA, Kote-​Jarai Z, Muir K, Pas­hayan N, Nickel J, Nöthen MM, Raf­nar T, Ross FM, da Silva Filho MI, Thom­sen H, Tures­son I, Vangs­ted A, Ander­sen NF, Waage A, Wal­ker BA, Wihl­borg AK, Broyl A, Davies FE, Thor­steins­dot­tir U, Lan­ger C, Hans­son M, Gold­schmidt H, Kai­ser M, Son­ne­veld P, Ste­fans­son K, Mor­gan GJ, Hem­minki K, Nils­son B, Houl­s­ton RS; PRAC­TI­CAL con­sor­tium. Iden­ti­fi­ca­tion of mul­ti­ple risk loci and regu­la­tory mecha­nisms influ­en­cing suscep­ti­bi­lity to mul­ti­ple mye­loma. Nat Com­mun. 2018 Sep 13;9(1):3707.

69. Bre­scia P, Schnei­der C, Hol­mes AB, Shen Q, Hus­sein S, Pas­qualucci L, Basso K, Dalla-​Favera R. MEF2B Instructs Ger­mi­nal Cen­ter Deve­lo­p­ment and Acts as an Onco­gene in B Cell Lym­phoma­ge­ne­sis. Can­cer Cell. 2018 Sep 10;34(3):453-465.e9.

68. Hage­mann JB, Haver­kamp S, Grü­ner B, Kuchen­bauer F, Essig A. Pul­mo­nary Cam­py­lo­b­ac­ter con­cisus Infec­tion in an Immu­n­o­com­pro­mi­sed Pati­ent with Under­ly­ing Mucor­my­co­sis. Int J Infect Dis. 2018 Sep 8;76:45-47.

67. Lang­gart­ner D, Füchsl AM, Kai­ser LM, Meier T, Foertsch S, Buske C, Reber SO, Mulaw MA. Bio­mar­kers for clas­si­fi­ca­tion and class pre­dic­tion of stress in a murine model of chro­nic sub­or­di­na­tion stress. PLoS One. 2018 Sep 5;13(9):e0202471. eColl­ec­tion 2018.

66. Cra­mer P, von Tre­sc­kow J, Bahlo J, Rob­recht S, Lan­ger­beins P, Al-​Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Sei­ler T, Fischer von Wei­kers­thal L, Hebart H, Kreu­zer KA, Bött­cher S, Rit­gen M, Kneba M, Wendt­ner CM, Stil­gen­bauer S, Eich­horst B, Hal­lek M. Ben­da­mus­tine fol­lo­wed by obi­nu­tu­zu­mab and vene­toclax in chro­nic lym­pho­cy­tic leu­ka­e­mia (CLL2-BAG): pri­mary end­point ana­ly­sis of a mul­ti­centre, open-​label, phase 2 trial. Lan­cet Oncol. 2018 Sep;19(9):1215-1228.

65. Bohl SR, Dol­nik A, Jen­sen T, Lang KM, Hack­an­son B, Gaid­zik VI, Paschka P, Knud­sen S, Döh­ner K, Döh­ner H, Claus R, Lüb­bert M, Bul­lin­ger L.Gene expres­sion ana­ly­sis of deci­ta­bine trea­ted AML: high impact of tumor sup­pres­sor gene expres­sion chan­ges.Leuk Lym­phoma. 2017 Sep;58(9):1-4. No abs­tract availa­ble.

64. Fuerst D, Frank S, Muel­ler C, Bee­len DW, Sche­te­lig J, Nie­der­wie­ser D, Finke J, Bun­jes D, Krö­ger N, Neu­chel C, Tsa­ma­dou C, Schre­zen­meier H, Bey­ers­mann J, Myti­li­neos J. Com­pe­ting risks out­co­mes in hema­to­poie­tic stem cell trans­plan­ta­tion from the per­spec­tive of time-​dependent effects. Hae­ma­to­lo­gica. 2018 Sep;103(9):1527-1534.

63. Tam CS, LeBlond V, Novotny W, Owen RG, Tede­schi A, Atwal S, Cohen A, Huang J, Buske C.A head-​to-head Phase III study com­pa­ring zanu­bru­ti­nib ver­sus ibru­ti­nib in pati­ents with Wal­den­ström macro­glo­bu­li­ne­mia. Future Oncol. 2018 Sep;14(22):2229-2237.

62. Stol­zen­burg A, Lück­er­ath K, Sam­nick S, Speer M, Kneer K, Schmid JS, Gri­go­leit GU, Hof­mann S, Beer AJ, Bun­jes D, Knop S, Buck AK, Ein­sele H, Lapa C. Pro­gno­stic value of [¹⁸F]FDG-​PET/CT in mul­ti­ple mye­loma pati­ents before and after allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion. Eur J Nucl Med Mol Ima­ging. 2018 Sep;45(10):1694-1704.

61. Jones J, Mato A, Coutre S, Byrd JC, Fur­man RR, Hill­men P, Oster­borg A, Tam C, Stil­gen­bauer S, Wierda WG, Hee­rema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM. Eva­lua­tion of 230 pati­ents with relap­sed/refrac­tory dele­tion 17p chro­nic lym­pho­cy­tic leu­ka­e­mia trea­ted with ibru­ti­nib from 3 cli­ni­cal tri­als. Br J Hae­ma­tol. 2018 Aug;182(4):504-512.

60. Alig S, Juri­no­vic V, Pas­tore A, Bara­ria D, Häbe S, Hell­muth JC, Kridel R, Gas­coyne R, Schmidt C, Zöll­ner A, Buske C, Drey­ling M, Unter­halt M, Hid­de­mann W, Hos­ter E, Wei­gert O. Impact of age on gene­tics and treat­ment effi­cacy in fol­li­cu­lar lym­phoma.Hae­ma­to­lo­gica. 2018 Aug;103(8):e364-e367. No abs­tract availa­ble.

59. Stil­gen­bauer S, Leblond V, Foà R, Bött­cher S, Ilhan O, Knauf W, Mikus­kova E, Ren­ner C, Tausch E, Wosz­czyk D, Gresko E, Lund­berg L, Moore T, Mor­ris T, Rob­son S, Bosch F. Obi­nu­tu­zu­mab plus ben­da­mus­tine in pre­viously untrea­ted pati­ents with CLL: a sub­group ana­ly­sis of the GREEN study. Leuke­mia. 2018 Aug;32(8):1778-1786.

58. Bom­mer M, Kull M, Teleanu V, Schwarz­wäl­der P, Feuring-​Buske M, Kro­enke J, Bun­jes D, Lan­ger C. Lep­to­menin­geal Mye­lo­ma­to­sis: A Rare but Devas­ta­ting Mani­fes­ta­tion of Mul­ti­ple Mye­loma Dia­gno­sed Using Cyto­logy, Flow Cyto­me­try, and Fluo­res­cent in situ Hybri­diza­tion. Acta Hae­ma­tol. 2018 Jul 11;139(4):247-254.

57. Buske C, Sadul­lah S, Kas­tri­tis E, Tede­schi A, García-​Sanz R, Bol­kun L, Leleu X, Wil­len­ba­cher W, Hájek R, Min­nema MC, Cheng M, Bilotti E, Graef T, Dimo­pou­los MA; European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia. Treat­ment and out­come pat­terns in European pati­ents with Wal­den­ström's macro­glo­bu­li­nae­mia: a large, obser­va­tio­nal, retro­spec­tive chart review.Lan­cet Hae­ma­tol. 2018 Jul;5(7):e299-e309. Review.

56. Stil­gen­bauer S, Eich­horst B, Sche­te­lig J, Hill­men P, Sey­mour JF, Coutre S, Jurczak W, Mul­ligan SP, Schuh A, Assouline S, Wendt­ner CM, Roberts AW, Davids MS, Blo­eh­dorn J, Munir T, Bött­cher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Ver­dugo M, Gor­don G, Hal­lek M, Wierda WG. Vene­toclax for Pati­ents With Chro­nic Lym­pho­cy­tic Leuke­mia With 17p Dele­tion: Results From the Full Popu­la­tion of a Phase II Pivo­tal Trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980.

55. Cor­tes J, Perl AE, Döh­ner H, Kant­ar­jian H, Mar­ti­nelli G, Kova­c­so­vics T, Rous­se­lot P, Stef­fen B, Dom­bret H, Estey E, Strick­land S, Alt­man JK, Bal­dus CD, Bur­nett A, Krä­mer A, Rus­sell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gam­mon G, Trone D, Laz­za­retto D, Levis M. Quiz­ar­ti­nib, an FLT3 inhi­bi­tor, as mono­the­rapy in pati­ents with relap­sed or refrac­tory acute mye­loid leu­ka­e­mia: an open-​label, mul­ti­centre, single-​arm, phase 2 trial. Lan­cet Oncol. 2018 Jul;19(7):889-903.

54. Mai­f­rede S, Nieborowska-​Skorska M, Sul­li­van K, Das­gupta Y, Podszywalow-​Bartnicka P, Le BV, Sole­cka M, Lian Z, Belyaeva EA, Ner­sesyan A, Machni­cki MM, Toma M, Chatain N, Ryd­za­nicz M, Zhao H, Jeli­nek J, Piwo­cka K, Sli­win­ski T, Sto­klosa T, Plo­ski R, Fischer T, Sykes SM, Koschmie­der S, Bul­lin­ger L, Valent P, Wasik M, Huang J, Skor­ski T. Tyro­sine kinase inhibitor-​induced defects in DNA repair sen­si­tize FLT3(ITD)-​positive leuke­mia cells to PARP1 inhi­bi­tors. Blood. 2018 Jul 5;132(1):67-77.

53. Paschka P, Schlenk RF, Weber D, Ben­ner A, Bul­lin­ger L, Heu­ser M, Gaid­zik VI, Thol F, Agra­wal M, Teleanu V, Lüb­bert M, Fied­ler W, Radsak M, Krau­ter J, Horst HA, Greil R, Mayer K, Künd­gen A, Mar­tens U, Heil G, Salih HR, Her­ten­stein B, Schwä­nen C, Wulf G, Lange E, Pfreund­schuh M, Ring­hof­fer M, Gir­schi­kof­sky M, Hei­ni­cke T, Krae­mer D, Göh­ring G, Gan­ser A, Döh­ner K, Döh­ner H. Adding dasa­ti­nib to inten­sive treat­ment in core-​binding fac­tor acute mye­loid leukemia-​results of the AMLSG 11-08 trial. Leuke­mia. 2018 Jul;32(7):1621-1630.

52. Hei­ne­mann M, Ranft A, Lan­ger T, Jür­gens H, Kreyer J, Vieth V, Schä­fers M, Weckes­ser M, Simon T, Has­sen­pflug W, Cor­ba­cio­glu S, Bielack S, Mayer-​Steinacker R, Kühne T, van den Berg H, Geld­erblom H, Bauer S, Steg­ger L, Dirk­sen U. Recur­rence of Ewing sar­coma: Is detec­tion by ima­ging follow-​up pro­to­col asso­cia­ted with sur­vi­val advan­tage? Pediatr Blood Can­cer. 2018 Jul;65(7)

51. Stein­bre­cher D, Jeba­raj BMC, Schnei­der C, Edel­mann J, Cym­ba­lista F, Leblond V, Del­mer A, Ibach S, Tausch E, Schef­fold A, Blo­eh­dorn J, Hal­lek M, Dre­ger P, Döh­ner H, Stil­gen­bauer S. Telo­mere length in poor-​risk chro­nic lym­pho­cy­tic leuke­mia: asso­cia­ti­ons with disease cha­rac­te­ristics and out­come. Leuk Lym­phoma. 2018 Jul;59(7):1614-1623.

50. Buske C, Sadul­lah S, Kas­tri­tis E, Tede­schi A, García-​Sanz R, Bol­kun L, Leleu X, Wil­len­ba­cher W, Hájek R, Min­nema MC, Cheng M, Bilotti E, Graef T, Dimo­pou­los MA; European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia. Treat­ment and out­come pat­terns in European pati­ents with Wal­den­ström's macro­glo­bu­li­nae­mia: a large, obser­va­tio­nal, retro­spec­tive chart review.Lan­cet Hae­ma­tol. 2018 Jul;5(7):e299-e309.

49. Hal­lek M, Che­son BD, Catovsky D, Caligaris-​Cappio F, Dighiero G, Döh­ner H, Hill­men P, Kea­ting M, Monts­er­rat E, Chio­razzi N, Stil­gen­bauer S, Rai KR, Byrd JC, Eich­horst B, O'Brien S, Robak T, Sey­mour JF, Kipps TJ. Gui­de­li­nes for dia­gno­sis, indi­ca­ti­ons for treat­ment, response assess­ment and sup­por­tive manage­ment of chro­nic lym­pho­cy­tic leuke­mia. Blood. 2018 Jun 21;131(25):2745-2760.

48. Dimo­pou­los MA, Tede­schi A, Trot­man J, García-​Sanz R, Mac­do­nald D, Leblond V, Mahe B, Her­baux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shus­tik C, Kas­tri­tis E, Treon SP, Li J, Sal­man Z, Graef T, Buske C. iNNO­VATE Study Group and the European Con­sor­tium for Wal­den­ström’s Macro­glo­bu­li­ne­mia. Phase 3 Trial of Ibru­ti­nib plus Ritu­xi­mab in Wal­den­ström's Macro­glo­bu­li­ne­mia. N Engl J Med. 2018 Jun 21;378(25):2399-2410.

47. Went M, Sud A, Law PJ, John­son DC, Wein­hold N, Försti A, van Duin M, Mit­chell JS, Chen B, Kui­per R, Ste­phens OW, Bertsch U, Campo C, Ein­sele H, Gre­gory WM, Hen­rion M, Hil­len­gass J, Hoff­mann P, Jack­son GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thom­sen H, Wal­ker BA, Broyl A, Davies FE, Lan­ger C, Hans­son M, Kai­ser M, Son­ne­veld P, Gold­schmidt H, Hem­minki K, Nils­son B, Mor­gan GJ, Houl­s­ton RS. Asses­sing the effect of obesity-​related traits on mul­ti­ple mye­loma using a Men­de­lian ran­do­mi­sa­tion approach. Blood Can­cer J. 2017 Jun 16;7(6):e573. No abs­tract availa­ble.

46. Chat­topad­hyay S, Thom­sen H, da Silva Filho MI, Wein­hold N, Hoff­mann P, Nöthen MM, Marina A, Jöckel KH, Schmidt B, Pech­li­va­nis S, Lan­ger C, Gold­schmidt H, Hem­minki K, Försti A. Enrich­ment of B cell recep­tor signa­ling and epi­der­mal growth fac­tor recep­tor pathways in mono­clo­nal gam­mo­pa­thy of unde­ter­mi­ned signi­ficance: a genome-​wide gene­tic inter­ac­tion study. Mol Med. 2018 Jun 11;24(1):30.

45. Bom­mer M, Wölfle-​Guter M, Bohl S, Kuchen­bauer F . The Dif­fe­ren­tial Dia­gno­sis and Treat­ment of Throm­bo­tic Micro­an­gio­pa­thies.Dtsch Arz­tebl Int. 2018 May 11;115(19):327-334.

44. Bohl SR, Bul­lin­ger L, Rücker FG. Epi­ge­ne­tic the­rapy: aza­cy­ti­dine and deci­ta­bine in acute mye­loid leuke­mia. Expert Rev Hema­tol. 2018 May;11(5):361-371.

43. Sestili S, Labo­pin M, Rug­geri A, Velardi A, Ciceri F, Maer­tens J, Kanz L, Aversa F, Lewalle P, Bun­jes D, Mohty M, Nag­ler A.T-​cell-depleted haplo­iden­ti­cal stem cell trans­plan­ta­tion results improve with time in adults with acute leuke­mia:A study from the Acute Leuke­mia Work­ing Party of the European Society of Blood and Mar­row Trans­plan­ta­tion (EBMT). Can­cer. 2018 May 15;124(10):2142-2150.

42. Mulinge E, Magambo J, Odongo D, Njenga S, Zeyhle E, Mbae C, Kagendo D, Addy F, Ebi D, Was­ser­mann M, Kern P, Romig T.Mole­cu­lar cha­rac­te­riza­tion of Echi­no­coc­cus spe­cies in dogs from four regi­ons of Kenya. Vet Para­si­tol. 2018 May 15;255:49-57.

41. Omer RA, Dau­g­schies A, Gaw­lowska S, Elna­has A, Kern P, Bas­hir S, Ali MSA, Osman A, Romig T. First detec­tion of Echi­no­coc­cus gra­nu­lo­sus sensu stricto (G1) in dogs in cen­tral Sudan. Para­si­tol Res. 2018 May;117(5):1657-1661.

40. Saus­sele S, Hehl­mann R, Faba­rius A, Jero­min S, Proetel U, Rinal­detti S, Kohl­bren­ner K, Ein­sele H, Falge C, Kanz L, Neu­bauer A, Kneba M, Ste­gel­mann F, Pfreund­schuh M, Wal­ler CF, Opp­li­ger Lei­bund­gut E, Heim D, Krause SW, Hof­mann WK, Has­ford J, Pfirr­mann M, Mül­ler MC, Hoch­haus A, Laus­eker M. Defi­ning the­rapy goals for major mole­cu­lar remis­sion in chro­nic mye­loid leuke­mia: results of the ran­do­mi­zed CML Study IV. Leuke­mia. 2018 May;32(5):1222-1228.

39. Schus­ter AJ, Kager L, Rei­chardt P, Baum­hoer D, Csóka M, Hecker-​Nolting S, Lang S, Loren­zen S, Mayer-​Steinacker R, von Kalle T, Kevric M, Wer­ner M, Wind­ha­ger R, Wirth T, Bielack SS. High-​Grade Osteo­s­ar­coma of the Foot: Pre­sen­ta­tion, Treat­ment, Pro­gno­stic Fac­tors, and Out­come of 23 Coope­ra­tive Osteo­s­ar­coma Study Group COSS Pati­ents. Sar­coma. 2018 May 2;2018:1632978. eColl­ec­tion 2018.

38. Jurczak W, Zin­zani PL, Gaidano G, Goy A, Pro­ven­cio M, Nagy Z, Robak T, Mad­docks K, Buske C, Ambark­hane S, Winder­lich M, Dirnberger-​Hertweck M, Korol­kie­wicz R, Blum KA. Phase IIa study of the CD19 anti­body MOR208 in pati­ents with relap­sed or refrac­tory B-​cell non-​Hodgkin's lym­phoma. Ann Oncol. 2018 May 1;29(5):1266-1272.

37. Mal­ci­kova J, Tausch E, Rossi D, Sut­ton LA, Soussi T, Zenz T, Kater AP, Nie­mann CU, Gon­za­lez D, Davi F, Gon­za­lez Diaz M, Moreno C, Gaidano G, Sta­ma­to­pou­los K, Rosen­quist R, Stil­gen­bauer S, Ghia P, Pos­pi­si­lova S; European Rese­arch Initia­tive on Chro­nic Lym­pho­cy­tic Leuke­mia (ERIC) — TP53 net­work. ERIC recom­men­da­ti­ons for TP53 muta­tion ana­ly­sis in chro­nic lym­pho­cy­tic leukemia-​update on metho­do­lo­gi­cal approa­ches and results inter­pre­ta­tion. Leuke­mia. 2018 May;32(5):1070-1080.

36. Mohr J, Dash BP, Schno­e­der TM, Wol­le­schak D, Her­zog C, Tubio San­ta­ma­ria N, Wei­nert S, Godav­ar­thy S, Zanetti C, Nau­mann M, Hart­le­ben B, Huber TB, Krause DS, Kähne T, Bul­lin­ger L, Hei­del FH. The cell fate deter­mi­nant Scribble is requi­red for main­ten­ance of hema­to­poie­tic stem cell func­tion. Leuke­mia. 2018 May;32(5):1211-1221.

35. Dürr C, Hanna BS, Schulz A, Lucas F, Zuck­nick M, Ben­ner A, Clear A, Ohl S, Öztürk S, Zenz T, Stil­gen­bauer S, Li-​Weber M, Kram­mer PH, Grib­ben JG, Lich­ter P, Seif­fert M. TNF recep­tor signa­ling is a dri­ver of chro­nic lym­pho­cy­tic leuke­mia that can be the­ra­peu­ti­cally tar­ge­ted by the fla­vo­noid wogo­nin.Hae­ma­to­lo­gica. 2018 Apr;103(4):688-697.

34. Bhaya­dia R, Kro­wiorz K, Haet­scher N, Jammal R, Emm­rich S, Obul­ka­sim A, Fied­ler J, Schwar­zer A, Rouhi A, Heu­ser M, Win­gert S, Bothur S, Döh­ner K, Mät­zig T, Ng M, Rein­hardt D, Döh­ner H, Zwaan CM, van den Heu­vel Eibrink M, Heckl D, For­nerod M, Thum T, Hum­phries RK, Rie­ger MA, Kuchen­bauer F, Klus­mann JH. Endo­ge­nous Tumor Sup­pres­sor microRNA-​193b: The­ra­peu­tic and Pro­gno­stic Value in Acute Mye­loid Leuke­mia. J Clin Oncol. 2018 Apr 1;36(10):1007-1016.

33. Frech M, Teich­ler S, Feld C, Bou­chard C, Ber­be­rich H, Sorg K, Mern­ber­ger M, Bul­lin­ger L, Bauer UM, Neu­bauer A. MYB indu­ces the expres­sion of the onco­ge­nic core­pres­sor SKI in acute mye­loid leukemia. Onco­tar­get. 2018 Apr 27;9(32):22423-22435. eColl­ec­tion 2018 Apr 27.

32. Schmid­ber­ger J, Krat­zer W, Stark K, Grü­ner B; Echi­no­coc­co­sis Work­ing Group. Alveo­lar echi­no­coc­co­sis in Ger­many, 1992-2016.An update based on the newly estab­lished natio­nal AE data­base. Infec­tion. 2018 Apr;46(2):197-206.

31. Viar­dot A, Bar­gou R.Bispe­ci­fic anti­bo­dies in hae­ma­to­lo­gi­cal mali­gnan­cies. Can­cer Treat Rev. 2018 Apr 4;65:87-95. [Epub ahead of print] Review.

30. Mathew NR, Baum­gart­ner F, Braun L, O'Sul­li­van D, Tho­mas S, Water­house M, Mül­ler TA, Hanke K, Taromi S, Apos­to­lova P, Illert AL, Mel­chin­ger W, Duquesne S, Schmitt-​Graeff A, Oss­wald L, Yan KL, Weber A, Tugues S, Spath S, Pfei­fer D, Follo M, Claus R, Lüb­bert M, Rum­melt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schult­heiss M, Bet­tin­ger D, Thimme R, Ull­rich E, Tan­ri­ver Y, Vuong GL, Arnold R, Hem­mati P, Wolf D, Dit­sch­kow­ski M, Jilg C, Wil­helm K, Lei­ber C, Gerull S, Hal­ter J, Len­gerke C, Pabst T, Schroe­der T, Kobbe G, Rös­ler W, Doost­kam S, Meckel S, Stabla K, Met­zel­der SK, Hal­bach S, Brum­mer T, Hu Z, Deng­jel J, Hack­an­son B, Schmid C, Hol­tick U, Scheid C, Spy­ri­do­ni­dis A, Stöl­zel F, Orde­mann R, Mül­ler LP, Sicre-​de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wag­ner EM, Cahn JY, Schnell J, Kuchen­bauer F, Bun­jes D, Cha­kra­verty R, Richard­son S, Gill S, Krö­ger N, Ayuk F, Vago L, Ciceri F, Mül­ler AM, Kondo T, Teshima T, Kla­e­ger S, Kus­ter B, Kim DDH, Weis­dorf D, van der Vel­den W, Dör­fel D, Bethge W, Hil­gen­dorf I, Hoch­haus A, Andrieux G, Bör­ries M, Busch H, Mage­nau J, Reddy P, Labo­pin M, Antin JH, Hen­den AS, Hill GR, Ken­nedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rez­vani K, Shah O, Negrin RS, Nag­ler A, Prinz M, Burchert A, Neu­bauer A, Bee­len D, Macken­sen A, von Bubnoff N, Herr W, Becher B, Socié G, Cali­gi­uri MA, Rug­gi­ero E, Bonini C, Häcker G, Duys­ter J, Finke J, Pearce E, Bla­zar BR, Zei­ser R. Erra­tum: Sora­fe­nib pro­mo­tes graft-​versus-leukemia acti­vity in mice and humans through IL-15 pro­duc­tion in FLT3-​ITD-mutant leuke­mia cells. Nat Med. 2018 Apr 10;24(4):526.

29. Buske C. In Reply. Dtsch Arz­tebl Int. 2018 Mar 16;115(11):190. No abs­tract availa­ble.

28. Pfei­fer H, Raum K, Mar­ko­vic S, Nowak V, Fey S, Oblän­der J, Press­ler J, Böhm V, Brüg­ge­mann M, Wun­derle L, Hütt­mann A, Wäsch R, Beck J, Stell­jes M, Viar­dot A, Lang F, Hoel­zer D, Hof­mann WK, Serve H, Weiss C, Goek­bu­get N, Ott­mann OG, Nowak D. Geno­mic CDKN2A/2B dele­ti­ons in adult Ph+ ALL are adverse despite allo­gen­eic stem cell trans­plan­ta­tion. Blood. 2018 Mar 29;131(13):1464-1475. Epub 2018 Jan 18.   

27. Buske C, Hut­chings M, Ladetto M, Goede V, Mey U, Sou­bey­ran P, Spina M, Stau­der R, Trnený M, Wed­ding U, Fields P; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers. ESMO Con­sen­sus Con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for the cli­ni­cal manage­ment of the elderly pati­ent with mali­gnant lym­phoma. Ann Oncol. 2018 Mar 1;29(3):544-562.

26. Kuchen­bauer F, Buske C. Revi­si­ting throm­bo­cy­to­pe­nia in acute pro­mye­lo­cy­tic leuke­mia. Leuke­mia. 2018 Mar 23. [Epub ahead of print] No abs­tract availa­ble.

25. Schu­ur­huis GJ, Heu­ser M, Free­man S, Béné MC, Buc­cisano F, Cloos J, Grim­wade D, Hafer­lach T, Hills RK, Houri­gan CS, Jor­gen­sen JL, Kern W, Lacombe F, Mau­r­illo L, Preud­homme C, van der Reij­den BA, Thiede C, Ven­ditti A, Vyas P, Wood BL, Wal­ter RB, Döh­ner K, Roboz GJ, Ossen­kop­pele GJ. Mini­mal/mea­sura­ble resi­dual disease in AML: con­sen­sus docu­ment from ELN MRD Work­ing Party. Blood. 2018 Mar 22;131(12):1275-1291.

24. Cra­mer P, Tre­sc­kow JV, Bahlo J, Engelke A, Lan­ger­beins P, Fink AM, Fischer K, Wendt­ner CM, Kreu­zer KA, Stil­gen­bauer S, Bött­cher S, Eich­horst B, Hal­lek M. CLL2-BXX Phase II tri­als: sequen­tial, tar­ge­ted treat­ment for era­di­ca­tion of mini­mal resi­dual disease in chro­nic lym­pho­cy­tic leuke­mia. Future Oncol. 2018 Mar;14(6):499-513.

23. Mathew NR, Baum­gart­ner F, Braun L, O'Sul­li­van D, Tho­mas S, Water­house M, Mül­ler TA, Hanke K, Taromi S, Apos­to­lova P, Illert AL, Mel­chin­ger W, Duquesne S, Schmitt-​Graeff A, Oss­wald L, Yan KL, Weber A, Tugues S, Spath S, Pfei­fer D, Follo M, Claus R, Lüb­bert M, Rum­melt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schult­heiss M, Bet­tin­ger D, Thimme R, Ull­rich E, Tan­ri­ver Y, Vuong GL, Arnold R, Hem­mati P, Wolf D, Dit­sch­kow­ski M, Jilg C, Wil­helm K, Lei­ber C, Gerull S, Hal­ter J, Len­gerke C, Pabst T, Schroe­der T, Kobbe G, Rös­ler W, Doost­kam S, Meckel S, Stabla K, Met­zel­der SK, Hal­bach S, Brum­mer T, Hu Z, Deng­jel J, Hack­an­son B, Schmid C, Hol­tick U, Scheid C, Spy­ri­do­ni­dis A, Stöl­zel F, Orde­mann R, Mül­ler LP, Sicre-​de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wag­ner EM, Cahn JY, Schnell J, Kuchen­bauer F, Bun­jes D, Cha­kra­verty R, Richard­son S, Gill S, Krö­ger N, Ayuk F, Vago L, Ciceri F, Mül­ler AM, Kondo T, Teshima T, Kla­e­ger S, Kus­ter B, Kim DDH, Weis­dorf D, van der Vel­den W, Dör­fel D, Bethge W, Hil­gen­dorf I, Hoch­haus A, Andrieux G, Bör­ries M, Busch H, Mage­nau J, Reddy P, Labo­pin M, Antin JH, Hen­den AS, Hill GR, Ken­nedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rez­vani K, Sha O, Negrin RS, Nag­ler A, Prinz M, Burchert A, Neu­bauer A, Bee­len D, Macken­sen A, von Bubnoff N, Herr W, Becher B, Socié G, Cali­gi­uri MA, Rug­gi­ero E, Bonini C, Häcker G, Duys­ter J, Finke J, Pearce E, Bla­zar BR, Zei­ser R.Sora­fe­nib pro­mo­tes graft-​versus-leukemia acti­vity in mice and humans through IL-15 pro­duc­tion in FLT3-​ITD-mutant leuke­mia cells. Nat Med. 2018 Mar;24(3):282-291.

22. Gröb­ner SN, Worst BC, Wei­schen­feldt J, Buch­hal­ter I, Kleinheinz K, Rud­neva VA, Johann PD, Bala­subra­ma­nian GP, Segura-​Wang M, Bra­betz S, Ben­der S, Hut­ter B, Sturm D, Pfaff E, Hüb­sch­mann D, Zip­prich G, Hein­old M, Eils J, Lawe­renz C, Erkek S, Lambo S, Was­zak S, Blatt­mann C, Bork­hardt A, Kuh­len M, Eggert A, Fulda S, Gess­ler M, Wegert J, Kapp­ler R, Baum­hoer D, Bur­dach S, Kirschner-​Schwabe R, Kontny U, Kulo­zik AE, Loh­mann D, Hett­mer S, Eckert C, Bielack S, Nath­rath M, Nie­meyer C, Rich­ter GH, Schulte J, Sie­bert R, Wes­ter­mann F, Molen­aar JJ, Vas­sal G, Witt H; ICGC PedBrain-​Seq Pro­ject; ICGC MMML-​Seq Pro­ject, Burk­hardt B, Kratz CP, Witt O, van Til­burg CM, Kramm CM, Fleisch­hack G, Dirk­sen U, Rut­kow­ski S, Früh­wald M, von Hoff K, Wolf S, Klin­ge­biel T, Kosci­el­niak E, Land­graf P, Kos­ter J, Res­nick AC, Zhang J, Liu Y, Zhou X, Waan­ders AJ, Zwi­j­nen­burg DA, Raman P, Brors B, Weber UD, Nor­th­cott PA, Pajt­ler KW, Kool M, Piro RM, Kor­bel JO, Schles­ner M, Eils R, Jones DTW, Lich­ter P, Cha­vez L, Zapatka M, Pfis­ter SM. Stil­gen­bauer S as Col­la­bo­ra­tor. The land­s­cape of geno­mic alte­ra­ti­ons across childhood can­cers. Nature. 2018 Mar 15;555(7696):321-327.

21. Grib­ben JG, Bosch F, Cym­ba­lista F, Geis­ler CH, Ghia P, Hill­men P, Moreno C, Stil­gen­bauer S.Opti­mi­sing out­co­mes for pati­ents with chro­nic lym­pho­cy­tic leu­ka­e­mia on ibru­ti­nib the­rapy: European recom­men­da­ti­ons for cli­ni­cal prac­tice. Br J Hae­ma­tol. 2018 Mar;180(5):666-679.

20. Schra­der A, Cris­patzu G, Ober­beck S, Mayer P, Püt­zer S, von Jan J, Vasyu­tina E, War­ner K, Weit N, Pflug N, Braun T, Anders­son EI, Yadav B, Ria­b­in­ska A, Mau­rer B, Ven­tura Fer­reira MS, Beier F, Alt­mül­ler J, Lanasa M, Her­ling CD, Hafer­lach T, Stil­gen­bauer S, Hopfin­ger G, Pei­fer M, Brüm­men­dorf TH, Nürn­berg P, Elenitoba-​Johnson KSJ, Zha S, Hal­lek M, Moriggl R, Rein­hardt HC, Stern MH, Must­joki S, Newr­zela S, From­molt P, Her­ling M. Actio­na­ble per­tur­ba­ti­ons of damage respon­ses by TCL1/ATM and epi­ge­ne­tic lesi­ons form the basis of T-PLL. Nat Com­mun. 2018 Feb 15;9(1):697.

19. Schnei­der E, Staf­fas A, Röh­ner L, Malm­berg ED, Ashouri A, Kro­wiorz K, Pochert N, Mil­ler C, Wei SY, Ara­ba­nian L, Buske C, Döh­ner H, Bul­lin­ger L, Fogel­strand L, Heu­ser M, Döh­ner K, Xiang P, Rusch­mann J, Petriv OI, Heravi-​Moussavi A, Han­sen CL, Hirst M, Hum­phries RK, Rouhi A, Palm­qvist L, Kuchen­bauer F. MicroRNA-​155 is a direct tar­get of Meis1, but not a dri­ver in acute mye­loid leuke­mia.Hae­ma­to­lo­gica. 2018 Feb;103(2):246-255.

18. Bern­hardt P, Krat­zer W, Schmid­ber­ger J, Grae­ter T, Grue­ner B; EMIL Study Group. Labo­ra­tory para­me­ters in lean NAFLD: com­pa­ri­son of sub­jects with lean NAFLD with obese sub­jects wit­hout hepa­tic stea­to­sis.BMC Res Notes. 2018 Feb 6;11(1):101.

17. Lis­son CS, Lis­son CG, Flos­dorf K, Mayer-​Steinacker R, Schult­heiss M, von Baer A, Barth TFE, Beer AJ, Baum­hauer M, Meier R, Beer M, Schmidt SA. Dia­gno­stic value of MRI-​based 3D tex­ture ana­ly­sis for tis­sue cha­rac­te­ri­sa­tion and discri­mi­na­tion of low-​grade chon­dro­sar­coma from enchon­droma: a pilot study. Eur Radiol. 2018 Feb;28(2):468-477.

16. Osin R, Pan­krath AL, Nie­der­wie­ser D, Döh­ner H, Hönig K, Vogel­hu­ber M, Meh­nert A, Weiß­flog G, Ernst J. [Dya­dic Coping of Pati­ents with Haemato-​Oncological Disea­ses and their Part­ners: Discre­pancy Inde­xes and Asso­cia­tion with Social Sup­port and Psy­cho­lo­gi­cal Distress]. Psy­cho­ther Psy­cho­som Med Psy­chol. 2018 Feb;68(2):55-65.

15. Solo­mon N, Zeyhle E, Subra­ma­nian K, Fields PJ, Romig T, Kern P, Car­ter JY, Wachira J, Men­giste A, Mac­pher­son CNL. Cystic echi­no­coc­co­sis in Tur­kana, Kenya: 30 years of ima­ging in an ende­mic region. Acta Trop. Acta Trop. 2018 Feb;178:182-189.   

14. Kly­menko T, Blo­eh­dorn J, Bahlo J, Rob­recht S, Akylzha­nova G, Cox K, Esten­fel­der S, Wang J, Edel­mann J, Stref­ford JC, Woj­dacz TK, Fischer K, Hal­lek M, Stil­gen­bauer S, Cragg M, Grib­ben J, Braun A. Lamin B1 regu­la­tes soma­tic muta­ti­ons and pro­gres­sion of B-​cell mali­gnan­cies. Leuke­mia. 2018 Feb;32(2):364-375. 

13. Beier D, Proe­scholdt M, Rei­nert C, Pietsch T, Jones DTW, Pfis­ter SM, Hat­tin­gen E, Sei­del C, Dir­ven L, Luer­ding R, Rei­j­ne­veld J, Warmuth-​Metz M, Bon­s­anto M, Bre­mer M, Combs S, Rie­ken S, Herr­lin­ger U, Kuntze H, Mayer-​Steinacker R, Mos­kopp D, Schnei­der T, Berin­ger A, Schle­gel U, Stum­mer W, Wel­ker H, Weyer­b­rock A, Paul­sen F, Rut­kow­ski S, Wel­ler M, Wick W, Kort­mann RD, Bog­dahn U, Hau P. Mul­ti­cen­ter pilot study of radio-​chemotherapy as first-​line treat­ment for adults with medul­lob­las­toma (NOA-07). Neuro Oncol. 2018 Feb 19;20(3):400-410.

12. Ladetto M, Buske C, Hut­chings M, Drey­ling M, Gaidano G, Le Gouill S, Lumi­nari S, Pott C, Zamò A, Zucca E; & the ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers. ESMO con­sen­sus con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for pro­gno­stic tools in mature B-​cell lym­pho­mas and chro­nic lym­pho­cy­tic leu­ka­e­mia.Ann Oncol. 2018 Feb 1;29(2):525.   

11. Man­dal T, Beck M, Kirs­ten N, Lindén M, Buske C. Tar­ge­ting murine leuke­mic stem cells by anti­body func­tio­na­li­zed meso­porous silica nano­par­ticles. Sci Rep. 2018 Jan 17;8(1):989.  

10. Jeck J, Kas­subek R, Cobur­ger J, Eden­ho­fer S, Schön­stei­ner SS, Ludolph AC, Schmitz B, Engelke J, Mayer-​Steinacker R, Lewe­renz J, Bul­lin­ger L. Beva­ci­zu­mab in temo­zo­lo­mide refrac­tory high-​grade glio­mas: single-​centre expe­ri­ence and review of the lite­ra­ture. Ther Adv Neu­rol Disord. 2018 Jan 21;11:1756285617753597. eColl­ec­tion 2018.

9. Huang X, Wiehr S, Wild AM, Voß­berg P, Hoff­mann W, Grü­ner B, Köh­ler C, Sobos­lay PT. The effects of taxa­nes, vor­i­no­stat and doxo­ru­bi­cin on growth and pro­li­fe­ra­tion of Echi­no­coc­cus mul­ti­lo­cu­la­ris metaces­to­des asses­sed with magne­tic reso­nance ima­ging and simul­ta­neous posi­tron emis­sion tomo­gra­phy. Onco­tar­get. 2018 Jan 10;9(10):9073-9087.

8. Buske C, Drey­ling M. [Mali­gnant B-​Cell Lym­phoma: Advan­ces in the The­rapy of Fol­li­cu­lar Lym­phoma and Mantle-​cell Lym­phoma]. Dtsch Med Wochen­schr. 2018 Jan;143(1):46-51. Epub 2018 Jan 9. Ger­man. No abs­tract availa­ble.   

7. Rücker FG, Dol­nik A, Blätte TJ, Teleanu V, Ernst A, Thol F, Heu­ser M, Gan­ser A, Döh­ner H, Döh­ner K, Bul­lin­ger L.Chro­mo­thrip­sis is lin­ked to TP53 alte­ra­tion, cell cycle impair­ment, and dis­mal out­come in acute mye­loid leuke­mia with com­plex karyo­type.  Hae­ma­to­lo­gica. 2018 Jan;103(1):e17-e20. No abs­tract availa­ble.   

6. Wais V, Künd­gen L, Bohl SR, von Hars­dorf S, Schlenk RF, Döh­ner K, Teleanu V, Bul­lin­ger L, Nguyen TM, Dro­g­nitz K, Moulin JC, Bin­nen­hei M, Bentz M, Döh­ner H, Bun­jes D, Kuchen­bauer F, Ring­hof­fer M. Reduced-​toxicity con­di­tio­ning for allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion in elderly or comor­bid pati­ents with AML using fludar­a­bine, BCNU and mel­phalan: disease stage at trans­plant deter­mi­nes out­come. Bone Mar­row Trans­plant. 2018 Jan;53(1):94-96.   

5. Bie­rings M, Bon­fim C, Pef­fault De Latour R, Aljurf M, Mehta PA, Knol C, Bou­lad F, Tbakhi A, Esqui­rol A, McQua­ker G, Sucak GA, Oth­man TB, Hal­kes CJM, Car­pen­ter B, Nie­der­wie­ser D, Zecca M, Krö­ger N, Michal­let M, Risi­tano AM, Ehnin­ger G, Por­cher R, Dufour C; EBMT SAA WP. Bun­jes D as Col­la­bo­ra­tor Trans­plant results in adults with Fan­coni anae­mia. Br J Hae­ma­tol. 2018 Jan;180(1):100-109.   

4. Pan­krath AL, Weiß­flog G, Meh­nert A, Nie­der­wie­ser D, Döh­ner H, Hönig K, Gün­del H, Vogel­hu­ber M, Fried­rich M, Ernst J. The rela­tion bet­ween dya­dic coping and rela­ti­onship satis­fac­tion in cou­ples dea­ling with hae­ma­to­lo­gi­cal can­cer. Eur J Can­cer Care (Engl). 2018 Jan;27(1).

3. Nickel K, Reno­vanz M, König J, Stö­ckel­maier L, Hick­mann AK, Nadji-​Ohl M, Engelke J, Wei­mann E, Freu­den­stein D, Gans­landt O, Bul­lin­ger L, Wirtz CR, Cobur­ger J. The pati­ents' view: impact of the extent of resec­tion, intra­ope­ra­tive ima­ging, and awake sur­gery on health-​related qua­lity of life in high-​grade glioma patients-​results of a mul­ti­cen­ter cross-​sectional study. Neu­ro­surg Rev. 2018 Jan;41(1):207-219.  

2. Wolf C, Gar­ding A, Filar­sky K, Bahlo J, Rob­recht S, Becker N, Zuck­nick M, Rouhi A, Wei­gel A, Claus R, Wei­chen­han D, Eich­horst B, Fischer K, Hal­lek M, Kuchen­bauer F, Plass C, Döh­ner H, Stil­gen­bauer S, Lich­ter P, Mer­tens D.NFATC1 acti­va­tion by DNA hypo­me­thy­la­tion in chro­nic lym­pho­cy­tic leuke­mia cor­re­la­tes with cli­ni­cal sta­ging and can be inhi­bi­ted by ibru­ti­nib.Int J Can­cer. 2018 Jan 15;142(2):322-333.   

1. Gaid­zik VI, Weber D, Paschka P, Kau­manns A, Krie­ger S, Cor­ba­cio­glu A, Krönke J, Kapp-​Schwoerer S, Krä­mer D, Horst HA, Schmidt-​Wolf I, Held G, Künd­gen A, Ring­hof­fer M, Götze K, Kind­ler T, Fied­ler W, Wat­tad M, Schlenk RF, Bul­lin­ger L, Teleanu V, Schle­gel­ber­ger B, Thol F, Heu­ser M, Gan­ser A, Döh­ner H, Döh­ner K.DNMT3A mutant tran­script levels per­sist in remis­sion and do not pre­dict out­come in pati­ents with acute mye­loid leuke­mia. Leuke­mia. 2018 Jan;32(1):30-37.

129.  Sey­mour JF, Döh­ner H, But­rym A, Wierz­bowska A, Sel­les­lag D, Jang JH, Kumar R, Caven­agh J, Schuh AC, Can­doni A, Récher C, Sandhu I, Del Cas­tillo TB, Al-​Ali HK, Falan­tes J, Stone RM, Min­den MD, Wea­ver J, Son­ger S, Beach CL, Dom­bret H.  Aza­ci­ti­dine improves cli­ni­cal out­co­mes in older pati­ents with acute mye­loid leu­ka­e­mia with myelodysplasia-​related chan­ges com­pa­red with con­ven­tio­nal care regi­mens.  BMC Can­cer. 2017 Dec 14;17(1):852.

128.  Hirsch S, Blätte TJ, Gra­se­dieck S, Coc­ci­ardi S, Rouhi A, Jongen-​Lavrencic M, Paschka P, Krönke J, Gaid­zik VI, Döh­ner H, Schlenk RF, Kuchen­bauer F, Döh­ner K, Dol­nik A, Bul­lin­ger L.  Cir­cu­lar RNAs of the nucleo­phos­min (NPM1) gene in acute mye­loid leuke­mia.  Hae­ma­to­lo­gica. 2017 Dec;102(12):2039-2047.

127.  Avet-​Loiseau H, Bah­lis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Lan­ger C, Pluta A, Nag­ler A, Kumar S, Ben-​Yehuda D, Raj­ku­mar SV, San-​Miguel J, Berg D, Lin J, van de Velde H, Essel­tine DL, di Bacco A, Moreau P, Richard­son PG.  Ixazo­mib signi­fi­cantly pro­longs progression-​free sur­vi­val in high-​risk relap­sed/refrac­tory mye­loma pati­ents.  Blood. 2017 Dec 14;130(24):2610-2618.

126.  Grei­ner J, Hof­mann S, Schmitt M, Götz M, Wies­neth M, Schre­zen­meier H, Bun­jes D, Döh­ner H, Bul­lin­ger L.  Acute mye­loid leuke­mia with muta­ted nucleo­phos­min 1 - an immu­n­o­ge­nic AML sub­type and poten­tial can­di­date for immune check­point inhi­bi­tion.  Hae­ma­to­lo­gica. 2017 Dec;102(12):e499-e501

125.  Bohl SR, Kuchen­bauer F, von Hars­dorf S, Klo­eve­korn N, Schön­stei­ner SS, Rouhi A, Schwarz­wäl­der P,Döh­ner H, Bun­jes D, Bom­mer M.  Throm­bo­tic Micro­an­gio­pa­thy after Allo­gen­eic Stem Cell Trans­plan­ta­tion - a Com­pa­ri­son of Ecu­li­zu­mab The­rapy and Con­ven­tio­nal The­rapy.  Biol Blood Mar­row Trans­plant. 2017 Dec;23(12):2172-2177.

124.  Hoech­stet­ter MA, Busch R, Eich­horst B, Büh­ler A, Wink­ler D, Eckart MJ, Vehling-​Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfin­ger G, Hart­mann F, Fuss H,  Aben­hardt W, Blau I, Freier W, Mül­ler L, Goebeler M, Wendt­ner CM, Bahlo J, Fischer K, Bentz M, Emme­rich B, Döh­ner H, Hal­lek M, Stil­gen­bauer S.  Early, risk-​adapted treat­ment with fludar­a­bine in Binet stage A chro­nic lym­pho­cy­tic leuke­mia pati­ents: results of the CLL1 trial of the Ger­man CLL study group.  Leuke­mia. 2017 Dec;31(12):2833-2837.

123.  Borch­mann P, Goer­gen H, Kobe C, Lohri A, Greil R, Eiche­nauer DA, Zijl­s­tra JM, Mar­kova J, Meiss­ner J, Feuring-​Buske M, Hütt­mann A, Dier­lamm J, Soe­k­ler M, Beck HJ, Wil­len­ba­cher W, Lud­wig WD, Pabst T, Topp MS, Hitz F, Bentz M, Kel­ler UB, Kühn­hardt D, Oster­mann H, Schmitz N, Her­ten­stein B, Aulitzky W, Masch­meyer G, Vie­ler T, Eich H, Baues C, Stein H, Fuchs M, Kuh­nert G, Diehl V, Diet­lein M, Engert A  PET-​guided treat­ment in pati­ents with advanced-​stage Hodg­kin's lym­phoma (HD18): final results of an open-​label, inter­na­tio­nal, ran­do­mi­sed phase 3 trial by the Ger­man Hodg­kin Study Group.  Lan­cet. 2017 Dec 23;390(10114):2790-2802.

122.  Scotch AH, Kosio­rek H, Scher­ber R, Dueck AC, Slot S, Zweegman S, Boek­horst PAWT, Com­man­deur S, Schou­ten H, Sack­mann F, Fuen­tes AK, Hernández-​Maraver D, Pahl HL, Griess­ham­mer M, Ste­gel­mann F, Döh­ner K, Leh­mann T, Bonatz K, Rei­ter A, Boyer F, Eti­enne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Har­ri­son CN, Radia D, Muxi P, Mal­do­nado N, Bes­ses C, Cer­van­tes F, Johans­son PL, Bar­bui T, Barosi G, Van­nuc­chi AM, Paoli C, Pas­sa­monti F, Andre­as­son B, Fer­rari ML, Ram­baldi A, Samu­els­son J, Bir­ge­gard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kilad­jian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.  Sym­ptom bur­den pro­file in mye­lo­fi­bro­sis pati­ents with throm­bo­cy­to­pe­nia: Les­sons and unmet needs.  Leuk Res. 2017 Dec;63:34-40. Epub 2017 Oct 14.

121.  Nagel G, Weber D, Fromm E, Erhardt S, Lüb­bert M, Fied­ler W, Kind­ler T, Krau­ter J, Bross­art P, Künd­gen A, Salih HR, Wes­ter­mann J, Wulf G, Her­ten­stein B, Wat­tad M, Götze K, Krae­mer D, Hei­ni­cke T, Gir­schi­kof­sky M, Derigs HG, Horst HA, Rudolph C, Heu­ser M, Göh­ring G, Teleanu V, Bul­lin­ger L, Thol F, Gaid­zik VI, Paschka P, Döh­ner K, Gan­ser A, Döh­ner H, Schlenk RF; German-​Austrian AML Study Group (AMLSG).  Epi­de­mio­lo­gi­cal, gene­tic, and cli­ni­cal cha­rac­te­riza­tion by age of newly dia­gno­sed acute mye­loid leuke­mia based on an aca­de­mic population-​based regis­try study (AMLSG BiO)  Ann Hema­tol. 2017 Dec;96(12):1993-2003. Epub 2017 Oct 31.

120.  Krönke J, Knop S, Lan­ger C.  Pro­gno­stic impact of Ika­ros expres­sion in lenalidomide-​treated mul­ti­ple mye­loma.  Onco­tar­get. 2017 Nov 21;8(63):106163-106164.

119.  Kovacs G, Rob­recht S, Fink AM, Bahlo J, Cra­mer P, von Tre­sc­kow J, Mau­rer C, Lan­ger­beins P, Fingerle-​Rowson G, Rit­gen M, Kneba M, Döh­ner H, Stil­gen­bauer S, Klap­per W, Wendt­ner CM, Fischer K, Hal­lek M, Eich­horst B, Bött­cher S.  Mini­mal Resi­dual Disease Assess­ment Improves Pre­dic­tion of Out­come in Pati­ents With Chro­nic Lym­pho­cy­tic Leuke­mia (CLL) Who Achieve Par­tial Response: Com­pre­hen­sive Ana­ly­sis of Two Phase III Stu­dies of the Ger­man CLL Study Group.  J Clin Oncol. 2016 Nov 1;34(31):3758-3765.

118.  Tiao G, Improgo MR, Tausch E, Fer­nan­des SM, Bahlo J, Rob­recht S, Fischer K, Hal­lek M, Stil­gen­bauer S, Kie­zun A, Getz G, Brown JR.  Ana­ly­sis of ITGB2 rare germ­line vari­ants in chro­nic lym­pho­cy­tic leuke­mia.  Blood. 2017 Nov 30;130(22):2443-2444.

117.  Raf­fel S, Fal­cone M, Knei­sel N, Hans­son J, Wang W, Lutz C, Bul­lin­ger L, Poschet G, Non­nen­ma­cher Y, Bar­n­ert A, Bahr C, Zeisber­ger P, Przy­bylla A, Sohn M, Tön­jes M, Erez A, Adler L, Jen­sen P, Scholl C, Fröh­ling S, Coc­ci­ardi S, Wuch­ter P, Thiede C, Flör­cken A, Wes­ter­mann J, Ehnin­ger G, Lich­ter P, Hil­ler K, Hell R, Herr­mann C, Ho AD, Kri­jgs­veld J, Radl­wim­mer B, Trumpp A.  BCAT1 restricts αKG levels in AML stem cells lea­ding to IDHmut-​like DNA hyper­me­thy­la­tion.  Nature. 2017 Nov 16;551(7680):384-388. Epub 2017 Nov 8.

116.  Stone RM, Lar­son RA, Döh­ner H.  Mido­stau­rin in FLT3-​Mutated Acute Mye­loid Leuke­mia.  N Engl J Med. 2017 Nov 9;377(19):1903.

115.  Shi­moni A, Labo­pin M, Savani B, Volin L, Ehnin­ger G, Kuball J, Bun­jes D, Schaap N, Vigou­roux S, Baci­ga­lupo A, Veel­ken H, Sierra J, Eder M, Nie­der­wie­ser D, Mohty M, Nag­ler A.  Long-​term sur­vi­val and late events after allo­gen­eic stem cell trans­plan­ta­tion from HLA-​matched sib­lings for acute mye­loid leuke­mia with myelo­ab­la­tive com­pa­red to reduced-​intensity con­di­tio­ning: a report on behalf of the acute leuke­mia work­ing party of European group for blood and mar­row trans­plan­ta­tion.  J Hema­tol Oncol. 2016 Nov 8;9(1):118.

114.  Xiang P, Wei W, Hofs N, Clemans-​Gibbon J, Maet­zig T, Lai CK, Dhil­lon I, May C, Rusch­mann J, Schnei­der E, Ros­ten P, Hu K, Kuchen­bauer F, Hood­less PA, Hum­phries RK.  A knock-​in mouse strain faci­li­ta­tes dyna­mic tracking and enrich­ment of MEIS1.  Blood Adv. 2017 Nov 7;1(24):2225-2235.

113.  Gru­nen­berg A, Buske C.  Mono­clo­nal IgM Gam­mo­pa­thy and Wal­den­ström's Macro­glo­bu­li­ne­mia.  Dtsch Arz­tebl Int. 2017 Nov 3;114(44):745-751.

112.  Fer­reri AJM, Cwy­nar­ski K, Pulczyn­ski E, Fox CP, Schorb E, La Rosée P, Bin­der M, Fab­bri A, Torri V, Minaca­pelli E, Fal­autano M, Ila­riucci F, Ambro­setti A, Roth A, Hem­ma­way C, John­son P, Lin­ton KM, Pukrop T, Sønderskov Gørløv J, Balz­a­rotti M, Hess G, Kel­ler U, Stil­gen­bauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Her­ten­stein B, Rum­mel M, Smith J, Pfreund­schuh M, Cabras G, Ang­rilli F, Pon­zoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Iller­haus G; Inter­na­tio­nal Ext­r­ano­dal Lym­phoma Study Group (IELSG).  Whole-​brain radio­the­rapy or auto­lo­gous stem-​cell trans­plan­ta­tion as con­so­li­da­tion stra­te­gies after high-​dose methotrexate-​based che­mo­im­mu­n­o­the­rapy in pati­ents with pri­mary CNS lym­phoma: results of the second ran­do­mi­sa­tion of the Inter­na­tio­nal Ext­r­ano­dal Lym­phoma Study Group-​32 phase 2 trial.  Lan­cet Hae­ma­tol. 2017 Nov;4(11):e510-e523. Epub 2017 Oct 17.

111.  Ein­sele H, Engel­hardt M, Tap­prich C, Mül­ler J, Lie­bisch P, Lan­ger C, Kropff M, Mügge LO, Jung W, Wolf HH, Metz­ner B, Hart C, Gra­matzki M, Her­ten­stein B, Pfreund­schuh M, Rös­ler W, Fischer T, Masch­meyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Sal­wen­der H, Hebart H, Straka C, Knop S.  Phase II study of bor­te­zo­mib, cyclo­phos­pha­mide and dexa­me­tha­sone as induc­tion the­rapy in mul­ti­ple mye­loma: DSMM XI trial.  Br J Hae­ma­tol. 2017 Nov;179(4):586-597.

110.  Tsa­ma­dou C, Fürst D, Vuci­nic V, Bun­jes D, Neu­chel C, Myti­li­neos D, Gra­matzki M, Arnold R, Wag­ner EM, Ein­sele H, Mül­ler C, Schre­zen­meier H, Myti­li­neos J.  HLA-E mis­match is asso­cia­ted with bet­ter hema­to­poie­tic stem cell trans­plan­ta­tion out­come in acute leuke­mia pati­ents.  Hae­ma­to­lo­gica. 2017 Nov;102(11):1947-1955.

109.  Feiner-​Gracia N, Beck M, Pujals S, Tosi S, Man­dal T, Buske C, Lin­den M, Alber­tazzi L  Super-​Resolution Microscopy Unveils Dyna­mic Hete­ro­genei­ties in Nano­par­ticle Pro­tein Corona.  Small. 2017 Nov;13(41).

108.  Hehl­mann R, Laus­eker M, Sau­ßele S, Pfirr­mann M, Krause S, Kolb HJ, Neu­bauer A, Hoss­feld DK, Nerl C, Grat­wohl A, Baer­lo­cher GM, Heim D, Brüm­men­dorf TH, Faba­rius A, Hafer­lach C, Schle­gel­ber­ger B, Mül­ler MC, Jero­min S, Proetel U, Kohl­bren­ner K, Vos­kanyan A, Rinal­detti S, Sei­f­arth W, Spieß B, Ball­ei­sen L, Goebeler MC, Hänel M, Ho A, Deng­ler J, Falge C, Kanz L, Kre­mers S, Burchert A, Kneba M, Ste­gel­mann F, Köhne CA, Lin­de­mann HW, Wal­ler CF, Pfreund­schuh M, Spie­ker­mann K, Ber­del WE, Mül­ler L, Edin­ger M, Mayer J, Bee­len DW, Bentz M, Link H, Her­ten­stein B, Fuchs R, Wernli M, Schle­gel F, Schlag R, de Wit M, Trüm­per L, Hebart H, Hahn M, Tho­malla J, Scheid C, Schaf­hau­sen P, Ver­beek W, Eckart MJ, Gas­smann W, Pez­zutto A, Schenk M, Bross­art P, Geer T, Bildat S, Schä­fer E, Hoch­haus A, Has­ford J.  Assess­ment of ima­ti­nib as first-​line treat­ment of chro­nic mye­loid leuke­mia: 10–year sur­vi­val results of the ran­do­mi­zed CML study IV and impact of non-​CML deter­mi­nants.  Leuke­mia. 2017 Nov;31(11):2398-2406.

107.  Yal­cin A, Kovar­ba­sic M, Wehrle J, Claus R, Becker H, Abdel­ka­rim M, Gaid­zik VI, Schmidts A, Wäsch R, Pahl HL, Döh­ner K, Bul­lin­ger L, Duys­ter J, Lüb­bert M, Hack­an­son B.  The oli­go­den­dro­cyte lineage tran­scrip­tion fac­tor 2 (OLIG2) is epi­ge­ne­ti­cally regu­la­ted in acute mye­loid leuke­mia.  Exp Hema­tol. 2017 Nov;55:76-85.e3.

106.  Thiel VN, Giaimo BD, Schwarz P, Sol­ler K, Vas V, Bart­kuhn M, Blätte TJ, Döh­ner K, Bul­lin­ger L, Borgg­refe T, Gei­ger H, Oswald F.  Hete­r­odi­me­riza­tion of AML1/ETO with CBFβ is requi­red for leu­ke­mo­ge­ne­sis but not for mye­lo­pro­li­fe­ra­tion.  Leuke­mia. 2017 Nov;31(11):2491-2502.

105.  Garz AK, Wolf S, Grath S, Gaid­zik V, Habrin­ger S, Vick B, Rude­lius M, Zie­gen­hain C, Herold S, Wei­ckert MT, Smets M, Peschel C, Oos­ten­dorp RAJ, Bult­mann S, Jere­mias I, Thiede C, Döh­ner K, Kel­ler U, Götze KS.  Aza­ci­ti­dine com­bi­ned with the sel­ec­tive FLT3 kinase inhi­bi­tor cre­no­la­nib dis­rupts stromal pro­tec­tion and inhi­bits expan­sion of resi­dual leukemia-​initiating cells in <i>FLT3</i>-ITD AML with con­cur­rent epi­ge­ne­tic muta­ti­ons.  Onco­tar­get. 2017 Oct 16;8(65):108738-108759. eColl­ec­tion 2017 Dec 12.

104.  Kobitzsch B, Gök­bu­get N, Schwartz S, Rein­hardt R, Brüg­ge­mann M, Viar­dot A, Wäsch R, Starck M, Thiel E, Hoel­zer D, Bur­meis­ter T.  Loss-​of-function but not dominant-​negative intra­ge­nic IKZF1 dele­ti­ons are asso­cia­ted with an adverse pro­gno­sis in adult BCR-​ABL-negative acute lym­phob­lastic leuke­mia.  Hae­ma­to­lo­gica. 2017 Oct;102(10):1739-1747.

103.  Al-​Sawaf O, Rob­recht S, Bahlo J, Fink AM, Cra­mer P, von Tre­sc­kow J, Mau­rer C, Berg­mann M, Sei­ler T, Lange E, Kneba M, Stil­gen­bauer S, Döh­ner H, Kiehl MG, Jäger U, Wendt­ner CM, Fischer K, Goede V, Hal­lek M, Eich­horst B, Hopfin­ger G.  Impact of gen­der on out­come after che­mo­im­mu­n­o­the­rapy in pati­ents with chro­nic lym­pho­cy­tic leuke­mia: a meta-​analysis by the Ger­man CLL study group.  Leuke­mia. 2017 Oct;31(10):2251-2253.

102.  Schef­fold A, Jeba­raj BM, Jara­millo S, Tausch E, Stein­bre­cher D, Hahn M, Bött­cher S, Rit­gen M, Bun­jes D, Zeis M, Stad­ler M, Uha­rek L, Scheid C, Hegen­bart U, Hal­lek M, Kneba M, Schmitz N, Döh­ner H, Dre­ger P, Stil­gen­bauer S.  Impact of telo­mere length on the out­come of allo­gen­eic stem cell trans­plan­ta­tion for poor-​risk chro­nic lym­pho­cy­tic leu­ka­e­mia: results from the GCLLSG CLL3X trial.  Br J Hae­ma­tol. 2017 Oct;179(2):342-346. No abs­tract availa­ble.

101.  Hess M, Lenz S, Blätte TJ, Bul­lin­ger L, Bin­der H.  Par­ti­tio­ned lear­ning of deep Boltz­mann machi­nes for SNP data.  Bio­in­for­ma­tics. 2017 Oct 15;33(20):3173-3180.

100.  Tiao G, Improgo MR, Kasar S, Poh W, Kam­bu­rov A, Landau DA, Tausch E, Taylor-​Weiner A, Cibulskis C, Bahl S, Fer­nan­des SM, Hoang K, Rhein­bay E, Kim HT, Bahlo J, Rob­recht S, Fischer K, Hal­lek M, Gabriel S, Lan­der ES, Stil­gen­bauer S, Wu CJ, Kie­zun A, Getz G, Brown JR.  Rare germ­line vari­ants in ATM are asso­cia­ted with chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2017 Oct;31(10):2244-2247.

99.  Liu X, Pichu­lik T, Wolz O, Dang TM, Stutz A, Dil­len C, Del­miro Gar­cia M, Kraus H, Dick­hö­fer S, Dai­ber E, Mün­zen­mayer L, Wahl S, Rie­ber N, Kümmerle-​Deschner J, Yazdi A, Franz-​Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stil­gen­bauer S, Grim­ba­cher B, Mil­ler L, Brun­ner C, Wolz C, Weber AN.  Human NLRP3 inflam­ma­some acti­vity is regu­la­ted by and poten­ti­ally tar­ge­ta­ble via BTK.  J Allergy Clin Immu­nol. 2017 Oct;140(4):1054-1067.e10. Epub 2017 Feb 16.

98.  Neu­en­hahn M, Albrecht J, Oden­dahl M, Schlott F, Dös­sin­ger G, Schie­mann M, Laksh­mi­pa­thi S, Mar­tin K, Bun­jes D,Hars­dorf S, Weis­sin­ger EM, Men­zel H, Ver­beek M, Uha­rek L, Krö­ger N, Wag­ner E, Kobbe G, Schroe­der T, Schmitt M, Held G, Herr W, Ger­meroth L, Bonig H, Tonn T, Ein­sele H, Busch DH, Gri­go­leit GU.  Trans­fer of mini­mally mani­pu­la­ted CMV-​specific T cells from stem cell or third-​party donors to treat CMV infec­tion after alloH­SCT.  Leuke­mia. 2017 Oct;31(10):2161-2171.

97.  Fink AM, Bahlo J, Rob­recht S, Al-​Sawaf O, Aldaoud A, Hebart H, Jentsch-​Ullrich K, Dör­fel S, Fischer K, Wendt­ner CM, Nöss­lin­ger T, Ghia P, Bosch F, Kater AP, Döh­ner H, Kneba M, Kreu­zer KA, Tausch E, Stil­gen­bauer S, Rit­gen M, Bött­cher S, Eich­horst B, Hal­lek M.  Lenali­do­mide main­ten­ance after first-​line the­rapy for high-​risk chro­nic lym­pho­cy­tic leu­ka­e­mia (CLLM1): final results from a ran­do­mi­sed, double-​blind, phase 3 study.  Lan­cet Hae­ma­tol. 2017 Oct; 4(10):e475-e486. Epub 2017 Sep 12.

96.  Zenz T, Kreuz M, Fuge M, Klap­per W, Horn H, Staiger AM, Win­ter D, Hel­f­rich H, Huel­lein J, Hans­mann ML, Stein H, Fel­ler A, Möl­ler P, Schmitz N, Trüm­per L, Loeff­ler M, Sie­bert R, Rosen­wald A, Ott G, Pfreund­schuh M, Stil­gen­bauer S; Ger­man High-​Grade Non-​Hodgkin Lym­phoma Study Group (DSHNHL).  TP53 muta­tion and sur­vi­val in aggres­sive B cell lym­phoma.  Int J Can­cer. 2017 Oct 1;141(7):1381-1388.

95.  Her­zig JK,Bul­lin­ger L, Tas­do­gan A, Zim­mer­mann P, Schle­gel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dol­nik A, Schnei­der E, Kuchen­bauer F, Hei­del FH, Buske C, Döh­ner H, Döh­ner K, Gaid­zik VI.  Pro­tein phos­phatase 4 regu­la­tory sub­u­nit 2 (PPP4R2) is recurrently dele­ted in acute mye­loid leuke­mia and requi­red for effi­ci­ent DNA dou­ble strand break repair.  Onco­tar­get. 2017 Sep 21;8(56):95038-95053.

94.  Krä­mer I, Stil­gen­bauer S, Diet­rich S, Bött­cher S, Zeis M, Stad­ler M, Bit­ten­bring J, Uha­rek L, Scheid C, Hegen­bart U, Ho A, Hal­lek M, Kneba M, Schmitz N, Döh­ner H, Dre­ger P  Allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion for high-​risk CLL: 10-year follow-​up of the GCLLSG CLL3X trial.  Blood. 2017 Sep 21;130(12):1477-1480. No abs­tract availa­ble.

93.  Jawhar M, Nau­mann N, Schwaab J, Baur­mann H, Cas­per J, Dang TA, Dietze L, Döh­ner K, Hänel A, Lathan B, Link H, Lotfi S, May­wald O, Mielke S, Mül­ler L, Platz­be­cker U, Prüm­mer O, Thomssen H, Töpelt K, Panse J, Vie­ler T, Hof­mann WK, Hafer­lach T, Hafer­lach C, Faba­rius A, Hoch­haus A, Cross NCP, Rei­ter A, Metz­ge­roth G.  Ima­ti­nib in mye­loid/lym­phoid neo­plasms with eosi­no­phi­lia and rear­ran­ge­ment of PDGFRB in chro­nic or blast phase.  Ann Hema­tol. 2017 Sep;96(9):1463-1470.

92.  Xochelli A, Balia­kas P, Kava­kio­tis I, Agat­han­ge­li­dis A, Sut­ton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shana­felt TD, Ple­vova K, Boud­jo­gra M, Rossi D, Davis Z, Navarro A, Sand­berg Y, Voj­de­man FJ, Scarfò L, Stav­roy­ianni N, Suda­ri­kov A, Vero­nese S, Tzenou T, Karan Dju­ra­se­vic T, Cather­wood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Peder­sen LB, Man­souri L, Smedby KE, Chu CC, Giudi­celli V, Lefranc MP, Panagio­ti­dis P, Juli­us­son G, Ana­gnos­to­pou­los A, Vla­ha­vas I, Antic D, Tren­tin L, Mon­tillo M, Nie­mann CU, Doh­ner H, Lan­ge­rak AW, Pos­pi­si­lova S, Hal­lek M, Campo E, Chio­razzi N, Magla­ve­ras N, Oscier D, Gaidano G, Jeli­nek D, Stil­gen­bauer S, Chou­varda I, Dar­zen­tas N, Belessi C, Davi F, Had­zi­di­mi­triou A, Rosen­quist R, Ghia P, Sta­ma­to­pou­los K.  Chro­nic Lym­pho­cy­tic Leuke­mia with Muta­ted IGHV4-34 Recep­tors: Sha­red and Dis­tinct Immu­n­o­ge­netic Fea­tures and Cli­ni­cal Out­co­mes.  Clin Can­cer Res. 2017 Sep 1;23(17):5292-5301.

91.  Liu Y, Stei­nes­tel K, Rouhi A, Arm­a­cki M, Diep­old K, Chio­sis G, Sim­met T, Seuf­fer­lein T, Azoi­tei N.  STK33 par­ti­ci­pa­tes to HSP90-​supported angio­ge­nic pro­gram in hypo­xic tumors by regu­la­ting HIF-1α/VEGF signa­ling pathway.  Onco­tar­get. 2017 Aug 24;8(44):77474-77488.

90.  Schwar­zer A, Emm­rich S, Schmidt F, Beck D, Ng M, Rei­mer C, Adams FF, Gra­se­dieck S, Witte D, Käb­ler S, Wong JWH, Shah A, Huang Y, Jammal R, Maroz A, Jongen-​Lavrencic M, Scham­bach A, Kuchen­bauer F, Pimanda JE, Rein­hardt D, Heckl D, Klus­mann JH.  The non-​coding RNA land­s­cape of human hema­to­poie­sis and leuke­mia.  Nat Com­mun. 2017 Aug 9;8(1):218.

89.  Zajac M, Dol­nik A, Sta­siak G, Zale­ska J, Kiel­bus M, Cza­pin­ski J, Schunn M, Cor­rea SC, Glodkowska-​Mrowka E, Sundaram RC, Jankowska-​Lecka O, Schlenk RF, Döh­ner H, Döh­ner K, Ste­pu­lak A, Bul­lin­ger L, Gianno­pou­los K.  Ana­ly­sis of NPM1 splice vari­ants reveals dif­fe­ren­tial expres­sion pat­terns of pro­gno­stic value in acute mye­loid leuke­mia.  Onco­tar­get. 2017 Aug 3;8(56):95163-95175.

88.  Stone RM, Man­dre­kar SJ, San­ford BL, Lau­mann K, Geyer S, Bloom­field CD, Thiede C, Prior TW, Döh­ner K, Mar­cucci G, Lo-​Coco F, Klis­ovic RB, Wei A, Sierra J, Sanz MA, Brand­wein JM, de Witte T, Nie­der­wie­ser D, Appel­baum FR, Medei­ros BC, Tall­man MS, Krau­ter J, Schlenk RF, Gan­ser A, Serve H, Ehnin­ger G, Ama­dori S, Lar­son RA, Döh­ner H.  Mido­stau­rin plus Che­mo­the­rapy for Acute Mye­loid Leuke­mia with a FLT3 Muta­tion.  N Engl J Med. 2017 Aug 3;377(5):454-464

87.  Kim WS, Buske C, Ogura M, Jurczak W, San­cho JM, Zhav­rid E, Kim JS, Hernández-​Rivas JÁ, Prok­ha­rau A, Vasi­lica M, Nagar­kar R, Osma­nov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coif­fier B.  Effi­cacy, phar­ma­co­ki­ne­tics, and safety of the bio­si­mi­lar CT-P10 com­pa­red with ritu­xi­mab in pati­ents with pre­viously untrea­ted advanced-​stage fol­li­cu­lar lym­phoma: a ran­do­mi­sed, double-​blind, parallel-​group, non-​inferiority phase 3 trial.  Lan­cet Hae­ma­tol. 2017 Aug;4(8):e362-e373.

86.  Ling­scheid T, Kurth F, Cle­rinx J, Marocco S, Tre­vino B, Schunk M, Muñoz J, Gjørup IE, Jeli­nek T, Deve­loux M, Fry G, Jänisch T, Schmid ML, Bouch­aud O, Puente S, Zam­m­ar­chi L, Mørch K, Björk­man A, Siika­mäki H, Neu­mayr A, Niel­sen H, Hell­gren  U, Paul M, Cal­leri G, Kosina P, Myr­vang B, Ramos JM, Just-​Nübling G, Bel­trame A,  Saraiva da Cunha J, Kern P, Rochat L, Stich A, Pon­gratz P, Gro­busch MP, Sut­torp N, Wit­zen­rath M, Hatz C, Zol­ler T, TropNet Schis­to­so­mia­sis Inves­ti­ga­tor Group.  Schis­to­so­mia­sis in European Tra­velers and Migrants: Ana­ly­sis of 14 Years TropNet Sur­veil­lance Data.  Am J Trop Med Hyg. 2017 Aug;97(2):567-574.

85.  Cor­nely OA, Leguay T, Maer­tens J, Veh­re­s­child MJGT, Ana­gnos­to­pou­los A, Cas­ta­gnola C, Verga L, Rie­ger C, Kon­dakci M, Här­ter G, Duarte RF, Allione B, Cor­don­nier C, Heus­sel CP, Mor­ris­sey CO, Agra­wal SG, Don­nelly JP, Bres­nik M, Hawkins MJ, Gar­ner W, Gök­bu­get N; AmBi­Guard Study Group.  Ran­do­mi­zed com­pa­ri­son of lipo­so­mal ampho­te­ri­cin B ver­sus pla­cebo to pre­vent inva­sive myco­ses in acute lym­phob­lastic leu­ka­e­mia.  J Anti­mi­crob Che­mo­ther. 2017 Aug 1;72(8):2359-2367.

84.  Knop S, Lan­ger C, Engel­hardt M, Mügge LO, Reichle A, Rös­ler W, Bas­ser­mann F, Her­ten­stein B, Kunitz A, Röl­lig C, Oster­mann H, Schäfer-​Eckart K, Ring­hof­fer M, Gün­ther A, Jung­hanss C, Bier­sack H, Schre­der M, Lie­bert A, Held S, Ein­sele H, Bar­gou RC.  Lenali­do­mide, adria­my­cin, dexa­me­tha­sone (RAD) for induc­tion fol­lo­wed by stem-​cell trans­plant in newly dia­gno­sed mye­loma.  Leuke­mia. 2017 Aug;31(8):1816-1819.

83.  Rei­chen­bach F, Wie­den­mann C, Schalk E, Becker D, Funk K, Scholz-​Kreisel P, Todt F, Wol­le­schak D, Doh­ner K, Mar­quardt JU, Hei­del F, Edlich F.  Mito­chon­drial BAX deter­mi­nes the pre­dis­po­si­tion to apo­pto­sis in human AML.  Clin Can­cer Res. 2017 Aug 15;23(16):4805-4816.

82.  Roberts AW, Stil­gen­bauer S, Sey­mour JF, Huang DC.  Vene­toclax in pati­ents with pre­viously trea­ted chro­nic lym­pho­cy­tic leuke­mia.  Clin Can­cer Res. 2017 Aug 15;23(16):4527-4533.

81.  Schuh AC, Döh­ner H, Pleyer L, Sey­mour JF, Fen­aux P, Dom­bret H.  Aza­ci­ti­dine in adult pati­ents with acute mye­loid leuke­mia.  Crit Rev Oncol Hema­tol. 2017 Aug;116:159-177. Review.

80.  Laus­eker M, Has­ford J, Saus­sele S, Kre­mers S, Krae­mer D, Lin­de­mann W, Hehl­mann R, Pfirr­mann M; Ger­man CML Study Group.  Smo­kers with chro­nic mye­loid leuke­mia are at a hig­her risk of disease pro­gres­sion and pre­ma­ture death.  Can­cer. 2017 Jul 1;123(13):2467-2471.

79.  Hoch­haus A, Saus­sele S, Rosti G, Mahon FX, Jans­sen JJWM, Hjorth-​Hansen H,Rich­ter J, Buske C; ESMO Gui­de­li­nes Com­mit­tee.  Chro­nic mye­loid leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51.

78.  Moreau P, San Miguel J, Son­ne­veld P, Mateos MV, Zama­gni E, Avet-​Loiseau H, Hajek R, Dimo­pou­los MA, Lud­wig H, Ein­sele H, Zweegman S, Facon T, Cavo M, Ter­pos E, Gold­schmidt H, Attal M, Buske C; ESMO Gui­de­li­nes Com­mit­tee..  Mul­ti­ple mye­loma: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up†.  Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. No abs­tract availa­ble.

77.  Knit­tel G, Reh­käm­per T, Korov­kina D, Lied­gens P, Fritz C, Tor­gov­nick A, Al-​Baldawi Y, Al-​Maarri M, Cun Y, Fedor­chenko O, Ria­b­in­ska A, Bel­eg­gia F, Nguyen PH, Wun­der­lich FT, Ort­mann M, Montesinos-​Rongen M, Tausch E, Stil­gen­bauer S, Fren­zel L, Her­ling M, Her­ling C, Bahlo J, Hal­lek M, Pei­fer M, Buett­ner R, Per­si­gehl T, Rein­hardt HC.  Two mouse models reveal an actio­na­ble PARP1 depen­dence in aggres­sive chro­nic lym­pho­cy­tic leuke­mia.  Nat Com­mun. 2017 Jul 28;8(1):153.

76.  Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Will­mund KV, Schulz A, Warn­ken U, Sei­ler J, Ben­ner A, Ness­ling M, Zenz T, Göbel M, Dürig J, Diede­richs S, Pag­getti J, Moussay E, Stil­gen­bauer S, Zapatka M, Lich­ter P, Seif­fert M.  Tumor-​derived exo­so­mes modu­late PD-L1 expres­sion in mono­cy­tes.  Sci Immu­nol. 2017 Jul 28;2(13).

75.  Thom­sen H, Campo C, Wein­hold N, Filho MI, Pour L, Gre­gora E, Vodi­cka P, Vodick­ova L, Hoff­mann P, Nöthen MM, Jöckel KH, Lan­ger C, Hajek R, Gold­schmidt H, Hem­minki K, Försti A.  Genome-​wide asso­cia­tion study on mono­clo­nal gam­mo­pa­thy of unk­nown signi­ficance (MGUS).  Eur J Hae­ma­tol. 2017 Jul;99(1):70-79

74.  Sey­mour JF, Döh­ner H, Min­den MD, Stone R, Gam­bini D, Doug­herty D, Beach CL, Wea­ver J, Dom­bret H.  Inci­dence rates of treatment-​emergent adverse events and rela­ted hos­pi­ta­liza­tion are redu­ced with aza­ci­ti­dine com­pa­red with con­ven­tio­nal care regi­mens in older pati­ents with acute mye­loid leuke­mia.  Leuk Lym­phoma. 2017 Jun;58(6):1412-1423.

73.  Beck M, Man­dal T, Buske C, Lindén M.  Serum pro­tein adsorp­tion enhan­ces active leuke­mia stem cell tar­ge­ting of meso­porous silica nano­par­ticles.  ACS Appl Mater Inter­faces. 2017 Jun 7;9(22):18566-18574.

72.  Stö­ckel­maier L, Reno­vanz M, König J, Nickel K, Hick­mann AK, Mayer-​Steinacker R, Nadji-​Ohl M, Gans­landt O, Bul­lin­ger L, Wirtz CR, Cobur­ger J.  The­rapy for recur­rent high-​grade glio­mas: Results of a pro­spec­tive mul­ti­cen­ter study on health-​related qua­lity of life.  World Neu­ro­surg. 2017 Jun;102:383-399.

71.  Ein­sele H, Knop S, Vogel M, Mül­ler J, Kropff M, Metz­ner B, Lan­ger C, Sayer H, Jung W, Dürk HA, Sal­wen­der H, Wandt H, Bas­ser­mann F, Gra­matzki M, Rös­ler W, Wolf HH, Brug­ger W, Engel­hardt M, Fischer T, Lie­bisch P, Straka C.  Response-​adapted con­so­li­da­tion with bor­te­zo­mib after ASCT improves progression-​free sur­vi­val in newly dia­gno­sed mul­ti­ple mye­loma.  Leuke­mia. 2017 Jun;31(6):1463-1466.

70.  Krönke J, Kuchen­bauer F, Kull M, Teleanu V, Bul­lin­ger L, Bun­jes D, Grei­ner A, Kol­mus S, Köpff S, Schre­der M, Mügge LO, Straka C, Engel­hardt M, Döh­ner H, Ein­sele H, Bas­ser­mann F, Bar­gou R, Knop S, Lan­ger C.  IKZF1 expres­sion is a pro­gno­stic mar­ker in newly dia­gno­sed standard-​risk mul­ti­ple mye­loma trea­ted with lenali­do­mide and inten­sive che­mo­the­rapy: a study of the Ger­man Mye­loma Study Group (DSMM).  Leuke­mia. 2017 Jun;31(6):1363-1367.

69.  Wat­tad M, Weber D, Döh­ner K, Krau­ter J, Gaid­zik VI, Paschka P, Heu­ser M, Thol F, Kind­ler T, Lüb­bert M, Salih HR, Künd­gen A, Horst HA, Bross­art P, Götze K, Nach­baur D, Köhne CH, Ring­hof­fer M, Wulf G, Held G, Sal­wen­der H, Ben­ner A, Gan­ser A, Döh­ner H, Schlenk RF.  Impact of sal­vage regi­mens on response and over­all sur­vi­val in acute mye­loid leuke­mia with induc­tion failure.  Leuke­mia. 2017 Jun;31(6):1306-1313.

68.  Thol F, Klesse S, Köh­ler L, Gab­doul­line R, Kloos A, Lie­bich A, Wich­man M, Cha­tur­vedi A, Fabisch J, Gaid­zik VI, Paschka P, Bul­lin­ger L, Bug G, Serve H, Göh­ring G, Schle­gel­ber­ger B, Lüb­bert M, Kirch­ner H, Wat­tad M, Krae­mer D, Her­ten­stein B, Heil G, Fied­ler W, Krau­ter J, Schlenk R, Döh­ner K, Döh­ner H, Gan­ser A, Heu­ser M.  Acute mye­loid leuke­mia deri­ved from lympho-​myeloid clo­nal hema­to­poie­sis.  Leuke­mia. 2017 Jun;31(6):1286-1295.

67.  Nieborowska-​Skorska M, Sul­li­van K, Das­gupta Y, Podszywalow-​Bartnicka P, Hoser G, Mai­f­rede S, Mar­ti­nez E, Di Mar­can­to­nio D, Bolton-​Gillespie E, Cramer-​Morales K, Lee J, Li M, Slu­pia­nek A, Grit­syuk D, Cerny-​Reiterer S, Seferynska I, Sto­klosa T, Bul­lin­ger L, Zhao H, Gor­bu­n­ova V, Piwo­cka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JCY, Bha­tia S, Bha­tia R, Eppert K, Min­den MD, Sykes SM, Skor­ski T.  Gene expres­sion and mutation-​guided syn­the­tic letha­lity era­di­ca­tes pro­li­fe­ra­ting and quies­cent leuke­mia cells.  J Clin Invest. 2017 Jun 1;127(6):2392-2406.

66.  Bris­sot E, Labo­pin M, Stell­jes M, Ehnin­ger G, Schwerdt­fe­ger R, Finke J, Kolb HJ, Gan­ser A, Schäfer-​Eckart K, Zan­der AR, Bun­jes D, Mielke S, Bethge WA, Mil­pied N, Kalhs P, Blau IW, Krö­ger N, Vitek A, Gra­matzki M, Hol­ler E, Schmid C, Esteve J, Mohty M, Nag­ler A.  Com­pa­ri­son of matched sib­ling donors ver­sus unre­la­ted donors in allo­gen­eic stem cell trans­plan­ta­tion for pri­mary refrac­tory acute mye­loid leuke­mia: a study on behalf of the Acute Leuke­mia Work­ing Party of the EBMT.  J Hema­tol Oncol. 2017 Jun 24;10(1):130.

65.  Rohde M, Bonn BR, Zim­mer­mann M, Lange J, Möri­cke A, Klap­per W, Oschlies I, Szc­ze­panow­ski M, Nagel I, Schrappe M, Loeff­ler M, Sie­bert R, Rei­ter A, Burk­hardt B; ICGC-​MMML-Seq; MMML-​MYC-SYS.  Rele­vance of ID3-TCF3-CCND3 pathway muta­ti­ons in ped­ia­tric aggres­sive B-​cell lym­phoma trea­ted accor­ding to the NHL-​BFM pro­to­cols.  Hae­ma­to­lo­gica.  2017 Jun;102(6):1091-1098.

64.  Sut­ton LA, Had­zi­di­mi­triou A, Balia­kas P, Agat­han­ge­li­dis A, Lan­ge­rak AW, Stil­gen­bauer S, Pos­pi­si­lova S, Davis Z, For­coni F, Davi F, Ghia P, Rosen­quist R, Sta­ma­to­pou­los K; European Rese­arch Initia­tive on CLL (ERIC).  Immu­n­o­glo­bu­lin genes in chro­nic lym­pho­cy­tic leuke­mia: key to under­stan­ding the disease and impro­ving risk stra­ti­fi­ca­tion.  Hae­ma­to­lo­gica. 2017 Jun;102(6):968-971. No abs­tract availa­ble.

63.  Went M, Sud A, Law PJ, John­son DC, Wein­hold N, Försti A, van Duin M, Mit­chell JS, Chen B, Kui­per R, Ste­phens OW, Bertsch U, Campo C, Ein­sele H, Gre­gory WM, Hen­rion M, Hil­len­gass J, Hoff­mann P, Jack­son GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thom­sen H, Wal­ker BA, Broyl A, Davies FE, Lan­ger C, Hans­son M, Kai­ser M, Son­ne­veld P, Gold­schmidt H, Hem­minki K, Nils­son B, Mor­gan GJ, Houl­s­ton RS.  Asses­sing the effect of obesity-​related traits on mul­ti­ple mye­loma using a Men­de­lian ran­do­mi­sa­tion approach.  Blood Can­cer J. 2017 Jun 16;7(6):e573.

62.  Eden­ho­fer SA, Stil­gen­bauer S.  Chro­nic Lym­pho­cy­tic Leuke­mia With TP53 Aberra­ti­ons: Breakthroughs and Chal­lenges.  J Oncol Pract. 2017 Jun;13(6):381-382.

61.  Braulke F, Schulz X, Ger­ming U, Schuler E, Platz­be­cker U, Nolte F, Hof­mann WK, Gia­gouni­dis A, Götze K, Lüb­bert M, Schlenk RF, Schanz J, Bacher U, Gan­ser A, Büsche G, Letsch A, Schaf­hau­sen P, Bug G, Brüm­men­dorf TH, Haas R, Trüm­per L, Shir­n­es­han K, Haase D.  Peri­phe­ral blood cyto­ge­ne­tics allows treat­ment moni­to­ring and early iden­ti­fi­ca­tion of treat­ment failure to lenali­do­mide in MDS pati­ents: results of the LE-​MON-5 trial.  Ann Hema­tol. 2017 Jun;96(6):887-894.

60.  Schuler PJ, Laban S, Doe­scher J, Bul­lin­ger L, Hoff­mann TK.  Novel Treat­ment Opti­ons in Head and Neck Can­cer.  Oncol Res Treat. 2017 May 17;40(6).

59.  Jara­millo S, Ben­ner A, Krau­ter J, Mar­tin H, Kind­ler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lüb­bert M, Künd­gen A, Bross­art P, Wat­tad M, Sal­wen­der H, Her­ten­stein B, Nach­baur D, Wulf G, Horst HA, Kir­chen H, Fied­ler W, Rag­ha­va­char A, Russ G, Kre­mers S, Kol­ler E, Runde V, Heil G, Weber D, Göh­ring G, Döh­ner K, Gan­ser A, Döh­ner H, Schlenk RF.  Con­den­sed ver­sus stan­dard sche­dule of high-​dose cyt­ara­bine con­so­li­da­tion the­rapy with peg­fil­gra­stim growth fac­tor sup­port in acute mye­loid leuke­mia.  Blood Can­cer J. 2017 May 26;7(5):e564.

58.  Ricken FJ, Nell J, Grü­ner B, Schmid­ber­ger J, Kal­ten­bach T, Krat­zer W, Hil­len­brand A, Henne-​Bruns D, Depla­zes P, Mol­ler P, Kern P, Barth TFE.  Alben­dazole incre­a­ses the inflam­ma­tory response and the amount of Em2-​positive small par­ticles of Echi­no­coc­cus mul­ti­lo­cu­la­ris (spems) in human hepa­tic alveo­lar echi­no­coc­co­sis lesi­ons.  PLoS Negl Trop Dis. 2017 May 25;11(5):e0005636. eColl­ec­tion 2017 May.

57.  Jäger D, Barth TFE, Brü­der­lein S, Scheu­erle A, Rin­ner B, von Witz­le­ben A, Lechel A, Meyer P, Mayer-​Steinacker R, Baer AV, Schult­heiss M, Wirtz CR, Möl­ler P, Mel­lert K.  HOXA7, HOXA9, and HOXA10 are dif­fe­ren­ti­ally expres­sed in cli­val and sacral chor­do­mas.  Sci Rep. 2017 May 17;7(1):2032.

56.  Fischer K, Al-​Sawaf O, Fink AM, Dixon M, Bahlo J, War­bur­ton S, Kipps TJ, Wein­kove R, Robin­son S, Sei­ler T, Opat S, Owen C, López J, Hum­ph­rey K, Hume­rick­house R, Tausch E, Fren­zel L, Eich­horst B, Wendt­ner CM, Stil­gen­bauer S, Lan­ge­rak AW, van Don­gen JJ, Boett­cher S, Rit­gen M, Goede V, Mobas­her M, Hal­lek M.  Vene­toclax and obi­nu­tu­zu­mab in chro­nic lym­pho­cy­tic leuke­mia.  Blood.  2017 May 11;129(19):2702-2705.

55.  Lal R, Lind K, Heit­zer E, Ulz P, Aubell K, Kas­ho­fer K, Mid­deke JM, Thiede C, Schulz E, Rosen­ber­ger A, Hofer S, Feil­hauer B, Rin­ner B, Sven­dova V, Schimek MG, Rücker FG, Hoe­f­ler G, Döh­ner K, Zebisch A, Wöl­f­ler A, Sill H.  Soma­tic TP53 muta­ti­ons cha­rac­te­rize pre­leuke­mic stem cells in acute mye­loid leuke­mia.  Blood. 2017 May 4;129(18):2587-2591.

54.  Schlenk RF, Frech P, Weber D, Bross­art P, Horst HA, Krae­mer D, Held G, Ring­hof­fer M, Bur­chardt A, Kobbe G, Götze K, Nach­baur D, Fischer T, Lüb­bert M, Salih HR, Sal­wen­der H, Wulf G, Kol­ler E, Wat­tad M, Fied­ler W, Kre­mers S, Kir­chen H, Her­ten­stein B, Paschka P, Gaid­zik VI, Teleanu V, Heu­ser M, Thol F, Döh­ner K, Krau­ter J, Gan­ser A, Döh­ner H; and for the German-​Austrian AMLSG.  Impact of pre­treat­ment cha­rac­te­ristics and sal­vage stra­tegy on out­come in pati­ents with relap­sed acute mye­loid leuke­mia.  Leuke­mia. 2017 May;31(5):1217-1220.

53.  Loh­mann G, Vasyu­tina E, Blo­eh­dorn J, Rein­art N, Schnei­der JI, Babu V, Knit­tel G, Cris­patzu G, Mayer P, Prinz C, Muenz­ner JK, Bier­sack B, Efre­mov DG, Chessa L, Her­ling CD, Stil­gen­bauer S, Hal­lek M, Schobert R, Rein­hardt HC, Schu­ma­cher B, Her­ling M.  Tar­ge­ting transcription-​coupled nucleo­tide excision repair over­co­mes resis­tance in chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2017 May;31(5):1177-1186.

52.  Buske C, Ogura M, Kwon HC, Yoon SW.  An intro­duc­tion to bio­si­mi­lar can­cer the­ra­peu­tics: defi­ni­ti­ons, ratio­nale for deve­lo­p­ment and regu­la­tory requi­re­ments.  Future Oncol. 2017 May;13(15s):5-16.

51.  Weiß­flog G, Hönig K, Gün­del H, Lang D, Nie­der­wie­ser D, Döh­ner H, Vogel­hu­ber M, Meh­nert A, Ernst J.  Asso­cia­ti­ons bet­ween dya­dic coping and sup­por­tive care needs: fin­dings from a study with hema­to­lo­gic can­cer pati­ents and their part­ners.  Sup­port Care Can­cer. 2017 May;25(5):1445-1454.

50.  Itkin T, Kumari A, Schnei­der E, Gur-​Cohen S, Lud­wig C, Brooks R, Kol­let O, Golan K, Khatib-​Massalha E, Russo CM, Chis­holm JD, Rouhi A, Gei­ger H, Horn­stein E, Kerr WG, Kuchen­bauer F, Lapi­dot T.  MicroRNA-​155 pro­mo­tes G-​CSF-induced mobi­liza­tion of murine hema­to­poie­tic stem and pro­ge­ni­tor cells via pro­pa­ga­tion of CXCL12 signa­ling.  Leuke­mia. 2017 May;31(5):1247-1250.

49.  Mohr S, Doebele C, Como­glio F, Berg T, Beck J, Boh­nen­ber­ger H, Alexe G, Corso J, Strö­bel P, Wach­ter A, Beiss­barth T, Schnüt­gen F, Cremer A, Haet­scher N, Göll­ner S, Rouhi A, Palm­qvist L, Rie­ger MA, Schroe­der T, Bönig H, Müller-​Tidow C, Kuchen­bauer F, Schütz E, Green AR, Urlaub H, Steg­maier K, Hum­phries RK, Serve H, Oel­le­rich T.  Hoxa9 and Meis1 Coope­ra­tively Induce Addic­tion to Syk Signa­ling by Sup­pres­sing miR-146a in Acute Mye­loid Leuke­mia.  Can­cer Cell. 2017 Apr 10;31(4):549-562.e11.

48.  Hal­vars­son BM, Wihl­borg AK, Ali M, Lemo­na­kis K, Johns­son E, Niroula A, Cibulskis C, Wein­hold N, Försti A, Alici E, Lan­ger C, Pfreund­schuh M, Gold­schmidt H, Mell­qvist UH, Tures­son I, Waage A, Hem­minki K, Golub T, Nahi H, Gull­berg U, Hans­son M, Nils­son B.  Direct evi­dence for a poly­ge­nic etio­logy in fami­lial mul­ti­ple mye­loma.  Blood Adv. 2017 Apr 7;1(10):619-623. eColl­ec­tion 2017 Apr 11.

47.  Budke CM, Casulli A, Kern P, Vuit­ton DA.  Cystic and alveo­lar echi­no­coc­co­sis: Suc­ces­ses and con­ti­nuing chal­lenges.  PLoS Negl Trop Dis. 2017 Apr 20;11(4):e0005477.

46.  Brown AL, Chur­pek JE, Mal­co­vati L, Döh­ner H, God­ley LA.  Reco­gni­tion of fami­lial mye­loid neo­pla­sia in adults.  Semin Hema­tol. 2017 Apr;54(2):60-68. Epub 2017 Apr 18. Review.

45.  Schmitt M, Schmitt A, Wies­neth M, Hückel­ho­ven A, Wu Z, Kuball J, Wang L, Schau­we­cker P, Hof­mann S, Götz M, Michels B, Mac­cari B, Wuch­ter P, Eck­stein V, Mer­tens T, Schnitz­ler P, Döh­ner H, Ho AD, Bun­jes DW, Dre­ger P, Schre­zen­meier H, Grei­ner J.  Pep­tide vac­ci­na­tion in the pre­sence of adju­vants in pati­ents after hema­to­poie­tic stem cell trans­plan­ta­tion with CD4+ T cell recon­sti­tu­tion eli­cits con­sis­tent CD8+ T cell respon­ses.  The­r­a­no­stics. 2017 Apr 10;7(6):1705-1718. eColl­ec­tion 2017.

44.  Kas­subek R, Bul­lin­ger L, Kas­subek J, Drey­haupt J, Ludolph AC, Alt­haus K, Lewe­renz J.  Iden­tify­ing ischemic stroke asso­cia­ted with can­cer: a mul­ti­ple model deri­ved from a case-​control ana­ly­sis.  J Neu­rol. 2017 Apr;264(4):781-791.

43.  Schlenk RF*, Ste­gel­mann F*, Rei­ter A, Jost E, Gat­ter­mann N, Hebart H, Wal­ler C, Hoch­haus A, Platz­be­cker U, Schaf­hau­sen P, Blau IW, Ver­beek W, Hei­del FH, Wer­ner M, Kreipe H, Teleanu V, Ben­ner A, Döh­ner H, Grieß­ham­mer M, Döh­ner K, *equal con­tri­bu­tion.  Poma­li­do­mide in mye­lo­pro­li­fe­ra­tive neoplasm-​associated mye­lo­fi­bro­sis.  Leuke­mia.2017 Apr;31(4):889-895.

42.  Jahn N, Agra­wal M, Bul­lin­ger L, Weber D, Cor­ba­cio­glu A, Gaid­zik VI, Schmal­b­rock L, Thol F, Heu­ser M, Krau­ter J, Göh­ring G, Künd­gen A, Fied­ler W, Wat­tad M, Held G, Köhne CH, Horst HA, Lüb­bert M, Gan­ser A, Schlenk RF, Döh­ner H, Döh­ner K, Paschka P.  Inci­dence and pro­gno­stic impact of ASXL2 muta­ti­ons in adult acute mye­loid leuke­mia pati­ents with t(8;21)(q22;q22): A study of the German-​Austrian AML study group (AMLSG).  Leuke­mia. 2017 Apr;31(4):1012-1015.

41.  Borch­mann P, Haver­kamp H, Lohri A, Mey U, Kreissl S, Greil R, Mar­kova J, Feuring-​Buske M, Meiss­ner J, Dühr­sen U, Oster­mann H, Kel­ler U, Masch­meyer G, Kuh­nert G, Diet­lein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.  Progression-​free sur­vi­val of early inte­rim PET-​positive pati­ents with advan­ced stage Hodg­kin's lym­phoma trea­ted with BEA­COP­Pes­cala­ted alone or in com­bi­na­tion with ritu­xi­mab (HD18): an open-​label, inter­na­tio­nal, ran­do­mi­sed phase 3 study by the Ger­man Hodg­kin Study Group.  Lan­cet Oncol. 2017 Apr;18(4):454-463. Epub 2017 Feb 22.

40.  Addy F, Was­ser­mann M, Banda F, Mbaya H, Aschen­born J, Aschen­born O, Kos­kei P, Umhang G, DE LA Rue M, Elmahdi IE, Macken­stedt U, Kern P, Romig T.  Gene­tic poly­mor­phism and popu­la­tion struc­ture of Echi­no­coc­cus ortleppi.  Para­si­to­logy. 2017 Apr;144(4):450-458. Epub 2016 Dec 12.

39.  Hil­len­brand A, Grue­ner B, Krat­zer W, Kern P, Grae­ter T, Barth TF, But­ten­schoen K, Henne-​Bruns D.  Impact of Safe Dis­tance on Long-​Term Out­come After Sur­gi­cal The­rapy of Alveo­lar Echi­no­coc­co­sis.  World J Surg. 2017 Apr;41(4):1012-1018.

38.  Sal­les G, Schus­ter SJ, de Vos S, Wagner-​Johnston ND, Viar­dot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Mar­tin P, Kim Y, Shreay S, Will M, Soren­sen B, Breu­leux M, Zin­zani PL, Gopal AK.  Effi­cacy and safety of ide­la­li­sib in pati­ents with relap­sed, rituximab-​ and alky­la­ting agent-​refractory fol­li­cu­lar lym­phoma: a sub­group ana­ly­sis of a phase 2 study.  Hae­ma­to­lo­gica. 2017 Apr;102(4):e156-e159. 2016 Dec 15. No abs­tract availa­ble.

37.  Gök­bu­get N, Zug­maier G, Klin­ger M, Kufer P, Stell­jes M, Viar­dot A, Horst HA, Neu­mann S, Brüg­ge­mann M, Ott­mann OG, Bur­meis­ter T, Wes­siepe D, Topp MS, Bar­gou R.  Long-​term relapse-​free sur­vi­val in a phase 2 study of bli­na­tu­mo­mab for the treat­ment of pati­ents with mini­mal resi­dual disease in B-​lineage acute lym­phob­lastic leuke­mia.  Hae­ma­to­lo­gica. 2017 Apr;102(4):e132-e135. No abs­tract availa­ble.

36.  Fürst D, Nie­der­wie­ser D, Bun­jes D, Wag­ner EM, Gra­matzki M, Wulf G, Mül­ler CR, Neu­chel C, Tsa­ma­dou C, Schre­zen­meier H, Myti­li­neos J.  Incre­a­sed age-​associated mor­ta­lity risk in HLA-​mismatched hema­to­poie­tic stem cell trans­plan­ta­tion.  Hae­ma­to­lo­gica. 2017 Apr;102(4):796-803.

35.  Hil­ler JK, Schmoor C, Gaid­zik VI, Schmidt-​Salzmann C, Yal­cin A, Abdel­ka­rim M, Blagitko-​Dorfs N, Döh­ner K, Bul­lin­ger L, Duys­ter J, Lüb­bert M, Hack­an­son B.  Eva­lua­ting the impact of gene­tic and epi­ge­ne­tic aberra­ti­ons on sur­vi­val and response in acute mye­loid leuke­mia pati­ents recei­ving epi­ge­ne­tic the­rapy.  Ann Hema­tol. 2017 Apr;96(4):559-565.

34.  Ernst J, Hinz A, Nie­der­wie­ser D, Döh­ner H, Hönig K, Vogel­hu­ber M, Meh­nert A, Weiss­flog G  Dya­dic coping of pati­ents with hema­to­lo­gic mali­gnan­cies and their part­ners and its rela­tion to qua­lity of life - a lon­gi­tu­di­nal study.  Leuk Lym­phoma. 2017 Mar;58(3):655-665.

33.  Kha­di­v­jam B, Ste­gen C, Hogue-​Racine MA, El Bilali N, Döh­ner K, Sodeik B, Lippé R.  The ATP-​Dependent RNA Heli­case DDX3X Modu­la­tes Her­pes Sim­plex Virus 1 Gene Expres­sion.  J Virol. 2017 Mar 29;91(8).

32.  Bul­lin­ger L, Döh­ner K, Döh­ner H.  Geno­mics of Acute Mye­loid Leuke­mia Dia­gno­sis and Pathways.  J Clin Oncol. 2017 Mar 20;35(9):934-946. Epub 2017 Feb 13.

31.  Mer­tens D, Stil­gen­bauer S.  Ibrutinib-​resistant CLL: unwan­ted and unwon­ted!  Blood. 2017 Mar 16;129(11):1407-1409. No abs­tract availa­ble.

30.  Tas­do­gan A, Kumar S, Allies G, Baus­in­ger J, Beckel F, Hof­e­meis­ter H, Mulaw M, Madan V, Scharffetter-​Kochanek K, Feuring-​Buske M, Doeh­ner K, Speit G, Ste­wart AF, Feh­ling HJ.  DNA Damage-​Induced HSPC Mal­func­tion Depends on ROS Accu­mu­la­tion Down­stream of IFN-1 Signa­ling and Bid Mobi­liza­tion.  Cell Stem Cell. 2017 Mar 2;20(3):415. No abs­tract availa­ble.

29.  van Gel­der M, de Wreede LC, Born­häu­ser M, Nie­der­wie­ser D, Karas M, Ander­son NS, Gra­matzki M, Dre­ger P, Michal­let M, Peter­sen E, Bun­jes D, Pot­ter M, Bee­len D, Cor­ne­lis­sen JJ, Yakoub-​Agha I, Rus­sell NH, Finke J, Scho­e­mans H, Vitek A, Urbano-​Ispízua Á, Blaise D, Volin L, Che­val­lier P, Cabal­lero D, Put­ter H, van Bie­zen A, Hen­seler A, Schön­land S, Krö­ger N, Sche­te­lig J.  Long-​term sur­vi­val of pati­ents with CLL after allo­gen­eic trans­plan­ta­tion: a report from the European Society for Blood and Mar­row Trans­plan­ta­tion.  Bone Mar­row Trans­plant. 2017 Mar;52(3):372-380. 2016 Dec 12.

28.  Staf­fas A, Ara­ba­nian LS, Wei SY, Jans­son A, Ståhlman S, Johans­son P, Fogel­strand L, Cam­menga J, Kuchen­bauer F, Palm­qvist L.  Upre­gu­la­tion of Flt3 is a pas­sive event in Hoxa9/Meis1-​induced acute mye­loid leuke­mia in mice.  Onco­gene. 2017 Mar;36(11):1516-1524.

27.  Gers­tung M,* Papaem­ma­nuil E,* Mar­tin­corena I, Bul­lin­ger L, Gaid­zik VI, Paschka P, Heu­ser M, Thol F, Bolli N, Ganly P, Gan­ser A, McDer­mott U, Döh­ner K, Schlenk RF, Döh­ner H,* Camp­bell PJ.*  Pre­cision onco­logy for acute mye­loid leuke­mia using a know­ledge bank approach.  Nat Genet. 2017 Mar;49(3):332-340. 2017 Jan 16.  *Equal con­tri­bu­tion

26.  Schwa­meis M, Kün­dig T, Huber G, von Bid­der L, Mei­nel L, Weis­ser R, Abe­rer E, Här­ter G, Weinke T, Jeli­nek T, Fät­ken­heuer G, Wol­lina U, Bur­chard GD, Aschoff R, Nischik R, Satt­ler G, Popp G, Lotte W, Wie­chert D, Eder G, Maus O, Staubach-​Renz P, Gräfe A, Gei­gen­ber­ger V, Naudts I, Sebas­tian M, Rei­der N, Weber R, Heck­mann M, Rei­sin­ger EC, Klein G, Want­zen J, Jilma B.  Topi­cal azi­thro­my­cin for the pre­ven­tion of Lyme bor­re­lio­sis: a ran­do­mi­sed, placebo-​controlled, phase 3 effi­cacy trial.  Lan­cet Infect Dis. 2017 Mar;17(3):322-329.

25.  Zel­e­netz AD, Barri­entos JC, Brown JR, Coif­fier B, Del­gado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marl­ton P, Mon­tillo M, Morsch­hau­ser F, Pris­tupa AS, Robak T, Shar­man JP, Simpson D, Smo­lej L, Tausch E, Ade­woye AH, Drei­ling LK, Kim Y, Stil­gen­bauer S, Hill­men P.  Ide­la­li­sib or pla­cebo in com­bi­na­tion with ben­da­mus­tine and ritu­xi­mab in pati­ents with relap­sed or refrac­tory chro­nic lym­pho­cy­tic leu­ka­e­mia: inte­rim results from a phase 3, ran­do­mi­sed, double-​blind, placebo-​controlled trial.  Lan­cet Oncol. 2017 Mar;18(3):297-311.

24.  Bogen A, Buske C, Hid­de­mann W, Boh­l­an­der SK, Christ O.  Varia­ble alde­hyde dehy­dro­genase acti­vity and effects on che­mo­sen­si­ti­vity of pri­mi­tive human leuke­mic cells.  Exp Hema­tol. 2017 Mar;47:54-63.

23.  Al-​Sawaf O, Fischer K, Her­ling CD, Rit­gen M, Bött­cher S, Bahlo J, Elter T, Stil­gen­bauer S, Eich­horst BF, Busch R, Elbers­kirch U, Aben­hardt W, Kneba M, Hal­lek M, Wendt­ner CM.  Alem­tu­zu­mab con­so­li­da­tion in chro­nic lym­pho­cy­tic leu­ka­e­mia: A phase I/II mul­ti­centre trial.  Eur J Hae­ma­tol. 2017 Mar;98(3):254-262.

22.  Edel­mann J, Tausch E, Landau DA, Rob­recht S, Bahlo J, Fischer K, Fink AM, Blo­eh­dorn J, Holz­mann K, Bött­cher S, Wer­ner L, Kneba M, Grib­ben JG, Neu­berg DS, Wu CJ, Hal­lek M, Döh­ner H, Stil­gen­bauer S.  Fre­quent evo­lu­tion of copy num­ber alte­ra­ti­ons in CLL fol­lo­wing first-​line treat­ment with FC(R) is enri­ched with TP53 alte­ra­ti­ons: results from the CLL8 trial.  Leuke­mia. 2017 Mar;31(3):734-738.

21.  Kern P, Mene­zes da Silva A, Akhan O, Müll­haupt B, Vizca­y­chipi KA, Budke C, Vuit­ton DA.  The Echi­no­coc­co­ses: Dia­gno­sis, Cli­ni­cal Manage­ment and Bur­den of Disease.  Adv Para­si­tol. 2017;96:259-369.

20.  Jewell RC, Kipps TJ, Dürig J, Gris­ke­vi­cius L, Stil­gen­bauer S, Smo­lej L, Mayer J, Hess G, Hernandez-​Ilizaliturri FJ, Padmanabhan-​Iyer S, Fang L, Gold­stein N, Gor­czyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Inves­ti­ga­tors.  Asso­cia­ti­ons of ofa­tu­mu­mab exposure and treat­ment out­co­mes in pati­ents with untrea­ted CLL recei­ving che­mo­im­mu­n­o­the­rapy.  Leuk Lym­phoma. 2017 Feb;58(2):348-356.

19.  Rossi A, Voigt­la­en­der M, Jan­je­to­vic S, Thiele B, Alawi M, März M, Brandt A, Han­sen T, Rad­loff J, Schön G, Hegen­bart U, Schön­land S, Lan­ger C, Boke­meyer C, Bin­der M.  Muta­tio­nal land­s­cape reflects the bio­lo­gi­cal con­ti­nuum of plasma cell dys­cra­sias.  Blood Can­cer J. 2017 Feb 24;7(2):e537.

18.  Bohl SR, Dol­nik A, Jen­sen T, Lang KM, Hack­an­son B, Gaid­zik VI, Paschka P, Knud­sen S, Döh­ner K, Döh­ner H, Claus R, Lüb­bert M, Bul­lin­ger L.  Gene expres­sion ana­ly­sis of deci­ta­bine trea­ted AML: high impact of tumor sup­pres­sor gene expres­sion chan­ges.  Leuk Lym­phoma. 2017 Feb 13:1-4. No abs­tract availa­ble.

17.  Dimo­pou­los MA, Trot­man J, Tede­schi A, Matous JV, Mac­do­nald D, Tam C, Tour­nil­hac O, Ma S, Oriol A, Heff­ner LT, Shus­tik C, García-​Sanz R, Cor­nell RF, de Lar­rea CF, Cas­tillo JJ, Gra­nell M, Kyrt­so­nis MC, Leblond V, Symeo­ni­dis A, Kas­tri­tis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNO­VATE Study Group and the European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia..  Ibru­ti­nib for pati­ents with rituximab-​refractory Wal­den­ström's macro­glo­bu­li­nae­mia (iNNO­VATE): an open-​label sub­study of an inter­na­tio­nal, mul­ti­centre, phase 3 trial.  Lan­cet Oncol. 2017 Feb;18(2):241-250. 2016 Dec 9.

16.  Qu Y, Sig­gens L, Cor­deddu L, Gaid­zik VI, Karls­son K, Bul­lin­ger L, Döh­ner K, Ekwall K, Leh­mann S, Lenn­arts­son A  Can­cer spe­ci­fic chan­ges in DNA methy­la­tion reveal aberrant silen­cing and acti­va­tion of enhan­cers in leuke­mia.  Blood. 2017 Feb 16;129(7):e13-e25.

15.  Cha­kra­bortty S, Agra­walla BK, Stum­per A, Vegi NM, Fischer S, Rei­chardt C, Kög­ler M, Diet­zek B, Feuring-​Buske M, Buske C, Rau S, Weil T.  Mito­chon­dria Tar­ge­ted Protein-​Ruthenium Pho­to­sen­si­ti­zer for Effi­ci­ent Pho­to­dy­na­mic Appli­ca­ti­ons.  J Am Chem Soc. 2017 Feb 15;139(6):2512-2519.

14.  Schön­stei­ner S*, Bau­der Miß­bach H, Ben­ner A, Mack S, Hamel T, Orth M, Land­wehr­meyer B, Süß­muth S, Geit­ner C, Mayer‑Stein­acker R, Ries­ter A, Prok­ein A, Erhardt E, Kun­e­cki J, Eisen­schink A, Rawer R, Döh­ner H, Kirch­ner R, Schlenk RF  A ran­do­mi­zed explo­ra­tory phase 2 study in pati­ents with che­mo­the­rapy‑rela­ted peri­phe­ral neu­ro­pa­thy eva­lua­ting whole‑body vibra­tion trai­ning as adjunct to an inte­gra­ted pro­gram inclu­ding mas­sage, pas­sive mobi­liza­tion and phy­si­cal exer­cises.  Exp Hema­tol Oncol. 2017 Feb 7;6:5. eColl­ec­tion 2017.

13.  Pleyer L, Döh­ner H, Dom­bret H, Sey­mour JF, Schuh AC, Beach CL, Swern AS, Burg­stal­ler S, Stau­der R, Gir­schi­kof­sky M, Sill H, Schlick K, Tha­ler J, Hal­ter B, Mach­herndl Spandl S, Zebisch A, Pich­ler A, Pfeil­stö­cker M, Autzin­ger EM, Lang A, Geiss­ler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.  Aza­ci­ti­dine for Front-​Line The­rapy of Pati­ents with AML: Repro­du­ci­ble Effi­cacy Estab­lished by Direct Com­pa­ri­son of Inter­na­tio­nal Phase 3 Trial Data with Regis­try Data from the Aus­trian Aza­ci­ti­dine Regis­try of the AGMT Study Group.  Int J Mol Sci. 2017 Feb 15;18(2).

12.  Huber H, Eden­ho­fer S, Esten­fel­der S, Stil­gen­bauer S.  Pro­file of vene­toclax and its poten­tial in the con­text of treat­ment of relap­sed or refrac­tory chro­nic lym­pho­cy­tic leuke­mia.  Onco Tar­gets Ther. 2017 Feb 7;10:645-656. eColl­ec­tion 2017.

11.  Eder S, Labo­pin M, Finke J, Bun­jes D, Oli­vi­eri A, Sant­a­rone S, Ram­baldi A, Kanz L, Mes­sina G, Mohty M, Nag­ler A.  Safety and effi­cacy of thiotepa-​based con­di­tio­ning for allo­gen­eic trans­plan­ta­tion in AML: a sur­vey from the ALWP of the EBMT.  Bone Mar­row Trans­plant. 2017 Feb;52(2):238-244.

10.  Platz­be­cker U, Avvi­sati G, Cic­coni L, Thiede C, Pao­loni F, Vignetti M, Fer­rara F, Divona M, Albano F, Effi­cace F, Fazi P, Sbor­gia M, Di Bona E, Breccia M, Bor­lenghi E, Cai­roli R, Ram­baldi A, Melillo L, La Nasa G, Fied­ler W, Bross­art P, Her­ten­stein B, Salih HR, Wat­tad M, Lüb­bert M, Brandts CH, Hänel M, Röl­lig C, Schmitz N, Link H, Frai­ria C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cor­te­lezzi A, Fab­biano F, Döh­ner K, Gan­ser A, Döh­ner H, Ama­dori S, Man­delli F, Ehnin­ger G, Schlenk RF, Lo-​Coco F.  Impro­ved Out­co­mes With Reti­noic Acid and Arse­nic Tri­oxide Com­pa­red With Reti­noic Acid and Che­mo­the­rapy in Non-​High-Risk Acute Pro­mye­lo­cy­tic Leuke­mia: Final Results of the Ran­do­mi­zed Italian-​German APL0406 Trial.  J Clin Oncol. 2017 Feb 20;35(6):605-612.

9.  Robak T, Stil­gen­bauer S, Tede­schi A.  Front-​line treat­ment of CLL in the era of novel agents.  Can­cer Treat Rev. 2017 Feb;53:70-78. Review

8.  Dezsényi B, Strausz T, Makrai Z, Cso­mor J, Danka J, Kern P, Rezza G, Barth TF, Casulli A.  Auto­cht­ho­nous human alveo­lar echi­no­coc­co­sis in a Hun­ga­rian pati­ent.  Infec­tion. 2017 Feb;45(1):107-110.

7.  Rouhi A, Mil­ler C, Gra­se­dieck S, Rein­hart S, Stolze B, Döh­ner H, Kuchen­bauer F, Bul­lin­ger L, Fröh­ling S, Scholl C.  Pro­spec­tive iden­ti­fi­ca­tion of resis­tance mecha­nisms to HSP90 inhi­bi­tion in KRAS mutant can­cer cells.  Onco­tar­get. 2017 Jan 31;8(5):7678-7690.

6.  Kurth F, Deve­loux M, Mechain M, Malvy D, Cle­rinx J, Antinori S, Gjørup IE, Gas­con J, Mørch K, Nicastri E, Ram­har­ter M, Bar­to­loni A, Vis­ser L, Rol­ling T, Zan­ger P, Cal­leri G, Salas-​Coronas J, Niel­sen H, Just-​Nübling G, Neu­mayr A, Hach­feld A, Schmid ML, Anto­nini P, Ling­scheid T, Kern P, Kapaun A, da Cunha JS, Pon­gratz P, Soriano-​Arandes A, Schunk M, Sut­torp N, Hatz C, Zol­ler T.  Severe mala­ria in Europe: an 8-year multi-​centre obser­va­tio­nal study.  Malar J. 2017 Jan 31;16(1):57.

5.  Döh­ner H, Estey E, Grim­wade D, Ama­dori S, Appel­baum FR, Büch­ner T, Dom­bret H, Ebert BL, Fen­aux P, Lar­son RA, Levine RL, Lo-​Coco F, Naoe T, Nie­der­wie­ser D, Ossen­kop­pele GJ, Sanz M, Sierra J, Tall­man MS, Tien HF, Wei AH, Löwen­berg B, Bloom­field CD.  Dia­gno­sis and manage­ment of AML in adults: 2017 ELN recom­men­da­ti­ons from an inter­na­tio­nal expert panel.  Blood. 2017 Jan 26;129(4):424-447.

4.  Cusan M, Vegi NM, Mulaw MA, Bame­zai S, Kai­ser LM, Desh­pande AJ, Greif PA, Quintanilla-​Fend L, Göll­ner S, Müller-​Tidow C, Hum­phries KR, Arm­strong SA, Hid­de­mann W, Feuring-​Buske M, Buske C.  Con­trol­led stem cell ampli­fi­ca­tion by HOXB4 depends on its uni­que proline-​rich region near the N-​terminus.  Blood. 2017 Jan 19;129(3):319-323.

3.  Neu­chel C, Fürst D, Nie­der­wie­ser D, Bun­jes D, Tsa­ma­dou C, Wulf G, Pfreund­schuh M, Wag­ner E, Stuh­ler G, Ein­sele H, Schre­zen­meier H, Myti­li­neos J.  Impact of Donor Acti­vating KIR Genes on HSCT Out­come in C1-​Ligand Nega­tive Mye­loid Disease Pati­ents Trans­plan­ted with Unre­la­ted Donors-​A Retro­spec­tive Study.  PLoS One. 2017 Jan 20;12(1):e0169512.

2.  Buske C.  Ofa­tu­mu­mab: ano­ther way to tar­get CD20 in Wal­den­ström's macro­glo­bu­li­nae­mia?  Lan­cet Hae­ma­tol. 2017 Jan;4(1):e4-e5.

1.  Geyer HL, Kosio­rek H, Dueck AC, Scher­ber R, Slot S, Zweegman S, Te Boek­horst PA, Senyak Z, Schou­ten HC, Sack­mann F, Ker­gue­len Fuen­tes A, Hernández-​Maraver D, Pahl HL, Griess­ham­mer M, Ste­gel­mann F, Döh­ner K, Leh­mann T, Bonatz K, Rei­ter A, Boyer F, Eti­enne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Har­ri­son CN, Radia D, Muxi P, Mal­do­nado N, Bes­ses C, Cer­van­tes F, Johans­son PL, Bar­bui T, Barosi G, Van­nuc­chi AM, Paoli C, Pas­sa­monti F, Andre­as­son B, Fer­rari ML, Ram­baldi A, Samu­els­son J, Can­non K, Bir­ge­gard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kilad­jian JJ, Zhang P, Gale RP, Mesa RA.  Asso­cia­ti­ons bet­ween gen­der, disease fea­tures and sym­ptom bur­den in the MPN popu­la­tion: An ana­ly­sis by the MPN QOL Inter­na­tio­nal Work­ing Group.  Hae­ma­to­lo­gica. 2017 Jan;102(1):85-93.  1.  Hoff­mann TK, Schuler PJ, Laban S, Gräss­lin R, Beer M, Beer AJ, Friebe-​Hoffmann U, Bul­lin­ger L, Möl­ler P, Wie­gel T.  Response Eva­lua­tion in Head and Neck Onco­logy: Defi­ni­tion and Pre­dic­tion.  ORL J Otor­hi­no­la­ryn­gol Relat Spec. 2017;79(1-2):14-23.

109. Robak T, Stil­gen­bauer S, Tede­schi A. Front-​line treat­ment of CLL in the era of novel agents. Can­cer Treat Rev. 2016 Dec 30;53:70-78. Review.

108. Gent­ner E, Vegi NM, Mulaw MA, Man­dal T, Bame­zai S, Claus R, Tas­do­gan A, Quintanilla-​Martinez L, Gru­nen­berg A, Döh­ner K, Döh­ner H, Bul­lin­ger L, Hafer­lach T, Buske C, Rawat VP, Feuring-​Buske M. VENTX indu­ces expan­sion of pri­mi­tive ery­throid cells and con­tri­bu­tes to the deve­lo­p­ment of acute mye­loid leuke­mia in mice. Onco­tar­get. 2016 Dec 27;7(52):86889-86901.

107. Ng SW, Mit­chell A, Ken­nedy JA, Chen WC, McLeod J, Ibra­hi­mova N, Arruda A, Popescu A, Gupta V, Schim­mer AD, Schuh AC, Yee KW, Bul­lin­ger L, Herold T, Gör­lich D, Büch­ner T, Hid­de­mann W, Ber­del WE, Wör­mann B, Cheok M, Preud­homme C, Dom­bret H, Met­ze­ler K, Buske C, Löwen­berg B, Valk PJ, Zand­s­tra PW, Min­den MD, Dick JE, Wang JC. A 17-gene stem­ness score for rapid deter­mi­na­tion of risk in acute leu­ka­e­mia. Nature. 2016 Dec 15;540(7633):433-437. 

106. Kro­wiorz K, Rusch­mann J, Lai C, Ngom M, Maet­zig T, Mar­tins V, Schef­fold A, Schnei­der E, Pochert N, Mil­ler C, Palm­qvist L, Staf­fas A, Mulaw M, Bohl SR, Buske C, Heu­ser M, Kraus J, O'Neill K, Han­sen CL, Petriv OI, Kest­ler H, Döh­ner H, Bul­lin­ger L, Döh­ner K, Hum­phries RK, Rouhi A, Kuchen­bauer F. MiR-139-5p is a potent tumor sup­pres­sor in adult acute mye­loid leuke­mia. Blood Can­cer J. 2016 Dec 9;6(12):e508. No abs­tract availa­ble.

105. Schlenk RF. Is there justi­fi­ca­tion for 4 cycles of con­so­li­da­tion the­rapy in AML? Best Pract Res Clin Hae­ma­tol. 2016 Dec;29(4):341-344. Review.

104. Fuerst D, Neu­chel C, Nie­der­wie­ser D, Bun­jes D, Gra­matzki M, Wag­ner E, Wulf G, Glass B, Pfreund­schuh M, Ein­sele H, Arnold R, Stuh­ler G, Schaefer-​Eckart K, Frei­tag S, Cas­per J, Kauf­mann M, Wat­tad M, Her­ten­stein B, Klein S, Ring­hof­fer M, Myti­li­neos D, Tsa­ma­dou C, Muel­ler C, Schre­zen­meier H, Myti­li­neos J. Matching for the MICA-129 poly­mor­phism is bene­fi­cial in unre­la­ted hema­to­poie­tic stem cell trans­plan­ta­tion. Blood. 2016 Dec 29;128(26):3169-3176.

103. Faber ZJ, Chen X, Ged­man AL, Boggs K, Cheng J, Ma J, Rad­tke I, Chao JR, Walsh MP, Song G, Anders­son AK, Dang J, Dong L, Liu Y, Hue­ther R, Cai Z, Mul­der H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vado­da­ria B, Wang J, Hed­lund E, Cao X, Yer­geau D, Naki­tandwe J, Pounds SB, Shurtleff S, Ful­ton RS, Ful­ton LL, Eas­ton J, Par­ga­nas E, Pui CH, Rub­nitz JE, Ding L, Mar­dis ER, Wil­son RK, Gru­ber TA, Mul­lig­han CG, Schlenk RF, Paschka P, Döh­ner K, Döh­ner H, Bul­lin­ger L, Zhang J, Klco JM, Dow­ning JR. The geno­mic land­s­cape of core-​binding fac­tor acute mye­loid leuke­mias. Nat Genet. 2016 Dec;48(12):1551-1556.  

102. Tas­do­gan A, Kumar S, Allies G, Baus­in­ger J, Beckel F, Hof­e­meis­ter H, Mulaw M, Madan V, Scharfetter-​Kochanek K, Feuring-​Buske M, Doeh­ner K, Speit G, Ste­wart AF, Feh­ling HJ. DNA Damage-​Induced HSPC Mal­func­tion Depends on ROS Accu­mu­la­tion Down­stream of IFN-1 Signa­ling and Bid Mobi­liza­tion. Cell Stem Cell. 2016 Dec 1;19(6):752-767.

101. Ladetto M, Buske C, Hut­chings M, Drey­ling M, Gaidano G, Le Gouill S, Lumi­nari S, Pott C, Zamò A, Zucca E; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers. ESMO con­sen­sus con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for pro­gno­stic tools in mature B-​cell lym­pho­mas and chro­nic lym­pho­cy­tic leu­ka­e­mia. Ann Oncol. 2016 Dec;27(12):2149-2160.

100. von Witz­le­ben A, Goertt­ler LT, Len­n­erz J, Weis­sin­ger S, Korn­mann M, Mayer-​Steinacker R, von Baer A, Schult­heiss M, Möl­ler P, Barth TF. In chor­doma, metasta­sis, recur­ren­ces, Ki-67 index, and a matrix-​poor phe­no­type are asso­cia­ted with pati­ents' shorter over­all sur­vi­val. Eur Spine J. 2016 Dec;25(12):4016-4024. Epub 2015 Sep 23.

99. Schnei­der E, Staf­fas A, Röh­ner L, Kro­wiorz K, Heu­ser M, Döh­ner K, Bul­lin­ger L, Döh­ner H, Fogel­strand L, Rouhi A,Kuchen­bauer F, Palm­qvist L. MicroRNA-​155 is upre­gu­la­ted in MLL rear­ran­ged AML but its absence does not affect leuke­mia deve­lo­p­ment. Exp Hema­tol. 2016 Dec;44(12):1166-1171. Epub 2016 Sep 13.

98. Kharfan-​Dabaja MA, Kumar A, Hama­dani M, Stil­gen­bauer S, Ghia P, Ana­setti C, Dre­ger P, Monts­er­rat E, Pera­les MA, Alyea EP, Awan FT, Ayala E, Barri­entos JC, Brown JR, Cas­tro J, Fur­man RR, Grib­ben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pav­le­tic SZ, Pinilla-​Ibarz J, Reddy NM, Sor­ror M, Bre­de­son C, Car­pen­ter P, Savani BN. Cli­ni­cal Prac­tice Recom­men­da­ti­ons for Use of Allo­gen­eic Hema­to­poie­tic Cell Trans­plan­ta­tion in Chro­nic Lym­pho­cy­tic Leuke­mia on Behalf of the Gui­de­li­nes Com­mit­tee of the Ame­ri­can Society for Blood and Mar­row Trans­plan­ta­tion. Biol Blood Mar­row Trans­plant. 2016 Dec;22(12):2117-2125.

97. Schlenk RF, Lüb­bert M, Ben­ner A, Lam­par­ter A, Krau­ter J, Herr W, Mar­tin H, Salih HR, Künd­gen A, Horst HA, Bross­art P, Götze K, Nach­baur D, Wat­tad M, Köhne CH, Fied­ler W, Bentz M, Wulf G, Held G, Her­ten­stein B, Sal­wen­der H, Gaid­zik V, Schle­gel­ber­ger B, Weber D, Döh­ner K, Gan­ser A, Döh­ner H; German-​Austrian Acute Mye­loid Leuke­mia Study Group. All-​trans reti­noic acid as adjunct to inten­sive treat­ment in youn­ger adult pati­ents with acute mye­loid leuke­mia: results of the ran­do­mi­zed AMLSG 07-04 study. Ann Hema­tol. 2016 Dec; 95(12):1931:1942.

96. Shi­moni A, Labo­pin M, Savani B, Volin L, Ehnin­ger G, Kuball J, Bun­jes D, Schaap N, Vigou­roux S, Baci­ga­lupo A, Veel­ken H, Sierra J, Eder M, Nie­der­wie­ser D, Mohty M, Nag­ler A. Long-​term sur­vi­val and late events after allo­gen­eic stem cell trans­plan­ta­tion from HLA-​matched sib­lings for acute mye­loid leuke­mia with myelo­ab­la­tive com­pa­red to reduced-​intensity con­di­tio­ning: a report on behalf of the acute leuke­mia work­ing party of European group for blood and mar­row trans­plan­ta­tion.  J Hema­tol Oncol. 2016 Nov 8;9(1):118.

95. Krat­zer W, Grue­ner B, Kal­ten­bach TE, Ansari-​Bitzenberger S, Kern P, Fuchs M, Mason RA, Barth TF, Haenle MM, Hil­len­brand A, Oez­tu­erk S, Grae­ter T. Pro­po­sal of an ultra­so­no­gra­phic clas­si­fi­ca­tion for hepa­tic alveo­lar echi­no­coc­co­sis: Echi­no­coc­co­sis mul­ti­lo­cu­la­ris Ulm classification-​ultrasound. World J Gas­tro­en­te­rol. 2015 Nov 21;21(43):12392-402.

94. Bul­lin­ger L. T-​lymphoid pro­ge­ni­tors - we know what they are, but know not what they may be. EMBO J. 2016 Nov 15;35(22):2383-2385.

93. Straka C, Lie­bisch P, Sal­wen­der H, Hen­ne­mann B, Metz­ner B, Knop S, Adler-​Reichel S, Ger­ecke C, Wandt H, Bentz M, Bru­em­men­dorf TH, Hen­trich M, Pfreund­schuh M, Wolf HH, Sezer O, Bar­gou R, Jung W, Trüm­per L, Her­ten­stein B, Hei­de­mann E, Bern­hard H, Lang N, Frick­hofen N, Hebart H, Schmid­maier R, San­der­mann A, Dechow T, Reichle A, Schna­bel B, Schäfer-​Eckart K, Lan­ger C, Gra­matzki M, Hinke A, Emme­rich B, Ein­sele H; DSMM (Deut­sche Stu­di­en­gruppe Mul­ti­ples Mye­lom). Auto­trans­plant with and wit­hout induc­tion che­mo­the­rapy in older mul­ti­ple mye­loma pati­ents: long-​term out­come of a ran­do­mi­zed trial. Hae­ma­to­lo­gica. 2016 Nov;101(11):1398-1406.

92. Shi­va­rov V, Dol­nik A, Lang KM, Krönke J, Kuchen­bauer F, Paschka P, Gaid­zik VI, Döh­ner H, Schlenk RF, Döh­ner K, Bul­lin­ger L. MicroRNA expres­sion based out­come pre­dic­tion in acute mye­loid leuke­mia - novel insights through cross-​platform inte­gra­tive ana­ly­ses. Hae­ma­to­lo­gica. 2016 Nov;101(11):e454-e456. Epub 2016 Jul 28.

91. Heza­veh K, Klo­et­gen A, Bern­hart SH, Maha­pa­tra KD, Lenze D, Rich­ter J, Haake A, Berg­mann AK, Brors B, Burk­hardt B, Cla­viez A, Drex­ler HG, Eils R, Haas S, Hoff­mann S, Karsch D, Klap­per W, Kleinheinz K, Kor­bel J, Kretz­mer H, Kreuz M, Küp­pers R, Lawe­renz C, Leich E, Loeff­ler M, Mantovani-​Loeffler L, López C, McHardy AC, Möl­ler P, Rohde M, Rosen­stiel P, Rosen­wald A, Schil­ha­bel M, Schles­ner M, Scholz I, Stad­ler PF, Stil­gen­bauer S, Sun­ga­lee S, Szc­ze­panow­ski M, Trüm­per L, Weni­ger MA, Sie­bert R, Bork­hardt A, Hum­mel M, Hoell JI. Alte­ra­ti­ons of miRNAs and miRNA-​regulated mRNA expres­sion in GC B cell lym­pho­mas deter­mi­ned by inte­gra­tive sequen­cing ana­ly­sis. Hae­ma­to­lo­gica. 2016 Nov;101(11):1380-1389. Epub 2016 Jul 6.

90. Theis F, Cor­ba­cio­glu A, Gaid­zik VI, Paschka P, Weber D, Bul­lin­ger L, Heu­ser M, Gan­ser A, Thol F, Schle­gel­ber­ger B, Göh­ring G, Köhne CH, Ger­ming U, Bross­art P, Horst HA, Haase D, Götze K, Ring­hof­fer M, Fied­ler W, Nach­baur D, Kind­ler T, Held G, Lüb­bert M, Wat­tad M, Salih HR, Krau­ter J, Döh­ner H, Schlenk RF, Döh­ner K. Cli­ni­cal impact of GATA2 muta­ti­ons in acute mye­loid leuke­mia pati­ents har­bo­ring CEBPA muta­ti­ons: A study of the AML study group (AMLSG). Leuke­mia. 2016 Nov;30(11):2248-2250. Epub 2016 Jul 4.

89. Par­ker H, Rose-​Zerilli MJ, Lar­rayoz M, Clif­ford R, Edel­mann J, Blakemore S, Gib­son J, Wang J, Ljung­ström V, Woj­dacz TK, Chap­lin T, Rogha­nian A, Davis Z, Par­ker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Also­l­ami R, Steele AJ, Pack­ham G, Rodríguez-​Vicente AE, Brown L, McNi­choll F, For­coni F, Pet­titt A, Hill­men P, Dyer M, Cragg MS, Che­lala C, Oakes CC, Rosen­quist R, Sta­ma­to­pou­los K, Stil­gen­bauer S, Knight S, Schuh A, Oscier DG, Stref­ford JC. Geno­mic dis­rup­tion of the his­tone methyl­trans­fer­ase SETD2 in chro­nic lym­pho­cy­tic leu­ka­e­mia. Leuke­mia. 2016 Nov;30(11):2179-2186. Epub 2016 May 20.

88. Gaid­zik VI, Teleanu V, Papaem­ma­nuil E, Weber D, Paschka P, Hahn J, Wall­ra­ben­stein T, Kol­bin­ger B, Köhne CH, Horst HA, Bross­art P, Held G, Künd­gen A, Ring­hof­fer M, Götze K, Rum­mel M, Gers­tung M, Camp­bell P, Kraus JM, Kest­ler HA, Thol F, Heu­ser M, Schle­gel­ber­ger B, Gan­ser A, Bul­lin­ger L, Schlenk RF, Döh­ner K, Döh­ner H. RUNX1 muta­ti­ons in acute mye­loid leuke­mia are asso­cia­ted with dis­tinct clinico-​pathologic and gene­tic fea­tures. Leuke­mia. 2016 Nov;30(11):2160-2168. Epub 2016 May 3.

87. Sey­mour JF, Döh­ner H, Min­den MD, Stone R, Gam­bini D, Doug­herty D, Beach CL, Wea­ver J, Dom­bret H. Inci­dence rates of treatment-​emergent adverse events and rela­ted hos­pi­ta­liza­tion are redu­ced with aza­ci­ti­dine com­pa­red with con­ven­tio­nal care regi­mens in older pati­ents with acute mye­loid leuke­mia. Leuk Lym­phoma. 2016 Oct 14:1-12.

86. Laza­rian G, Tausch E, Ecla­che V, Sebaa A, Bian­chi V, Letestu R, Col­lon JF, Lefeb­vre V, Gar­dano L, Varin-​Blank N, Soussi T, Stil­gen­bauer S, Cym­ba­lista F, Baran-​Marszak F. TP53 muta­ti­ons are early events in chro­nic lym­pho­cy­tic leuke­mia disease pro­gres­sion and pre­cede evo­lu­tion to com­plex karyo­ty­pes. Int J Can­cer. 2016 Oct 15;139(8):1759-63.

85. Goede V, Bahlo J, Chata­line V, Eich­horst B, Dürig J, Stil­gen­bauer S, Kolb G, Hon­ecker F, Wed­ding U, Hal­lek M. Eva­lua­tion of ger­ia­tric assess­ment in pati­ents with chro­nic lym­pho­cy­tic leuke­mia: Results of the CLL9 trial of the Ger­man CLL study group. Leuk Lym­phoma. 2016;57(4):789-96.

84. Goede V, Busch R, Bahlo J, Chata­line V, Kre­mers S, Mül­ler L, Reschke D, Schlag R, Schmidt B, Vehling-​Kaiser U, Wed­ding U, Stil­gen­bauer S, Hal­lek M. Low-​dose fludar­a­bine with or wit­hout dar­be­poe­tin alfa in pati­ents with chro­nic lym­pho­cy­tic leuke­mia and comor­bi­dity: pri­mary results of the CLL9 trial of the Ger­man CLL Study Group.. Leuk Lym­phoma. 2016;57(3):596-603. 

83. Wal­li­ser C, Herm­kes E, Schade A, Wiese S, Dein­zer J, Zapatka M, D Eacu­te­sir Eacute L, Mer­tens D, Stil­gen­bauer S, Gier­schik P. The Phos­pho­li­pase C-γ2 Mutants R665W and L845F Iden­ti­fied in Ibrutinib-​Resistant Chro­nic Lym­pho­cy­tic Leuke­mia Pati­ents are Hyper­sen­si­tive to the Rho GTPase Rac2. J Biol Chem. 2016 Oct 14;291(42):22136-22148. Epub 2016 Aug 19.

82. O'Brien S, Jones JA, Coutre SE, Mato AR, Hill­men P, Tam C, Öster­borg A, Sid­diqi T, Thir­man MJ, Fur­man RR, Ilhan O, Kea­ting MJ, Call TG, Brown JR, Stevens-​Brogan M, Li Y, Clow F, James DF, Chu AD, Hal­lek M, Stil­gen­bauer S. Ibru­ti­nib for pati­ents with relap­sed or refrac­tory chro­nic lym­pho­cy­tic leu­ka­e­mia with 17p dele­tion (RESONATE-​17): a phase 2, open-​label, mul­ti­centre study. Lan­cet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13.

81. Mau­rer C, Lan­ger­beins P, Bahlo J, Cra­mer P, Fink AM, Pflug N, Engelke A, von Tre­sc­kow J, Kovacs G, Stil­gen­bauer S, Wendt­ner CM, Mül­ler L, Rit­gen M, Sei­ler T, Fischer K, Hal­lek M, Eich­horst B. Effect of first-​line treat­ment on second pri­mary mali­gnan­cies and Rich­ter's trans­for­ma­tion in pati­ents with chro­nic lym­pho­cy­tic leuke­mia (CLL). Leuke­mia. 2016 Oct;30(10):2019-2025. Epub 2016 May 2.

80. Sobh M, Michal­let M, Gahr­ton G, Iaco­belli S, van Bie­zen A, Schön­land S, Peter­sen E, Schaap N, Boni­fazi F, Volin L, Mei­jer E, Nie­der­wie­ser D, El-​Cheikh J, Tabrizi R, Fegeux N, Finke J, Bun­jes D, Cor­ne­lis­sen J, Ein­sele H, Bruno B, Pot­ter M, Fanin R, Mohty M, Gar­de­ret L, Krö­ger N. Allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion for mul­ti­ple mye­loma in Europe: Trends and out­co­mes over 25 years. A study by the EBMT CMWP. Leuke­mia. 2016 Oct;30(10):2047-2054. Epub 2016 Apr 27.

79. Deol A, Seng­s­aya­deth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Bat­ti­walla M, Born­hau­ser M, Cahn JY, Camitta B, Chen YB, Cut­ler CS, Gale RP, Gang­uly S, Hama­dani M, Ina­moto Y, Jagasia M, Kam­ble R, Kor­eth J, Laza­rus HM, Lies­veld J, Lit­zow MR, Marks DI, Nis­hi­hori T, Ols­son RF, Res­hef R, Rowe JM, Saad AA, Sabloff M, Schou­ten HC, Shea TC, Soif­fer RJ, Uy GL, Wal­ler EK, Wier­nik PH, Wirk B, Wool­frey AE, Bun­jes D, Devine S, de Lima M, Sand­maier BM, Weis­dorf D, Khoury HJ, Saber W. Does FLT3 muta­tion impact sur­vi­val after hema­to­poie­tic stem cell trans­plan­ta­tion for acute mye­loid leuke­mia? A Cen­ter for Inter­na­tio­nal Blood and Mar­row Trans­plant Rese­arch (CIB­MTR) ana­ly­sis. Can­cer. 2016 Oct;122(19):3005-14.

78. Eich­horst B, Robak T, Monts­er­rat E, Ghia P, Hill­men P, Hal­lek M, Buske C; ESMO Gui­de­li­nes Com­mit­tee. appen­dix 6: Chro­nic lym­pho­cy­tic leu­ka­e­mia: eUp­date published online Sep­tem­ber 2016 (http://www.esmo.org/Gui­de­li­nes/Haematological-​Malignancies)Ann Oncol. 2016 Sep;27(suppl 5):v143-v144. No abs­tract availa­ble.

77. Hoel­zer D, Bassan R, Dom­bret H, Fiel­ding A, Ribera JM, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Acute lym­phob­lastic leu­ka­e­mia in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2016 Sep;27(suppl 5):v69-v82. 

76. Leblond V, Kas­tri­tis E, Advani R, Ansell SM, Buske C, Cas­tillo JJ, García-​Sanz R, Gertz M, Kimby E, Kyria­kou C, Mer­lini G, Min­nema MC, Morel P, Morra E, Rum­mel M, Wecha­le­kar A, Pat­ter­son CJ, Treon SP, Dimo­pou­los MA. Treat­ment recom­men­da­ti­ons for Wal­den­ström macro­glo­bu­li­ne­mia from the Eighth Inter­na­tio­nal Work­shop on WM. Blood. 2016 Sep 8;128(10):1321-8.

75. Papaem­ma­nuil E, Döh­ner H, Camp­bell PJ. Geno­mic Clas­si­fi­ca­tion in Acute Mye­loid Leuke­mia. N Engl J Med. 2016 Sep 1;375(9):900-1. No abs­tract availa­ble.

74. Moss­ner M, Jann JC, Nowak D, Platz­be­cker U, Gia­gouni­dis A, Götze K, Letsch A, Haase D, Shir­n­es­han K, Braulke F, Schlenk RF, Hafer­lach T, Schaf­hau­sen P, Bug G, Lüb­bert M, Gan­ser A, Büsche G, Schuler E, Nowak V, Press­ler J, Oblän­der J, Fey S, Mül­ler N, Lauinger-​Lörsch E, Metz­ge­roth G, Weiß C, Hof­mann W, Ger­ming U, Nolte F. Pre­va­lence, clo­nal dyna­mics and cli­ni­cal impact of TP53 muta­ti­ons in pati­ents with mye­lo­dys­plastic syn­drome with iso­la­ted dele­tion (5q) trea­ted with lenali­do­mide: Results from a pro­spec­tive multi-​center study of the Ger­man MDS study group (GMDS). Leuke­mia. 2016 Sep;30(9):1956-9.

73. Schmitt T, Mayer-​Steinacker R, Mayer F, Grün­wald V, Schütte J, Hart­mann JT, Kas­per B, Hüs­ing J, Hajda J, Ottawa G, Mech­ters­hei­mer G, Mikus G, Bur­henne J, Leh­mann L, Hei­lig CE, Ho AD, Ege­rer G. Vor­i­no­stat in refrac­tory soft tis­sue sar­co­mas - Results of a multi-​centre phase II trial of the Ger­man Soft Tis­sue Sar­coma and Bone Tumour Work­ing Group (AIO). Eur J Can­cer. 2016 Sep;64:74-82.

72. Was­ser­mann M, Wol­deyes D, Gerbi BM, Ebi D, Zeyhle E, Macken­stedt U, Petros B, Tila­hun G, Kern P, Romig T. A novel zoo­no­tic geno­type rela­ted to Echi­no­coc­cus gra­nu­lo­sus sensu stricto from southern Ethio­pia. Int J Para­si­tol. 2016 Sep;46(10):663-8.

71. Mau­rer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cra­mer P, Gross-​Ophoff C, Lan­ger­beins P, Fink AM, Eich­horst B, Kreu­zer KA, Fischer N, Tausch E, Stil­gen­bauer S, Bött­cher S, Döh­ner H, Kneba M, Drey­ling M, Bin­der M, Hal­lek M, Wendt­ner CM, Berg­mann M, Fischer K; Ger­man CLL Study Group. Ben­da­mus­tine and Ritu­xi­mab in Com­bi­na­tion with Lenali­do­mide in Pati­ents with Chro­nic Lym­pho­cy­tic Leuke­mia. Eur J Hae­ma­tol. 2016 Sep;97(3):253-60.

70. Lueck SC, Russ AC, Bot­zen­hardt U, Schlenk RF, Zobel K, Des­hayes K, Vucic D, Döh­ner H, Döh­ner K, Fulda S, Bul­lin­ger L. Smac mime­tic indu­ces cell death in a large pro­por­tion of pri­mary acute mye­loid leuke­mia samp­les, which cor­re­la­tes with defi­ned mole­cu­lar mar­kers. Onco­tar­get. 2016 Aug 2;7(31):49539-49551. 

69. Hieke S, Ben­ner A, Schlenk RF, Schu­ma­cher M, Bul­lin­ger L, Bin­der H. Inte­gra­ting mul­ti­ple mole­cu­lar sources into a cli­ni­cal risk pre­dic­tion signa­ture by extra­c­ting com­ple­men­tary infor­ma­tion. BMC Bio­in­for­ma­tics. 2016 Aug 30;17(1):327.

68. Meyer-​Pannwitt V, Stein­bre­cher D, Stil­gen­bauer S, Mer­tens D. Rapid detec­tion of ATM/p53 func­tion with p27Kip FACS ana­ly­sis: a novel dia­gno­stic tool for chro­nic lym­po­cy­tic leuke­mia? Leuk Lym­phoma. 2016 Aug 22:1-2. No abs­tract availa­ble.

67. Schef­fold A, Holt­man IR, Dieni S, Brou­wer N, Katz SF, Jeba­raj BM, Kahle PJ, Hen­ge­rer B, Lechel A, Stil­gen­bauer S, Bod­deke EW, Eggen BJ, Rudolph KL, Biber K. Telo­mere shor­tening leads to an acce­le­ra­tion of synucleinopa­thy and impai­red micro­glia response in a gene­tic mouse model. Acta Neu­ro­pa­thol Com­mun. 2016 Aug 22;4(1):87.

66. Palumbo A, Chanan-​Khan A, Wei­sel K, Nooka AK, Masszi T, Bek­sac M, Spi­cka I, Hungria V, Mun­der M, Mateos MV, Mark TM, Qi M, Schec­ter J, Amin H, Qin X, Dera­edt W, Ahmadi T, Spen­cer A, Son­ne­veld P; CAS­TOR Inves­ti­ga­tors. Col­la­bo­ra­tors: [...] Lan­ger C ...Dara­tu­mu­mab, Bor­te­zo­mib, and Dexa­me­tha­sone for Mul­ti­ple Mye­loma. N Engl J Med. 2016 Aug 25;375(8):754-66.

65. Louise Free­man C, Dixon M, Hough­ton R, Kreu­zer KA, Fingerle-​Rowson G, Her­ling M, Hum­ph­rey K, Bött­cher S, de Costa CS, Igle­sias V, Stil­gen­bauer S, Grib­ben J, Hal­lek M, Goede V. Role of CD20 expres­sion and other pre-​treatment risk fac­tors in the deve­lo­p­ment of infusion-​related reac­tions in pati­ents with CLL trea­ted with obi­nu­tu­zu­mab. Leuke­mia. 2016 Aug;30(8):1763-6.

64. Daria D, Kirs­ten N, Muranyi A, Mulaw M, Ihme S, Kech­ter A, Bul­lin­ger L, Döh­ner K, Döh­ner H, Feuring-​Buske M, Buske C. GPR56 con­tri­bu­tes to the deve­lo­p­ment of acute mye­loid leuke­mia in mice. Leuke­mia. 2016 Aug;30(8):1734-41.

63. Iller­haus G, Kasenda B, Ihorst G, Ege­rer G, Lam­precht M, Kel­ler U, Wolf HH, Hirt C, Stil­gen­bauer S, Bin­der M, Hau P, Edin­ger M, Frick­hofen N, Bentz M, Möhle R, Röth A, Pfreund­schuh M, von Baum­gar­ten L, Deckert M, Hader C, Fri­cker H, Valk E, Schorb E, Frit­sch K, Finke J. High-​dose che­mo­the­rapy with auto­lo­gous hae­mo­poie­tic stem cell trans­plan­ta­tion for newly dia­gno­sed pri­mary CNS lym­phoma: a pro­spec­tive, single-​arm, phase 2 trial. Lan­cet Hae­ma­tol. 2016 Aug;3(8):e388-97.

62. Her­mine O, Hos­ter E, Walew­ski J, Bosly A, Stil­gen­bauer S, Thieb­le­mont C, Szymczyk M, Bou­ab­dal­lah R, Kneba M, Hal­lek M, Sal­les G, Feu­gier P, Ribrag V, Birk­mann J, Forst­point­ner R, Haioun C, Hänel M, Casas­no­vas RO, Finke J, Peter N, Bou­ab­dal­lah K, Seb­ban C, Fischer T, Dühr­sen U, Metz­ner B, Masch­meyer G, Kanz L, Schmidt C, Dela­rue R, Brousse N, Klap­per W, Mac­in­tyre E, Delfau-​Larue MH, Pott C, Hid­de­mann W, Unter­halt M, Drey­ling M; European Man­tle Cell Lym­phoma Net­work. Addi­tion of high-​dose cyt­ara­bine to immu­n­o­chemo­the­rapy before auto­lo­gous stem-​cell trans­plan­ta­tion in pati­ents aged 65 years or youn­ger with man­tle cell lym­phoma (MCL Youn­ger): a ran­do­mi­sed, open-​label, phase 3 trial of the European Man­tle Cell Lym­phoma Net­work. Lan­cet. 2016 Aug 6;388(10044):565-75. Epub 2016 Jun 14.

61. Li S, Garrett-​Bakelman FE, Chung SS, San­ders MA, Hri­cik T, Rapa­port F, Patel J, Dil­lon R, Vijay P, Brown AL, Perl AE, Can­non J, Bul­lin­ger L, Luger S, Becker M, Lewis ID, To LB, Del­wel R, Löwen­berg B, Döh­ner H, Döh­ner K, Guz­man ML, Hassane DC, Roboz GJ, Grim­wade D, Valk PJ, D'Andrea RJ, Car­roll M, Park CY, Neu­berg D, Levine R, Mel­nick AM, Mason CE. Dis­tinct evo­lu­tion and dyna­mics of epi­ge­ne­tic and gene­tic hete­ro­gen­eity in acute mye­loid leuke­mia. Nat Med. 2016 Jul;22(7):792-9.

60. Eich­ner R, Hei­der M, Fernández-​Sáiz V, van Beb­ber F, Garz AK, Lemeer S, Rude­lius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platz­be­cker U, Ger­ming U, Lan­ger C, Knop S, Ein­sele H, Peschel C, Haass C, Kel­ler U, Schmid B, Götze KS, Kus­ter B, Bas­ser­mann F. Immu­n­o­mo­du­la­tory drugs dis­rupt the cereblon-​CD147-MCT1 axis to exert anti­tu­mor acti­vity and tera­to­ge­ni­city. Nat Med. 2016 Jul;22(7):735-43.

59. Jewell RC, Kipps TJ, Dürig J, Gris­ke­vi­cius L, Stil­gen­bauer S, Smo­lej L, Mayer J, Hess G, Hernandez-​Ilizaliturri FJ, Padmanabhan-​Iyer S, Fang L, Gold­stein N, Gor­czyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Inves­ti­ga­tors. Asso­cia­ti­ons of ofa­tu­mu­mab exposure and treat­ment out­co­mes in pati­ents with untrea­ted CLL recei­ving che­mo­im­mu­n­o­the­rapy. Leuk Lym­phoma. 2016 Jul 7:1-9.

58. Mit­chell JS, Li N, Wein­hold N, Försti A, Ali M, van Duin M, Thor­leifs­son G, John­son DC, Chen B, Hal­vars­son BM, Gudb­jarts­son DF, Kui­per R, Ste­phens OW, Bertsch U, Bro­de­rick P, Campo C, Ein­sele H, Gre­gory WA, Gull­berg U, Hen­rion M, Hil­len­gass J, Hoff­mann P, Jack­son GH, Johns­son E, Jöud M, Kris­tins­son SY, Len­hoff S, Lenive O, Mell­qvist UH, Miglio­rini G, Nahi H, Nelan­der S, Nickel J, Nöthen MM, Raf­nar T, Ross FM, da Silva Filho MI, Swa­mi­na­than B, Thom­sen H, Tures­son I, Vangs­ted A, Vogel U, Waage A, Wal­ker BA, Wihl­borg AK, Broyl A, Davies FE, Thor­steins­dot­tir U, Lan­ger C, Hans­son M, Kai­ser M, Son­ne­veld P, Ste­fans­son K, Mor­gan GJ, Gold­schmidt H, Hem­minki K, Nils­son B, Houl­s­ton RS. Genome-​wide asso­cia­tion study iden­ti­fies mul­ti­ple suscep­ti­bi­lity loci for mul­ti­ple mye­loma. Nat Com­mun. 2016 Jul 1;7:12050.

57. Skorka K, Zale­ska J, Zajac M, Kar­cz­mar­czyk A, Tomczak W, Wla­siuk P, Kowal M, Goetz M, Grei­ner J, Schmitt M, Gianno­pou­los K. Indi­rect induc­tion of regu­la­tory T cells accom­pa­nies immune respon­ses during pep­tide vac­ci­na­tion of chro­nic lym­pho­cy­tic leu­ka­e­mia pati­ents. Br J Hae­ma­tol. 2016 Jul;174(1):155-7.

56. Eich­horst B, Fink AM, Bahlo J, Busch R, Kovacs G, Mau­rer C, Lange E, Köp­p­ler H, Kiehl M, Sök­ler M, Schlag R, Vehling-​Kaiser U, Köch­ling G, Plö­ger C, Gre­gor M, Ples­ner T, Trneny M, Fischer K, Döh­ner H, Kneba M, Wendt­ner CM, Klap­per W, Kreu­zer KA, Stil­gen­bauer S, Bött­cher S, Hal­lek M; inter­na­tio­nal group of inves­ti­ga­tors; Ger­man CLL Study Group (GCLLSG). First-​line che­mo­im­mu­n­o­the­rapy with ben­da­mus­tine and ritu­xi­mab ver­sus fludar­a­bine, cyclo­phos­pha­mide, and ritu­xi­mab in pati­ents with advan­ced chro­nic lym­pho­cy­tic leu­ka­e­mia (CLL10): an inter­na­tio­nal, open-​label, ran­do­mi­sed, phase 3, non-​inferiority trial. Lan­cet Oncol. 2016 Jul;17(7):928-42.

55. Bohl S, von Hars­dorf S, Mulaw M, Hof­mann S, Babiak A, Maier CP, Schnell J, Hütter-​Krönke LM, Scholl K, Wais V, Schlenk RF, Bul­lin­ger L, Ring­hof­fer M, Döh­ner H, Bun­jes D, Bom­mer M, Kuchen­bauer F. Strong impact of extra­me­dul­lary invol­vement in high-​risk AML pati­ents with active disease recei­ving the FLAMSA con­di­tio­ning regi­men for HSCT. Bone Mar­row Trans­plant. 2016 Jul;51(7):994-6.

54. Schuler E, Gia­gouni­dis A, Haase D, Shir­n­es­han K, Büsche G, Platz­be­cker U, Nolte F, Götze K, Schlenk RF, Gan­ser A, Letsch A, Braulke F, Lüb­bert M, Bug G, Schaf­hau­sen P, Bacher U, Gat­ter­mann N, Wul­fert M, Haas R, Ger­ming U. Results of a mul­ti­cen­ter pro­spec­tive phase II trial inves­ti­ga­ting the safety and effi­cacy of lenali­do­mide in pati­ents with mye­lo­dys­plastic syn­dro­mes with iso­la­ted del(5q) (LE-​MON 5). Leuke­mia. 2016 Jul;30(7):1580-2.

53. Hütter-​Krönke ML, Ben­ner A, Döh­ner K, Krau­ter J, Weber D, Moess­ner M, Köhne CH, Horst HA, Schmidt-​Wolf IG, Rum­mel M, Götze K, Kol­ler E, Pet­zer AL, Sal­wen­der H, Fied­ler W, Kir­chen H, Haase D, Kre­mers S, Theo­bald M, Matz­dorff AC, Gan­ser A, Döh­ner H, Schlenk RF. Sal­vage the­rapy with high-​dose cyt­ara­bine and mit­ox­an­trone in com­bi­na­tion with all-​trans reti­noic acid and gem­tu­zu­mab ozoga­micin in acute mye­loid leuke­mia refrac­tory to first induc­tion the­rapy. Hae­ma­to­lo­gica. 2016 Jul;101(7):839-45.

52. Vegi NM, Klapp­a­cher J, Oswald F, Mulaw MA, Man­doli A, Thiel VN, Bame­zai S, Feder K, Mar­tens JH, Rawat VP, Man­dal T, Quintanilla-​Martinez L, Spie­ker­mann K, Hid­de­mann W, Döh­ner K,Döh­ner H, Stun­nen­berg HG, Feuring-​Buske M, Buske C. MEIS2 Is an Onco­ge­nic Part­ner in AML1-​ETO-Positive AML. Cell Rep. 2016 Jul 12;16(2):498-507.

51. Her­ling CD, Klau­mün­zer M, Krings Rocha C, Alt­mül­ler J, Thiele H, Bahlo J, Kluth S, Cris­patzu G, Her­ling M, Schil­ler J, Engelke A, Tausch E, Döh­ner H, Fischer K, Goede V, Nürn­berg P, Rein­hardt HC, Stil­gen­bauer S, Hal­lek M, Kreu­zer KA. Com­plex karyo­ty­pes, KRAS and POT1 muta­ti­ons impact out­come in CLL after chlor­am­bu­cil based chemo-​ or che­mo­im­mu­n­o­the­rapy. Blood. 2016 Jul 21;128(3):395-404.

50. Shostak A, Rup­pert B, Ha N, Bruns P, Toprak UH; ICGC MMML-​Seq Pro­ject, Eils R, Schles­ner M, Diern­fell­ner A, Brun­ner M. Col­la­bo­ra­tors (70) [...]Mantovani-​Löffler L, Staib P, Stil­gen­bauer S, Ott G, Küp­pers R[...]. MYC/MIZ1-​dependent gene repres­sion inver­sely coor­di­na­tes the cir­ca­dian clock with cell cycle and pro­li­fe­ra­tion. Nat Com­mun. 2016 Jun 24;7:11807.

49. Wendt­ner CM, Hal­lek M, Fraser GA, Michal­let AS, Hill­men P, Dürig J, Kalay­cio M, Grib­ben JG, Stil­gen­bauer S, Buh­ler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-​Khan A. Safety and effi­cacy of dif­fe­rent lenali­do­mide star­ting doses in pati­ents with relap­sed or refrac­tory chro­nic lym­pho­cy­tic leuke­mia: results of an inter­na­tio­nal mul­ti­cen­ter double-​blinded ran­do­mi­zed phase II trial. Leuk Lym­phoma. 2016 Jun;57(6):1291-9.

48. Ernst J, Hinz A, Nie­der­wie­ser D, Döh­ner H, Hönig K, Vogel­hu­ber M, Meh­nert A, Weiss­flog G. Dya­dic coping of pati­ents with hema­to­lo­gic mali­gnan­cies and their part­ners and its rela­tion to qua­lity of life - a lon­gi­tu­di­nal study. Leuk Lym­phoma. 2016 Jun 22:1-11. 

47. Kepp­ler S, Weiβbach S, Lan­ger C, Knop S, Pischi­ma­rov J, Kull M, Stüh­mer T, Stein­brunn T, Bar­gou R, Ein­sele H, Rosen­wald A, Leich E. Rare SNPs in recep­tor tyro­sine kina­ses are nega­tive out­come pre­dic­tors in mul­ti­ple mye­loma. Onco­tar­get. 2016 Jun 21;7(25):38762-38774.

46. Ernst A, Jones DT, Maass KK, Rode A, Deeg KI, Michael Chel­liah Jeba­raj B, Kors­hu­nov A, Hove­stadt V, Tain­sky MA, Pajt­ler KW, Ben­der S, Bra­betz S, Gröb­ner S, Kool M, Devens F, Edel­mann J, Zhang C, Castelo-​Branco P, Tabori U, Mal­kin D, Rippe K, Stil­gen­bauer S, Pfis­ter SM, Zapatka M, Lich­ter P. Telo­mere dys­func­tion and chro­mo­thrip­sis. Int J Can­cer. 2016 Jun 15;138(12):2905-14.

45. Schmid F, Schmid M, Müs­sel C, Sträng JE, Buske C, Bul­lin­ger L, Kraus JM, Kest­ler HA. GiANT: Gene set uncer­tainty in enrich­ment ana­ly­sis. Bio­in­for­ma­tics. 2016 Jun 15;32(12):1891-4.

44. Papaem­ma­nuil E, Gers­tung M, Bul­lin­ger L, Gaid­zik VI, Paschka P, Roberts ND, Pot­ter NE, Heu­ser M, Thol F, Bolli N, Gun­dem G, Van Loo P, Mar­tin­corena I, Ganly P, Mudie L, McLa­ren S, O'Meara S, Raine K, Jones DR, Teague JW, But­ler AP, Grea­ves MF, Gan­ser A, Döh­ner K, Schlenk RF, Döh­ner H, Camp­bell PJ. Geno­mic Clas­si­fi­ca­tion and Pro­gno­sis in Acute Mye­loid Leuke­mia. N Engl J Med. 2016 Jun 9;374(23):2209-21.

43. Savani BN, Labo­pin M, Krö­ger N, Finke J, Ehnin­ger G, Nie­der­wie­ser D, Schwerdt­fe­ger R, Bun­jes D, Glass B, Socie' G, Ljung­man P, Crad­dock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Gie­bel S, Mohty M, Nag­ler A. Expan­ding trans­plant opti­ons to pati­ents over 50 years-​ Impro­ved out­come after redu­ced inten­sity con­di­tio­ning mismatched-​unrelated donor trans­plan­ta­tion for pati­ents with acute mye­loid leuke­mia: A report from the Acute Leuke­mia Work­ing Party of the EBMT. Hae­ma­to­lo­gica.  2016 Jun;101(6):773-80.

42. Filar­sky K, Gar­ding A, Becker N, Wolf C, Zuck­nick M, Claus R, Wei­chen­han D, Plass C, Döh­ner H, Stil­gen­bauer S, Lich­ter P, Mer­tens D. Krüppel-​Like Fac­tor 4 (KLF4) inac­ti­va­tion in chro­nic lym­pho­cy­tic leuke­mia cor­re­la­tes with pro­mo­ter DNA-​methylation and can be rever­sed by inhi­bi­tion of NOTCH signa­ling. Hae­ma­to­lo­gica. 2016 Jun;101(6):e249-53.

41. Rücker FG, Lang KM, Füt­te­rer M, Koma­rica V, Schmid M, Döh­ner H, Schlenk RF,Döh­ner K, Knud­sen S, Bul­lin­ger L. Mole­cu­lar dis­sec­tion of val­proic acid effects in acute mye­loid leuke­mia iden­ti­fies pre­dic­tive net­works. Epi­ge­ne­tics. 2016 Jun 16:1-9.

40. Jors K, Sei­bel K, Bar­den­heuer H, Buch­heidt D, Mayer-​Steinacker R, Vieh­rig M, Xan­der C, Becker G. Edu­ca­tion in End-​of-Life Care: What Do Expe­ri­en­ced Pro­fes­sio­nals Find Important? J Can­cer Educ. 2016 Jun;31(2):272-8.

39. Cobur­ger J, Mer­kel A, Sche­rer M, Schwartz F, Gess­ler F, Roder C, Pala A, König R, Bul­lin­ger L, Nagel G, Jungk C, Bis­das S, Nabavi A, Gans­landt O, Sei­fert V, Tata­giba M, Senft C, Meh­dorn M, Unter­berg AW, Röss­ler K, Wirtz CR. Low-​Grade Glioma Sur­gery in Intra­ope­ra­tive Magne­tic Reso­nance Ima­ging I: Results of a Mul­ti­cen­ter Retro­spec­tive Assess­ment of the Ger­man Study Group for Intra­ope­ra­tive Magne­tic Reso­nance Ima­ging. Neu­ro­sur­gery. 2016 Jun;78(6):775-86.

38. Stil­gen­bauer S, Eich­horst B, Sche­te­lig J, Coutre S, Sey­mour J, Munir T, Puv­vada S, Wendt­ner C, Roberts A, Jurczak W, Mul­ligan S, Bött­cher S, Mobas­her M, Zhu M, Desai M, Chyla B, Ver­dugo M, Heit­ner Enschede S, Cerri E, Hume­rick­house R, Gor­don G, Hal­lek M, Wierda W. Vene­toclax in relap­sed or refrac­tory chro­nic lym­pho­cy­tic leu­ka­e­mia with 17p dele­tion: a mul­ti­centre, open-​label, phase 2 study. Lan­cet Oncol 2016 Jun;17(6):768-78.

37. Kul­karni U, Kars­ten CM, Koh­ler T, Ham­mer­schmidt S, Bom­mert K, Tiburzy B, Meng L, Thieme L, Recke A, Lud­wig RJ, Pol­lok K, Kalies K, Bogen B, Boett­cher M, Kam­radt T, Hau­ser AE, Lan­ger C, Huber-​Lang M, Fin­kel­man FD, Köhl J, Wong DM, Manz RA. IL-10 media­tes plasmacytosis-​associated immun­ode­fi­ci­ency by inhi­bi­ting complement-​mediated neu­tro­phil migra­tion. J Allergy Clin Immu­nol. 2016 May;137(5):1487-1497.

36. Iva­nova L, Buch A, Döh­ner K, Pohl­mann A, Binz A, Prank U, Sand­baum­hü­ter M, Bau­erfeind R, Sodeik B. Con­ser­ved tryp­tophan motifs in the large tegu­ment pro­tein pUL36 are requi­red for effi­ci­ent secon­dary enve­lo­p­ment of Her­pes Sim­plex Virus cap­sids. J Virol. 2016 May 12;90(11):5368-83.

35. Merz M, Jan­sen L, Cas­tro FA, Hil­len­gass J, Sal­wen­der H, Wei­sel K, Scheid C, Lutt­mann S, Emrich K, Holl­ec­zek B, Kata­li­nic A, Nen­ne­cke A, Straka C, Lan­ger C, Engel­hardt M, Ein­sele H, Krö­ger N, Bee­len D, Dre­ger P, Bren­ner H, Gold­schmidt H; GEKID Can­cer Sur­vi­val Work­ing Group and the DRST. Sur­vi­val of elderly pati­ents with mul­ti­ple myeloma-​Effect of upfront auto­lo­gous stem cell trans­plan­ta­tion. Eur J Can­cer. 2016 May 10;62:1-8.

34. Arreba-​Tutusaus P, Mack TS, Bul­lin­ger L, Schnö­der TM, Pola­netzki A, Wei­nert S, Bal­laschk A, Wang Z, Desh­pande AJ, Arm­strong SA, Döh­ner K, Fischer T, Hei­del FH. Impact of FLT3-ITD loca­tion on sen­si­ti­vity to TKI-​therapy in vitro and in vivo. Leuke­mia. 2016 May;30(5):1220-5. 

33. Herr­lin­ger U, Schä­fer N, Stein­bach JP, Weyer­b­rock A, Hau P, Gold­brun­ner R, Fried­rich F, Rohde V, Rin­gel F, Schle­gel U, Sabel M, Ronel­len­fitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vaj­koczy P, Ger­lach R, Kort­mann RD, Meh­dorn M, Tüt­ten­berg J, Mayer-​Steinacker R, Fiet­kau R, Breh­mer S, Mack F, Stu­plich M, Kebir S, Koh­nen R, Dunkl E, Leut­geb B, Proe­scholdt M, Pietsch T, Urbach H, Belka C, Stum­mer W, Glas M. Beva­ci­zu­mab Plus Iri­no­tecan Ver­sus Temo­zo­lo­mide in Newly Dia­gno­sed O6-​Methylguanine-DNA Methyl­trans­fer­ase Non­me­thy­la­ted Glio­blas­toma: The Ran­do­mi­zed GLA­RIUS Trial. J Clin Oncol. 2016 May 10;34(14):1611-9.

32. Hieke S, Ben­ner A, Schlenk RF, Schu­ma­cher M, Bul­lin­ger L, Bin­der H. Iden­tify­ing Pro­gno­stic SNPs in Cli­ni­cal Cohorts: Com­ple­menting Uni­va­riate Ana­ly­ses by Resam­pling and Mul­ti­va­ria­ble Mode­ling. PLoS One. 2016 May 9;11(5):e0155226. eColl­ec­tion 2016.

31. Fer­reri AJ, Cwy­nar­ski K, Pulczyn­ski E, Pon­zoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambro­setti A, Roth A, Hem­ma­way C, Fer­rari A, Lin­ton KM, Rudà R, Bin­der M, Pukrop T, Balz­a­rotti M, Fab­bri A, John­son P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stil­gen­bauer S, Her­ten­stein B, Kel­ler U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Iller­haus G; Inter­na­tio­nal Ext­r­ano­dal Lym­phoma Study Group (IELSG). Che­mo­im­mu­n­o­the­rapy with metho­tre­xate, cyt­ara­bine, thio­tepa, and ritu­xi­mab (MATRix regi­men) in pati­ents with pri­mary CNS lym­phoma: results of the first ran­do­mi­sa­tion of the Inter­na­tio­nal Ext­r­ano­dal Lym­phoma Study Group-​32 (IELSG32) phase 2 trial. Lan­cet Hae­ma­tol. 2016 May;3(5):e217-27.

30. Hein­zel­mann F, Bethge W, Bee­len DW, Engel­hard M, Krö­ger N, Dre­ger P, Nie­der­wie­ser D, Finke J, Bun­jes D, Tischer J, Kobbe G, Hol­ler E, Born­häu­ser M, Stell­jes M, Baur­mann H, Mül­ler A, Hau­bitz I, Schre­zen­meier H, Mül­ler C, Ottin­ger H. Allo­gen­eic hema­to­poie­tic cell trans­plan­ta­tion as cura­tive the­rapy for non-​transformed fol­li­cu­lar lym­pho­mas. Bone Mar­row Trans­plant. 2016 May;51(5):654-62.

29. Vey N, Delaunay J, Mar­ti­nelli G, Fied­ler W, Raf­foux E, Pre­bet T, Gomez-​Roca C, Papa­yan­nidis C, Kebenko M, Paschka P, Chris­ten R, Gua­rin E, Bröske AM, Baeh­ner M, Brews­ter M, Walz AC, Michie­lin F, Runza V, Mer­esse V, Recher C.  Phase I cli­ni­cal study of RG7356, an anti-​CD44 huma­ni­zed anti­body, in pati­ents with acute mye­loid leuke­mia. Onco­tar­get. 2016 May 31;7(22):32532-42.

28. Theil­a­cker C, Lude­wig K, Serr A, Schimpf J, Held J, Böge­lein M, Bahr V, Rusch S, Pohl A, Kogel­mann K, Frie­seke S, Bog­dan­ski R, Brunk­horst FM, Kern WV; Splenec­tomy, Pneu­mo­coc­cus, and Ful­mi­nant Infec­tion SPLEEN OFF Study Group. Col­la­bo­ra­tors: [...] Döh­ner H ... Over­whel­ming Postsplenec­tomy Infec­tion: A Pro­spec­tive Mul­ti­cen­ter Cohort Study. Clin Infect Dis. 2016 Apr 1;62(7):871-8.

27. Moreau P, Masszi T, Grz­asko N, Bah­lis NJ, Hans­son M, Pour L, Sandhu I, Ganly P, Baker BW, Jack­son SR, Stoppa AM, Simpson DR, Gim­sing P, Palumbo A, Gar­de­ret L, Cavo M, Kumar S, Tou­zeau C, Buadi FK, Lau­bach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richard­son PG; TOURMALINE-​MM1 Study Group (Lan­ger C). Oral Ixazo­mib, Lenali­do­mide, and Dexa­me­tha­sone for Mul­ti­ple Mye­loma. N Engl J Med. 2016 Apr 28;374(17):1621-34.

26. Pflug N, Kluth S, Veh­re­s­child JJ, Bahlo J, Tacke D, Biehl L, Eich­horst B, Fischer K, Cra­mer P, Fink AM, von Bergwelt-​Baildon M, Stil­gen­bauer S, Hal­lek M, Cor­nely OA, Veh­re­s­child MJ. Effi­cacy of anti­neo­plastic treat­ment is asso­cia­ted with the use of anti­bio­tics that modu­late inte­sti­nal micro­biota. Onco­im­mu­no­logy. 2016 Apr 22;5(6):e1150399. eColl­ec­tion 2016.

25. Hos­ter E, Rosen­wald A, Ber­ger F, Bernd HW, Hart­mann S, Lod­denkem­per C, Barth TF, Brousse N, Pileri S, Rym­kie­wicz G, Kodet R, Stil­gen­bauer S, Forst­point­ner R, Thieb­le­mont C, Hal­lek M, Coif­fier B, Vehling-​Kaiser U, Bou­ab­dal­lah R, Kanz L, Pfreund­schuh M, Schmidt C, Ribrag V, Hid­de­mann W, Unter­halt M, Kluin-​Nelemans JC, Her­mine O, Drey­ling MH, Klap­per W. Pro­gno­stic Value of Ki-67 Index, Cyto­logy, and Growth Pat­tern in Mantle-​Cell Lym­phoma: Results From Ran­do­mi­zed Tri­als of the European Man­tle Cell Lym­phoma Net­work. J Clin Oncol. 2016 Apr 20;34(12):1386-94.

24. Goebeler ME, Knop S, Viar­dot A*, Kufer P, Topp MS, Ein­sele H, Nop­pe­ney R, Hess G, Kal­lert S, Macken­sen A, Ruper­tus K, Kanz L, Libi­cher M, Nagor­sen D, Zug­maier G, Klin­ger M, Wolf A, Dorsch B, Qued­nau BD, Schmidt M, Scheele J, Bae­u­erle PA, Leo E, Bar­gou RC. (*con­tri­bu­ted equally). Bispe­ci­fic T-​Cell Enga­ger (BiTE) Anti­body Con­struct Bli­na­tu­mo­mab for the Treat­ment of Pati­ents With Relap­sed/Refrac­tory Non-​Hodgkin Lym­phoma: Final Results From a Phase I Study. J Clin Oncol. 2016 Apr 1;34(10):1104-11.

23. Grae­ter T, Krat­zer W, Oez­tu­erk S, Haenle MM, Mason RA, Hil­len­brand A, Kull T, Barth TF, Kern P, Grue­ner B. Pro­po­sal of a com­pu­ted tomo­gra­phy clas­si­fi­ca­tion for hepa­tic alveo­lar echi­no­coc­co­sis. World J Gas­tro­en­te­rol. 2016 Apr 7;22(13):3621-31.

22. Tausch E, Mer­tens D, Stil­gen­bauer S. Geno­mic Fea­tures: Impact on Patho­ge­nesis and Treat­ment of Chro­nic Lym­pho­cy­tic Leuke­mia. Oncol Res Treat. 2016;39(1-2):34-40.

21. Casalegno-​Garduño R, Schmitt A, Spit­schak A, Grei­ner J, Wang L, Hil­gen­dorf I, Hirt C, Ho AD, Freund M, Schmitt M. Immune respon­ses to WT1 in pati­ents with AML or MDS after che­mo­the­rapy and allo­gen­eic stem cell trans­plan­ta­tion. Int J Can­cer. 2016 Apr 1;138(7):1792-801.

20. Kossak-​Roth U, Sau­ßele S, Aul C, Büch­ner T, Döh­ner H, Dugas M, Ehnin­ger G, Gan­ser A, Gia­gouni­dis A, Gök­bu­get N, Griess­ham­mer M, Has­ford J, Heu­ser M, Hid­de­mann W, Hoch­haus A, Hoel­zer D, Nie­der­wie­ser D, Rei­ter A, Röl­lig C, Hehl­mann R. [Leuke­mia rese­arch in Ger­many: the Com­pe­tence Net­work Acute and Chro­nic Leuke­mias]. [Article in Ger­man]. Bun­des­ge­sund­heits­blatt Gesund­heits­for­schung Gesund­heits­schutz. 2016 Apr;59(4):444-53.

19. Gru­nen­berg A, Buske C. [Wal­den­ström's macro­glo­bu­li­ne­mia : Cur­rent deve­lo­p­ments in dia­gno­stics and the­rapy]. Inter­nist (Berl). 2016 Mar;57(3):238-44.

18. Mar­tin P, Mad­docks K, Leo­nard JP, Ruan J, Goy A, Wagner-​Johnston N, Rule S, Advani R, Ibe­rri D, Phil­lips T, Spur­geon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmie­lowska E, Stil­gen­bauer S, Blo­eh­dorn J, Por­tell C, Wil­liams ME, Drey­ling M, Barr PM, Chen-​Kiang S, DiLi­berto M, Fur­man RR, Blum KA. Post-​ibrutinib out­co­mes in pati­ents with man­tle cell lym­phoma. Blood. 2016 Mar 24;127(12):1559-63.

17. Viar­dot A, Goebeler ME, Hess G, Neu­mann S, Pfreund­schuh M, Adrian N, Zettl F, Libi­cher M, Sayehli C, Stiegl­maier J, Zhang A, Nagor­sen D, Bar­gou RC. Phase 2 study of bispe­ci­fic T-​cell enga­ger (BiTE®) anti­body bli­na­tu­mo­mab in relap­sed/refrac­tory dif­fuse large B cell lym­phoma. Blood. 2016 Mar 17;127(11):1410-6.

16. Tar­ge­ted The­rapy Alone for Acute Pro­mye­lo­cy­tic Leuke­mia. Lo-​Coco F, Di Donato L, Schlenk RF; for GIMEMA; Ger­man–Aus­trian Acute Mye­loid Leuke­mia Study Group and Study Alli­ance Leuke­mia. N Engl J Med. 2016 Mar 24;374(12):1197-1198.

15. Büh­ler A, Wendt­ner CM, Kipps TJ, Ras­senti L, Fraser GA, Michal­let AS, Hill­men P, Dürig J, Gre­gory SA, Kalay­cio M, Aurran-​Schleinitz T, Tren­tin L, Grib­ben JG, Chanan-​Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hal­lek M, Stil­gen­bauer S. Lenali­do­mide treat­ment and pro­gno­stic mar­kers in relap­sed or refrac­tory chro­nic lym­pho­cy­tic leuke­mia: data from the pro­spec­tive, mul­ti­cen­ter phase-​II CLL-009 trial. Blood Can­cer J. 2016 Mar 11;6:e404.

14. Cahu X, Labo­pin M, Gie­bel S, Aljurf M, Kyrcz-​Krzemien S, Socié G, Eder M, Boni­fazi F, Bun­jes D, Vigou­roux S, Michal­let M, Stell­jes M, Zucker­man T, Finke J, Pass­weg J, Yakoub-​Agha I, Nie­der­wie­ser D, Sucak G, Sengeløv H, Polge E, Nag­ler A, Esteve J, Mohty M. Impact of con­di­tio­ning with TBI in adult pati­ents with T-​cell ALL who receive a myelo­ab­la­tive allo­gen­eic stem cell trans­plan­ta­tion: a report from the acute leuke­mia work­ing party of EBMT. Bone Mar­row Trans­plant. 2016 Mar;51(3):351-7.

13. Oakes CC, Sei­fert M, Asse­nov Y, Gu L, Prze­ko­po­witz M, Rup­pert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Boga­ty­rova O, Wei­chen­han D, Brors B, Ras­senti L, Kipps TJ, Mer­tens D, Zapatka M, Lich­ter P, Döh­ner H, Küp­pers R, Zenz T, Stil­gen­bauer S, Byrd JC, Plass C. DNA methy­la­tion dyna­mics during B cell matu­ra­tion under­lie a con­ti­nuum of disease phe­no­ty­pes in chro­nic lym­pho­cy­tic leuke­mia. Nat Genet. 2016 Mar;48(3):253-64.

12. Grat­wohl A, Pfirr­mann M, Zan­der A, Krö­ger N, Bee­len D, Novotny J, Nerl C, Scheid C, Spie­ker­mann K, Mayer J, Sayer HG, Falge C, Bun­jes D, Döh­ner H, Gan­ser A, Schmidt-​Wolf I, Schwerdt­fe­ger R, Baur­mann H, Kuse R, Schmitz N, Weh­meier A, Fischer JT, Ho AD, Wil­helm M, Goebeler ME, Lin­de­mann HW, Bor­mann M, Her­ten­stein B, Sch­li­mok G, Baer­lo­cher GM, Aul C, Pfreund­schuh M, Fabian M, Staib P, Edin­ger M, Schatz M, Fauser A, Arnold R, Kind­ler T, Wulf G, Ros­se­let A, Hell­mann A, Schä­fer E, Prüm­mer O, Schenk M, Has­ford J, Heim­pel H, Hoss­feld DK, Kolb HJ, Büsche G, Hafer­lach C, Schnitt­ger S, Mül­ler MC, Rei­ter A, Ber­ger U, Sau­ßele S, Hoch­haus A, Hehl­mann R. Long-​term out­come of pati­ents with newly dia­gno­sed chro­nic mye­loid leukemia-​A ran­do­mi­zed com­pa­ri­son of stem cell trans­plan­ta­tion with drug treat­ment. Leuke­mia. 2016 Mar;30(3):562-9.

11. Bom­mer M, Bul­lin­ger L.  Men­in­geo­sis car­ci­no­ma­tosa. Der Onko­loge. 2016;22(5):321-328.

10. Nowek K, Sun SM, Dijk­s­tra MK, Bul­lin­ger L, Döh­ner H, Erke­land SJ, Löwen­berg B, Jongen-​Lavrencic M. Expres­sion of a pas­sen­ger miR-9* pre­dicts favorable out­come in adults with acute mye­loid leuke­mia less than 60 years of age. Leuke­mia. 2016 Feb;30(2):303-9.

9. Gru­nen­berg A, Buske C. [New deve­lo­p­ments in Wal­den­ström's macro­glo­bu­li­ne­mia]. Dtsch Med Wochen­schr. 2016 Feb;141(3):170-2.

8. Chanan-​Khan A, Cra­mer P, Demir­kan F, Fraser G, Silva RS, Gro­si­cki S, Pris­tupa A, Jans­sens A, Mayer J, Bart­lett NL, Dil­huydy MS, Pyly­penko H, Loscer­ta­les J, Avigdor A, Rule S, Villa D, Samoi­lova O, Panagio­ti­dis P, Goy A, Mato A, Pav­lovsky MA, Karls­son C, Mah­ler M, Sal­man M, Sun S, Phelps C, Bala­subra­ma­nian S, Howes A, Hal­lek M; HELIOS inves­ti­ga­tors. Col­la­bo­ra­tors: ...Stil­gen­bauer S... Ibru­ti­nib com­bi­ned with ben­da­mus­tine and ritu­xi­mab com­pa­red with pla­cebo, ben­da­mus­tine, and ritu­xi­mab for pre­viously trea­ted chro­nic lym­pho­cy­tic leu­ka­e­mia or small lym­pho­cy­tic lym­phoma (HELIOS): a ran­do­mi­sed, double-​blind, phase 3 study. Lan­cet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5.

7. Engert A, Bal­du­ini C, Brand A, Coif­fier B, Cor­don­nier C, Döh­ner H, de Wit TD, Eichin­ger S, Fibbe W, Green T, de Haas F, Iolas­con A, Jaf­fredo T, Rodeg­hiero F, Sal­les G, Schu­ringa JJ; other authors of the EHA Road­map for European Hema­to­logy Rese­arch. The European Hema­to­logy Asso­cia­tion Road­map for European Hema­to­logy Rese­arch: a con­sen­sus docu­ment. Hae­ma­to­lo­gica. 2016 Feb;101(2):115-208.

6. Ber­endt J, Oechsle K, Tho­mas M, van Oor­schot B, Schmitz A, Rad­bruch L, Simon ST, Gärt­ner J, Thuß-​Patience P, Schuler US, Hense J, Gog C, Vieh­rig M, Mayer-​Steinacker R, Stachura P, Stiel S, Ost­ga­the C. [State of inte­gra­tion of pal­lia­tive care at Com­pre­hen­sive Can­cer Cen­ters fun­ded by Ger­man Can­cer Aid]. Dtsch Med Wochen­schr. 2016 Jan;141(2):e16-e23. Ger­man.

5. Schir­mer M, Tren­tin L, Queu­de­ville M, Sey­fried F, Demir S, Tausch E, Stil­gen­bauer S, Eck­hoff SM, Meyer LH, Deba­tin KM. Intrin­sic and chemo-​sensitizing acti­vity of SMAC-​mimetics on high-​risk childhood acute lym­phob­lastic leuke­mia. Cell Death Dis. 2016 Jan 14;7:e2052.

4. God­frey AL, Chen E, Mas­sie CE, Sil­ber Y, Pagano F, Bel­los­illo B, Gugliel­melli P, Har­ri­son CN, Reilly JT, Ste­gel­mann F, Bijou F, Lip­pert E, Boi­ron JM, Döh­ner K, Van­nuc­chi AM, Bes­ses C, Green AR. STAT1 acti­va­tion in asso­cia­tion with JAK2 exon 12 muta­ti­ons. Hae­ma­to­lo­gica. 2016 Jan;101(1):e15-9. No abs­tract availa­ble.

3. Geyer H, Scher­ber R, Kosio­rek H, Dueck AC, Kilad­jian JJ, Xiao Z, Slot S, Zweegman S, Sack­mann F, Fuen­tes AK, Hernández-​Maraver D, Döh­ner K, Har­ri­son CN, Radia D, Muxi P, Bes­ses C, Cer­van­tes F, Johans­son PL, Andre­as­son B, Ram­baldi A, Bar­bui T, Bonatz K, Rei­ter A, Boyer F, Eti­enne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Mal­do­nado N, Barosi G, Fer­rari ML, Gale RP, Bir­ge­gard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Te Boek­horst PA, Com­man­deur S, Schou­ten H, Pahl HL, Griess­ham­mer M, Ste­gel­mann F, Leh­mann T, Senyak Z, Van­nuc­chi AM, Pas­sa­monti F, Samu­els­son J, Mesa RA. Sym­pto­ma­tic Pro­files of Pati­ents With Poly­cyt­he­mia Vera: Impli­ca­ti­ons of Ina­de­qua­tely Con­trol­led Disease. J Clin Oncol. 2016 Jan 10;34(2):151-9.

2. Nowek K, Sun SM, Bul­lin­ger L, Bin­dels EM, Exalto C, Dijk­s­tra MK, van Lom K, Döh­ner H, Erke­land SJ, Löwen­berg B, Jongen-​Lavrencic M. Aberrant expres­sion of miR-9/9* in mye­loid pro­ge­ni­tors inhi­bits neu­tro­phil dif­fe­ren­tia­tion by post-​transcriptional regu­la­tion of ERG. Leuke­mia.2016 Jan;30(1):229-37.

1. Fischer K, Bahlo J, Fink AM, Goede V, Her­ling CD, Cra­mer P, Lan­ger­beins P, von Tre­sc­kow J, Engelke A, Mau­rer C, Kovacs G, Her­ling M, Tausch E, Kreu­zer KA, Eich­horst B, Bött­cher S, Sey­mour JF, Ghia P, Marl­ton P, Kneba M, Wendt­ner CM, Döh­ner H, Stil­gen­bauer S, Hal­lek M. Long term remis­si­ons after FCR che­mo­im­mu­n­o­the­rapy in pre­viously untrea­ted pati­ents with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15.

86.  Faba­rius A, Kal­manti L, Dietz CT, Laus­eker M, Rinal­detti S, Hafer­lach C, Göh­ring G, Schle­gel­ber­ger B, Jot­te­rand M, Hanf­stein B, Sei­f­arth W, Hänel M, Köhne CH, Lin­de­mann HW, Ber­del WE, Staib P, Mül­ler MC, Proetel U, Ball­ei­sen L, Goebeler ME, Deng­ler J, Falge C, Kanz L, Burchert A, Kneba M, Ste­gel­mann F, Pfreund­schuh M, Wal­ler CF, Spie­ker­mann K, Brüm­men­dorf TH, Edin­ger M, Hof­mann WK, Pfirr­mann M, Has­ford J, Krause S, Hoch­haus A, Sau­ßele S, Hehl­mann R, SAKK and the Ger­man CML Study Group.  Impact of unba­lan­ced minor route ver­sus major route karyo­ty­pes at dia­gno­sis on pro­gno­sis of CML.  Ann Hema­tol. 2015 Dec;94(12): 2015-24 2015-24.

85.  Stil­gen­bauer S.  Pro­gno­stic mar­kers and stan­dard manage­ment of chro­nic lym­pho­cy­tic leuke­mia.  Hema­to­logy Am Soc Hema­tol Educ Pro­gram. 2015 Dec 5;2015(1):368-77.

84.  Zug­maier G, Gök­bu­get N, Klin­ger M, Viar­dot A, Stell­jes M, Neu­mann S, Horst HA, Marks R, Faul C, Died­rich H, Reichle A, Brüg­ge­mann M, Hol­land C, Schmidt M, Ein­sele H, Bar­gou RC, Topp MS.  Long-​term sur­vi­val and T-​Cell kine­tics in adult pati­ents with relap­sed/refrac­tory B-​precursor acute lym­phob­lastic leuke­mia who achie­ved mini­mal resi­dual disease response fol­lo­wing treat­ment with Anti-​CD19 BiTE® anti­body con­struct bli­na­tu­mo­mab.  Blood. 2015 Dec 10;126(24):2578-84.    

83.  Opel D, Schnai­ter A, Dodier D, Jova­no­vic M, Ger­har­din­ger A, Idler I, Mer­tens D, Bul­lin­ger L, Stil­gen­bauer S, Fulda S.  Tar­ge­ting inhi­bi­tor of apo­pto­sis pro­te­ins by Smac mime­tic eli­cits cell death in poor pro­gno­stic sub­groups of chro­nic lym­pho­cy­tic leuke­mia.  Int J Can­cer. 2015 Dec 15;137(12):2959-70.

82.  van den Berg H, Pau­lus­sen M, Le Teuff G, Jud­son I, Geld­erblom H, Dirk­sen U, Brennan B, Whelan J, Laden­stein RL, Marec-​Berard P, Kru­seova J, Hjorth L, Kühne T, Bri­chard B, Wheat­ley K, Craft A, Juer­gens H, Gaspar N, Le Deley MC; Euro-​EWING99 Group. Urban Ch, Meis­ter B, Fink FM, Kerbl R, Stol­lin­ger O, Schmitt K, Ebets­ber­ger G, Jones N, Laden­stein R, Gad­ner H, Maes P, Bri­chard B, Maz­zeo F, Gil T, Dhooge C, Ver­mor­ken JB, Klein A, Kru­seova J, Krarup-​Hansen A, Niel­sen O, Capra M, Pau­t­ard B, Rial­land X, Mail­lart P, Plou­vier E, Vérité C, Bui N'guyen B, Bou­t­ard P, Del­cambre C, Bay JO, Demeocq F, Couil­lault G, Isam­bert N, Plan­taz D, Des­fachel­les AS, Piguet C, Marec-​Bérard P, Blay JY, Gen­tet JC, Duf­faud F, Ber­tucci F, Sir­vent N, Schmitt C, Rios M, Cor­ra­dini N, Rol­land F, Deville A, Thyss A, Michon J, Tabone MD, Pierga JY, Mil­lot F, Mun­zer M, Edan C, Van­nier JP, Guil­le­met C, Brun E, Ber­ger C, Castex MP, Roche H, Lejars O, Lin­as­sier C, Ober­lin O, Le Cesne A, Bauer S, Ebe­ling P, Flass­hove M, Hart­mann JT, Rei­chardt P, Mer­tens R, Osieka R, Gne­kow A, Sch­li­mok G, Henze G, Thuss-​Patience P, Wick­mann L, Rei­chardt P, Poten­berg J, Rei­chardt P, Bode U, Schmidt-​Wolf IG, Eberl W, Wolff T, Pek­run A, Hof­mann A, And­ler W, Schnei­der D, Lau­ter­bach I, Zick­ler P, Göbel U, Bork­hardt A, Sauer­brey A, Hol­ter W, Bauer S, Ebe­ling P, Flass­hove M, Eggert A, Klin­ge­biel T, Nie­meyer C, Heinz J, Rei­ter A, Rum­mel M, Runde V, Lako­mek M, Trüm­per L, Beck J, Döl­ken G, Lin­de­mann HW, Kör­holz D, Schmoll HJ, Schnep­pen­heim R, Hoss­feld DK, Boke­meyer C, Keles H, Welte K, Klein C, Kulo­zik A, Ege­rer G, Cyran J, Strum­berg D, Freier W, Graf N, Pfreund­schuh M, Gruhn B, Lei­pold A, Bentz M, Wehin­ger H, Schrappe M, Nolte H, Bert­hold F, Wolf J, Stern­schulte W, Voel­pel S, Frie­ling T, Moess­ner J, Selle D, Bucsky D, Bar­tels H, Moh­ren M, Fischer T, Kluba U, Gut­jahr P, Dittrich M, Rei­ter S, Dür­ken M, Neu­bauer A, Beyer J, Chris­ti­an­sen H, Erd­len­bruch B, Bur­dach S, Schmid I, Meyer zum Büschen­felde C, Peschel C, Oduncu F, Jür­gens H, Ber­del W, Held H, Hofmann-​Wackersreuther G, Mül­ler H, Peters O, Andree­sen R, Krause S, Heits F, Geib-​König R, Kas­bohm M, Bür­ger D, Burg­hard R, Dicker­hoff R, Bielack S, Fed­der­sen I, Cle­mens MR, Hand­gre­tinger R, Hart­mann JT, Deba­tin KM, Mayer-​Steinacker R, Schoen­gen A, Schle­gel P, Lee V, Chik KW, van den Berg H, Roden­huis S, Geld­erblom AJ, Hoo­ger­brugge P, Bök­ker­ink JP, Pie­ters R, Cor­bett R, Öster­lundh G, Beh­rendtz M, Holm­qvist BM, Hjorth L, Peter­sen C, Jakob­son Å, Hjal­mars U, Ljung­man G, Angst R, Kühne T, Pau­lus­sen M, Leyv­raz S, Rischew­ski J, Feld­ges A, Grei­ner J, Hess U, Exner GU, Nig­gli F, Knuth A, King D, McCar­thy A, Henry P, Mor­land B, Rees H, Nichol­son J, Traune­cker H, Wal­lace H, Ronghe M, Simpson E, Cowie F, White J, Pic­ton S, Lewis I, Leahy M, Stark D, Selby PJ, Heney D, Pizer B, McDo­well H, Michal­ski A, Whelan J, Chis­holm J, Pritchard-​Jones K, Jud­son I, Brennan B, Hale J, Ver­rill M, Wal­ker D, Sokal M, Whee­ler K, Lee V, Ger­r­ard M, Woll P, Lori­gan P, Robin­son M, Koh­ler J. Impact of gen­der on effi­cacy and acute toxi­city of alky­la­ting agent -​based che­mo­the­rapy in Ewing sar­coma: secon­dary ana­ly­sis of the Euro-​Ewing99-R1 trial. Eur J Can­cer. 2015 Nov;51(16):2453-64.  

81. Krat­zer W, Grue­ner B, Kal­ten­bach TE, Ansari-​Bitzenberger S, Kern P, Fuchs M, Mason RA, Barth TF, Haenle MM, Hil­len­brand A, Oez­tu­erk S, Grae­ter T. Pro­po­sal of an ultra­so­no­gra­phic clas­si­fi­ca­tion for hepa­tic alveo­lar echi­no­coc­co­sis: Echi­no­coc­co­sis mul­ti­lo­cu­la­ris Ulm classification-​ultrasound. World J Gas­tro­en­te­rol. 2015 Nov;21(43): 12392-402.

80. San­der S, Chu VT, Yasuda T, Fran­k­lin A, Graf R, Calado DP, Li S, Imami K, Sel­bach M, Di Vir­gi­lio M, Bul­lin­ger L, Rajew­sky K. PI3 Kinase and FOXO1 Tran­scrip­tion Fac­tor Acti­vity Dif­fe­ren­ti­ally Con­trol B Cells in the Ger­mi­nal Cen­ter Light and Dark Zones.  Immu­nity. 2015 Dec 15;43(6):1075-86. Epub 2015 Nov 24.

79. Hof­mann S, Mead A, Mali­novskis A, Hard­wick NR, Guinn BA. Ana­lo­gue pep­ti­des for the immu­n­o­the­rapy of human acute mye­loid leuke­mia. Can­cer Immu­nol Immu­n­o­ther. 2015 Nov;64(11): 1357-67.

78. Cham­bers ES, Viar­dot A, Psichas A, Mor­ri­son DJ, Mur­phy KG, Zac-​Varghese SE, Mac­Dou­gall K, Pres­ton T, Ted­ford C, Fin­lay­son GS, Blun­dell JE, Bell JD, Tho­mas EL, Mt-​Isa S, Ashby D, Gib­son GR, Kolida S, Dhillo WS, Bloom SR, Mor­ley W, Clegg S, Frost G. Effects of tar­ge­ted deli­very of pro­pio­nate to the human colon on appe­tite regu­la­tion, body weight main­ten­ance and adi­po­sity in over­weight adults. Gut. 2015 Nov;64(11):1744-54.

77. Kurth F, Deve­loux M, Mechain M, Cle­rinx J, Antinori S, Gjørup IE, Gas­con J, Mørch K, Nicastri E, Ram­har­ter M, Bar­to­loni A, Vis­ser L, Rol­ling T, Zan­ger P, Cal­leri G, Salas-​Coronas J, Niel­sen H, Just-​Nübling G, Neu­mayr A, Hach­feld A, Schmid ML, Anto­nini P, Pon­gratz P, Kern P, Saraiva da Cunha J, Soriano-​Arandes A, Schunk M, Sut­torp N, Hatz C, Zol­ler T; TropNet Severe Mala­ria Inves­ti­ga­tor Group. Intra­venous Artes­unate Redu­ces Para­site Cle­arance Time, Dura­tion of Inten­sive Care, and Hos­pi­tal Treat­ment in Pati­ents With Severe Mala­ria in Europe: The TropNet Severe Mala­ria Study. Clin Infect Dis.  2015 Nov 1;61(9):1441-4.

76. Buske C, Kirch­hoff F, Münch J. EPI-X4, a novel endo­ge­nous ant­ago­nist of CXCR4. Onco­tar­get. 2015 Nov 3;6(34):35137-8.

75. Cra­mer P, Isfort S, Bahlo J, Stil­gen­bauer S, Döh­ner H, Berg­mann M, Stauch M, Kneba M, Lange E, Lan­ger­beins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendt­ner CM, Hal­lek M, Eich­horst B. Out­come of advan­ced chro­nic lym­pho­cy­tic leuke­mia fol­lo­wing dif­fe­rent firstline-​ and relapse-​therapies: A meta­ana­ly­sis of five pro­spec­tive tri­als of the Ger­man CLL Study Group (GCLLSG). Hae­ma­to­lo­gica. 2015 Nov;100(11):1451-9.

74. Schnei­der V, Zhang L, Rojew­ski M, Fekete N, Schre­zen­meier H, Erle A, Bul­lin­ger L, Hof­mann S, Götz M, Döh­ner K, Ihme S, Döh­ner H, Buske C, Feuring-​Buske M, Grei­ner J.  Leuke­mic pro­ge­ni­tor cells are suscep­ti­ble to tar­ge­ting by sti­mu­la­ted cyto­to­xic T cells against immu­n­o­ge­nic leukemia-​associated anti­gens. Int J Can­cer. 2015 Nov 1;137(9):2083-92. 

73. Viar­dot A, Herfarth K, Drey­ling . Indo­lent lym­phoma. The­rapy stra­te­gies. Onko­loge. 2015 Oct;21(10): 936-945.

72. Landau DA, Tausch E, Taylor-​Weiner AN, Ste­wart C, Rei­ter JG, Bahlo J, Kluth S, Bozic I, Law­rence M, Bött­cher S, Car­ter SL, Cibulskis K, Mer­tens D, Soug­nez CL, Rosen­berg M, Hess JM, Edel­mann J, Kless S, Kneba M, Rit­gen M, Fink A, Fischer K, Gabriel S, Lan­der ES, Nowak MA, Döh­ner H, Hal­lek M, Neu­berg D, Getz G, Stil­gen­bauer S, Wu CJ. Muta­ti­ons dri­ving CLL and their evo­lu­tion in pro­gres­sion and relapse. Nature. 2015 Oct 22;526(7574):525-30.

71. Vasyu­tina E, Bou­cas JM, Blo­eh­dorn J, Aszyk C, Cris­patzu G, Stie­fel­ha­gen M, Breuer A, Mayer P, Len­gerke C, Döh­ner H, Beut­ner D, Rosen­wald A, Stil­gen­bauer S, Hal­lek M, Ben­ner A, Her­ling M. The regu­la­tory inter­ac­tion of EVI1 with the TCL1A onco­gene impacts cell sur­vi­val and cli­ni­cal out­come in CLL. Leuke­mia. 2015 Oct;29(10):2003-14.

70. Len­n­erz JK, Hoff­mann K, Bubolz AM, Les­sel D, Welke C, Rüt­her N, Viar­dot A, Möl­ler P. Sup­pres­sor of cyto­kine signa­ling 1 gene muta­tion sta­tus as a pro­gno­stic bio­mar­ker in clas­si­cal Hodg­kin lym­phoma. Onco­tar­get. 2015 Oct 6;6(30):29097-110.

69. Gent­ner B, Pochert N, Rouhi A, Boc­calatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-​Hösle M, Rusch­mann J, Muranyi A, Lei­er­se­der S, Argi­ro­pou­los B, Star­czy­now­ski DT, Kar­san A, Heu­ser M, Hogge D, Camargo FD, Engel­hardt S, Döh­ner H, Buske C, Jongen-​Lavrencic M, Nal­dini L, Hum­phries RK, Kuchen­bauer F. MicroRNA-​223 dose-​levels fine-​tune pro­li­fe­ra­tion and dif­fe­ren­tia­tion in human cord blood pro­ge­ni­tors and acute mye­loid leuke­mia. Exp Hema­tol. 2015 Oct;43(10):858-868.e7.

68. Wagener R, Aukema SM, Schles­ner M, Haake A, Burk­hardt B, Cla­viez A, Drex­ler HG, Hum­mel M, Kreuz M, Loeff­ler M, Roso­low­ski M, López C, Möl­ler P, Rich­ter J, Rohde M, Betts MJ, Rus­sell RB, Bern­hart SH, Hoff­mann S, Rosen­stiel P, Schil­ha­bel M, Szc­ze­panow­ski M, Trüm­per L, Klap­per W, Sie­bert R, ICGC MMML-​Seq-Project , "Mole­cu­lar Mecha­nisms in Mali­gnant Lym­pho­mas" Net­work Pro­ject of the Deut­sche Krebs­hilfe , Rich­ter G, Sie­bert R, Wag­ner S, Haake A, Rich­ter J, Eils R, Lawe­renz C, Radom­ski S, Scholz I, Borst C, Burk­hardt B, Cla­viez A, Drey­ling M, Eberth S, Ein­sele H, Frick­hofen N, Haas S, Hans­mann ML, Karsch D, Kneba M, Lis­feld J, Mantovani-​Löffler L, Rohde M, Stad­ler C, Staib P, Stil­gen­bauer S, Ott G, Trüm­per L, Zenz T, Hans­mann ML, Kube D, Küp­pers R, Weni­ger M, Haas S, Hum­mel M, Klap­per W, Kos­tezka U, Lenze D, Möl­ler P, Rosen­wald A, Szc­ze­panow­ski M, Ammer­pohl O, Aukema SM, Bin­der V, Bork­hardt A, Haake A, Heza­veh K, Hoell J, Leich E, Lich­ter P, Lopez C, Nagel I, Pischi­ma­riov J, Radl­wim­mer B, Rich­ter J, Rosen­stiel P, Rosen­wald A, Schil­ha­bel M, Schrei­ber S, Vater I, Wag­ner R, Sie­bert R, Bern­hart SH, Bin­der H, Brors B, Doose G, Eils J, Eils R, Hoff­mann S, Hopp L, Kretz­mer H, Kreuz M, Kor­bel J, Lan­gen­ber­ger D, Loeff­ler M, Radom­ski S, Roso­low­ski M, Schles­ner M, Stad­ler PF, Sun­ga­lee S, Barth TF, Bernd HW, Cogliatti SB, Fel­ler AC, Hans­mann ML, Hum­mel M, Klap­per W, Lenze D, Möl­ler P, Müller-​Hermelink HK, Ott G, Rosen­wald A, Stein H, Szc­ze­panow­ski M, Wacker HH, Barth TF, Behr­mann P, Daniel P, Dier­lammm J, Haralam­bieva E, Har­der L, Hol­ter­hus PM, Küp­pers R, Kube D, Lich­ter P, Martín-​Subero JI, Möl­ler P, Murga-​Peñas EM, Ott G, Pott C, Psche­rer A, Rosen­wald A, Schwae­nen C, Sie­bert R, Traut­mann H, Vock­e­rodt M, Wes­sen­dorf S, Ben­tink S, Ber­ger H, Hasen­cle­ver D, Kreuz M, Loeff­ler M, Roso­low­ski M, Spang R, Stür­zen­ho­f­e­cker B, Trüm­per L, Weh­ner M, Loeff­ler M, Sie­bert R, Stein H, Trüm­per L. The PCBP1 gene enco­ding poly(rC) bin­ding pro­tein I is recurrently muta­ted in Bur­kitt lym­phoma. Genes Chro­mo­so­mes Can­cer. 2015 Sep;54(9): 555-64.

67. Heu­ser M, Meg­gen­dor­fer M, Cruz MM, Fabisch J, Klesse S, Köh­ler L, Göh­ring G, Gans­ter C, Shir­n­es­han K, Guter­muth A, Cerny-​Reiterer S, Krönke J, Panagiota V, Hafer­lach C, Koenecke C, Platz­be­cker U, Thiede C, Schroe­der T, Kobbe G, Ehr­lich S, Stamer K, Döh­ner K, Valent P, Schle­gel­ber­ger B, Kro­e­ger N, Gan­ser A, Haase D, Hafer­lach T, Thol F. Fre­quency and pro­gno­stic impact of casein kinase 1A1 muta­ti­ons in MDS pati­ents with dele­tion of chro­mo­some 5q. Leuke­mia. 2015 Sep;29(9):1942-5. No abs­tract availa­ble.

66. Robak T, Matu­tes E, Catovsky D, Zin­zani PL, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Hairy cell leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2015 Sep;26 Suppl 5:v100-v107. Review. No abs­tract availa­ble.

65. Van­nuc­chi AM, Bar­bui T, Cer­van­tes F, Har­ri­son C, Kilad­jian JJ, Krö­ger N, Thiele J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Phil­adel­phia chromosome-​negative chro­nic mye­lo­pro­li­fe­ra­tive neo­plasms: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2015 Sep;26 Suppl 5:v85-v99. Review. No abs­tract availa­ble.

64. Eich­horst B, Robak T, Monts­er­rat E, Ghia P, Hill­men P, Hal­lek M, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Chro­nic lym­pho­cy­tic leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2015 Sep;26 Suppl 5:v78-v84. No abs­tract availa­ble.

63. Laban S, Doe­scher J, Schuler PJ, Bul­lin­ger L, Brun­ner C, Veit JA, Hoff­mann TK. [Immu­n­o­the­rapy of head and neck tumors : High­lights of the ASCO Mee­ting 2015]. HNO. 2015 Sep;63(9):612-9.

62. Goede V, Bahlo J, Chata­line V, Eich­horst B, Dürig J, Stil­gen­bauer S, Kolb G, Hon­ecker F, Wed­ding U, Hal­lek M. Eva­lua­tion of ger­ia­tric assess­ment in pati­ents with chro­nic lym­pho­cy­tic leuke­mia: Results of the CLL9 trial of the Ger­man CLL Study Group. Leuk Lym­phoma. 2015 Sep 17:1-21.

61. Döh­ner H, Weis­dorf DJ, Bloom­field CD. Acute Mye­loid Leuke­mia. N Engl J Med. 2015 Sep 17;373(12):1136-52.

60. Doose G, Haake A, Bern­hart SH, López C, Dug­g­im­pudi S, Wojciech F, Berg­mann AK, Bork­hardt A, Burk­hardt B, Cla­viez A, Dimit­rova L, Haas S, Hoell JI, Hum­mel M, Karsch D, Klap­per W, Kleo K, Kretz­mer H, Kreuz M, Küp­pers R, Lawe­renz C, Lenze D, Loeff­ler M, Mantovani-​Löffler L, Möl­ler P, Ott G, Rich­ter J, Rohde M, Rosen­stiel P, Rosen­wald A, Schil­ha­bel M, Schnei­der M, Scholz I, Stil­gen­bauer S, Stun­nen­berg HG, Szc­ze­panow­ski M, Trüm­per L, Weni­ger MA; ICGC MMML-​Seq Con­sor­tium, Hoff­mann S, Sie­bert R, Iac­ca­rino I. MINCR is a MYC-​induced lncRNA able to modu­late MYC's tran­scrip­tio­nal net­work in Bur­kitt lym­phoma cells. Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5261-70.

59. von Witz­le­ben A, Goertt­ler LT, Mari­en­feld R, Barth H, Lechel A, Mel­lert K, Böhm M, Korn­mann M, Mayer-​Steinacker R, von Baer A, Schult­heiss M, Fla­na­gan AM, Möl­ler P, Brü­der­lein S, Barth TF. Pre­cli­ni­cal Cha­rac­te­riza­tion of Novel Chor­doma Cell Sys­tems and Their Tar­ge­ting by Phar­mo­co­lo­gi­cal Inhi­bi­tors of the CDK4/6 Cell Cycle Pathway. Can­cer Res. 2015 Sep 15;75(18):3823-31.

58. Heu­ser M, Meg­gen­dor­fer M, Cruz MM, Fabisch J, Klesse S, Köh­ler L, Göh­ring G, Gans­ter C, Shir­n­es­han K, Guter­muth A, Cerny-​Reiterer S, Krönke J, Panagiota V, Hafer­lach C, Koenecke C, Platz­be­cker U, Thiede C, Schroe­der T, Kobbe G, Ehr­lich S, Stamer K, Döh­ner K, Valent P, Schle­gel­ber­ger B, Kro­e­ger N, Gan­ser A, Haase D, Hafer­lach T, Thol F. Fre­quency and pro­gno­stic impact of casein kinase 1A1 muta­ti­ons in MDS pati­ents with dele­tion of chro­mo­some 5q. Leuke­mia. 2015 Sep;29(9):1942-5. No abs­tract availa­ble.

57. Tawana K, Wang J, Ren­ne­ville A, Bödör C, Hills R, Love­day C, Savic A, Van Delft FW, Tre­leaven J, Geor­gia­des P, Uglow E, Asou N, Uike N, Debel­jak M, Jaz­bec J, Ancliff P, Gale R, Tho­mas X, Mia­lou V, Döh­ner K, Bul­lin­ger L, Muel­ler B, Pabst T, Stell­jes M, Schle­gel­ber­ger B, Woz­niak E, Iqbal S, Okosun J, Araf S, Frank AK, Lau­rid­sen FB, Porse B, Ner­lov C, Owen C, Dokal I, Grib­ben J, Smith M, Preud­homme C, Che­lala C, Caven­agh J, Fitz­gib­bon J. Disease evo­lu­tion and out­co­mes in fami­lial AML with germ­line CEBPA muta­ti­ons. Blood. 2015 Sep 3;126(10):1214-23.

56. Maaß C, Klet­ting P, Bun­jes D, Mah­ren B, Beer AJ, Glat­ting G. Population-​Based Mode­ling Improves Treat­ment Plan­ning Before (90)Y-​Labeled Anti-​CD66 Anti­body Radio­im­mu­n­o­the­rapy. Can­cer Bio­ther Radio­ph­arm. 2015 Sep;30(7):285-290.

55. Baer C, Oakes CC, Rup­pert AS, Claus R, Kim-​Wanner SZ, Mer­tens D, Zenz T, Stil­gen­bauer S, Byrd JC, Plass C. Epi­ge­ne­tic silen­cing of miR-708 enhan­ces NF-κB signa­ling in chro­nic lym­pho­cy­tic leuke­mia. Int J Can­cer. 2015 Sep;137(6):1352-61.

54. Wang ML, Blum KA, Mar­tin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Roma­guera JE, Wil­liams ME, Barri­entos JC, Chmie­lowska E, Rad­ford J, Stil­gen­bauer S, Drey­ling M, Jedrze­jczak WW, John­son P, Spur­geon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-​term follow-​up of MCL pati­ents trea­ted with single-​agent ibru­ti­nib: Updated safety and effi­cacy results. Blood. 2015 Aug 6;126(6):739-45.

53. Hess G, Kel­ler U, Scholz CW, Witzens-​Harig M, Atta J, Buske C, Kir­schey S, Ruckes C, Med­ler C, van Oordt C, Klap­per W, Theo­bald M, Drey­ling M. Safety and effi­cacy of tem­si­ro­li­mus in com­bi­na­tion with ben­da­mus­tine and ritu­xi­mab in relap­sed man­tle cell and fol­li­cu­lar lym­phoma. Leuke­mia. 2015 Aug;29(8):1695-701.

52. Goede V, Busch R, Bahlo J, Chata­line V, Kre­mers S, Mül­ler L, Reschke D, Schlag R, Schmidt B, Vehling-​Kaiser U, Wed­ding U, Stil­gen­bauer S, Hal­lek M. Low-​dose fludar­a­bine with or wit­hout dar­be­poe­tin alfa in pati­ents with chro­nic lym­pho­cy­tic leuke­mia and comor­bi­dity: Pri­mary results of the CLL9 trial of the Ger­man CLL Study Group. Leuk Lym­phoma. 2015 Aug 21:1-22.

51. Wang ML, Blum KA, Mar­tin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Roma­guera JE, Wil­liams ME, Barri­entos JC, Chmie­lowska E, Rad­ford J, Stil­gen­bauer S, Drey­ling M, Jedrze­jczak WW, John­son P, Spur­geon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-​term follow-​up of MCL pati­ents trea­ted with single-​agent ibru­ti­nib: Updated safety and effi­cacy results. Blood. 2015 Aug 6;126(6):739-45.

50. Wues­ten­berg J, Grue­ner B, Oez­tu­erk S, Mason RA, Haenle MM, Grae­ter T, Akinli AS, Kern P, Krat­zer W. Dia­gno­stics in cystic echi­no­coc­co­sis: sero­logy ver­sus ultra­so­no­gra­phy. Turk J Gas­tro­en­te­rol. 2014 Aug;25(4):398-404.

49. Goyal SD, Zhang MJ, Wang HL, Akpek G, Cope­lan EA, Frey­tes C, Gale RP, Hama­dani M, Ina­moto Y, Kam­ble RT, Laza­rus HM, Marks DI, Nis­hi­hori T, Ols­son RF, Res­hef R, Rit­chie DS, Saber W, Savani BN, Seber A, Shea TC, Tall­man MS, Wirk B, Bun­jes DW, Devine SM, de Lima M, Weis­dorf DJ, Uy GL. Allo­gen­eic hema­to­poie­tic cell trans­plant for AML: no impact of pre-​transplant extra­me­dul­lary disease on out­come. Bone Mar­row Trans­plant. 2015 Aug;50(8):1057-62.

48. Öster­borg A, Jewell RC, Padmanabhan-​Iyer S, Kipps TJ, Mayer J, Stil­gen­bauer S, Wil­liams CD, Hell­mann A, Fur­man RR, Robak T, Hill­menn P, Trněný M, Dyer MJ, Pio­trowska M, Kozak T, Gupta IV, Phil­lips JL, Gold­stein N, Stru­em­per H, Losic N, Lisby S, Wierda WG. Ofa­tu­mu­mab mono­the­rapy in fludarabine-​refractory chro­nic lym­pho­cy­tic leuke­mia: final results from a pivo­tal study. Hae­ma­to­lo­gica. 2015 Aug;100(8):e311-4.

47. Mora-​Jensen H, Jend­holm J, Rapin N, Klar­s­kov Ander­sen M, Roug AS, Otzen Bag­ger F, Bul­lin­ger L, Win­ther O, Bor­re­gaard N, Porse BT, Theilgaard-​Mönch K. Cel­lu­lar ori­gin of pro­gno­stic chro­mo­so­mal aberra­ti­ons in AML pati­ents. Leuke­mia. 2015 Aug;29(8):1785-9.

46. Knas T, Buck M, Ste­gel­mann F, Möl­ler P, Barth TF. [Detec­tion of the BCR-​ABL fusion: Com­pa­ra­tive ana­ly­sis of six com­mer­cially availa­ble FISH fusion pro­bes]. Patho­loge. 2015 Jul;36(4): 372-84.

45. Krönke J, Fink EC, Hol­len­bach PW, Mac­Beth KJ, Hurst SN, Ude­shi ND, Cham­ber­lain PP, Mani DR, Man HW, Gan­dhi AK, Svin­kina T, Schnei­der RK, McCon­key M, Järås M, Grif­fiths E, Wetz­ler M, Bul­lin­ger L, Cathers BE, Carr SA, Cho­pra R, Ebert BL. Lenali­do­mide indu­ces ubi­qui­ti­na­tion and degra­dation of CK1α in del(5q) MDS. Nature. 2015 Jul 9;523(7559):183-8.

44. Kor­tüm KM, Lan­ger C, Monge J, Bru­ins L, Zhu YX, Shi CX, Jed­low­ski P, Egan JB, Ojha J, Bul­lin­ger L, Kull M, Ahmann G, Rasche L, Knop S, Fon­seca R, Ein­sele H, Ste­wart AK, Brag­gio E. Lon­gi­tu­di­nal ana­ly­sis of 25 sequen­tial sample-​pairs using a custom mul­ti­ple mye­loma muta­tion sequen­cing panel (M(3)P). Ann Hema­tol. 2015 Jul;94(7):1205-11.

43. Dom­bret H, Sey­mour JF, But­rym A, Wierz­bowska A, Sel­les­lag D, Jang JH, Kumar R, Caven­agh J, Schuh AC, Can­doni A, Récher C, Sandhu I, Ber­nal del Cas­tillo T, Al-​Ali HK, Mar­ti­nelli G, Falan­tes J, Nop­pe­ney R, Stone RM, Min­den MD, McIn­tyre H, Son­ger S, Lucy LM, Beach CL, Döh­ner H. Inter­na­tio­nal phase 3 study of aza­ci­ti­dine vs con­ven­tio­nal care regi­mens in older pati­ents with newly dia­gno­sed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291-9.

42. Thol F, Schlenk RF, Heu­ser M, Gan­ser A. How I treat refrac­tory and early relap­sed acute mye­loid leuke­mia. Blood. 2015 Jul 16;126(3):319-27.

41. Lan­ger­beins P, Bahlo J, Rhein C, Cra­mer P, Pflug N, Fischer K, Stil­gen­bauer S, Kreu­zer KA, Wendt­ner CM, Eich­horst B, Hal­lek M. The CLL12 trial pro­to­col: a placebo-​controlled double-​blind Phase III study of ibru­ti­nib in the treat­ment of early-​stage chro­nic lym­pho­cy­tic leuke­mia pati­ents with risk of early disease pro­gres­sion. Future Oncol. 2015 Jul;11(13):1895-903. 

40. Rich­ter PJ, Holt­fre­ter M, Orhun A, Müller-​Stöver I, Kubitz R, Hil­len­brand A, Krat­zer W, Grä­ter T, Grü­ner B. [Echi­no­coc­co­sis]. MMW Fort­schr Med. 2015 Jun;157(12): 56-63.

39. Haaß W, Klei­ner H, Weiß C, Hafer­lach C, Schle­gel­ber­ger B, Mül­ler MC, Hehl­mann R, Hof­mann WK, Faba­rius A, Sei­f­arth W, Schwei­ze­ri­sche Arbeits­ge­mein­schaft für Kli­ni­sche Krebs­for­schung , Ger­man CML Study Group , Wernli M, Bar­getzi M, Fischer von Wei­kers­thal L, Gro V, Mül­ler S, Hahn M, Sch­li­mok G, Rei­chert D, Jans­sen J, Fur­kert J, Man­del T, Majunke PJ, Paliege R, Rei­chert P, Fuss H, Neben K, Staiger HJ, Heim D, Grat­wohl A, Tichelli A, Kors­ten S, Hen­es­ser D, Le Coutre P, Arnold R, Lud­wig WD, Ratei R, Teutsch C, Lud­wig F, Urmers­bach A, Blau I, Ihle H, Sper­ling C, Sche­lenz C, Koschuth A, Kin­green D, Heß­ling J, Der­wahl KM, Olden­kott B, Eng­lisch HJ, Lud­wig F, Thiel E, Bur­meis­ter T, Not­ter M, de Wit M, Rothaug W, Büschel G, Beyer J, Dah­men E, Biaggi C, Lämmle B, Friess D, Baer­lo­cher G, Opp­li­ger Lei­bund­gut E, Tobler A, Just M, Schä­fer E, Beh­rin­ger D, Brandt M, Schmie­gel W, Vau­pel HA, Ver­beek W, Ko YD, Wei­den­hö­fer S, Sauer­bruch T, Hahn-​Ast C, Jan­zen V, Schmidt-​Wolf I, Trenn G, van der Linde M, Pom­me­rien W, Fritz L, Krau­ter J, Lor­dick F, Frit­sch G, Pflü­ger KH, Diek­mann C, Kull­mer J, Doe­ring G, Mun­zin­ger H, Her­ten­stein B, Peyn A, Mayer J, Zácková D, Kuji­ck­ova J, Stier S, Wejda B, Möller-​Faßbender F, Hänel M, Morg­ner A, Herbst R, Matek W, Lam­berti C, Zöl­ler T, Koch B, Marth T, Hen­zel A, Wag­ner S, Woska E, Neu­mann F, Hoff­knecht MM, Ill­mer T, Wolf T, Ehnin­ger G, Kiani A, Platz­be­cker U, Aul C, Badra­k­han CD, Gia­gouni­dis A, Flaß­hove M, Hen­neke F, Moritz T, Simon M, Mül­ler LL, Janz R, Eckart M, Häcker B, Rech D, Macken­sen A, Krause SW, Staib P, Schle­gel F, Wät­zig K, Rudolph R, Wat­tad M, Baur FK, Heit W, Bee­len DW, Hütt­mann A, Novotny J, Tren­schel R, Lin­de­mann A, Linck D, Jäger E, Al-​Batran SE, Ott­mann OG, Serve H, Rei­ber T, Sem­sek D, Wal­ler C, Küh­ne­mund A, Hoeff­kes HG, Lam­bertz H, Schulz L, Tajro­beh­kar K, Mit­ter­mül­ler J, Rum­mel MJ, Bur­chardt A, Pralle H, Runde V, Klei M, West­hei­der J, Hoyer A, Tes­sen HW, Hesse A, Trüm­per L, Bin­der C, Schmidt CA, Hirt C, Sie­ber M, Eschen­burg H, Wil­helm S, Depen­busch R, Rösel S, Eimer­ma­cher H, Spohn C, Moel­ler R, Schmitz N, Nickel­sen M, Engel E, Haa­tanen T, Holl­burg W, Platz D, Kös­ter H, Boke­meyer C, Schaf­hau­sen P, Grote-​Metke A, Bech­tel B, Hemeier M, Sosada M, Gan­ser A, Schle­gel­ber­ger B, Ho AD, Rohlfing S, Deng­ler J, Peter­sen V, Porow­ski P, Hahn L, Dietz­fel­bin­ger H, Grö­schel W, Bar­tho­lo­mäus A, Pfreund­schuh M, Kem­mer­ling M, Han­sen R, Reeb M, Link H, Mahl­mann S, Mez­ger J, Schatz M, Schmier M, Gat­ter J, Neu­mann S, Heymanns J, Stein­metz HT, Schmitz S, Scheid C, Plan­ker M, Frie­ling T, Lol­lert A, Neise M, Schrö­der M, Greif D, Kempf B, März W, Kre­mers S, Mül­ler L, Hart­mann F, Heil G, Gold­mann B, Hein­kele P, Gre­gor M, Theo­bald M, Fischer T, Tho­mas S, Hen­sel M, Plö­ger C, Schus­ter D, Brust J, Hie­ber U, Hehl­mann R, Neu­bauer A, Burchert A, Grae­ven U, Lange C, Schmidt G, Völkl S, Schmidt B, Hitz H, Spie­ker­mann K, Hid­de­mann W, Hafer­lach T, Hafer­lach C, Schnitt­ger S, Stöt­zer O, Scheid­eg­ger C, Fischer C, Ber­del WE, Kop­pele A, Hebart H, Snaga A, Schmidt P, Hoff­mann R, Reschke D, Zir­pel I, Sauer M, Lenk G, Eimer­ma­cher H, Theil­mann L, Sandrit­ter B, Schenk M, Deng­ler R, Herr W, Krause S, Braun B, Gün­ther E, Wacker A, Pihusch R, Bal­dus M, Matz­dorff A, Poll­meier G, Grim­min­ger W, Hebart H, Geer T, Schanz S, Jür C, Gas­smann W, Seitz K, Kaes­ber­ger J, Mück R, Iller­haus G, Denz­lin­ger C, Fiech­t­ner H, Sprin­ger G, Hoff­mann D, Jacki SH, Kanz L, Bross-​Bach U, Döh­ner H, Ste­gel­mann F, Kal­hori N, Lan­ger W, Nusch A, Wei J, Kamp T, Schadeck-​Gressel C, Schwerdt­fe­ger R, Jos­ten KM, Klein O, Fett W, Strot­köt­ter H, Maintz C, Gro­schek M, Schlag R, Elsel W, Schü­ler F, Döl­ken G, Lin­de­mann HW, Wolf HH, Schmoll HJ, Brau­mann D, Hoel­zer P, Klee­berg U, Hoss­feld D, Lange E, Schu­bert J, Wei­scher H, Dürk HA, Kirch­ner HH, Bu EC, Sie­vers B, Freier W, Kai­ser U, Peest D, Römer E, Her­mann T, Fauser A, Val­verde ML, Men­zel J, Kem­per J, Hoch­haus A, La Rosée P, Bentz M, Wil­helm S, Prüm­mer O, Kneba M, Strack U, Schoch R, Seve­rin K, Stauch M, Kar­bach U, Vehling-​Kaiser U, Köch­ling G, Wei U, Mid­deke H, Neu­haus T, Mar­tin H, Fet­scher S, Schmie­lau J, Kämpfe D, Uppen­kamp M, Wei B, Thum P, Wuil­le­min W, Hof­mann WK, Griess­ham­mer M, Tisch­ler HJ, Becker M, Hanf­stein B, Mül­ler M, Sau­ßele S, Lun­scken C, Kolb HJ, Lutz L, Hen­trich M, Nerl C, Wendt­ner C, Ber­del WE, Ladda E, Gnad M, Suna H, Schmidt E, Koschmie­der S, Falge C, Wandt H, Wil­helm M, Köhne CH, Schwei­ger C, Müller-​Naendrup C, Früh­auf S, Ranft K, Theil­mann L, Den­causse Y, Baake G, Rit­ter PR, Kloke O, Becker M, Gött­ler B, Völkl S, Schick HD, Wei­den­hö­fer S, Wei­din­ger P, Wacker D, Weh­meyer J, Kreu­ser ED, Schlenska-​Lange A, Edin­ger R, Andree­sen R, Weh­meier A, Stahl­hut K, Käfer G, Cerny T, Hess U, Priebe-​Richter C, Stange-​Budumlu O, Demandt M, Freu­nek G, Hei­de­mann E, Schlei­cher J, Mer­gen­tha­ler HG, Boe­wer C, Zel­ler C, Lau­bens­tein HP, Ren­den­bach B, Cle­mens M, Walad­khani AR, Forst­bauer H, Mül­ler F, Brett­ner S, Rag­ha­va­char A, Kunz­mann V, Goebeler ME, Gmür J. Clo­nal Evo­lu­tion and Blast Cri­sis Cor­re­late with Enhan­ced Pro­teo­ly­tic Acti­vity of Sepa­rase in BCR-​ABL b3a2 Fusion Type CML under Ima­ti­nib The­rapy. PLoS ONE. 2015 Jun;10(6): e0129648.

38. Kay­ser S, Wal­ter RB, Stock W, Schlenk RF. Mini­mal Resi­dual Disease in Acute Mye­loid Leukemia-​Current Sta­tus and Future Per­spec­ti­ves. Curr Hema­tol Malig Rep. 2015 Jun;10(2):132-44. 

37. Stil­gen­bauer S, Fur­man RR, Zent CS. Manage­ment of Chro­nic Lym­pho­cy­tic Leuke­mia. Am Soc Clin Oncol Educ Book. 2015;35:164-175.

36. Buske C, Sey­mour J. Immu­n­o­chemo­the­rapy in Wal­den­ström macro­glo­bu­li­ne­mia - still the back­bone of treat­ment. Leuk Lym­phoma. 2015 Jun 9:1-6. No abs­tract availa­ble.

35. Delforge M, Minuk L, Eisen­mann JC, Arnulf B, Canepa L, Fra­gasso A, Leyv­raz S, Lan­ger C, Ezaydi Y, Vogl DT, Giraldo-​Castellano P, Yoon SS, Zar­nitsky C, Escoffre-​Barbe M, Lemieux B, Song K, Bah­lis NJ, Guo S, Mon­zini MS, Ervin-​Haynes A, Houck V, Facon T. Health-​related qua­lity of life in pati­ents with newly dia­gno­sed mul­ti­ple mye­loma in the FIRST trial: lenali­do­mide plus low-​dose dexa­me­tha­sone ver­sus mel­phalan, pred­ni­sone, tha­li­do­mide. Hae­ma­to­lo­gica. 2015 Jun;100(6):826-33.

34. Fied­ler W, Kay­ser S, Kebenko M, Jan­ning M, Krau­ter J, Schit­ten­helm M, Götze K, Weber D, Göh­ring G, Teleanu V, Thol F, Heu­ser M, Döh­ner K, Gan­ser A, Döh­ner H, Schlenk RF. A phase I/II study of suniti­nib and inten­sive che­mo­the­rapy in pati­ents over 60 years of age with acute mye­loid leu­ka­e­mia and acti­vating FLT3 muta­ti­ons. Br J Hae­ma­tol. 2015 Jun;169(5):694-700.

33. Kern P. Series: Immune Response to Para­si­tic Infec­tions (Volume 2) Immu­nity to Hel­m­inths and Novel The­ra­peu­tic Approa­ches. Clin Infect Dis. 2015 Jun 1;60(11):1734.

32. Lerch K, Meyer AH, Stroux A, Hirt C, Kel­ler U, Viar­dot A, Marks R, Schrei­ber S, Pez­zutto A, Scholz CW. Impact of prior treat­ment on out­come of trans­for­med fol­li­cu­lar lym­phoma and relap­sed de novo dif­fuse large B cell lym­phoma: a retro­spec­tive mul­ti­centre ana­ly­sis. Ann Hema­tol. 2015 Jun;94(6):981-8.

31. Schnö­der TM, Arreba-​Tutusaus P, Griehl I, Bul­lin­ger L, Busch­beck M, Lane SW, Döh­ner K, Plass C, Lipka DB, Hei­del FH, Fischer T. Epo-​induced ery­throid matu­ra­tion is depen­dent on Plcγ1 signa­ling. Cell Death Dif­fer. 2015 Jun;22(6):974-85.

30. Kal­manti L, Saus­sele S, Laus­eker M, Mül­ler MC, Dietz CT, Hein­rich L, Hanf­stein B, Proetel U, Faba­rius A, Krause SW, Rinal­detti S, Deng­ler J, Falge C, Oppliger-​Leibundgut E, Burchert A, Neu­bauer A, Kanz L, Ste­gel­mann F, Pfreund­schuh M, Spie­ker­mann K, Scheid C, Pfirr­mann M, Hoch­haus A, Has­ford J, Hehl­mann R. Safety and effi­cacy of ima­ti­nib in CML over a period of 10 years: data from the ran­do­mi­zed CML-​study IV. Leuke­mia. 2015 May;29(5): 1123-32.

29. Gris­hina O, Schmoor C, Döh­ner K, Hack­an­son B, Lub­rich B, May AM, Cies­lik C, Mül­ler MJ, Lüb­bert M. DECI­DER: pro­spec­tive ran­do­mi­zed mul­ti­cen­ter phase II trial of low-​dose deci­ta­bine (DAC) admi­nis­te­red alone or in com­bi­na­tion with the his­tone deace­tylase inhi­bi­tor val­proic acid (VPA) and all-​trans reti­noic acid (ATRA) in pati­ents >60 years with acute mye­loid leuke­mia who are ine­li­gi­ble for induc­tion che­mo­the­rapy. BMC Can­cer. 2015 May 26;15(1):430.

28. Mef­fert C, Gaert­ner J, Sei­bel K, Jors K, Bar­den­heuer H, Buch­heidt D, Mayer-​Steinacker R, Vieh­rig M, Paul C, Stock S, Xan­der C, Becker G. Early Pal­lia­tive Care-​Health ser­vices rese­arch and imple­men­ta­tion of sus­taina­ble chan­ges: the study pro­to­col of the EVI pro­ject. BMC Can­cer. 2015 May 29;15(1):443.

27. Schnei­der D, Dühren-​von Min­den M, Alk­ha­tib A, Setz C, van Ber­gen CA, Benkißer-​Petersen M, Wil­helm I, Vill­rin­ger S, Kry­sov S, Pack­ham G, Zir­lik K, Römer W, Buske C, Ste­ven­son FK, Veel­ken H, Jumaa H. Lec­tins from oppor­tu­ni­stic bac­te­ria inter­act with acqui­red varia­ble region glycans of sur­face Ig in fol­li­cu­lar lym­phoma. Blood. 2015 May 21;125(21):3287-96.

26. Wil­ler A, Jak­ob­sen JS, Ohls­son E, Rapin N, Waage J, Bil­ling M, Bul­lin­ger L, Karls­son S, Porse BT. TGIF1 is a nega­tive regu­la­tor of MLL-​rearranged acute mye­loid leuke­mia. Leuke­mia. 2015 May;29(5):1018-31.

25. Lanasa MC, Andrit­sos L, Brown JR, Gabri­love J, Caligaris-​Cappio F, Ghia P, Lar­son RA, Kipps TJ, Leblond V, Mil­ligan DW, Jans­sens A, John­son AJ, Hee­rema NA, Büh­ler A, Stil­gen­bauer S, Devin J, Hal­lek M, Byrd JC, Gre­ver MR. Final results of EFC6663: A mul­ti­cen­ter, inter­na­tio­nal, phase 2 study of alvo­ci­dib for pati­ents with fludarabine-​refractory chro­nic lym­pho­cy­tic leuke­mia. Leuk Res. 2015 May;39(5):495-500.

24. Grae­ter T, Ehing F, Oez­tu­erk S, Mason RA, Haenle MM1, Krat­zer W, Seuf­fer­lein T, Grue­ner B. Hepat­o­bi­li­ary com­pli­ca­ti­ons of alveo­lar echi­no­coc­co­sis: A long-​term follow-​up study. World J Gas­tro­en­te­rol. 2015 Apr 28;21(16):4925-32.

23. Döh­ner K, Paschka P, Döh­ner H. [Acute mye­loid leuke­mia]. Inter­nist (Berl). 2015 Apr;56(4):354-63. Ger­man.

22. Kal­ten­meier C, Gaw­an­bacht A, Beyer T, Lind­ner S, Trz­aska T, van der Merwe JA, Här­ter G, Grü­ner B, Fabri­cius D, Lotfi R, Schwarz K, Schütz C, Hönig M, Schulz A, Kern P, Bom­mer M, Schre­zen­meier H, Kirch­hoff F, Jahrs­dör­fer B. CD4+ T Cell-​Derived IL-21 and Depri­va­tion of CD40 Signa­ling Favor the In Vivo Deve­lo­p­ment of Gran­zyme B-​Expressing Regu­la­tory B Cells in HIV Pati­ents. J Immu­nol. 2015 Apr 15;194(8):3768-77.

21. Moreno C, Mon­tillo M, Panay­io­ti­dis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geis­ler C, Hill­men P, Dou­bek M, Trněný M, Obrt­li­kova P, Lau­renti L, Stil­gen­bauer S, Smo­lej L, Ghia P, Cym­ba­lista F, Jae­ger U, Sta­ma­to­pou­los K, Stav­roy­ianni N, Car­ri­ng­ton P, Zou­abi H, Leblond V, Gomez-​Garcia JC, Rubio M, Marasca R, Musu­raca G, Rigacci L, Farina L, Pao­lini R, Pos­pi­si­lova S, Kimby E, Brad­ley C, Monts­er­rat E. Ofa­tu­mu­mab in poor-​prognosis chro­nic lym­pho­cy­tic leuke­mia: a Phase 4, non-​-interventional, obser­va­tio­nal study from the European Rese­arch Initia­tive on Chro­nic Lym­pho­cy­tic Leuke­mia. Hae­ma­to­lo­gica. 2015 Apr;100(4):511-6.

20. Kay­ser S, Schlenk RF, Grim­wade D, Yosuico VE, Wal­ter RB. Mini­mal resi­dual disease-​directed the­rapy in acute mye­loid leuke­mia. Blood. 2015 Apr 9;125(15):2331-2335.

19. Thol F, Scherr M, Kirch­ner A, Shahs­war R, Batt­mer K, Kade S, Cha­tur­vedi A, Koenecke C, Stad­ler M, Platz­be­cker U, Thiede C, Schroe­der T, Kobbe G, Bug G, Ott­mann O, Hof­mann W, Krö­ger N, Fied­ler W, Schlenk R, Döh­ner K, Döh­ner H, Krau­ter J, Eder M, Gan­ser A, Heu­ser M. Cli­ni­cal and func­tio­nal impli­ca­ti­ons of microRNA muta­ti­ons in a cohort of 935 pati­ents with mye­lo­dys­plastic syn­dro­mes and acute mye­loid leuke­mia. Hae­ma­to­lo­gica. 2015 Apr;100(4):e122-4.

18. Wang L, Jin N, Schmitt A, Grei­ner J, Mal­che­rek G, Hun­de­mer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Gold­schmidt H, Schmitt M. T cell-​based tar­ge­ted immu­n­o­the­ra­pies for pati­ents with mul­ti­ple mye­loma. Int J Can­cer. 2015 Apr 15;136(8):1751-68.

17. Tap­per W, Jones AV, Kra­lo­vics R, Haru­tyunyan AS, Zoi K, Leung W, God­frey AL, Gugliel­melli P, Cal­la­way A, Ward D, Ara­naz P, White HE, Wag­horn K, Lin F, Chase A, Joanna Bax­ter E, Maclean C, Nan­ga­lia J, Chen E, Evans P, Short M, Jack A, Wal­lis L, Oscier D, Dun­combe AS, Schuh A, Mead AJ, Grif­fiths M, Ewing J, Gale RE, Schnitt­ger S, Hafer­lach T, Ste­gel­mann F, Döh­ner K, Gral­lert H, Strauch K, Tanaka T, Ban­di­nelli S, Gianno­pou­los A, Pieri L, Man­na­relli C, Giss­lin­ger H, Barosi G, Caz­zola M, Rei­ter A, Har­ri­son C, Camp­bell P, Green AR, Van­nuc­chi A, Cross NC. Gene­tic varia­tion at MECOM, TERT, JAK2 and HBS1L-MYB pre­dis­po­ses to mye­lo­pro­li­fe­ra­tive neo­plasms. Nat Com­mun. 2015 Apr 7;6:6691.

16. Weiß­bach S, Lan­ger C, Puppe B, Nedeva T, Bach E, Kull M, Bar­gou R, Ein­sele H, Rosen­wald A, Knop S, Leich E. The mole­cu­lar spec­trum and cli­ni­cal impact of DIS3 muta­ti­ons in mul­ti­ple mye­loma. Br J Hae­ma­tol. 2015 Apr;169(1):57-70.

15. Tam CS, Stil­gen­bauer S. How best to manage pati­ents with chro­nic lym­pho­cy­tic leu­ek­mia with 17p dele­tion and/or TP53 muta­tion? Leuk Lym­phoma. 2015 Mar;56(3):587-93.

14. Paschka P, Schlenk RF, Gaid­zik VI, Her­zig J, Aulitzky T, Bul­lin­ger L, Späth D, Teleanu V, Künd­gen A, Köhne CH, Bross­art P, Held G, Horst HA, Ring­hof­fer M, Götze K, Nach­baur D, Kind­ler T, Heu­ser M, Thol F, Gan­ser A, Döh­ner H, Döh­ner K. ASXL1 muta­ti­ons in youn­ger adult pati­ents with acute mye­loid leuke­mia: A study of the German-​Austrian Acute Mye­loid Leuke­mia Study Group. Hae­ma­to­lo­gica. 2015 Mar;100(3):324-30.

13. Bejanyan N, Weis­dorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bun­jes DW, Zhang MJ. Sur­vi­val of Pati­ents with Acute Mye­loid Leuke­mia Relap­sing after Allo­gen­eic Hema­to­poie­tic Cell Trans­plan­ta­tion: A Cen­ter for Inter­na­tio­nal Blood and Mar­row Trans­plant Rese­arch Study. Biol Blood Mar­row Trans­plant. 2015 Mar;21(3):454-9.

12. Stolze B, Rein­hart S, Bull­lin­ger L, Fröh­ling S, Scholl C. Com­pa­ra­tive ana­ly­sis of KRAS codon 12, 13, 18, 61, and 117 muta­ti­ons using human MCF10A iso­ge­nic cell lines. Sci Rep. 2015 Feb;5: 8535.

11. Kor­tüm KM, Lan­ger C, Monge J, Bru­ins L, Egan JB, Zhu YX, Shi CX, Jed­low­ski P, Schmidt J, Ojha J, Bul­lin­ger L, Lie­bisch P, Kull M, Cham­pion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fon­seca R, Ein­sele H, Ste­wart AK, Brag­gio E. Tar­ge­ted sequen­cing using a 47 gene mul­ti­ple mye­loma muta­tion panel (M3 P) in -17p high risk disease. Br J Hae­ma­tol. 2015 Feb;168(4):507-10.

10. Balia­kas P, Had­zi­di­mi­triou A, Sut­ton LA, Rossi D, Minga E, Vil­lamor N, Lar­rayoz M, Kmin­kova J, Agat­han­ge­li­dis A, Davis Z, Tausch E, Sta­lika E, Kan­torova B, Man­souri L, Scarfò L, Cor­tese D, Nav­rka­lova V, Rose-​Zerilli MJ, Smedby KE, Juli­us­son G, Ana­gnos­to­pou­los A, Makris AM, Navarro A, Del­gado J, Oscier D, Belessi C, Stil­gen­bauer S, Ghia P, Pos­pi­si­lova S, Gaidano G, Campo E, Stref­ford JC, Sta­ma­to­pou­los K, Rosen­quist R. Recur­rent muta­ti­ons refine pro­gno­sis in chro­nic lym­pho­cy­tic leuke­mia. Leuke­mia. 2015 Feb;29(2):329-36.

9. Kal­ten­bach TE, Grae­ter T, Mason RA, Krat­zer W1, Oez­tu­erk S, Haenle MM, Grue­ner B, Gott­stein M. Deter­mi­na­tion of vita­lity of liver lesi­ons by alveo­lar echi­no­coc­co­sis. Com­pa­ri­son of para­me­tric con­trast enhan­ced ultra­sound (Sono­Vue®) with quan­ti­fied 18F-​FDG-PET-CT. Nukle­ar­me­di­zin. 2015 Feb 16;54(1):43-9.

8. Ort­mann CA, Kent DG, Nan­ga­lia J, Sil­ber Y, Wedge DC, Grin­feld J, Bax­ter EJ, Mas­sie CE, Papaem­ma­nuil E, Menon S, God­frey AL, Dimitro­pou­lou D, Gugliel­melli P, Bel­los­illo B, Bes­ses C, Döh­ner K, Har­ri­son CN, Vas­si­liou GS, Van­nuc­chi A, Camp­bell PJ, Green AR. Effect of Muta­tion Order on Mye­lo­pro­li­fe­ra­tive Neo­plasms. N Engl J Med. 2015 Feb 12;372(7):601-612.

7. Veloso Alves Pereira I, Buch­mann B, Sand­mann L, Sprinzl K, Schlaphoff V, Döh­ner K, Von­dran F, Sar­ra­zin C, Manns MP, Pinto Mar­ques Souza de Oli­veira C, Sodeik B, Cie­sek S, von Hahn T. Pri­mary Bili­ary Acids Inhi­bit Hepa­ti­tis D Virus (HDV) Entry into Human Hep­atoma Cells Expres­sing the Sodium-​Taurocholate Cotrans­por­ting Poly­pep­tide (NTCP). PLoS One. 2015 Feb 3;10(2):e0117152.

6. Esch­bach J, von Einem B, Mül­ler K, Bayer H, Schef­fold A, Mor­ri­son BE, Rudolph KL, Thal DR, Wit­ting A, Weydt P, Otto M, Fau­ler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weis­haupt JH, Dan­zer KM. Mutual exacer­ba­tion of per­oxi­some proliferator-​activated recep­tor gamma coac­ti­va­tor 1alpha dere­gu­la­tion and alpha-​synuclein oli­go­me­riza­tion. Ann Neu­rol. 2015 Jan;77(1): 15-32.

5. Vers­luis J, Labo­pin M, Nie­der­wie­ser D, Socie G, Schlenk RF, Mil­pied N, Nag­ler A, Blaise D, Rocha V, Cor­ne­lis­sen JJ, Mohty M. Pre­dic­tion of non-​relapse mor­ta­lity in reci­pi­ents of redu­ced inten­sity con­di­tio­ning allo­gen­eic stem cell trans­plan­ta­tion with AML in first com­plete remis­sion. Leuke­mia. 2015 Jan;29(1):51-7. 

4. Grö­schel S, San­ders MA, Hoo­gen­boe­zem R, Zei­lema­ker A, Haver­mans M, Erpe­linck C, Bin­dels EM, Bever­loo HB, Döh­ner H, Löwen­berg B, Döh­ner K, Del­wel R, Valk PJ. Muta­tio­nal spec­trum of mye­loid mali­gnan­cies with inv(3)/t(3;3) reveals a pre­do­mi­nant invol­vement of RAS/RTK signa­ling pathways. Blood. 2015 Jan 1;125(1):133-9.

3. Bhat­tach­a­rya N, Rei­chen­zel­ler M, Caudron-​Herger M, Haebe S, Brady N, Die­ner S, Nothing M, Döh­ner H, Stil­gen­bauer S, Rippe K, Mer­tens D. Loss of coope­ra­ti­vity of secre­ted CD40L and incre­a­sed dose-​response to IL4 on CLL cell via­bi­lity cor­re­la­tes with enhan­ced acti­va­tion of NF-kB and STAT6. Int J Can­cer. 2015 Jan 1;136(1):65-73.

2. Goede V, Klein C, Stil­gen­bauer S. Obi­nu­tu­zu­mab (GA101) for the Treat­ment of Chro­nic Lym­pho­cy­tic Leuke­mia and Other B-​Cell Non-​Hodgkin's Lym­pho­mas: A Gly­co­en­gi­nee­red Type II CD20 Anti­body. Oncol Res Treat. 2015;38(4):185-92.

1. Hunt L, Green­wood D, Heim­pel H, Noel N, White­way A, King MJ. Toward the har­mo­niza­tion of result pre­sen­ta­tion for the eosin-​5'-​maleimide bin­ding test in the dia­gno­sis of hereditary sphe­ro­cy­to­sis. Cyto­me­try B Clin Cytom. 2015 Jan;88(1): 50-7.

89.  Pat­le­wicz G, Kuseva C, Meh­med A, Popova Y, Dimit­rova G, Ellis G, Hun­zi­ker R, Kern P, Low L, Ringeis­sen S, Roberts DW, Meke­nyan O.  TIMES-​SS--recent refi­ne­ments resul­ting from an indus­trial skin sen­si­ti­sa­tion con­sor­tium.  SAR QSAR Envi­ron Res. 2014;25(5):367-91. Epub 2014 May 1.  

88.  Pfreund­schuh M, Poe­schel V, Zey­na­lova S, Hänel M, Held G, Schmitz N, Viar­dot A, Drey­ling MH, Hal­lek M, Muel­ler C, Wie­sen MH, Witzens-​Harig M, Tru­em­per L, Kel­ler U, Rixe­cker T, Zwick C, Muraw­ski N.  Opti­miza­tion of Ritu­xi­mab for the Treat­ment of Dif­fuse Large B-​Cell Lym­phoma (II): Exten­ded Ritu­xi­mab Exposure Time in the SMARTE-​R-CHOP-14 Trial of the Ger­man High-​Grade Non-​Hodgkin Lym­phoma Study Group.  J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17.  

87.  Tausch E, Stil­gen­bauer S.  [Chro­nic lym­pho­cy­tic leuke­mia: cur­rent stan­dards and novel approa­ches.]  [Article in Ger­man]  Inter­nist (Berl). 2014 Dec;55(12):1400-9.  

86. Topp MS, Gök­bu­get N, Zug­maier G, Klap­pers P, Stell­jes M, Neu­mann S, Viar­dot A, Marks R, Died­rich H, Faul C, Reichle A, Horst HA, Brüg­ge­mann M, Wes­siepe D, Hol­land C, Ale­kar S, Mer­gen N, Ein­sele H, Hoel­zer D, Bar­gou RC.  Phase II Trial of the Anti-​CD19 Bispe­ci­fic T Cell-​Engager Bli­na­tu­mo­mab Shows Hema­to­lo­gic and Mole­cu­lar Remis­si­ons in Pati­ents With Relap­sed or Refrac­tory B-​Precursor Acute Lym­phob­lastic Leuke­mia.  J Clin Oncol. 2014 Dec 20;32(36):4134-40. Epub 2014 Nov 10.  

85.  Dechow T, Steidle S, Götze KS, Rude­lius M, Behnke K, Pech­loff K, Kratzat S, Bul­lin­ger L, Fend F, Sobe­ron V, Mit­ova N, Li Z, Tha­ler M, Bauer J, Piet­sch­mann E, Albers C, Grund­ler R, Schmidt-​Supprian M, Ruland J, Peschel C, Duys­ter J, Rose-​John S, Bas­ser­mann F, Kel­ler U.  GP130 acti­va­tion indu­ces mye­loma and col­la­bo­ra­tes with MYC.  J Clin Invest. 2014 Dec 1;124(12):5263-74. Epub 2014 Nov 10.  

84.  Hoel­zer D, Walew­ski J, Döh­ner H, Viar­dot A, Hid­de­mann W, Spie­ker­mann K, Serve H, Dühr­sen U, Hütt­mann A, Thiel E, Deng­ler J, Kneba M, Schaich M, Schmidt-​Wolf IG, Beck J, Her­ten­stein B, Reichle A, Domanska-​Czyz K, Fiet­kau R, Horst HA, Rie­der H, Schwartz S, Bur­meis­ter T, Gök­bu­get N.  Impro­ved out­come of adult Bur­kitt lym­phoma/leuke­mia pati­ents with ritu­xi­mab and inten­sive che­mo­the­rapy: report of a large pro­spec­tive mul­ti­cen­ter trial.  Blood. 2014 Dec 18;124(26):3870-9. Epub 2014 Oct 30.  

83.  Dre­ger P, Sche­te­lig J, Ander­sen N, Cor­ra­dini P, van Gel­der M, Grib­ben J, Kimby E, Michal­let M, Moreno C, Stil­gen­bauer S, Monts­er­rat E.  Mana­ging high-​risk chro­nic lym­pho­cy­tic leuke­mia during tran­si­tion to a new treat­ment era: stem cell trans­plan­ta­tion or novel agents?  Blood. 2014 Dec 18;124(26):3841-9. Epub 2014 Oct 9.  

82.  Lan­ger­beins P, Busch R, Anheier N, Dürig J, Berg­mann M, Goebeler ME, Hurtz HJ, Stauch MB, Stil­gen­bauer S, Döh­ner H, Fink AM, Cra­mer P, Fischer K, Wendt­ner CM, Hal­lek M, Eich­horst B.  Poor effi­cacy and tole­ra­bi­lity of R-​CHOP in relap­sed/refrac­tory chro­nic lym­pho­cy­tic leuke­mia and Rich­ter trans­for­ma­tion.  Am J Hema­tol. 2014 Dec;89(12):E239-43. Epub 2014 Sep 26.  

81.  Bru­e­di­gam C, Bag­ger FO, Hei­del FH, Paine Kuhn C, Guig­nes S, Song A, Aus­tin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bul­lin­ger L, Hill GR, Arm­strong SA, Wil­liams DA, Lane SW.  Telo­me­rase Inhi­bi­tion Effec­tively Tar­gets Mouse and Human AML Stem Cells and Delays Relapse fol­lo­wing Che­mo­the­rapy.  Cell Stem Cell. 2014 Dec 4;15(6):775-90.  

80.  Schlenk RF, Kay­ser S, Bul­lin­ger L, Kobbe G, Cas­per J, Ring­hof­fer M, Held G, Bross­art P, Lüb­bert M, Salih HR, Kind­ler T, Horst HA, Wulf G, Nach­baur D, Götze K, Lam­par­ter A, Paschka P, Gaid­zik VI, Teleanu V, Späth D, Ben­ner A, Krau­ter J, Gan­ser A, Döh­ner H, Döh­ner K.  Dif­fe­ren­tial impact of alle­lic ratio and inser­tion site in FLT3-ITD posi­tive AML with respect to allo­gen­eic hema­to­poie­tic stem cell trans­plan­ta­tion.  Blood. 2014 Nov 27;124(23):3441-9. Epub 2014 Sep 30.  

79.  Wein­hold N, Försti A, da Silva Filho M, Nickel J, Campo C, Hoff­mann P, Nöthen MM, Hose D, Gold­schmidt H, Jauch A, Lan­ger C, Hegen­bart U, Schön­land SO, Hem­minki K.  Immu­n­o­glo­bu­lin light chain amy­lo­i­do­sis sha­res gene­tic suscep­ti­bi­lity with mul­ti­ple mye­loma.  Leuke­mia. 2014 Nov;28(11):2254-6. Epub 2014 Jul 3.  

78.  Just B, Kern P, Luthardt R, Rudolph H, Grü­ner B, Wahl­ers K.  Echi­no­coc­cus cysts affec­ting oro­ma­xillo­facial structures-​-a sys­te­ma­tic review.  Oral Dis. 2014 Nov;20(8):756-61. Epub 2014 Mar 7.  

77.  Te Raa GD, Malčiková J, Mraz M, Trbu­sek M, Le Garff-​Tavernier M, Merle-​Béral H, Greil R, Mer­kel O, Pospíšilová S, Lin K, Pet­titt AR, Stan­ko­vic T, van Oers MH, Elde­ring E, Stil­gen­bauer S, Zenz T, Kater AP; European Rese­arch Initia­tive on CLL (ERIC).  Assess­ment of TP53 func­tio­na­lity in chro­nic lym­pho­cy­tic leu­ka­e­mia by dif­fe­rent assays; an ERIC-​wide approach.  Br J Hae­ma­tol. 2014 Nov;167(4):565-9. Epub 2014 Jun 30.  

76.  Risueño A, Roson-​Burgo B, Dol­nik A, Hernandez-​Rivas JM, Bul­lin­ger L, De Las Rivas J.  A robust esti­ma­tion of exon expres­sion to iden­tify alter­na­tive spli­ced genes applied to human tis­sues and can­cer samp­les.  BMC Geno­mics. 2014 Oct 8;15(1):879.  

75.  von Baer, Ehr­hardt, Baum­hoer, Mayer-​Steinacker, Schult­heiss, Abdul-​Nou, Ment­zel, Fend, Möl­ler, Jundt, Barth.  Immu­n­o­hi­sto­che­mi­cal and FISH ana­ly­sis of MDM2 and CDK4 in a dedif­fe­ren­tia­ted extra­skel­etal osteo­s­ar­coma ari­sing in the vas­tus late­ra­lis mus­cle: Dif­fe­ren­tial dia­gno­sis and dia­gno­stic algo­rithm.  Pathol Res Pract. 2014 Oct;210(10):698-703. Epub 2014 May 22.  

74.  Effi­cace F, Man­delli F, Avvi­sati G, Cot­tone F, Fer­rara F, Di Bona E, Spec­chia G, Breccia M, Levis A, Sica S, Fini­zio O, Kropp MG, Fio­ri­toni G, Cer­qui E, Vignetti M, Ama­dori S, Schlenk RF, Platz­be­cker U, Lo-​Coco F.  Ran­do­mi­zed Phase III Trial of Reti­noic Acid and Arse­nic Tri­oxide Ver­sus Reti­noic Acid and Che­mo­the­rapy in Pati­ents With Acute Pro­mye­lo­cy­tic Leuke­mia: Health-​Related Quality-​of-Life Out­co­mes.  J Clin Oncol. 2014 Oct 20;32(30):3406-12. Epub 2014 Sep 22.  

73.  Jors K, Adami S, Xan­der C, Mef­fert C, Gaert­ner J, Bar­den­heuer H, Buch­heidt D, Mayer-​Steinacker R, Vieh­rig M, George W, Becker G.  Dying in can­cer cen­ters: Do the cir­cums­tances allow for a dig­ni­fied death?  Can­cer. 2014 Oct 15;120(20):3254-60. Epub 2014 Sep 8.  

72.  Mbaya H, Magambo J, Njenga S, Zeyhle E, Mbae C, Mulinge E, Was­ser­mann M, Kern P, Romig T.  Echi­no­coc­cus spp. in cen­tral Kenya: a dif­fe­rent story.  Para­si­tol Res. 2014 Oct;113(10):3789-94. Epub 2014 Jul 24.  

71.  Riz­zieri D, Vey N, Tho­mas X, Huguet-​Rigal F, Schlenk RF, Krau­ter J, Kind­ler T, Gjert­sen BT, Blau IW, Jac­obsen TF, Johan­sen M, Berge­land T, Gianella-​Borradori A, Krug U.  A phase II study of ela­cyt­ara­bine in com­bi­na­tion with idaru­bi­cin and of hENT1 expres­sion in pati­ents with acute mye­loid leuke­mia and per­sis­tent blasts after the first induc­tion course.  Leuk Lym­phoma. 2014 Sep;55(9):2114-9. Epub 2014 Jan 24.  

70.  Muraw­ski N, Pfreund­schuh M, Zey­na­lova S, Poe­schel V, Hänel M, Held G, Schmitz N, Viar­dot A, Drey­ling M, Hal­lek M, Witzens-​Harig M, Trüm­per L, Rixe­cker T, Zwick C.  Opti­miza­tion of ritu­xi­mab for the treat­ment of DLBCL (I) : Dose-​dense ritu­xi­mab in the DENSE-​R-CHOP-14 trial of the DSHNHL.  Ann Oncol. 2014 Sep;25(9):1800-6. Epub 2014 Jun 13.  

69.  Yun H, Damm F, Yap D, Schwar­zer A, Cha­tur­vedi A, Jyots­ana N, Lüb­bert M, Bul­lin­ger L, Döh­ner K, Gef­fers R, Apa­ri­cio S, Hum­phries RK, Gan­ser A, Heu­ser M.  Impact of MLL5 expres­sion on deci­ta­bine effi­cacy and DNA methy­la­tion in acute mye­loid leuke­mia.  Hae­ma­to­lo­gica. 2014 Sep;99(9):1456-64. Epub 2014 Jun 3.  

68.  Feur­stein S, Rücker FG, Bul­lin­ger L, Hof­mann W, Manuk­jan G, Göh­ring G, Leh­mann U, Heu­ser M, Gan­ser A, Döh­ner K, Schle­gel­ber­ger B, Stei­ne­mann D.  Haplo­in­suf­fi­ci­ency of ETV6 and CDKN1B in pati­ents with acute mye­loid leuke­mia and com­plex karyo­type.  BMC Geno­mics. 2014 Sep 11;15(1):784.
 

67.  Fen­aux P, Haase D, Sanz GF, San­tini V, Buske C; ESMO Gui­de­li­nes Work­ing Group.  Mye­lo­dys­plastic syn­dro­mes: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2014 Sep. Epub 2014 Jul 25.  

66.  Stad­ler CR, Vegi N, Mulaw MA, Edmaier KE, Rawat VP, Dol­nik A, Bul­lin­ger L, Heil­meier B, Quintanilla-​Fend L, Spie­ker­mann K, Hid­de­mann W, Döh­ner K, Döh­ner H, Feuring-​Buske M, Buske C.  The leu­ke­mo­ge­ni­city of Hoxa9 depends on alter­na­tive spli­cing.  Leuke­mia. 2014 Sep;28(9):1838-43. Epub 2014 Feb 18.  

65.  Zug­maier G, Topp MS, Ale­kar S, Viar­dot A, Horst HA, Neu­mann S, Stell­jes M, Bar­gou RC, Goebeler M, Wes­siepe D, Degen­hard E, Gök­bu­get N, Klin­ger M.  Long-​term follow-​up of serum immu­n­o­glo­bu­lin levels in blinatumomab-​treated pati­ents with mini­mal resi­dual disease-​positive B-​precursor acute lym­phob­lastic leuke­mia.  Blood Can­cer J. 2014 Sep 5;4:244.  

64.  Escu­dier B, Porta C, Schmi­din­ger M, Algaba F, Patard JJ, Khoo V, Eisen T, Hor­wich A; ESMO Gui­de­li­nes Work­ing Group.  Col­la­bo­ra­tors (20): Cer­van­tes A, Pen­the­rou­da­kis G, Felip E, Pav­li­dis N, Sta­hel RA, Car­d­oso F, Senkus-​Konefka E, Arnold D, Rou­gier P, Hor­wich A, Sessa C, Colombo N, Lici­tra L, Buske C, Ladetto M, Peters S, Casali P, Keil­holz U, Cherny N, Herr­stedt J.  Renal cell car­ci­noma: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2014 Sep  

63.  Drey­ling M, Geis­ler C, Her­mine O, Kluin-​Nelemans HC, Le Gouill S, Rule S, Shpil­berg O, Walew­ski J, Ladetto M; ESMO Gui­de­li­nes Work­ing Group.
Col­la­bo­ra­tors (20): Cer­van­tes A, Pen­the­rou­da­kis G, Felip E, Pav­li­dis N, Sta­hel RA, Car­d­oso F, Senkus-​Konefka E, Arnold D, Rou­gier P, Hor­wich A, Sessa C, Colombo N, Lici­tra L, Buske C, Ladetto M, Peters S, Casali P, Keil­holz U, Cherny N, Herr­stedt J.  Newly dia­gno­sed and relap­sed man­tle cell lym­phoma: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2014 Sep  

62.  Kagendo D, Magambo J, Agola EL, Njenga SM, Zeyhle E, Mulinge E, Gitonga P, Mbae C, Muchiri E, Was­ser­mann M, Kern P, Romig T.  A sur­vey for Echi­no­coc­cus spp. of car­ni­vo­res in six wild­life con­ser­va­tion areas in Kenya.  Para­si­tol Int. 2014 Aug;63(4):604-11. Epub 2014 Apr 13.  

61.  Wues­ten­berg J, Grue­ner B, Oez­tu­erk S, Mason RA, Haenle MM, Grae­ter T, Akinli AS, Kern P, Krat­zer W.  Dia­gno­stics in cystic echi­no­coc­co­sis: sero­logy ver­sus ultra­so­no­gra­phy.  Turk J Gas­tro­en­te­rol. 2014 Aug;25(4):398-404.  

60.  Becker H, Maharry K, Mrózek K, Voli­nia S, Eis­feld AK, Rad­ma­cher MD, Kohl­schmidt J, Met­ze­ler KH, Schwind S, Whit­man SP, Mend­ler JH, Wu YZ, Nico­let D, Paschka P, Powell BL, Car­ter TH, Wetz­ler M, Kolitz JE, Car­roll AJ, Baer MR, Cali­gi­uri MA, Stone RM, Mar­cucci G, Bloom­field CD.  Pro­gno­stic gene muta­ti­ons and dis­tinct gene- and microRNA-​expression signa­tu­res in acute mye­loid leuke­mia witha sole tri­somy 8.  Leuke­mia. 2014 Aug;28(8):1754-8. Epub Mar 21. No abs­tract availa­ble.  

59.  Döh­ner H, Lüb­bert M, Fied­ler W, Fouil­lard L, Haa­l­and A, Brand­wein JM, Lepretre S, Reman O, Tur­lure P, Ott­mann OG, Müller-​Tidow C, Krä­mer A, Raf­foux E, Döh­ner K, Schlenk RF, Voss F, Taube T, Frit­sch H, Maer­tens J.  Ran­do­mi­zed, phase 2 trial com­pa­ring low-​dose cyt­ara­bine with or wit­hout vola­ser­tib in AML pati­ents not sui­ta­ble for inten­sive induc­tion the­rapy.  Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8.  

58.  Schnei­der V, Zhang L, Bul­lin­ger L, Rojew­ski M, Hof­mann S, Wies­neth M, Schre­zen­meier H, Götz M, Bot­zen­hardt U, Barth TF, Döh­ner K, Döh­ner H, Grei­ner J.  Leuke­mic stem cells of acute mye­loid leuke­mia pati­ents car­ry­ing NPM1 muta­tion are can­di­da­tes for tar­ge­ted immu­n­o­the­rapy.  Leuke­mia. 2014 Aug;28(8):1759-62. Epub 2014 Mar 28. No abs­tract availa­ble.  

57.  Tausch E, Mer­tens D, Stil­gen­bauer S.  Advan­ces in trea­ting chro­nic lym­pho­cy­tic leuke­mia.  F1000Prime Rep. 2014 Aug 1;6:65. eColl­ec­tion 2014.  

56.  Shi­va­rov V, Bul­lin­ger L.  Expres­sion pro­fi­ling of leuke­mia pati­ents: Key les­sons and future direc­tions.  Exp Hema­tol. 2014 Aug;42(8):651-60. Epub 2014 Apr 15.  

55.  Port M, Bött­cher M, Thol F, Gan­ser A, Schlenk R, Wasem J, Neu­mann A, Pou­rya­mout L.  Pro­gno­stic signi­ficance of FLT3 inter­nal tan­dem dupli­ca­tion, nucleo­phos­min 1, and CEBPA gene muta­ti­ons for acute mye­loid leuke­mia pati­ents with nor­mal karyo­type and youn­ger than 60 years: a sys­te­ma­tic review and meta-​analysis.  Ann Hema­tol. 2014 Aug;93(8):1279-86. Epub 2014 May 7.  

54.  Kühn MWM, Bul­lin­ger L, Grö­schel S, Krönke J, Edel­mann J, Rücker FG, Eiwen K, Paschka P, Gaid­zik VG, Holz­mann K, Schlenk RF, Döh­ner H, Döh­ner K.  Genome-​wide geno­typ­ing of acute mye­loid leuke­mia with trans­lo­ca­tion t(9;11)(p22;q23) reveals novel recur­rent geno­mic alte­ra­ti­ons.  Hae­ma­to­lo­gica. 2014 Aug;99(8):e133-5. Epub 2014 May 23.  

53.  Pfirr­mann M, Saus­sele S, Hoch­haus A, Rei­ter A, Ber­ger U, Hoss­feld DK, Nerl C, Scheid C, Spie­ker­mann K, Mayer J, Hell­mann A, Lech­ner K, Falge C, Sayer HG, Bun­jes D, Gan­ser A, Bee­len DW, Bal­do­mero H, Schanz U, Heim­pel H, Kolb HJ, Has­ford J, Grat­wohl A, Hehl­mann R; for the Schwei­ze­ri­sche Arbeits­ge­mein­schaft für Kli­ni­sche For­schung (SAKK) and the Ger­man CML Study Group.  Explai­ning sur­vi­val dif­fe­ren­ces bet­ween two con­se­cu­tive stu­dies with allo­gen­eic stem cell trans­plan­ta­tion in pati­ents with chro­nic mye­loid leuke­mia.  J Can­cer Res Clin Oncol. 2014 Aug;140(8):1367-81. Epub 2014 Apr 10.  

52.  Hof­mann C, Stüh­mer T, Schmiedl N, Wetz­ker R, Mot­tok A, Rosen­wald A, Lan­ger C, Zovko J, Chat­ter­jee M, Ein­sele H, Bar­gou RC, Stein­brunn T.  PI3K-​dependent mul­ti­ple mye­loma cell sur­vi­val is media­ted by the PIK3CA iso­form.  Br J Hae­ma­tol. 2014 Aug;166(4):529-39. Epub 2014 Apr 26.  

51.  Ben­ner A, Man­souri L, Rossi D, Majid A, Wil­lan­der K, Par­ker A, Bond G, Pav­lova S, Nückel H, Mer­kel O, Ghia P, Monts­er­rat E, Kaderi MA, Rosen­quist R, Gaidano G, Dyer MJ, Söderk­vist P, Lin­der­holm M, Oscier D, Tva­ruz­kova Z, Pos­pi­si­lova S, Dühr­sen U, Greil R, Döh­ner H, Stil­gen­bauer S, Zenz T; European Rese­arch Initia­tive on CLL (ERIC).  MDM2 pro­mo­tor poly­mor­phism and disease cha­rac­te­ristics in chro­nic lym­pho­cy­tic leuke­mia: results of an indi­vi­dual pati­ent data-​based meta-​analysis.  Hae­ma­to­lo­gica. 2014 Aug;99(8):1285-91.  

50.  Muraw­ski N, Held G, Zie­pert M, Kempf B, Viar­dot A, Hänel M, Witzens-​Harig M, Mahl­berg R, Rübe C, Fle­cken­stein J, Zwick C, Glass B, Schmitz N, Zey­na­lova S, Pfreund­schuh M.  The role of radio­the­rapy and intra­the­cal CNS pro­phy­la­xis in ext­ra­lympha­tic cra­nio­facial aggres­sive B-​cell lym­pho­mas.  Blood. 2014 Jul 31;124(5):720-8. Epub 2014 Jun 17.  

49.  Proetel U, Pletsch N, Laus­eker M, Mül­ler MC, Hanf­stein B, Krause SW, Kal­manti L, Schrei­ber A, Heim D, Baer­lo­cher GM, Hof­mann WK, Lange E, Ein­sele H, Wernli M, Kre­mers S, Schlag R, Mül­ler L, Hänel M, Link H, Her­ten­stein B, Pfirr­man M, Hoch­haus A, Has­ford J, Hehl­mann R, Sau­ßele S; Ger­man Chro­nic Mye­loid Leuke­mia Study Group; Schwei­ze­ri­sche Arbeits­ge­mein­schaft für Kli­ni­sche Krebs­for­schung (SAKK).  Older pati­ents with chro­nic mye­loid leuke­mia (≥65 years) pro­fit more from hig­her ima­ti­nib doses than youn­ger pati­ents: a sub­ana­ly­sis of the ran­do­mi­zed CML-​Study IV.  Ann Hema­tol. 2014 Jul;93(7):1167-76.  

48.  Weis­ser M, Yeh RF, Duchateau-​Nguyen G, Palermo G, Nguyen TQ, Shi X, Stin­son SY, Yu N, Dufour A, Robak T, Salo­gub GN, Dmos­zynska A, Solal-​Celigny P, War­zocha K, Loscer­ta­les J, Cata­lano J, Lar­ratt L, Ros­siev VA, Bence-​Bruckler I, Geis­ler CH, Mon­tillo M, Fischer K, Fink AM, Hal­lek M, Blo­eh­dorn J, Busch R, Ben­ner A, Döh­ner H, Valente N, Wen­ger MK, Stil­gen­bauer S, Dornan D.  PTK2 expres­sion and immu­n­o­chemo­the­rapy out­come in chro­nic lym­pho­cy­tic leuke­mia.  Blood. 2014 Jul 17;124(3):420-5. Epub 2014 Jun 10.  

47.  Sasca D, Häh­nel PS, Szy­bin­ski J, Kha­waja K, Kriege O, Pante SV, Bul­lin­ger L, Strand S, Strand D, Theo­bald M, Kind­ler T.  SIRT1 pre­vents geno­to­xic stress-​induced p53 acti­va­tion in acute mye­loid leuke­mia.  Blood. 2014 Jul 3;124(1):121-33. Epub 2014 May 22.  

46.  Pflug N, Bahlo J, Shana­felt TD, Eich­horst BF, Berg­mann MA, Elter T, Bauer K, Mal­chau G, Rabe KG, Stil­gen­bauer S, Döh­ner H, Jäger U, Eckart MJ, Hopfin­ger G, Busch R, Fink AM, Wendt­ner CM, Fischer K, Kay NE, Hal­lek M.  Deve­lo­p­ment of a com­pre­hen­sive pro­gno­stic index for pati­ents with chro­nic lym­pho­cy­tic leuke­mia.  Blood. 2014 Jul 3;124(1):49-62. Epub 2014 May 5.  

45.  Pla­cke T, Faber K, Nonami A, Put­wain SL, Salih HR, Hei­del FH, Krä­mer A, Root DE, Bar­bie DA, Krivt­sov AV, Arm­strong SA, Hahn WC, Huntly BJ, Sykes SM, Mil­som MD, Scholl C, Fröh­ling S.  Requi­re­ment for CDK6 in MLL-​rearranged acute mye­loid leuke­mia.  Blood. 2014 Jul 3;124(1):13-23. Epub 2014 Apr 24.  

44.  Hagn M, Black­well SE, Beyer T, Ebel V, Fabri­cius D, Lind­ner S, Stil­gen­bauer S, Sim­met T, Tam C, Nee­son P, Tra­pani JA, Schre­zen­meier H, Wei­ner GJ, Jahrs­dör­fer B.  B-CLL cells acquire APC- and CTL-​like phe­no­ty­pic cha­rac­te­ristics after sti­mu­la­tion with CpG ODN and IL-21.  Int Immu­nol. 2014 Jul;26(7):383-95. Epub 2014 Feb 4.  

43.  Bubolz AM, Weis­sin­ger SE, Sten­zin­ger A, Arndt A, Stei­nes­tel K, Brü­der­lein S, Cario H, Lubatschofski A, Welke C, Ana­gnos­to­pou­los I, Barth TF, Beer AJ, Möl­ler P, Gott­stein M, Viar­dot A, Len­n­erz JK.  Poten­tial cli­ni­cal impli­ca­ti­ons of BRAF muta­ti­ons in his­tio­cy­tic pro­li­fe­ra­ti­ons.  Onco­tar­get. 2014 Jun 30;5(12):4060-70.  

42.  Tas­sara M, Döh­ner K, Bross­art P, Held G, Götze K, Horst HA, Ring­hof­fer M, Köhne CH, Kre­mers S, Rag­ha­va­char A, Wulf G, Kir­chen H, Nach­baur D, Derigs HG, Wat­tad M, Kol­ler E, Brug­ger W, Matz­dorff A, Greil R, Heil G, Paschka P, Gaid­zik VI, Gött­li­cher M, Döh­ner H, Schlenk RF.  Val­proic acid in com­bi­na­tion with all-​trans reti­noic acid and inten­sive induc­tion the­rapy for acute mye­loid leuke­mia in older pati­ents.  Blood. 2014 Jun 26;123(26):4027-4036. Epub 2014 May 5.  

41.  Knud­sen PB, Hanna B, Ohl S, Sell­ner L, Zenz T, Döh­ner H, Stil­gen­bauer S, Lar­sen TO, Lich­ter P, Seif­fert M.  Chae­to­gl­obo­sin A pre­fe­ren­ti­ally indu­ces apo­pto­sis in chro­nic lym­pho­cy­tic leuke­mia cells by tar­ge­ting the cyto­ske­le­ton.  Leuke­mia. 2014 Jun;28(6):1289-98.  

40.  Goede V, Cra­mer P, Busch R, Berg­mann M, Stauch M, Hopfin­ger G, Stil­gen­bauer S, Doeh­ner H, Wes­ter­mann A, Wendt­ner CM, Eich­horst B, Hal­lek M.  Inter­ac­tions bet­ween comor­bi­dity and treat­ment of chro­nic lym­pho­cy­tic leuke­mia: trial results of the Ger­man CLL Study Group.  Hae­ma­to­lo­gica. 2014 Jun;99(6):1095-1100.  

39.  Woyach JA, Fur­man RR, Liu TM, Ozer HG, Zapatka M, Rup­pert AS, Xue L, Li DH, Steg­gerda SM, Ver­sele M, Dave SS, Zhang J, Yil­maz AS, Jaglow­ski SM, Blum KA, Lozan­ski A, Lozan­ski G, James DF, Barri­entos JC, Lich­ter P, Stil­gen­bauer S, Buggy JJ, Chang BY, John­son AJ, Byrd JC.  Resis­tance Mecha­nisms for the Bruton's Tyro­sine Kinase Inhi­bi­tor Ibru­ti­nib.  N Engl J Med. 2014 Jun 12;370(24):2286-94. Epub 2014 May 28.  

38.  Geyer HL, Ema­nuel RM, Dueck AC, Kilad­jian JJ, Xiao Z, Slot S, Zweegman S, Sack­mann F, Ker­gue­len Fuen­tes A, Hernández-​Maraver D, Döh­ner K, Har­ri­son CN, Radia D, Muxi P, Bes­ses C, Cer­van­tes F, Johans­son PL, Andre­as­son B, Ram­baldi A, Bar­bui T, Van­nuc­chi AM, Pas­sa­monti F, Samu­els­son J, Bir­ge­gard G, Mesa RA.  Dis­tinct clus­te­ring of sym­pto­ma­tic bur­den amongst mye­lo­pro­li­fe­ra­tive neo­plasm pati­ents: retro­spec­tive assess­ment in 1470 pati­ents.  Blood. 2014 Jun 12;123(24):3803-10.  

37.  Knud­sen PB, Hanna B, Ohl S, Sell­ner L, Zenz T, Döh­ner H, Stil­gen­bauer S, Lar­sen TO, Lich­ter P, Seif­fert M.  Chae­to­gl­obo­sin A pre­fe­ren­ti­ally indu­ces apo­pto­sis in chro­nic lym­pho­cy­tic leuke­mia cells by tar­ge­ting the cyto­ske­le­ton.  Leuke­mia. 2014 Jun;28(6):1289-98. Epub 2013 Nov 27.

36.  Qu Y, Lenn­arts­son A, Gaid­zik VI, Dene­berg S, Karimi M, Bengtzén S, Hög­lund M, Bul­lin­ger L, Döh­ner K, Leh­mann S.  Dif­fe­ren­tial methy­la­tion in CN-​AML pre­fe­ren­ti­ally tar­gets non-​CGI regi­ons and is dic­ta­ted by DNMT3A muta­tio­nal sta­tus and asso­cia­ted with pre­do­mi­nant hypo­me­thy­la­tion of HOX genes.  Epi­ge­ne­tics. 2014 May 27;9(8).  

35.  Thol F, Schlenk RF.  Gem­tu­zu­mab ozoga­micin in acute mye­loid leuke­mia revi­si­ted.  Expert Opin Biol Ther. 2014 May 28:1-11.  

34.  Pas­tore F, Dufour A, Bent­haus T, Met­ze­ler KH, Maharry KS, Schnei­der S, Ksi­en­zyk B, Mel­lert G, Zell­meier E, Kaka­dia PM, Unter­halt M, Feuring-​Buske M, Buske C, Braess J, Sauer­land MC, Hein­ecke A, Krug U, Ber­del WE, Buech­ner T, Woer­mann B, Hid­de­mann W, Boh­l­an­der SK, Mar­cucci G, Spie­ker­mann K, Bloom­field CD, Hos­ter E  Com­bi­ned Mole­cu­lar and Cli­ni­cal Pro­gno­stic Index for Relapse and Sur­vi­val in Cyto­ge­ne­ti­cally Nor­mal Acute Mye­loid Leuke­mia.  J Clin Oncol. 2014 May 20;32(15):1586-94.  

33.  Hos­ter E, Klap­per W, Her­mine O, Kluin-​Nelemans HC, Walew­ski J, van Hoof A, Trneny M, Geis­ler CH, Di Rai­mondo F, Szymczyk M, Stil­gen­bauer S, Thieb­le­mont C, Hal­lek M, Forst­point­ner R, Pott C, Ribrag V, Door­duijn J, Hid­de­mann W, Drey­ling MH, Unter­halt M.  Con­fir­ma­tion of the Mantle-​Cell Lym­phoma Inter­na­tio­nal Pro­gno­stic Index in Ran­do­mi­zed Tri­als of the European Mantle-​Cell Lym­phoma Net­work.  J Clin Oncol. 2014 May 1;32(13):1338-46.  

32.  Stil­gen­bauer S1, Schnai­ter A, Paschka P, Zenz T, Rossi M, Döh­ner K, Büh­ler A, Bött­cher S, Rit­gen M, Kneba M, Wink­ler D, Tausch E, Hoth P, Edel­mann J, Mer­tens D, Bul­lin­ger L, Berg­mann M, Kless S, Mack S, Jäger U, Pat­ten N, Wu L, Wen­ger MK, Fingerle-​Rowson G, Lich­ter P, Caz­zola M, Wendt­ner CM, Fink AM, Fischer K, Busch R, Hal­lek M, Döh­ner H.  Gene muta­ti­ons and treat­ment out­come in chro­nic lym­pho­cy­tic leuke­mia: results from the CLL8 trial.  Blood. 2014 May 22;123(21):3247-54.  

31.  Nag­ler A, Labo­pin M, Ber­ger R, Bun­jes D, Cam­pos A, Socié G, Krö­ger N, Goker H, Yakoub-​Agha I, Shi­moni A, Mohty M, Rocha V.  Allo­gen­eic hema­to­poie­tic SCT for adults AML using i.v. BU in the con­di­tio­ning regi­men: out­co­mes and risk fac­tors for the occur­rence of hepa­tic sinu­so­idal obstruc­tive syn­drome.  Bone Mar­row Trans­plant. 2014 May;49(5):628-33.  

30.  Son­net M, Claus R, Becker N, Zuck­nick M, Peter­sen J, Lipka DB, Oakes CC, Andru­lis M, Lier A, Mil­som MD, Witte T, Gu L, Kim-​Wanner SZ, Schirm­a­cher P, Wul­fert M, Gat­ter­mann N, Lüb­bert M, Rosen­bauer F, Rehli M, Bul­lin­ger L, Wei­chen­han D, Plass C.  Early aberrant DNA methy­la­tion events in a mouse model of acute mye­loid leuke­mia.  Genome Med. 2014 Apr 30;6(4):34.  

29.  Grö­schel S, San­ders MA, de Wit E, Bouw­man BAM, Erpe­linck C, van der Vel­den VHJ, Haver­mans M, Avel­lino R, van Lom K, Rom­bouts EJ, van Duin M, Döh­ner K, Bever­loo HB, Brad­ner JE, Döh­ner H, Löwen­berg B, Valk PJM, Bin­dels EMJ, de Laat W, Del­wel R.  A Sin­gle Onco­ge­nic Enhan­cer Rear­ran­ge­ment Cau­ses Con­co­mitant EVI1 and GATA2 Dere­gu­la­tion in Leuke­mia.  Cell. 2014 Apr 10;157(2):369-81.  

28.  Häh­nel PS, Enders B, Sasca D, Roos WP, Kaina B, Bul­lin­ger L, Theo­bald M, Kind­ler T.  Tar­ge­ting com­po­n­ents of the alter­na­tive NHEJ pathway sen­si­ti­zes KRAS-​mutant leuke­mic cells to che­mo­the­rapy.  Blood. 2014 Apr 10;123(15):2355-66.  

27.  Wein­hold N, John­son D, Raws­tron AC, Försti A, Doughty C, Vijay­a­krishnan J, Bro­de­rick P, Dahir N, Begum DB,  Hos­king FJ, Young K,  Wal­ker BA,  Hoff­mann P,  Mühl­ei­sen TW, Lan­ger C, Dör­ner E, Jöckel K-H, Eisele L, Nöthen MM, Hose D, Davies FE,  Gold­schmidt H,  Mor­gan GJ, Hem­minki K, and Houl­s­ton RS.  Inhe­ri­ted gene­tic suscep­ti­bi­lity to mono­clo­nal gam­mo­pa­thy of unk­nown signi­ficance  Blood. 2014 Apr 17;123(16):2513-7.  

26.  Alach­kar H, San­tha­nam R, Maharry K, Met­ze­ler KH, Huang X, Kohl­schmidt J, Mend­ler JH, Benito JM, Hickey C, Neviani P, Dor­rance AM, Anghe­lina M, Kha­life J, Tarig­hat SS, Voli­nia S, Whit­man SP, Paschka P, Hoel­ler­bauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Car­roll AJ, Per­rotti D, Andreeff M, Cali­gi­uri MA, Kono­pleva M, Gar­zon R, Bloom­field CD, Mar­cucci G.  SPARC pro­mo­tes leuke­mic cell growth and pre­dicts acute mye­loid leuke­mia out­come.  J Clin Invest. 2014 Apr 1;124(4):1512-24.  

25.  Aukema SM1, Kreuz M, Koh­ler CW, Roso­low­ski M, Hasen­cle­ver D, Hum­mel M, Küp­pers R, Lenze D, Ott G, Pott C, Rich­ter J, Rosen­wald A, Szc­ze­panow­ski M, Schwae­nen C, Stein H, Traut­mann H, Wes­sen­dorf S, Trüm­per L, Loeff­ler M, Spang R, Kluin PM, Klap­per W, Sie­bert R.  Bio­lo­gic cha­rac­te­riza­tion of adult MYC-​translocation posi­tive mature B-​cell lym­pho­mas other than mole­cu­lar Bur­kitt lym­phoma.  Hae­ma­to­lo­gica. 2014 Apr;99(4):726-35.  

24.  Goede V, Fischer K, Busch R, Engelke A, Eich­horst B, Wendt­ner CM, Cha­go­rova T, de la Serna J, Dil­huydy MS, Ill­mer T, Opat S, Owen CJ, Samoy­lova O, Kreu­zer KA, Stil­gen­bauer S, Döh­ner H, Lan­ge­rak AW, Rit­gen M, Kneba M, Asi­ka­nius E, Hum­ph­rey K, Wen­ger M, Hal­lek M.  Obi­nu­tu­zu­mab plus Chlor­am­bu­cil in Pati­ents with CLL and Coexis­ting Con­di­ti­ons.  N Engl J Med. 2014 Mar 20;370(12):1101-10.   

23.  Becker H, Yoshida K, Blagitko-​Dorfs N, Claus R, Pan­tic M, Abdel­ka­rim M, Niemöl­ler C, Greil C, Hack­an­son B, Shirai­shi Y, Chiba K, Tanaka H, Miyano S, Döh­ner K, Schnitt­ger S, Hen­neke P, Nie­meyer CM, Flo­tho C, Pfei­fer D, Ogawa S, Lüb­bert M.  Tra­cing the deve­lo­p­ment of acute mye­loid leuke­mia in CBL syn­drome.  Blood. 2014 Mar 20;123(12):1883-6.
 

22.  Mer­tens D, Stil­gen­bauer S.  Pro­gno­stic and Pre­dic­tive Fac­tors in Pati­ents With Chro­nic Lym­pho­cy­tic Leuke­mia: Rele­vant in the Era of Novel Treat­ment Approa­ches?  J Clin Oncol. 2014 Mar 20;32(9):869-72.
 

21.  Yes­hu­run M, Labo­pin M, Blaise D, Cor­ne­lis­sen JJ, Sen­ge­loev H, Vin­de­lov L, Kuball J, Che­val­lier P, Crad­dock C, Socie G, Bil­ger K, Schou­ten HC, Fegueux N, Goker H, Maer­tens J, Bun­jes D, Arnold R, Nag­ler A, Mohty M.  Impact of postremis­sion con­so­li­da­tion che­mo­the­rapy on out­come after reduced-​intensity con­di­tio­ning allo­gen­eic stem cell trans­plan­ta­tion for pati­ents with acute mye­loid leuke­mia in first com­plete remis­sion: A report from the Acute Leuke­mia Work­ing Party of the European Group for Blood and Mar­row Trans­plan­ta­tion.  Can­cer. 2014 Mar 15;120(6):855-63.
 

20.  Fur­man RR, Shar­man JP, Coutre SE, Che­son BD, Pagel JM, Hill­men P, Barri­entos JC, Zel­e­netz AD, Kipps TJ, Flinn I, Ghia P, Era­dat H, Ervin T, Lamanna N, Coif­fier B, Pet­titt AR, Ma S, Stil­gen­bauer S, Cra­mer P, Aiello M, John­son DM, Mil­ler LL, Li D, Jahn TM, Dan­sey RD, Hal­lek M, O'Brien SM.  Ide­la­li­sib and Ritu­xi­mab in Relap­sed Chro­nic Lym­pho­cy­tic Leuke­mia.  N Engl J Med. 2014 Mar 13;370(11):997-1007.  

19.  Gopal AK, Kahl BS, de Vos S, Wagner-​Johnston ND, Schus­ter SJ, Jurczak WJ, Flinn IW, Flowers CR, Mar­tin P, Viar­dot A, Blum KA, Goy AH, Davies AJ, Zin­zani PL, Drey­ling M, John­son D, Mil­ler LL, Holes L, Li D, Dan­sey RD, God­frey WR, Sal­les GA.  PI3Kδ Inhi­bi­tion by Ide­la­li­sib in Pati­ents with Relap­sed Indo­lent Lym­phoma.  N Engl J Med. 2014 Mar 13;370(11):1008-18.  

18.  Oakes CC, Claus R, Gu L, Asse­nov Y, Hüllein J, Zuck­nick M, Bieg M, Brocks D, Boga­ty­rova O, Schmidt CR, Ras­senti L, Kipps TJ, Mer­tens D, Lich­ter P, Doh­ner H, Stil­gen­bauer S, Byrd JC, Zenz T, Plass C.  Evo­lu­tion of DNA methy­la­tion is lin­ked to gene­tic aberra­ti­ons in chro­nic lym­pho­cy­tic leuke­mia.  Can­cer Dis­cov. 2014 Mar;4(3):348-61.
 

17.  Pan R, Hog­dal L, Benito J, Bucci D, Bort­ha­kur G, Cor­tes J, DeAn­gelo D, Debose L, Döh­ner H, Gaid­zik V, Galin­sky I, Golf­man L, Han L, Hafer­lach T, Haru­tyunyan K, Hu J, Lever­son J, Mar­cucci G, Mu H, Müschen M, New­man R, Park E, Ruvolo P, Ruvolo V, Ryan J, Schin­dela S, Zweidler-​McKay P, Stone R, Kant­ar­jian H, Andreeff M, Kono­pleva M, Letai A.  Sel­ec­tive BCL-2 inhi­bi­tion by ABT-199 cau­ses on tar­get cell death in acute mye­loid leuke­mia.  Can­cer Dis­co­very. 2014 Mar;4(3):362-75.  

16.  Platz­be­cker U, Al-​Ali HK, Gat­ter­mann N, Haase D, Jan­zen V, Krau­ter J, Götze K, Schlenk R, Nolte F, Letsch A, Ott­mann OG, Künd­gen A, Lüb­bert M, Ger­ming U, Wermke M, Rein­hard H, Weiss C, Lie­der K, Ehnin­ger G, Leis­mann O, Gia­gouni­dis A.  Phase 2 study of oral pano­bi­no­stat (LBH589) with or wit­hout ery­thro­poie­tin in hea­vily transfusion-​dependent IPSS low or int-1 MDS pati­ents.  Leuke­mia. 2014 Mar;28(3):696-8;
 

15.  Thol F, Bol­lin R, Gehl­haar M, Wal­ter C, Dugas M, Such­a­nek KJ, Kirch­ner A, Huang L, Cha­tur­vedi A, Wich­mann M, Wiehl­mann L, Shahs­war R, Damm F, Göh­ring G, Schle­gel­ber­ger B, Schlenk R, Döh­ner K, Döh­ner H, Krau­ter J, Gan­ser A, Heu­ser M.  Muta­ti­ons in the cohe­sin com­plex in acute mye­loid leuke­mia: cli­ni­cal and pro­gno­stic impli­ca­ti­ons.  Blood. 2014 Feb 6;123(6):914-20.
 

14.  Rapin N, Bag­ger FO, Jend­holm J, Mora-​Jensen H, Krogh A, Kohl­mann A, Thiede C, Bor­re­gaard N, Bul­lin­ger L, Win­ther O, Theilgaard-​Mönch K, Porse BT.  Com­pa­ring can­cer vs. nor­mal gene expres­sion pro­files iden­ti­fies new disease enti­ties and com­mon tran­scrip­tio­nal pro­grams in AML pati­ents.  Blood. 2014 Feb 6;123(6):894-904.
 

13.  Här­ter G, Frick­mann H, Zenk S, Wich­mann D, Ammann B, Kern P, Flei­scher B, Tan­nich E, Pop­pert S.  Dia­gno­sis of neu­ro­schis­to­so­mia­sis by anti­body spe­ci­fi­city index and semi-​quantitative real-​time PCR from cere­bro­s­pi­nal fluid and serum.  J Med Micro­biol. 2014 Feb;63(Pt 2):309-12. Epub 2013 Nov 13.   

12.  Daw­son MA, Gud­gin EJ, Hor­ton SJ, Gio­to­pou­los G, Meduri E, Rob­son S, Can­niz­zaro E, Osaki H, Wiese M, Put­wain S, Fong CY, Grove C, Craig J, Ditt­mann A, Lugo D, Jef­frey P, Dre­wes G, Lee K, Bul­lin­ger L, Prin­jha RK, Kou­za­ri­des T, Vas­si­liou GS, Huntly BJ.  Recur­rent muta­ti­ons, inclu­ding NPM1c, acti­vate a BRD4-​dependent core tran­scrip­tio­nal pro­gram in acute mye­loid leuke­mia.  Leuke­mia. 2014 Feb;28(2):311-20   11.  Herr­mann MD, Len­n­erz JK, Bul­lin­ger L, Bar­tho­lo­mae S, Holz­mann K, West­hoff MA, Cor­ba­cio­glu S, Deba­tin KM.  Tran­si­tory dasatinib-​resistant sta­tes in KIT­mut t(8;21) acute mye­loid leuke­mia cells cor­re­late with alte­red KIT expres­sion.  Exp Hema­tol. 2014 Feb;42(2):90-100.
 

10.  Bur­meis­ter T, Bar­tels G, Grö­ger D, Traut­mann H, Schwartz S, Lenz K, Tietze-​Bürger C, Viar­dot A, Wäsch R, Horst HA, Rein­hardt R, Gök­bu­get N, Hoel­zer D, Kneba M, Brüg­ge­mann M.  Germ­line vari­ants in IKZF1, ARID5B, and CEBPE as risk fac­tors for adult-​onset acute lym­phob­lastic leuke­mia: an ana­ly­sis from the GMALL study group.  Hae­ma­to­lo­gica. 2014 Feb;99(2):e23-5.  

9.  Wetz­ler M, Mrózek K, Kohl­schmidt J, Dom­bret H, Döh­ner H, Pil­orge S, Krug U, Car­roll AJ, Lar­son RA, Mar­cucci G, Hid­de­mann W, Büch­ner T, Bloom­field C.  Inten­sive induc­tion is effec­tive in sel­ect octo­ge­na­rian acute mye­loid leuke­mia pati­ents: pro­gno­stic signi­ficance of karyo­type and sel­ec­ted mole­cu­lar mar­kers used in the European Leuke­mia­Net clas­si­fi­ca­tion.  Hae­ma­to­lo­gica. 2014 Feb;99(2):308-13.  

8.          Griess­ham­mer M, Döh­ner K.  Chro­nic mye­lo­pro­li­fe­ra­tive neo­plasms.  Dtsch Med Wochen­schr. 2014 Feb;139(6):243-6.  

7.  Kay­ser S and Levis MJ  FLT3 tyro­sine kinase inhi­bi­tors in acute mye­loid leuke­mia: cli­ni­cal impli­ca­ti­ons and limi­ta­ti­ons  Leuk Lym­phoma, 2014 Feb;55(2):243-55.  

6.  Alle­gra D, Bilan V, Gar­ding A, Döh­ner H, Stil­gen­bauer S, Kuchen­bauer F, Mer­tens D.  Defec­tive DROSHA proces­sing con­tri­bu­tes to down­re­gu­la­tion of MiR-15/-16 in chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2014 Jan;28(1):98-107.   

5.  Skórka K, Bhat­tach­a­rya N, Własiuk P, Kowal M, Mer­tens D, Dmoszyńska A, Gianno­pou­los K.  Tha­li­do­mide regu­la­tion of NF-κB pro­te­ins limits Tregs acti­vity in chro­nic lym­pho­cy­tic leuke­mia.  Adv Clin Exp Med. 2014 Jan-​Feb;23(1):25-32.   

4.  Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Schef­fold A, Rudolph KL, Buske C.  Expres­sion of the lym­phoid enhan­cer fac­tor 1 is requi­red for nor­mal hema­to­poie­tic stem and pro­ge­ni­tor cell func­tion.  Leuke­mia. 2014 Jan;28(1):227-30.  

3.  Wong CC, Mar­tin­corena I, Rust AG, Ras­hid M, Ali­fran­gis C, Alex­an­drov LB, Tif­fen JC, Kober C; Chro­nic Mye­loid Dis­or­ders Work­ing Group of the Inter­na­tio­nal Can­cer Genome Con­sor­tium, Green AR, Mas­sie CE, Nan­ga­lia J, Lem­pi­daki S, Döh­ner H, Döh­ner K, Bray SJ, McDer­mott U, Papaem­ma­nuil E, Camp­bell PJ, Adams DJ.  Inac­ti­vating CUX1 muta­ti­ons pro­mote tumo­rige­ne­sis.  Nat Genet. 2014 Jan;46(1):33-8.  

2.  Neu­kir­chen J, Laus­eker M, Blum S, Gia­gouni­dis A, Lüb­bert M, Mar­tino S, Sira­gusa S, Schlenk RF, Platz­be­cker U, Hof­mann WK, Götze K, Palumbo GA, Magrin S, Künd­gen A, Aul C, Hil­de­brandt B, Has­ford J, Kobbe G, Haas R, Ger­ming U.  Vali­da­tion of the revi­sed Inter­na­tio­nal Pro­gno­stic Scoring Sys­tem (IPSS-​R) in pati­ents with mye­lo­dys­plastic syn­drome: A mul­ti­cen­ter study.  Leuk Res. 2014 Jan;38(1):57-64.  

1.  Babiak A, Stein­hau­ser M, Götz M, Herbst C, Döh­ner H, Grei­ner J.  Fre­quent T cell respon­ses against immu­n­o­ge­nic tar­gets in lung can­cer pati­ents for tar­ge­ted immu­n­o­the­rapy.  Oncol Rep. 2014 Jan;31(1):384-90.  

94. Schlenk RF, Döh­ner H.  Geno­mic appli­ca­ti­ons in the cli­nic: use in treat­ment para­digm of acute mye­loid leuke­mia.  Hema­to­logy Am Soc Hema­tol Educ Pro­gram. 2013;2013:324-30.

93.  Paschka P, Döh­ner K.  Core-​binding fac­tor acute mye­loid leuke­mia: can we improve on HiDAC con­so­li­da­tion?  Hema­to­logy Am Soc Hema­tol Educ Pro­gram. 2013;2013:209-19.

92.  Schit­ten­helm MM, Illing B, Ahmut F, Rasp KH, Blu­men­stock G, Döh­ner K, Lopez CD, Kampa-​Schittenhelm KM.  Attenu­a­ted Expres­sion of Apo­pto­sis Sti­mu­la­ting Pro­tein of p53-2 (ASPP2) in Human Acute Leuke­mia Is Asso­cia­ted with The­rapy Failure.  PLoS One. 2013 Nov 27;8(11):e80193.

91.  Held G, Zey­na­lova S, Muraw­ski N, Zie­pert M, Kempf B, Viar­dot A, Drey­ling M, Hal­lek M, Witzens-​Harig M, Fle­cken­stein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreund­schuh M.  Impact of Ritu­xi­mab and Radio­the­rapy on Out­come of Pati­ents With Aggres­sive B-​Cell Lym­phoma and Skel­etal Invol­vement.  J Clin Oncol. 2013 Nov 10;31(32):4115-22.

90.  Gerull S, Stern M, Apper­ley J, Bee­len D, Brinch L, Bun­jes D, But­ler A, Gan­ser A, Gha­vam­za­deh A, Koh MB, Komar­ni­cki M, Krö­ger N, Maer­tens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socie' G, Tischer J, Oneto R, Pass­weg J, Marsh J.  Syn­gen­eic trans­plan­ta­tion in aplastic ane­mia: pretrans­plant con­di­tio­ning and peri­phe­ral blood are asso­cia­ted with impro­ved engraft­ment - an obser­va­tio­nal study on behalf of the Severe Aplastic Ane­mia and Ped­ia­tric Disea­ses Work­ing Par­ties of the European Group for Blood and Mar­row Trans­plan­ta­tion.  Hae­ma­to­lo­gica. 2013 Nov;98(11):1804-9.

89.  Höff­ken G1, Kern P, Buch­holz U, Ewig S, Scha­berg T.  [Infor­ma­ti­ons and recom­men­da­ti­ons of the Ger­man Respi­ra­tory Society and the Paul-​Ehrlich-Society for che­mo­the­rapy con­cer­ning the out­break of influ­enza A(H7N9) virus infec­tions in humans]. [Article in Ger­man]  Pneu­mo­lo­gie. 2013 Nov;67(11):599-604.

88.  Buske C, Leblond V, Dimo­pou­los M, Kimby E, Jäger U, Drey­ling M; ESMO Gui­de­li­nes Work­ing Group.  Wal­den­strom's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9. No abs­tract availa­ble.

87.  Fey MF, Buske C; ESMO Gui­de­li­nes Work­ing Group.  Acute mye­lob­lastic leu­ka­e­mias in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up.  Ann Oncol. 2013 Oct;24 Suppl 6:vi138-43. Epub 2013 Aug 22. No abs­tract availa­ble.

86.  Chi­gri­nova E, Rinaldi A, Kwee I, Rossi D, Ran­co­ita PM, Stref­ford JC, Oscier D, Sta­ma­to­pou­los K, Papa­daki T, Ber­ger F, Young KH, Mur­ray F, Rosen­quist R, Grei­ner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Ing­hi­rami G, Ladetto M, For­coni F, Cogliatti S, Vota­vova H, Swerd­low SH, Stil­gen­bauer S, Piris MA, Matolcsy A, Spa­gnolo D, Niki­tin E, Zamò A, Gat­tei V, Bha­gat G, Ott G, Zucca E, Gaidano G, Ber­toni F.  Two main gene­tic pathways lead to the trans­for­ma­tion of chro­nic lym­pho­cy­tic leuke­mia to Rich­ter Syn­drome.  Blood. 2013 Oct 10;122(15):2673-82.

85.  Fürst D, Mül­ler C, Vuci­nic V, Bun­jes D, Herr W, Gra­matzki M, Schwerdt­fe­ger R, Arnold R, Ein­sele H, Wulf G, Pfreund­schuh M, Glass B, Schre­zen­meier H, Schwarz K, Myti­li­neos J.  High reso­lu­tion HLA-​matching in hema­to­poie­tic stem cell trans­plan­ta­tion: a retro­spec­tive col­la­bo­ra­tive ana­ly­sis.  Blood. 2013 Oct 31;122(18):3220-9.

84.  Pel­lag­atti A, Ben­ner A, Mills K, Caz­zola M, Gia­gouni­dis A, Perry J, Mal­co­vati L, Della Porta MG, Jäders­ten M, Verma A, McDo­nald EJ, Killick S, Hellstrom-​Lindberg E, Bul­lin­ger L, Wains­coat J, Boult­wood J.  Iden­ti­fi­ca­tion of gene expres­sion based pro­gno­stic mar­kers in the hema­to­poie­tic stem cells of pati­ents with mye­lo­dys­plastic syn­dro­mes.  J Clin Oncol. 2013 Oct 1;31(28):3557-64.

83.  Mei­lin­ger M, Sto­eckl C, Poll­hei­mer M, Kern P, Rei­sin­ger EC, See­ber K, Krause R, Flick H, Hoe­nigl M.  Pro­gres­sive alveo­lar echi­no­coc­co­sis after dis­con­ti­nua­tion of anthel­m­in­tic the­rapy.  Para­sit Vec­tors. 2013 Oct 1;6(1):287.

82.  Müller-​Tidow C, Bug G, Lüb­bert M, Krä­mer A, Krau­ter J, Valent P, Nach­baur D, Ber­del WE, Ott­mann OG, Frit­sch H, Mun­zert G, Garin-​Chesa P, Flei­scher F, Taube T, Döh­ner H.  A ran­do­mi­zed, open-​label, phase I/II trial to inves­ti­gate the maxi­mum tole­ra­ted dose of the Polo-​like kinase inhi­bi­tor BI 2536 in elderly pati­ents with refrac­tory/relap­sed acute mye­loid leu­ka­e­mia.  Br J Hae­ma­tol. 2013 Oct;163(2):214-222.

81.  Chubb D, Wein­hold N, Bro­de­rick P, Chen B, John­son DC, Försti A, Vijay­a­krishnan J, Miglio­rini G, Dob­bins SE, Hol­royd A, Hose D, Wal­ker BA, Davies FE, Gre­gory WA, Jack­son GH, Irving JA, Pratt G, Fegan C, Fen­ton JAL, Neben K, Hoff­mann P, Nöthen M, Mühl­ei­sen TW, Eisele L, Ross FM, Straka C, Ein­sele H, Lan­ger C, Dör­ner E, Allan JM, Jauch A, Mor­gan GJ, Hem­minki K, Houl­s­ton RS, Gold­schmidt H.  Com­mon varia­tion at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influ­en­ces mul­ti­ple mye­loma risk.  Nat Genet 2013 Oct;45(10):1221-5.

80.  Ring­hof­fer S, Rojew­ski M, Döh­ner H, Bun­jes D, Ring­hof­fer M.  T cell recon­sti­tu­tion after allo­gen­eic stem cell trans­plan­ta­tion: assess­ment by the mea­su­re­ment of the sjTREC/βTREC-​ratio and thy­mic naive T cells.  Hae­ma­to­lo­gica. 2013 Oct;98(10):1600-1608.

79.  Wahl­ers K, Mene­zes CN, Romig T, Kern P, Gro­busch MP.  Cystic echi­noc­co­sis in South Africa: the worst yet to come?  Acta Trop. 2013 Oct;128(1): 1-6.

78.  Kaasch AJ1, Rieg S, Kuet­scher J, Brodt HR, Wid­mann T, Herr­mann M, Meyer C, Welte T, Kern P, Haars U, Reu­ter S, Hüb­ner I, Strauss R, Sinha B, Brunk­horst FM, Hell­mich M, Fät­ken­heuer G, Kern WV, Sei­fert H; pre­SA­BATO study group.  Delay in the admi­nis­tra­tion of appro­priate anti­mi­cro­bial the­rapy in Sta­phy­lo­coc­cus aureus blood­stream infec­tion: a pro­spec­tive mul­ti­cen­ter hospital-​based cohort study.  Infec­tion. 2013 Oct;41(5):979-85.

77.  Iolas­con A1, Heim­pel H, Wahlin A, Tamary H.  Con­ge­ni­tal dys­ery­thro­poie­tic ane­mias: mole­cu­lar insights and dia­gno­stic approach.  Blood. 2013 Sep 26;122(13):2162-6.   76.  Astori A, Fredly H, Aloy­sius TA, Bul­lin­ger L, Mansat-​De Mas V, de la Grange P, Del­hom­meau F, Hagen KM, Récher C, Dusanter-​Fourt I, Knapps­kog S, Lil­leh­aug JR, Pen­dino F, Bruse­rud O.  CXXC5 (Retinoid-​Inducible Nuclear Fac­tor, RINF) is a Poten­tial The­ra­peu­tic Tar­get in High-​Risk Human Acute Mye­loid Leuke­mia.  Onco­tar­get. 2013 Sep;4(9):1438-48.

75.  Chris­to­peit M, Kuss O, Finke J, Bacher U, Bee­len DW, Born­häu­ser M, Schwerdt­fe­ger R, Bethge WA, Basara N, Gra­matzki M, Tischer J, Kolb HJ, Uha­rek L, Meyer RG, Bun­jes D, Scheid C, Mar­tin H, Nie­der­wie­ser D, Krö­ger N, Bertz H, Schre­zen­meier H, Schmid C.  Second Allo­graft for Hema­to­lo­gic Relapse of Acute Leuke­mia After First Allo­gen­eic Stem-​Cell Trans­plan­ta­tion From Rela­ted and Unre­la­ted Donors: The Role of Donor Change.  J Clin Oncol. 2013 Sep 10;31(26):3259-3271.

74.  Fink AM, Bött­cher S, Rit­gen M, Fischer K, Pflug N, Eich­horst B, Wendt­ner CM, Wink­ler D, Büh­ler A, Zenz T, Staib P, Mayer J, Hen­sel M, Hopfin­ger G, Wen­ger M, Fingerle-​Rowson G, Döh­ner H, Kneba M, Stil­gen­bauer S, Busch R and  Hal­lek M.  Pre­dic­tion of poor out­come in CLL pati­ents fol­lo­wing first-​line 2 treat­ment with fludar­a­bine, cyclo­phos­pha­mide and ritu­xi­mab.  Leuke­mia. 2013 Sep;27(9):1949-52.

73.  Mogoye BK1, Mene­zes CN, Wong ML, Stacey S, von Delft D, Wahl­ers K, Was­ser­mann M, Romig T, Kern P, Gro­busch MP, Frean J.  First insights into spe­cies and geno­ty­pes of Echi­no­coc­cus in South Africa.  Vet Para­si­tol. 2013 Sep 23;196(3-4):427-32.

72.  Piech­nik A, Dmos­zynska A, Omio­tek M, Mlak R, Kowal M, Stil­gen­bauer S, Bul­lin­ger L, Gianno­pou­los K.  The VEGF recep­tor, neuropilin-​1 (NRP1) repres­ents a pro­mi­sing novel tar­get for chro­nic lym­pho­cy­tic leuke­mia pati­ents.  Int J Can­cer. 2013 Sep 15;133(6):1489-96.

71.  Tho­den J1, Pott­hoff A, Bogner JR, Brock­meyer NH, Esser S, Grabmeier-​Pfistershammer K, Haas B, Hahn K, Här­ter G, Hart­mann M, Herz­mann C, Hut­te­rer J, Jor­dan AR, Lange C, Mauss S, Meyer-​Olson D, Most­haf F, Oette M, Reu­ter S, Rie­ger A, Rosen­kranz T, Ruhnke M, Schaaf B, Schwarze S, Stell­brink HJ, Sto­cker H, Sto­ehr A, Stoll M, Trä­der C, Vogel M, Wag­ner D, Wyen C, Hoff­mann C.  The­rapy and pro­phy­la­xis of oppor­tu­ni­stic infec­tions in HIV-​infected pati­ents: a gui­de­line by the Ger­man and Aus­trian AIDS socie­ties (DAIG/ÖAG) (AWMF 055/066).  Infec­tion. 2013 Sep;41 Suppl 2:S91-115.

70.  Graux C, Sonet A, Maer­tens J, Duys­ter J, Grei­ner J, Cha­lan­don Y, Mar­ti­nelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-​Borradori A, Lon­ge­rey B, Asa­tiani E, Rejeb N, Ott­mann OG  A phase I dose-​escalation study of MSC1992371A, an oral inhi­bi­tor of aurora and other kina­ses, in advan­ced hema­to­lo­gic mali­gnan­cies  Leuk Res. 2013 Sep;37(9):1100-6.

69.  Göbel M, Eisele L, Möll­mann M, Hütt­mann A, Johans­son P, Schol­ty­sik R, Berg­mann M, Busch R, Döh­ner H, Hal­lek M, Sei­ler T, Stil­gen­bauer S, Klein-​Hitpass L, Dühr­sen U, Dürig J.  Pro­gra­nu­lin is a novel inde­pen­dent pre­dic­tor of disease pro­gres­sion and over­all sur­vi­val in chro­nic lym­pho­cy­tic leuke­mia.  PLoS One. 2013 Aug 23;8(8):e72107.   68.  Schlenk RF, Tas­ke­sen E, van Nor­den Y, Krau­ter J, Gan­ser A, Bul­lin­ger L, Gaid­zik VI, Paschka P, Cor­ba­cio­glu A, Göh­ring G, Künd­gen A, Held G, Götze K, Vel­lenga E, Kuball J, Schanz U, Pass­weg J, Pabst T, Maer­tens J, Ossen­kop­pele GJ, Del­wel R, Döh­ner H, Cor­ne­lis­sen JJ, Döh­ner K, Löwen­berg B.  The value of allo­gen­eic and auto­lo­gous hema­to­poie­tic stem cell trans­plan­ta­tion in pro­gno­sti­cally favorable acute mye­loid leuke­mia with dou­ble mutant CEBPA.  Blood. 2013 Aug 29;122(9):1576-82.

67.  Göbel M1, Eisele L, Möll­mann M, Hütt­mann A, Johans­son P, Schol­ty­sik R, Berg­mann M, Busch R, Döh­ner H, Hal­lek M, Sei­ler T, Stil­gen­bauer S, Klein-​Hitpass L, Dühr­sen U, Dürig J.  Pro­gra­nu­lin is a novel inde­pen­dent pre­dic­tor of disease pro­gres­sion and over­all sur­vi­val in chro­nic lym­pho­cy­tic leuke­mia.  PLoS One. 2013 Aug 23;8(8):e72107. eColl­ec­tion 2013.

66.  Schnai­ter A, Paschka P, Rossi M, Zenz T, Büh­ler A, Wink­ler D, Caz­zola M, Döh­ner K, Edel­mann J, Mer­tens D, Kless S, Mack S, Busch R, Hal­lek M, Döh­ner H, Stil­gen­bauer S.  NOTCH1, SF3B1 and TP53 muta­ti­ons in fludarabine-​refractory CLL pati­ents trea­ted with alem­tu­zu­mab: results from the CLL2H trial of the GCLLSG.  Blood. 2013 Aug 15;122(7):1266-70.

65.  Grei­ner J, Schnei­der V, Schmitt M, Götz M, Döh­ner K, Wies­neth M, Döh­ner H, Hof­mann S..  Immune respon­ses against the muta­ted region of cyto­plas­ma­tic NPM1 might con­tri­bute to the favorable cli­ni­cal out­come of AML pati­ents with NPM1 muta­ti­ons (NPM1mut).  Blood. 2013 Aug 8;122(6):1087-8.

64.  Wang ML, Rule S, Mar­tin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Roma­guera JE, Wil­liams ME, Barri­entos JC, Chmie­lowska E, Rad­ford J, Stil­gen­bauer S, Drey­ling M, Jedrze­jczak WW, John­son P, Spur­geon SE, Li L, Zhang L, New­berry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kun­kel LA, Blum KA.  Tar­ge­ting BTK with Ibru­ti­nib in Relap­sed or Refrac­tory Mantle-​Cell Lym­phoma.  N Engl J Med. 2013 Aug 8;369(6):507-16.

63.  Copley MR1, Babo­vic S, Benz C, Knapp DJ, Beer PA, Kent DG, Woh­rer S, Treloar DQ, Day C, Rowe K, Mader H, Kuchen­bauer F, Hum­phries RK, Eaves CJ.  The Lin28b-​let-7-Hmga2 axis deter­mi­nes the hig­her self-​renewal poten­tial of fetal hae­ma­to­poie­tic stem cells.  Nat Cell Biol. 2013 Aug;15(8):916-25

62.  Dick­son GJ, Libe­r­ante FG, Ket­tyle LM, O'Hagan K, Fin­ne­gan DP, Bul­lin­ger L, Geerts D, McMul­lin MF, Lap­pin TR, Mills KI, Thomp­son A.  HOXA/PBX3 kno­ck­down impairs growth and sen­si­ti­zes Cyto­ge­ne­ti­cally Nor­mal AML cells to che­mo­the­rapy.  Hae­ma­to­lo­gica. 2013 Aug;98(8):1216-25.

61.  Hüllein J, Jethwa A, Stolz T, Blume C, Sell­ner L, Sill M, Lan­ger C, Jauch A, Paru­zyn­ski A, von Kalle C, Schmidt M, Glimm H, Zenz T.  Next-​generation sequen­cing of can­cer con­sen­sus genes in lym­phoma.  Leuk Lym­phoma 2013 Aug;54(8):1831-5.

60.  te Raa GD1, Mal­ci­kova J, Pos­pi­si­lova S, Trbu­sek M, Mraz M, Garff-​Tavernier ML, Merle-​Béral H, Lin K, Pet­titt AR, Mer­kel O, Stan­ko­vic T, van Oers MH, Elde­ring E, Stil­gen­bauer S, Zenz T, Kater AP; European Rese­arch Initia­tive on CLL (ERIC).  Over­view of availa­ble p53 func­tion tests in rela­tion to TP53 and ATM gene alte­ra­ti­ons and che­mo­re­sis­tance in chro­nic lym­pho­cy­tic leuke­mia.  Leuk Lym­phoma. 2013 Aug;54(8):1849-53.

59.  Cra­mer P, Fink AM, Busch R, Eich­horst B, Wendt­ner C, Pflug N, Lan­ger­beins P, Bahlo J, Goede V, Schu­bert F, Döh­ner H, Sti­gen­bauer S, Dre­ger P, Kneba M, Bött­cher S, Mayer J, Hal­lek M, Fischer K.  Second-​line The­ra­pies of Pati­ents initi­ally trea­ted with Fludar­a­bine and Cyclo­phos­pha­mide (FC) or Fludar­a­bine, Cyclo­phos­pha­mide and Ritu­xi­mab (FCR) for Chro­nic Lym­pho­cy­tic Leuke­mia (CLL) within the CLL8-​Protocol of the Ger­man CLL Study Group (GCLLSG).  Leuk Lym­phoma. 2013 Aug;54(8):1821-2.

58.  Kug­ler SJ, Schnai­ter A, Stil­gen­bauer S, Mer­tens D.  Mis­sing the Notch in NOTCH1.  Leuk Lym­phoma. 2013 Aug;54(8):1579-80. No abs­tract availa­ble.

57.  Herold T, Mulaw MA, Juri­no­vic V, Sei­ler T, Met­ze­ler KH, Dufour A, Schnei­der S, Kaka­dia PM, Spie­ker­mann K, Mans­mann U, Hid­de­mann W, Buske C, Drey­ling M, Boh­l­an­der SK.  High expres­sion of MZB1 pre­dicts adverse pro­gno­sis in chro­nic lym­pho­cy­tic leuke­mia, fol­li­cu­lar lym­phoma and dif­fuse large B-​cell lym­phoma and is asso­cia­ted with a uni­que gene expres­sion signa­ture.  Leuk Lym­phoma. 2013 Aug;54(8):1652-7.

56.  Haderk F, Hanna B, Rich­ter K, Schnöl­zer M, Zenz T, Stil­gen­bauer S, Lich­ter P, Seif­fert M.  Extra­cel­lu­lar vesicles in chro­nic lym­pho­cy­tic leuke­mia.  Leuk Lym­phoma. 2013 Aug;54(8):1826-1830.

55.  Braulke F, Jung K, Schanz J, Götze K, Müller-​Thomas C, Platz­be­cker U, Ger­ming U, Brüm­men­dorf TH, Bug G, Ott­mann O, Gia­gouni­dis AA, Stad­ler M, Hof­mann WK, Schaf­hau­sen P, Lüb­bert M, Schlenk RF, Blau IW, Gans­ter C, Pfeif­fer S, Shir­n­es­han K, Metz M, Det­ken S, Sera­phin J, Jentsch-​Ullrich K, Böhme A, Schmidt B, Trüm­per L, Haase D.  Mole­cu­lar cyto­ge­ne­tic moni­to­ring from CD34+ peri­phe­ral blood cells in mye­lo­dys­plastic syn­dro­mes: First results from a pro­spec­tive mul­ti­cen­ter Ger­man dia­gno­stic study.  Leuk Res. 2013 Aug;37(8):900-6.

54.  Kor­eth J, Pidala J, Perez WS, Deeg HJ, Garcia-​Manero G, Mal­co­vati L, Caz­zola M, Park S, Itzyk­son R, Ades L, Fen­aux P, Jaders­ten M, Hellstrom-​Lindberg E, Gale RP, Beach CL, Lee SJ, Horo­witz MM, Green­berg PL, Tall­man MS, Diper­sio JF, Bun­jes D, Weis­dorf DJ, Cut­ler C.  Role of Reduced-​Intensity Con­di­tio­ning Allo­gen­eic Hema­to­poie­tic Stem-​Cell Trans­plan­ta­tion in Older Pati­ents With De Novo Mye­lo­dys­plastic Syn­dro­mes: An Inter­na­tio­nal Col­la­bo­ra­tive Decision Ana­ly­sis.  J Clin Oncol. 2013 Jul 20;31(21):2662-70.

53.  Lo-​Coco F, Avvi­sati G, Vignetti M, Thiede C, Orlando SM, Iaco­belli S, Fer­rara F, Fazi P, Cic­coni L, Di Bona E, Spec­chia G, Sica S, Divona M, Levis A, Fied­ler W, Cer­qui E, Breccia M, Fio­ri­toni G, Salih HR, Caz­zola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-​Toal M, Her­ten­stein B, Wat­tad M, Lüb­bert M, Hänel M, Schmitz N, Link H, Kropp MG, Ram­baldi A, La Nasa G, Luppi M, Ciceri F, Fini­zio O, Ven­ditti A, Fab­biano F, Döh­ner K, Sauer M, Gan­ser A, Ama­dori S, Man­delli F, Döh­ner H, Ehnin­ger G, Schlenk RF, Platz­be­cker U; Gruppo Ita­liano Malat­tie Ema­to­lo­gi­che dell'Adulto, the Ger­man–Aus­trian Acute Mye­loid Leuke­mia Study Group, and Study Alli­ance Leuke­mia.  Reti­noic Acid and Arse­nic Tri­oxide for Acute Pro­mye­lo­cy­tic Leuke­mia.  N Engl J Med. 2013 Jul 11;369(2):111-121.

52.  Krönke J, Bul­lin­ger L, Teleanu V, Tschürtz F, Gaid­zik VI, Kühn MW, Rücker FG, Holz­mann K, Paschka P, Kapp-​Schwoerer S, Späth D, Kind­ler T, Schit­ten­helm M, Krau­ter J, Gan­ser A, Göh­ring G, Schle­gel­ber­ger B, Schlenk RF, Döh­ner H, Döh­ner K.  Clo­nal evo­lu­tion in relap­sed NPM1 muta­ted acute mye­loid leuke­mia.  Blood. 2013 Jul 4;122(1):100-8.

51.  Schnei­der V, Egen­rie­der S, Götz M, Herbst C, Grei­ner J, Hof­mann S.  Spe­ci­fic immune respon­ses against epi­to­pes deri­ved from Aurora kinase A and B in acute mye­loid leuke­mia.  Leuk Lym­phoma. 2013 Jul;54(7):1500-4.

50.  Bli­j­le­vens N1, de Château M, Kri­van G, Rabitsch W, Szo­mor A, Pyt­lik R, Lissmats A, John­sen HE, de Witte T, Ein­sele H, Ruutu T, Nie­der­wie­ser D; CLWP of the EBMT. Ange­lucci E, Ben­boubker L, Bli­j­le­vens N, Browne P, Bour­his JH, Bun­jes D, Carella AM, Craw­ley C, Chris­ti­an­sen I, Clau­sen J, Dre­ger P, Ein­sele H, Cook G, Cook M, Facon T, Fil­litz M, Gar­de­ret L, Grat­wohl A, Har­rous­seau JL, Iaco­pino P, Melacrino AO, Jebavy L, Kra­love H, Johans­son JE, Kas­paru H, Ket­te­rer N, Kien­ast J, Kobbe G, Kri­van G, Deli­liers GL, Lemoli RM, Lin­kesch W, Loson­czy H, Maer­tens J, Lutz D, Meloni G, Masszi T, Mor­gan G, Nie­der­wie­ser D, Pyt­lik R, Rabitsch W, Rahem­tulla A, Rossi JF, Rus­sell N, Ruutu T, Saglio G, Sonet A, Szo­mor A, Van Droo­gen­bro­eck PH, Zachee P.  In a high-​dose mel­phalan set­ting, pali­fer­min com­pa­red with pla­cebo had no effect on oral muco­si­tis or rela­ted pati­ent's bur­den.  Bone Mar­row Trans­plant. 2013 Jul;48(7):966-71.

49.  Stolze B, Scholl C.  [Exploi­ting func­tio­nal depen­den­cies in can­cer cells for the deve­lo­p­ment of tar­ge­ted the­ra­pies]  Dtsch Med Wochen­schr 138:1369-1372, 2013. Article in Ger­man.

48.  Wu Y, Ihme S, Feuring-​Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T.  A Core-​Shell Albu­min Copo­ly­mer Nano­trans­por­ter for High Capa­city Loading and Two-​Step Release of Doxo­ru­bi­cin with Enhan­ced Anti-​Leukemia Acti­vity.  Adv Heal­thc Mater. 2013 Jun;2(6):884-94.

47.  Gra­se­dieck S, Sor­ren­tino A, Lan­ger C, Buske C, Döh­ner H, Mer­tens D, Kuchen­bauer F.  Cir­cu­la­ting microR­NAs in hema­to­lo­gi­cal disea­ses: prin­ci­ples, chal­lenges and per­spec­ti­ves.  Blood. 2013 Jun 20;121(25):4977-84.

46.  Zwick C, Fadle N, Regitz E, Kemele M, Stil­gen­bauer S, Büh­ler A, Pfreund­schuh M, Preuss KD.  Auto­an­ti­ge­nic tar­gets of B-​cell recep­tors deri­ved from chro­nic lym­pho­cy­tic leuke­mias bind to and induce pro­li­fe­ra­tion of leuke­mic cells.  Blood. 2013 Jun 6;121(23):4708-17.

45.  Gaid­zik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuend­gen A, von Lilienfeld-​Toal M, Brug­ger W, Derigs HG, Kre­mers S, Greil R, Rag­ha­va­char A, Ring­hof­fer M, Salih HR, Wat­tad M, Kir­chen HG, Runde V, Heil G, Pet­zer AL, Gir­schi­kof­sky M, Heu­ser M, Kay­ser S, Goeh­ring G, Teleanu MV, Schle­gel­ber­ger B, Gan­ser A, Krau­ter J, Bul­lin­ger L, Döh­ner H, and Döh­ner K.  Cli­ni­cal impact of DNMT3A muta­ti­ons in youn­ger adult pati­ents with acute mye­loid leuke­mia: results of the AML Study Group (AMLSG)  Blood. 2013 Jun 6;121(23):4769-77.

44.  Hopfin­ger G, Busch R, Pflug N, Weit N, Wes­ter­mann A, Fink AM, Cra­mer P, Rein­art N, Wink­ler D, Fingerle-​Rowson G, Stil­gen­bauer S, Döh­ner H, Kand­ler G, Eich­horst B, Hal­lek M, Her­ling M.  Sequen­tial che­mo­im­mu­n­o­the­rapy of fludar­a­bine, mit­ox­an­trone, and cyclo­phos­pha­mide induc­tion fol­lo­wed by alem­tu­zu­mab con­so­li­da­tion is effec­tive in T-​cell pro­lym­pho­cy­tic leuke­mia.  Can­cer. 2013 Jun 15;119(12):2258-67.

43.  Jeba­raj BM, Kienle D, Büh­ler A, Wink­ler D, Döh­ner H, Stil­gen­bauer S, Zenz T.  BRAF muta­ti­ons in Chro­nic Lym­pho­cy­tic Leuke­mia.  Leuk Lym­phoma. 2013 Jun;54(6):1177-82.

42.  Basak GW, de Wreede LC, van Bie­zen A, Wiktor-​Jedrzejczak W, Schmid C, Schat­ten­berg A, Dazzi F, von dem Borne P, Peter­sen E, Bee­len D, Aba­yomi A, Volin L, Buzyn A, Gur­man G, Bun­jes D, Ola­var­ria E, de Witte T, Chro­nic Leuke­mia Work­ing Party EBM  Donor lym­pho­cyte infu­si­ons for the treat­ment of chro­nic mye­lo­ge­nous leu­ka­e­mia relapse fol­lo­wing peri­phe­ral blood or bone mar­row stem cell trans­plan­ta­tion.  Bone Mar­row Trans­plant. 2013 Jun;48(6):837-42.

41.  Jutzi JS, Bogeska R, Niko­lo­ski G, Schmid CA, See­ger TS, Ste­gel­mann F, Schwem­mers S, Grün­der A, Pee­ken JC, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks C, Wang W, Döh­ner K, Jan­sen JH, Pahl HL.  MPN pati­ents har­bor recur­rent trun­ca­ting muta­ti­ons in tran­scrip­tion fac­tor NF-E2.  J Exp Med. 2013 May 6;210(5):1003-19.

40.  Heinz WJ, Ege­rer G, Lel­lek H, Boehme A, Grei­ner J.  Posa­co­na­zole after pre­vious anti­fun­gal the­rapy with vorico­na­zole for the­rapy of inva­sive asper­gil­lus disease, a retro­spec­tive ana­ly­sis.  Myco­ses. 2013 May;56(3):304-10.

39.  Bin­der H, Ben­ner A, Bul­lin­ger L, Schu­ma­cher M.  Tail­o­ring sparse mul­ti­va­ria­ble regres­sion tech­ni­ques for pro­gno­stic single-​nucleotide poly­mor­phism signa­tu­res.  Stat Med. 2013 May 10;32(10):1778-91.

38.  Kampa-​Schittenhelm KM, Hein­rich MC, Akmut F, Rasp KH, Illing B, Döh­ner H, Döh­ner K, Schit­ten­helm MM.  Cell cycle-​dependent acti­vity of the novel dual PI3K-​MTORC1/2 inhi­bi­tor NVP-​BGT226 in acute leuke­mia.  Mol Can­cer. 2013 May 24;12(1):46.

37.  Bul­lin­ger L, Schlenk RF, Goetz M, Bot­zen­hardt U, Hof­mann S, Russ AC, Babiak A, Zhang L, Schnei­der V, Doh­ner K, Schmitt M, Doh­ner H, Grei­ner J.  PRAME indu­ced inhi­bi­tion of reti­noic acid recep­tor signaling-​mediated dif­fe­ren­tia­tion - a pos­si­ble tar­get for ATRA response in AML wit­hout t(15;17).  Clin Can­cer Res. 2013 May 1;19(9):2562-71.

36.  Kumar M1, Witt B, Knipp­schild U, Koch S, Meena JK, Hein­lein C, Weise JM, Kre­pu­lat F, Kuchen­bauer F, Iben S, Rudolph KL, Dep­pert W, Günes C.  CEBP fac­tors regu­late telo­me­rase reverse tran­scrip­tase pro­mo­ter acti­vity in whey aci­dic protein-​T mice during mam­mary car­ci­no­ge­nesis.  Int J Can­cer. 2013 May 1;132(9):2032-43.

35.  Dre­ger P, Schnai­ter A, Zenz T, Bött­cher S, Rossi M, Paschka P, Büh­ler A, Diet­rich S, Busch R, Rit­gen M, Bun­jes D, Zeis M, Stad­ler M, Uha­rek L, Scheid C, Hegen­bart U, Hal­lek M, Kneba M, Schmitz N, Döh­ner H, Stil­gen­bauer S.  TP53, SF3B1, and NOTCH1 muta­ti­ons and out­come of allo­trans­plan­ta­tion for chro­nic lym­pho­cy­tic leuke­mia: six-​year follow-​up of the GCLLSG CLL3X trial.  Blood. 2013 Apr 18;121(16):3284-8.

34.  Krivt­sov AV, Figueroa ME, Sinha AU,Stubbs MC, Feng Z, Valk PJM, Del­wel R, Döh­ner K, Bul­lin­ger L, Kung AL, Mel­nick AM, Arm­strong SA.  Cell of ori­gin deter­mi­nes cli­ni­cally rele­vant sub­ty­pes of MLL-​rearranged AML.  Leuke­mia. 2013 Apr;27(4):852-60.

33.  Gar­ding A, Bhat­tach­a­rya N, Claus R, Rup­pel M, Tschuch C, Filar­sky K, Idler I, Zuck­nick M, Caudron-​Herger M, Oakes C, Fleig V, Kekli­ko­glou I, Alle­gra D, Serra L, Tha­ku­rela S, Tiwari V, Wei­chen­han D, Ben­ner A, Radl­wim­mer B, Zent­graf H, Wie­mann S, Rippe K, Plass C, Döh­ner H, Lich­ter P, Stil­gen­bauer S, Mer­tens D.  Epi­ge­ne­tic Upre­gu­la­tion of lncR­NAs at 13q14.3 in Leuke­mia Is Lin­ked to the In Cis Down­re­gu­la­tion of a Gene Clus­ter That Tar­gets NF-kB.  PLoS Genet. 2013 Apr;9(4):e1003373.

32.  Schnai­ter A, Stil­gen­bauer S.  17p dele­tion in chro­nic lym­pho­cy­tic leuke­mia: risk stra­ti­fi­ca­tion and the­ra­peu­tic approach.  Hema­tol Oncol Clin North Am. 2013 Apr;27(2):289-301.

31.  Pfeif­fer T, Schleu­ning M, Mayer J, Haude KH, Tischer J, Buch­holz S, Bun­jes D, Bug G, Hol­ler E, Meyer RG, Grei­nix H, Scheid C, Chris­to­peit M, Schnitt­ger S, Braess J, Sch­li­mok G, Spie­ker­mann K, Gan­ser A, Kolb HJ, Schmid C.  Influ­ence of mole­cu­lar sub­groups on out­come of acute mye­loid leuke­mia with nor­mal karyo­type in 141 pati­ents under­go­ing sal­vage allo­gen­eic stem cell trans­plan­ta­tion in pri­mary induc­tion failure or beyond first relapse.  Hae­ma­to­lo­gica. 2013 Apr;98(4):518-25.

30.  Rich­ter D1, Rich­ter J, Grü­ner B, Kranz K, Franz J, Kern P.  In vitro effi­cacy of tric­la­ben­dazole and clor­su­lon against the lar­val stage of Echi­no­coc­cus mul­ti­lo­cu­la­ris.  Para­si­tol Res. 2013 Apr;112(4):1655-60.

29.  Lan­ger C, Rücker FG, Buske C, Döh­ner H, Kuchen­bauer F.  Tar­ge­ted the­ra­pies through microR­NAs: pulp or fic­tion?  Ther Adv Hema­tol. 2012 Apr;3(2):97-104.

28.  van Vliet MH, Dumee B, Simons E, Bul­lin­ger L, Döh­ner K, Döh­ner H, Viëtor H, Löwen­berg B, Valk PJ, van Beers EH.  Detec­tion of Mutant NPM1 mRNA in Acute Mye­loid Leuke­mia Using Custom Gene Expres­sion Arrays.  Genet Test Mol Bio­mar­kers. 2013 Apr;17(4):295-300.

27.  Ghiel­mini M, Vitolo U, Kimby E, Mon­toto S, Walew­ski J, Pfreund­schuh M, Feder­ico M, Hos­kin P, McNa­mara C, Caligaris-​Cappio F, Stil­gen­bauer S, Mar­cus R, Trneny M, Dre­ger P, Monts­er­rat E, Drey­ling M; Panel Mem­bers of the 1st ESMO Con­sen­sus Con­fe­rence on Mali­gnant Lym­phoma.  ESMO Gui­de­li­nes con­sen­sus con­fe­rence on mali­gnant lym­phoma 2011 part 1: dif­fuse large B-​cell lym­phoma (DLBCL), fol­li­cu­lar lym­phoma (FL) and chro­nic lym­pho­cy­tic leuke­mia (CLL).  Ann Oncol. 2013 Mar;24(3):561-76.

26.  Li Z, Herold T, He C, Valk PJM, Chen P, Juri­no­vic V, Mans­mann U, Rad­ma­cher M, Maharry K, Sun M, Yang X, Huang H, Jiang X, Sauer­land M, Büch­ner T, Hid­de­mann W, Elkahloun A, Neilly MB, Zhang Y, Lar­son RA, Le Beau MM, Cali­gi­uri MA, Döh­ner K, Bul­lin­ger L, Liu PP, Del­wel R, Mar­cucci G, Lowen­berg B, Bloom­field CD, Row­ley JD, Boh­l­an­der SK, Chen J.  Iden­ti­fi­ca­tion of a 24-Gene Pro­gno­stic Signa­ture That Improves the European Leuke­mia­Net Risk Clas­si­fi­ca­tion of Acute Mye­loid Leuke­mia: An Inter­na­tio­nal Col­la­bo­ra­tive Study of 1,324 Pati­ents.  J Clin Oncol. 2013 Mar 20;31(9):1172-81.

25.  Schulz A, Dürr C, Zenz T, Döh­ner H, Stil­gen­bauer S, Lich­ter P, Seif­fert M.  Lenali­do­mide redu­ces sur­vi­val of chro­nic lym­pho­cy­tic leuke­mia cells in pri­mary co-​cultures by alte­ring the mye­loid micro­en­vi­ron­ment.  Blood. 2013 Mar 28;121(13):2503-11.

24.  Diff­ner E, Beck D, Gud­gin E, Thoms JA, Kne­ze­vic K, Pri­dans C, Fos­ter S, Goode D, Lim WK, Boe­len L, Met­ze­ler KH, Mick­lem G, Boh­l­an­der SK, Buske C, Bur­nett A, Otters­bach K, Vas­si­liou GS, Oli­vier J, Wong JW, Gött­gens B, Huntly BJ, Pimanda JE.  Acti­vity of a hep­tad of tran­scrip­tion fac­tors is asso­cia­ted with stem cell pro­grams and cli­ni­cal out­come in acute mye­loid leuke­mia.  Blood. 2013 Mar 21;121(12):2289-300.

23.  Kampa-​Schittenhelm KM, Hein­rich MC, Akmut F, Döh­ner H, Döh­ner K, Schit­ten­helm MM.  Quiz­ar­ti­nib (AC220) is a potent second gene­ra­tion class III tyro­sine kinase inhi­bi­tor that dis­plays a dis­tinct inhi­bi­tion pro­file against mutant-​FLT3, -​PDGFRA and -KIT iso­forms.  Mol Can­cer. 2013 Mar 7;12(1):19.

22.  de Wit M, Ort­ner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-​Steinacker R, Boke­meyer C, Jor­dan K.  Manage­ment of Cyto­to­xic Extra­va­sa­tion - ASORS Expert Opi­nion for Dia­gno­sis, Pre­ven­tion and Treat­ment.  Onko­lo­gie. 2013;36(3):127-35.

21.  Kle­ger A, Schnell J, Essig A, Wag­ner M, Bom­mer M, Seuf­fer­lein T, Här­ter G.  Fecal Trans­plant in Refrac­tory Clos­tri­dium dif­fi­cile Coli­tis.  Dtsch Arz­tebl Int. 2013 Feb;110(7):108-15.

20.  Li Z, Zhang Z, Li Y, Arno­vitz S, Chen P, Huang H, Jiang X, Hong G, Kun­jamma RB, Ren H, He C, Wang C, Elkahloun A, Valk P, Doeh­ner K, Neilly MB, Bul­lin­ger L, Del­wel R, Lowen­berg B, Liu PP, Mor­gan R, Row­ley JD, Yuan C, Chen J.  PBX3 is an important cofac­tor of HOXA9 in leu­ke­mo­ge­ne­sis.  Blood. 2013 Feb 21;121(8):1422-31.

19.  Jeba­raj BM, Kienle D, Lechel A, Mer­tens D, Heu­ber­ger M, Ott G, Rosen­wald A, Barth TF, Möl­ler P, Zenz T, Döh­ner H, Stil­gen­bauer S.  Telo­mere length in man­tle cell lym­phoma.  Blood. 2013 Feb 14;121(7):1184-7.   18.  Gar­ding A, Bhat­tach­a­rya N, Haebe S, Muel­ler F, Wei­chen­han D, Idler I, Ick­stadt K, Stil­gen­bauer S, Mer­tens D.  TCL1A and ATM are coex­pres­sed in chro­nic lym­pho­cy­tic leuke­mia cells wit­hout dele­tion of 11q.  Hae­ma­to­lo­gica. 2013 Feb;98(2):269-73.

17.  Bom­mert KS, Effen­ber­ger M, Leich E, Küspert M, Mur­phy D, Lan­ger C, Janz S, Moll R, Motto A, Rosen­wald A, Bar­gou R, Bom­mert K.  The feed-​forward loop bet­ween YB-1 and MYC is essen­tial for Mul­ti­ple Mye­loma cell sur­vi­val.  Leuke­mia. 2013 Feb;27(2):441-50.

16.  Rücker FG, Russ AC, Coc­ci­ardi S, Kett H, Schlenk RF, Bot­zen­hardt U, Lan­ger C, Krau­ter J, Fröh­ling S, Schle­gel­ber­ger B, Gan­ser A, Lich­ter P, Zenz T, Döh­ner H, Döh­ner K, Bul­lin­ger L.  Alte­red miRNA and gene expres­sion in acute mye­loid leuke­mia with com­plex karyo­type iden­tify net­works of pro­gno­stic rele­vance.  Leuke­mia. 2013 Feb;27(2):353-61.

15.  Leich E, Weiß­bach S, Klein H-U, Grieb T, Pischi­ma­rov J, Stüh­mer S, Chat­ter­jee M, Stein­brunn T, Lan­ger C, Eilers M, Ein­sele, H, *Bar­gou R, and *Rosen­wald A:  Mul­ti­ple Mye­loma is Affec­ted by Mul­ti­ple and Hete­ro­ge­neous Soma­tic Muta­ti­ons in Adhesion-​ and Recep­tor Tyro­sine Kinase Signa­ling Mole­cu­les.  Blood Can­cer J. 2013 Feb 8;3:e102. (*equal con­tri­bu­tion).

14.  Schlenk RF, Döh­ner K, Döh­ner H.  [Acute mye­loid leuke­mia : Gene­tic dia­gno­stics and mole­cu­lar the­rapy.]  Inter­nist (Berl). 2013 Feb;54(2):171-8. Ger­man.   13.  Sala­ver­ria I1, Martin-​Guerrero I, Burk­hardt B, Kreuz M, Zenz T, Oschlies I, Arnold N, Bau­dis M, Bens S, García-​Orad A, Lis­feld J, Schwae­nen C, Szc­ze­panow­ski M, Wes­sen­dorf S, Pfreund­schuh M, Trüm­per L, Klap­per W, Sie­bert R.  High reso­lu­tion copy num­ber ana­ly­sis of IRF4 translocation-​positive dif­fuse large B-​cell and fol­li­cu­lar lym­pho­mas.  Genes Chro­mo­so­mes Can­cer. 2013 Feb;52(2):150-5.

12.  Paschka P, Du J, Schlenk RF, Gaid­zik VI, Bul­lin­ger L, Cor­ba­cio­glu A, Späth D, Kay­ser S, Schle­gel­ber­ger B, Krau­ter J, Gan­ser A, Köhne CH, Held G, von Lilienfeld-​Toal M, Kir­chen H, Rum­mel M, Götze K, Horst HA, Ring­hof­fer M, Lüb­bert M, Wat­tad M, Salih HR, Künd­gen A, Döh­ner H, Döh­ner K.  Secon­dary gene­tic lesi­ons in acute mye­loid leuke­mia with inv(16) or t(16;16): a study of the German-​Austrian AML Study Group (AMLSG).  Blood. 2013 Jan 3;121(1):170-7.

11.  Fernández-​Sáiz V, Targosz B, Lemeer S, Eich­ner R, Lan­ger C, Bul­lin­ger L, Rei­ter C, Slotta-​Huspenina J, Schroe­der S, Knorn A, Kurutz J, Peschel C, Pagano M, Kus­ter B, Bas­ser­mann F.  SCFF­bxo9 and CK2direct the cel­lu­lar response to growth fac­tor with­dra­wal via Tel2/Tti1 degra­dation and pro­mote sur­vi­val in mul­ti­ple mye­loma.  Nat Cell Biol. 2013 Jan;15(1):72-81.

10.  Neu­mann M, Cos­kun E, Frans­e­cky L, Moch­mann LH, Bartram I, Far­hadi Sar­tangi N, Heesch S, Gök­bu­get N, Schwartz S, Brandts C, Schlee C, Haas R, Dühr­sen U, Griess­ham­mer M, Döh­ner H, Ehnin­ger G, Bur­meis­ter T, Blau O, Thiel E, Hoel­zer D, Hof­mann WK, Bal­dus CD.  FLT3 muta­ti­ons in early T-​cell pre­cur­sor ALL cha­rac­te­rize a stem cell like leuke­mia and iIm­ply the cli­ni­cal use of tyro­sine kinase inhi­bi­tors.  PLoS One. 2013;8(1):e53190.

9.  Wei QX, Claus R, Hiel­scher T, Mer­tens D, Raval A, Oakes CC, Tan­ner SM, de la Cha­pelle A, Byrd JC, Stil­gen­bauer S, Plass C.  Germ­line Allele-​Specific Expres­sion of DAPK1 in Chro­nic Lym­pho­cy­tic Leuke­mia.  PLoS One. 2013;8(1):e55261.

8.  Hei­del FH, Bul­lin­ger L, Arreba-​Tutusaus P, Wang Z, Gaebel J, Hirt C, Nie­der­wie­ser D, Lane SW, Döh­ner K, Vasiouk­hin V, Fischer T, Arm­strong SA.  The cell fate deter­mi­nant Llgl1 influ­en­ces HSC fit­ness and pro­gno­sis in AML.  J Exp Med. 2013 Jan 14;210(1):15-22.

7.  Faber K, Bul­lin­ger L, Ragu C, Gar­ding A, Mer­tens D, Mil­ler C, Mar­tin D, Wal­cher D, Döh­ner K, Döh­ner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröh­ling S.  CDX2-​driven leu­ke­mo­ge­ne­sis invol­ves KLF4 repres­sion and dere­gu­la­ted PPAR? signa­ling.  J Clin Invest. 2013 Jan 2;123(1):299-314.

6.  Scholz CW, Pinto A, Lin­kesch W, Lindén O, Viar­dot A, Kel­ler U, Hess G, Las­to­ria S, Lerch K, Fri­geri F, Arca­mone M, Stroux A, Fre­ricks B, Pott C, Pez­zutto A.  90Yttrium-​Ibritumomab-Tiuxetan as First-​Line Treat­ment for Fol­li­cu­lar Lym­phoma: 30 Months of Follow-​Up Data From an Inter­na­tio­nal Mul­ti­cen­ter Phase II Cli­ni­cal Trial.  J Clin Oncol. 2013 Jan 20;31(3):308-13.

5.  Hof­mann S, Götz M, Schnei­der V, Gui­al­laume P, Bun­jes D, Döh­ner H, Wies­neth M, Grei­ner J.  Donor lym­pho­cyte infu­sion poly­spe­ci­fic CD8+ T cell respon­ses with con­cur­rent mole­cu­lar remis­sion in AML with NPM1 muta­tion.  J Clin Oncol. 2013 Jan 20;31(3):e44-7.

4.  Grö­schel S, Schlenk RF, Engel­mann J, Rock­ova V, Teleanu V, Kühn WM, Eiwen K, Erpe­linck C, Haver­mans M, Lüb­bert M, Ger­ming U, Schmidt-​Wolf IGH, Berna Bever­loo H, Schu­ur­huis GJ, Ossen­kop­pele GJ, Schle­gel­ber­ger B, Krau­ter J, Gan­ser A, Valk PJM, Löwen­berg B, Döh­ner K, Döh­ner H*, Del­wel R*  Dere­gu­la­ted expres­sion of EVI1 defi­nes a poor pro­gno­stic sub­set of MLL-​rearranged acute mye­loid leuke­mias: a study of the German-​Austrian AMLSG and Dutch-​Belgian HOVON groups.  J Clin Oncol. 2013 Jan 1;31(1):95-103. (* equal con­tri­bu­tion)   3.  Sun SM, Rock­ova V, Bul­lin­ger L, Dijk­s­tra MK, Döh­ner H, Löwen­berg B, Jongen-​Lavrencic M.  The pro­gno­stic rele­vance of miR-212 expres­sion with sur­vi­val in cyto­ge­ne­ti­cally and mole­cu­larly hete­ro­ge­neous AML.  Leuke­mia. 2013 Jan;27(1):100-6.

2.  Lin K, Lane B, Car­ter A, John­son GG, Onwua­zor O, Oates M, Zenz T, Stil­gen­bauer S, Ather­ton M, Dou­glas A, Ebra­himi B, Sher­ring­ton PD, Pet­titt AR.  The gene expres­sion signa­ture asso­cia­ted with TP53 muta­tion/dele­tion in chro­nic lym­pho­cy­tic leu­ka­e­mia is domi­na­ted by the under-​expression of TP53 and other genes on chro­mo­some 17p.  Br J Hae­ma­tol. 2013 Jan;160(1):53-62.

1.  Herz­berg PY1, Lee SJ, Heuss­ner P, Mumm FH, Hil­gen­dorf I, von Hars­dorf S, Hem­mati P, Rie­ger K, Grei­nix HT, Freund M, Hol­ler E, Wolff D.  Per­so­na­lity influ­en­ces quality-​of-life assess­ments in adult pati­ents after allo­gen­eic hema­to­poie­tic SCT: results from a joint eva­lua­tion of the pro­spec­tive Ger­man Mul­ti­cen­ter Vali­da­tion Trial and the Fred Hut­chin­son Can­cer Rese­arch Cen­ter.  Bone Mar­row Trans­plant. 2013 Jan;48(1):129-34.  © 2017 Uni­ver­si­täts­kli­ni­kum Ulm

106.  Rich­ter J, Schles­ner M, Hoff­mann S, Kreuz M, Leich E, Burk­hardt B, Roso­low­ski M, Ammer­pohl O, Wagener R, Bern­hart SH, Lenze D, Szc­ze­panow­ski M, Paul­sen M, Lipin­ski S, Rus­sell RB, Adam-​Klages S, Apic G, Cla­viez A, Hasen­cle­ver D, Hove­stadt V, Hor­nig N, Kor­bel JO, Kube D, Lan­gen­ber­ger D, Lawe­renz C, Lis­feld J, Meyer K, Picelli S, Pischi­ma­rov J, Radl­wim­mer B, Rausch T, Rohde M, Schil­ha­bel M, Schol­ty­sik R, Spang R, Traut­mann H, Zenz T, Bork­hardt A, Drex­ler HG, Möl­ler P, MacLeod RA, Pott C, Schrei­ber S, Trüm­per L, Loeff­ler M, Stad­ler PF, Lich­ter P, Eils R, Küp­pers R, Hum­mel M, Klap­per W, Rosen­stiel P, Rosen­wald A, Brors B, Sie­bert R; ICGC MMML-​Seq Pro­ject  Recur­rent muta­tion of the ID3 gene in Bur­kitt lym­phoma iden­ti­fied by inte­gra­ted genome, exome and tran­scriptome sequen­cing.  Nat Genet. 2012 Dec;44(12):1316-20.  

105.  Addy F, Ala­konya A, Wamae N, Magambo J, Mbae C, Mulinge E, Zeyhle E, Was­ser­mann M, Kern P, Romig T  Pre­va­lence and diver­sity of cystic echi­no­coc­co­sis in live­stock in Maa­sai­land, Kenya.  Obstet Gynecol. 2012 Dec;111(6):2289-94.  

104.  Barth TF, Herr­mann TS, Tappe D, Stark L, Grü­ner B, But­ten­schoen K, Hil­len­brand A, Juchems M, Henne-​Bruns D, Kern P, Seitz HM, Möl­ler P, Rausch RL, Kern P, Depla­zes P  Sen­si­tive and spe­ci­fic immu­n­o­hi­sto­che­mi­cal dia­gno­sis of human alveo­lar echi­no­coc­co­sis with the mono­clo­nal anti­body Em2G11.  PLoS Negl Trop Dis. 2012;6(10): e1877  

103.  Grzy­w­no­wicz M, Zale­ska J, Mer­tens D, Tomczak W, Wla­siuk P, Kosior K, Piech­nik A, Bojarska-​Junak A, Dmos­zynska A, Gianno­pou­los K  Pro­grammed death-​1 and its ligand are novel immu­n­o­to­le­rant mole­cu­les expres­sed on leuke­mic B cells in chro­nic lym­pho­cy­tic leuke­mia.  PLoS ONE. 2012;7(4): e35178
 102.  Kel­ler F, Wies­ner S, Bun­jes D, Hart­mann B, Schmitt M.  Safety and effi­cacy of ever­o­li­mus after kid­ney and hema­to­poie­tic stem cell trans­plan­ta­tion.  Ann Trans­plant. 2012 Dec 31;17(4):52-8.  

101.  Topp MS, Gök­bu­get N, Zug­maier G, Degen­hardt E, Goebeler ME, Klin­ger M, Neu­mann Md SA, Horst HA, Raff T, Viar­dot A, Stell­jes M, Schaich M, Köhne-​Volland R, Brueg­ge­mann M, Ott­mann OG, Bur­meis­ter T, Bae­u­erle PA, Nagor­sen D, Schmidt M, Ein­sele H, Rieth­mül­ler G, Kneba M, Hoel­zer D, Kufer P, Bar­gou RC.  Long-​term follow-​up of hema­to­lo­gi­cal relapse-​free sur­vi­val in a phase 2 study of bli­na­tu­mo­mab in pati­ents with mini­mal resi­dual disease (MRD) of B-​precursor acute lym­phob­lastic leuke­mia (ALL).  Blood. 2012 Dec 20;120(26):5185-7.  

100.  Kühn MW, Bla­gieva R, Beha D, Hänle M, Reis­ter F, Henne-​Bruns D, Pil­cher C, Böhm BO, von Wichert G.  [A 31-​year-old pregnant woman with refrac­tory hyper­cal­ce­mia.]  Inter­nist (Berl). 2012 Dec;53(12):1490-5 .  

99.  Bame­zai S, Rawat VP, Buske C.  The Piwi - piRNA Axis: Pivo­tal Beyond Trans­po­son Silen­cing.  Stem Cells. 2012 Dec;30(12):2603-11.  

98.  Elter T, James R, Busch R, Wink­ler D, Rit­gen M, Bött­cher S, Kahl C, Gas­smann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Büh­ler A, Döh­ner H, Wendt­ner CM, Stil­gen­bauer S, Engert A, Hal­lek M.  Fludar­a­bine and cyclo­phos­pha­mide in com­bi­na­tion with alem­tu­zu­mab (FCCam) in pati­ents with pri­mary high-​risk, relap­sed or refrac­tory chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2012 Dec;26(12):2549-52.  

97.  Gis­sel­brecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Mil­pied NJ, Rad­ford J, Ket­te­rer N, Shpil­berg O, Dühr­sen U, Hag­berg H, Ma DD, Viar­dot A, Lowen­thal R, Brière J, Sal­les G, Mos­ko­witz CH, Glass B.  Ritu­xi­mab Main­ten­ance The­rapy After Auto­lo­gous Stem-​Cell Trans­plan­ta­tion in Pati­ents With Relap­sed CD20+ Dif­fuse Large B-​Cell Lym­phoma: Final Ana­ly­sis of the Col­la­bo­ra­tive Trial in Relap­sed Aggres­sive Lym­phoma.  J Clin Oncol. 2012 Dec 20;30(36):4462-9.  

96.  Schmitz N, Nickel­sen M, Zie­pert M, Hae­nel M, Borch­mann P, Schmidt C, Viar­dot A, Bentz M, Peter N, Ehnin­ger G, Doel­ken G, Ruebe C, Tru­em­per L, Rosen­wald A, Pfreund­schuh M, Loeff­ler M, Glass B; for the Ger­man High-​Grade Lym­phoma Study Group (DSHNHL).  Con­ven­tio­nal che­mo­the­rapy (CHOEP-​14) with ritu­xi­mab or high-​dose che­mo­the­rapy (Mega­CHOEP) with ritu­xi­mab for young, high-​risk pati­ents with aggres­sive B-​cell lym­phoma: an open-​label, ran­do­mi­sed, phase 3 trial (DSHNHL 2002-1).  Lan­cet Oncol. 2012 Dec;13(12):1250-1259.  

95.  Edel­mann J, Holz­mann K, Mil­ler F, Wink­ler D, Büh­ler A, Zenz T, Bul­lin­ger L, Kühn MW, Ger­har­din­ger A,  Blo­eh­dorn J, Rad­tke I,  Su X, Ma J, Pounds S, Hal­lek M, Lich­ter P, Kor­bel J, Busch R, Mer­tens D, Dow­ning JR, Stil­gen­bauer S and Döh­ner H.  High-​Resolution Geno­mic Pro­fi­ling of Chro­nic Lym­pho­cy­tic Leuke­mia Reveals New Recur­rent Geno­mic Alte­ra­ti­ons.  Blood. 2012 Dec 6;120(24):4783-94.  

94.  Zhang L, Götz M, Hof­mann S, Grei­ner J  Immu­n­o­ge­nic tar­gets for spe­ci­fic immu­n­o­the­rapy in mul­ti­ple mye­loma.
Clin Dev Immu­nol. 2012;2012: 820394  

93  Lech­ner CJ, Grü­ner B, Huang X, Hoff­mann WH, Kern P, Sobos­lay PT  Parasite-​specific IL-17-type cyto­kine respon­ses and solu­ble IL-17 recep­tor levels in Alveo­lar Echi­no­coc­co­sis pati­ents.  Clin Dev Immu­nol. 2012;2012: 735342  

92.  Ema­nuel RM, Dueck AC, Geyer HL, Kilad­jian JJ, Slot S, Zweegman S, te Boek­horst PA, Com­man­deur S, Schou­ten HC, Sack­mann F, Ker­gue­len Fuen­tes A, Hernández-​Maraver D, Pahl HL, Griess­ham­mer M, Ste­gel­mann F, Doeh­ner K, Leh­mann T, Bonatz K, Rei­ter A, Boyer F, Eti­enne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Har­ri­son CN, Radia D, Muxi P, Mal­do­nado N, Bes­ses C, Cer­van­tes F, Johans­son PL, Bar­bui T, Barosi G, Van­nuc­chi AM, Pas­sa­monti F, Andre­as­son B, Ferarri ML, Ram­baldi A, Samu­els­son J, Bir­ge­gard G, Tef­feri A, Mesa RA  Mye­lo­pro­li­fe­ra­tive neo­plasm (MPN) sym­ptom assess­ment form total sym­ptom score: pro­spec­tive inter­na­tio­nal assess­ment of an abbre­via­ted sym­ptom bur­den scoring sys­tem among pati­ents with MPNs.  J Clin Oncol. 2012 Nov 20;30(33): 4098-103  

91.  Wahl­ers K, Mene­zes CN, Wong ML, Zeyhle E, Ahmed ME, Ocaido M, Sti­j­nis C, Romig T, Kern P, Gro­busch MP  Cystic echi­no­coc­co­sis in sub-​Saharan Africa.  Lan­cet Infect Dis. 2012 Nov;12(11):871-80.  

90.  Witzens-​Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Rei­ser M, Pott C, Pelz H, La Rosée P, Kirch­ner H, Kiewe P, Kel­ler U, Buske C, Viar­dot A, Drey­ling M.  Cur­rent treat­ment of man­tle cell lym­phoma: results of a natio­nal sur­vey and con­sen­sus mee­ting. Ann Hema­tol. 2012 Nov;91(11):1765-72. Review.   89.  Sei­fert M, Sell­mann L, Blo­eh­dorn J, Wein F, Stil­gen­bauer S, Dürig J, Küp­pers R.  Cel­lu­lar ori­gin and patho­phy­sio­logy of chro­nic lym­pho­cy­tic leuke­mia.  J Exp Med. 2012 Nov 19;209(12):2183-98.  

88.  Bethge WA, von Hars­dorf S, Born­hau­ser M, Feder­mann B, Stell­jes M, Tren­schel R, Baur­mann H, Ditt­mann H, Faul C, Vogel W, Kanz L, Bun­jes D.  Dose-​escalated radio­im­mu­n­o­the­rapy as part of redu­ced inten­sity con­di­tio­ning for allo­gen­eic trans­plan­ta­tion in pati­ents with advan­ced high-​grade non-​Hodgkin lym­phoma.  Bone Mar­row Trans­plant. 2012 Nov;47(11):1397-402.  

87.  Gra­se­dieck S, Sch­öler N, Bom­mer M, Niess JH, Tumani H, Rouhi A, Blo­eh­dorn J, Lie­bisch P, Mer­tens D, Döh­ner H, Buske C, Lan­ger C*, Kuchen­bauer F.  Impact of serum sto­rage con­di­ti­ons on microRNA sta­bi­lity.  Leuke­mia. 2012 Nov;26(11):2414-6. *equal con­tri­bu­tion  

86.  Ringdén O, Labo­pin M, Bee­len DW, Volin L, Ehnin­ger G, Finke J, Grei­nix HT, Kyrcz-​Krzemien S, Bun­jes D, Brinch L, Nie­der­wie­ser D, Arnold R, Mohty M, Rocha V; for the Acute Leuke­mia Work­ing Party of the European Group for Blood and Mar­row Trans­plan­ta­tion (EBMT).  Bone mar­row or peri­phe­ral blood stem cell trans­plan­ta­tion from unre­la­ted donors in adult pati­ents with acute mye­loid leuke­mia, an Acute Leuke­mia Work­ing Party ana­ly­sis in 2262 pati­ents.  J Intern Med. 2012 Nov;272(5):472-483.  

85.  Gru­ber TA, Ged­man AL, Zhang J, Koss CS, Marada S, Ta HQ, Chen S-C, Su X, Ogden SK, Dang J, Wu G, Gupta V, Anders­son AK, Pounds S, Shi L, Eas­ton J, Bar­bato MI, Mul­der HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R,  Par­ker M, Ma J, Rad­tke I, Ding L, Caz­za­niga G, Biondi A, Korn­blau SM, Ravandi F, Kant­ar­jian H, Nimer SP,  Döh­ner K, Döh­ner H, Ley TJ, Bal­le­rini P, Shurtleff S, Tomi­zawa D, Ada­chi S, Haya­shi Y, Tawa A, Shih LY, Liang D-C, Rub­nitz JE, Pui C-H, Mar­dis ER, Wil­son RK, and Dow­ning JR.  An Inv(16)(p13.3q24.3)-​Encoded CBFA2T3-GLIS2 Fusion Pro­tein Defi­nes an Aggres­sive Sub­type of Ped­ia­tric Acute Mega­ka­ryo­blastic Leuke­mia.  Can­cer Cell. 2012 Nov 13; 22: 683–697.  

84.  Dol­nik A, Engel­mann JC, Scharfenberger-​Schmeer M, Mauch J, Kelkenberg-​Schade S, Hal­de­mann B, Fries T, Krönke J, Kühn MWM, Paschka  P, Kay­ser S, Wolf S, Gaid­zik VI, Schlenk RF, Rücker FG, Döh­ner H, Lot­taz C, Döh­ner K, Bul­lin­ger L.
Com­monly alte­red geno­mic regi­ons in acute mye­loid leuke­mia are enri­ched for soma­tic muta­ti­ons invol­ved in chromatin-​remodeling and spli­cing.  Blood. 2012 Nov 1;120(18):e83-92.  

83.  Struve S, Wendt­ner CM  [Pre­ven­tion and treat­ment of venous throm­bo­em­bo­lism in pati­ents with can­cer].  Dtsch Med Wochen­schr. 2012;137(40): 2007-9  

82.  Fröh­ling S  Widespread over-​expression of the non-​clustered home­obox gene HLX in acute mye­loid leuke­mia.  Hae­ma­to­lo­gica. 2012;97(10): 1453  

81.  Schmitz R, Young RM, Ceri­belli M, Jha­var S, Xiao W, Zhang M, Wright G, Shaf­fer AL, Hod­son DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohl­ham­mer H, Rosen­wald A, Kluin P, Müller-​Hermelink HK, Ott G, Gas­coyne RD, Con­nors JM, Rimsza LM, Campo E, Jaffe ES, Dela­bie J, Sme­land EB, Ogwang MD, Rey­nolds SJ, Fisher RI, Bra­ziel RM, Tubbs RR, Cook JR, Wei­sen­bur­ger DD, Chan WC, Pit­taluga S, Wil­son W, Wald­mann TA, Rowe M, Mbu­lai­teye SM, Rickin­son AB, Staudt LM  Bur­kitt lym­phoma patho­ge­nesis and the­ra­peu­tic tar­gets from struc­tu­ral and func­tio­nal geno­mics.  Nature. 2012 Oct 4;490(7418):116-20.  

80. Bruns H, Ste­gel­mann F, Fabri M, Döh­ner K, van Zand­ber­gen G, Wag­ner M, Skin­ner M, Mod­lin RL, Sten­ger S.  Abel­son Tyro­sine Kinase Con­trols Pha­go­so­mal Aci­di­fi­ca­tion Requi­red for Kil­ling of Myco­bac­te­rium tuber­cu­lo­sis in Human Macro­pha­ges.  J Immu­nol. 2012 Oct 15;189(8):4069-78.  

79.  Döh­ner K, Ste­gel­mann F, Schlenk RF, Griess­ham­mer M.  [Novel the­ra­peu­tic opti­ons in the treat­ment of BCR/ABL-​negative mye­lo­pro­li­fe­ra­tive neo­plasms].  Dtsch Med Wochen­schr. 2012 Oct;137(42):2171-8. Ger­man.  

78.  Nagel G, Stocks T, Späth D, Hjartåker A, Lind­k­vist B, Hall­mans G, Jons­son H, Bjørge T, Man­jer J, Hägg­ström C, Enge­land A, Ulmer H, Sel­mer R, Con­cin H, Stat­tin P, Schlenk RF.  Meta­bo­lic fac­tors and blood can­cers among 578,000 adults in the meta­bo­lic syn­drome and can­cer pro­ject (Me-​Can).  Ann Hema­tol. 2012 Oct;91(10):1519-31.  

77.  Büch­ner T, Schlenk RF, Schaich M, Döh­ner K, Krahl R, Krau­ter J, Heil G, Krug U, Sauer­land MC, Hein­ecke A, Späth D, Kra­mer M, Scholl S, Ber­del WE, Hid­de­mann W, Hoel­zer D, Hehl­mann R, Has­ford J, Hoff­mann V, Döh­ner H, Ehnin­ger G, Gan­ser A, Nie­der­wie­ser DW, Pfirr­mann M.  Acute Mye­loid Leuke­mia: Dif­fe­rent Treat­ment Stra­te­gies ver­sus a Com­mon Stan­dard Arm – a Com­bi­ned Pro­spec­tive Ana­ly­sis by the Ger­man AML Inter­group  J Clin Oncol. 2012 Oct 10;30(29):3604-10.  

76.  Schol­ty­sik R, Nagel I, Kreuz M, Vater I, Gie­fing M, Schwae­nen C, Wes­sen­dorf S, Trüm­per L, Loeff­ler M, Sie­bert R, Küp­pers R  Recur­rent dele­ti­ons of the TNFSF7 and TNFSF9 genes in 19p13.3 in dif­fuse large B-​cell and Bur­kitt lym­pho­mas.  Int J Can­cer.2012 Sep 1;131(5): E830-5  

75.  Cor­ne­lis­sen JJ, Grat­wohl A, Schlenk RF, Sierra J, Born­häu­ser M, Juli­us­son G, Råcil Z, Rowe JM, Rus­sell N, Mohty M, Löwen­berg B, Socié G, Nie­der­wie­ser D, Ossen­kop­pele GJ.  The European Leuke­mia­Net AML Work­ing Party con­sen­sus state­ment on allo­gen­eic HSCT for pati­ents with AML in remis­sion: an integrated-​risk adap­ted approach.  Nat Rev Clin Oncol. 2012 Sep 4;9(10):579-90.  

74.  God­frey AL, Chen E, Pagano F, Ort­mann CA, Sil­ber Y, Bel­los­illo B, Gugliel­melli P, Har­ri­son CN, Reilly JT, Ste­gel­mann F, Bijou F, Lip­pert E, McMul­lin MF, Boi­ron JM, Döh­ner K, Van­nuc­chi AM, Bes­ses C, Camp­bell PJ, Green AR.
JAK2V617F-​homozygosity ari­ses com­monly and recurrently in PV and ET, but PV is cha­rac­te­ri­zed by expan­sion of a domi­nant homo­zy­gous sub­clone.
Blood. 2012 Sep 27;120(13):2704-7.  

73.  Fischer K, Cra­mer P, Busch R, Bött­cher S, Bahlo J, Schu­bert J, Pflü­ger KH, Schott S, Goede V, Isfort S, von Tre­sc­kow J, Fink AM, Büh­ler A, Wink­ler D, Kreu­zer KA, Staib P, Rit­gen M, Kneba M, Döh­ner H, Eich­horst BF, Hal­lek M, Stil­gen­bauer S, Wendt­ner CM.  Ben­da­mus­tine in Com­bi­na­tion With Ritu­xi­mab for Pre­viously Untrea­ted Pati­ents With Chro­nic Lym­pho­cy­tic Leuke­mia: A Mul­ti­cen­ter Phase II Trial of the Ger­man Chro­nic Lym­pho­cy­tic Leuke­mia Study Group.  J Clin Oncol. 2012 Sep 10;30(26):3209-16.  

72.  Sockel K, Bornhae­u­ser M, Mischak-​Weissinger E, Tren­schel R, Wermke M, Unzi­cker C, Kobbe G, Finke J, Ger­ming U, Mohr B, Grei­ner J, Bee­len D, Thiede C, Ehnin­ger G, Platz­be­cker U; on behalf of the Ger­man MDS and Coope­ra­tive Trans­plant Study Group (GCTSG).  Lenali­do­mide main­ten­ance after allo­gen­eic HSCT seems to trig­ger acute graft-​versus-host disease in pati­ents with high-​risk mye­lo­dys­plastic syn­dro­mes or acute mye­loid leuke­mia and del(5q): results of the LEN­A­MAINT trial.  Hae­ma­to­lo­gica. 2012 Sep;97(9):e34-e35. No abs­tract availa­ble.  

71.  Met­ze­ler KH, Heil­meier B, Edmaier KE, Rawat VP, Dufour A, Döh­ner K, Feuring-​Buske M, Braess J, Spie­ker­mann K, Büch­ner T, Sauer­land MC, Döh­ner H, Hid­de­mann W, Boh­l­an­der SK, Schlenk RF, Bul­lin­ger L, Buske C.  High expres­sion of lym­phoid enhancer-​binding factor-​1 (LEF1) is a novel favorable pro­gno­stic fac­tor in cyto­ge­ne­ti­cally nor­mal acute mye­loid leuke­mia.  Blood. 2012 Sep 6;120(10):2118-26.  

70.  Gök­bu­get N, Stanze D, Beck J, Died­rich H, Horst HA, Hütt­mann A, Kobbe G, Kreu­zer KA, Lei­mer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stell­jes M, Stuhl­mann R, Viar­dot A, Wen­de­lin K, Freund M, Hoel­zer D.  Out­come of relap­sed adult lym­phob­lastic leuke­mia depends on response to sal­vage che­mo­the­rapy, pro­gno­stic fac­tors and rea­liza­tion of stem cell trans­plan­ta­tion.  Blood. 2012 Sep 6;120(10):2032-2041.  

69.  Hanf­stein B, Mül­ler MC, Hehl­mann R, Erben P, Laus­eker M, Faba­rius A, Schnitt­ger S, Hafer­lach C, Göh­ring G, Proetel U, Kolb HJ, Krause SW, Hof­mann WK, Schu­bert J, Ein­sele H, Deng­ler J, Hänel M, Falge C, Kanz L, Neu­bauer A, Kneba M, Ste­gel­mann F, Pfreund­schuh M, Wal­ler CF, Bran­ford S, Hug­hes TP, Spie­ker­mann K, Baer­lo­cher GM, Pfirr­mann M, Has­ford J, Sau­ßele S, Hoch­haus A; for the SAKK and the Ger­man CML Study Group.  Early mole­cu­lar and cyto­ge­ne­tic response is pre­dic­tive for long-​term progression-​free and over­all sur­vi­val in chro­nic mye­loid leuke­mia (CML).  Leuke­mia. 2012 Sep;26(9):2096-102.  

68.  Nag­ler A, Labo­pin M, Shi­moni A, Nie­der­wie­ser D, Mufti GJ, Zan­der AR, Arnold R, Grei­nix H, Cor­ne­lis­sen JJ, Jack­son GH, Crad­dock C, Bun­jes DW, Gan­ser A, Rus­sell NH, Kyrcz-​Krzemien S, Rocha V, Mohty M.  Mobi­li­zed Peri­phe­ral Blood Stem Cells Com­pa­red with Bone Mar­row as the Stem Cell Source for Unre­la­ted Donor Allo­gen­eic Trans­plan­ta­tion with Redu­ced Inten­sity Con­di­tio­ning in Pati­ents with Acute Mye­loid Leuke­mia in Com­plete Remis­sion: an Ana­ly­sis from the Acute Leuke­mia Work­ing Party of the European group for Blood and Mar­row Trans­plan­ta­tion.  Biol Blood Mar­row Trans­plant. 2012 Sep;18(9):1422-9.  

67.  Kächele V, Schneider-​Kappus W, Bom­mer M  [Pro­noun­ced pan­cy­to­pe­nia with con­co­mitant jaun­dice in a 66-​year-old woman].  Dtsch Med Wochen­schr. 2012;137(34-35): 1693-6  

66.  Sanda T, Law­ton LN, Barrasa MI, Fan ZP, Kohl­ham­mer H, Gutier­rez A, Ma W, Tata­rek J, Ahn Y, Kel­li­her MA, Jamie­son CH, Staudt LM, Young RA, Look AT  Core tran­scrip­tio­nal regu­la­tory cir­cuit con­trol­led by the TAL1 com­plex in human T cell acute lym­phob­lastic leuke­mia.
Can­cer Cell. 2012 Aug 14;22(2):209-21  

65.  Mar BG*, Bul­lin­ger L*, Basu E, Sch­lis K, Sil­ver­man LB, Döh­ner K, Arm­strong SA.  Sequen­cing his­tone modify­ing enzy­mes iden­ti­fies UTX muta­ti­ons in acute lym­phob­lastic leuke­mia.  Leuke­mia. 2012 Aug;26(8):1881-3.  (*authors con­tri­bu­ted equally).  

64.  Kluin-​Nelemans HC, Hos­ter E, Her­mine O, Walew­ski J, Trneny M, Geis­ler CH, Stil­gen­bauer S, Thieb­le­mont C, Vehling-​Kaiser U, Door­duijn JK, Coif­fier B, R, Tilly H, Kanz L, Feu­gier P, Szymczyk M, Hal­lek M, Kre­mers S, Lepeu G, San­hes L, Zijl­s­tra JM, Bou­ab­dal­lah R, Lug­ten­burg PJ, Macro M, Pfreund­schuh M, Procházka V, Di Rai­mondo F, Ribrag V, Uppen­kamp M, André M, Klap­per W, Hid­de­mann W, Unter­halt M, Drey­ling MH.  Treat­ment of older pati­ents with mantle-​cell lym­phoma.  N Engl J Med. 2012 Aug 9;367(6):520-31.  

63.  Grei­ner J, Ono Y, Hof­mann  S, Schmitt A, Meh­ring E, Götz M, Guil­laume P, Döh­ner K, Myti­li­neos J, Döh­ner H, Schmitt M.  Muta­ted regi­ons of nucleo­phos­min 1 (NPM1) eli­cit both CD4+ and CD8+ T cell respon­ses in pati­ents with acute mye­loid leuke­mia (AML).  Blood. 2012 Aug 9;120(6):1282-9.  

62.  San­der S, Calado DP, Sri­ni­va­san L, Köchert K, Zhang B, Roso­low­ski M, Rodig SJ, Holz­mann K, Stil­gen­bauer S, Sie­bert R, Bul­lin­ger L, Rajew­sky K.  Syn­ergy bet­ween PI3K Signa­ling and MYC in Bur­kitt Lym­phoma­ge­ne­sis.  Can­cer Cell. 2012 Aug 14;22(2):167-79.  

61.  Guss­cott S, Kuchen­bauer F, Hum­phries RK, Weng AP  Notch-​mediated repres­sion of miR-223 con­tri­bu­tes to IGF1R regu­la­tion in T-ALL.  Leuk Res. 2012 Jul;36(7):905-11.  

60.  Pos­pi­si­lova S, Gon­za­lez D, Mal­ci­kova J, Trbu­sek M, Rossi D, Kater AP, Cym­ba­lista F, Eich­horst B, Hal­lek M, Döh­ner H, Hill­men P, van Oers M, Grib­ben J, Ghia P, Monts­er­rat E, Stil­gen­bauer S, Zenz T, European Rese­arch Initia­tive on CLL (ERIC)  ERIC recom­men­da­ti­ons on TP53 muta­tion ana­ly­sis in chro­nic lym­pho­cy­tic leuke­mia.  Leuke­mia. 2012 Jul;26(7):1458-61.  

59.  Faderl S, Wetz­ler M, Riz­zieri DA, Schil­ler GJ, Jagasia M, Stuart R, Gang­uly S, Avi­gan D, Craig M, Col­lins R, Maris M, Kova­c­so­vics T, Gold­berg S, Sei­ter K, Hari P, Grei­ner J, Vey N, Recher C, Ravandi F, Wang E, Vas­con­cel­les M, Hueb­ner D, Kant­ar­jian HM.  Clo­f­a­ra­bine Plus Cyt­ara­bine Com­pa­red with Cyt­ara­bine Alone in Older Pati­ents with Relap­sed or Refrac­tory Acute Mye­lo­ge­nous Leuke­mia: Results from the Ran­do­mi­zed, Double-​Blind, Placebo-​Controlled Phase 3 CLAS­SIC I Trial.  J Clin Oncol. 2012 Jul 10;30(20):2492-9.  

58.  Wick W, Plat­ten M, Meis­ner C, Fels­berg J, Taba­ta­bai G, Simon M, Nikkhah G, Paps­dorf K, Stein­bach JP, Sabel M, Combs SE, Ves­per J, Braun C, Mei­xensber­ger J, Ket­ter R, Mayer-​Steinacker R, Rei­fen­ber­ger G, Wel­ler M; for the NOA-08 Study Group of the Neuro-​oncology Work­ing Group (NOA) of the Ger­man Can­cer Society.  Temo­zo­lo­mide che­mo­the­rapy alone ver­sus radio­the­rapy alone for mali­gnant astro­cy­toma in the elderly: the NOA-08 ran­do­mi­sed, phase 3 trial.  Lan­cet Oncol. 2012 Jul;13(7):707-15.  

57.  Claus R, Lucas DM, Stil­gen­bauer S, Rup­pert AS, Yu L, Zuck­nick M, Mer­tens D, Büh­ler A, Oakes CC, Lar­son RA, Kay NE, Jeli­nek DF, Kipps TJ, Ras­senti LZ, Grib­ben JG, Döh­ner H, Hee­rema NA, Mar­cucci G, Plass C, Byrd JC.  Quan­ti­ta­tive DNA Methy­la­tion Ana­ly­sis Iden­ti­fies a Sin­gle CpG Dinucleo­tide Important for ZAP-70 Expres­sion and Pre­dic­tive of Pro­gno­sis in Chro­nic Lym­pho­cy­tic Leuke­mia.  J Clin Oncol. 2012 Jul 10;30(20):2483-91.  

56.  Rawat VP, Hum­phries RK, Buske C.  Beyond HOX: the role of ParaHox genes in nor­mal and mali­gnant hema­to­poie­sis.  Blood. 2012 Jul 19;120(3):519-27.  

55.  Claus R, Hack­an­son B, Poetsch AR, Zuck­nick M, Son­net M, Blagitko-​Dorfs N, Hil­ler J, Wilop S, Brüm­men­dorf TH, Galm O, Platz­be­cker U, Byrd JC, Döh­ner K, Döh­ner H, Lüb­bert M, Plass C.  Quan­ti­ta­tive ana­ly­ses of DAPK1 methy­la­tion in AML and MDS.  Int J Can­cer. 2012 Jul 15;131(2):E138-42.  

54.  Lam­mel V, Sto­eckle C, Pad­berg B, Zwei­fel R, Kienle DL, Rein­hart WH, Simon HU  Hype­r­eo­si­no­phi­lia dri­ven by GM-​CSF in large-​cell car­ci­noma of the lung.
Lung Can­cer. 2012 Jun;76(3):493-5.   53.  Bouch­aud O, Mühl­ber­ger N, Parola P, Cal­leri G, Mat­teelli A, Peyerl-​Hoffmann G, Méchaï F, Gau­tret P, Cle­rinx J, Krems­ner PG, Jeli­nek T, Kai­ser A, Bel­trame A, Schmid ML, Kern P, Probst M, Bar­to­loni A, Weinke T, Gro­busch MP  The­rapy of uncom­pli­ca­ted fal­ci­parum mala­ria in Europe: MAL­THER - a pro­spec­tive obser­va­tio­nal mul­ti­centre study.  Malar J. 2012 Jun 22;11:212.  

52.  Yang Y, Shaf­fer AL, Emre NC, Ceri­belli M, Zhang M, Wright G, Xiao W, Powell J, Pla­tig J, Kohl­ham­mer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Bala­subra­ma­nian S, Mathews LA, Shinn P, Guha R, Fer­rer M, Tho­mas C, Wald­mann TA, Staudt LM  Exploi­ting syn­the­tic letha­lity for the the­rapy of ABC dif­fuse large B cell lym­phoma.
Can­cer Cell. 2012 Jun 12;21(6): 723-37  

51.  Klin­ger M, Brandl C, Zug­maier G, Hijazi Y, Bar­gou RC, Topp MS, Gök­bu­get N, Neu­mann S, Goebeler M, Viar­dot A, Stell­jes M, Brüg­ge­mann M, Hoel­zer D, Degen­hard E, Nagor­sen D, Bae­u­erle PA, Wolf A, Kufer P.  Immu­no­phar­ma­co­lo­gi­cal response of pati­ents with B-​lineage acute lym­phob­lastic leuke­mia to con­ti­nuous infu­sion of T cell-​engaging CD19/CD3-​bispecific BiTE anti­body bli­na­tu­mo­mab.  Blood. 2012 Jun 28;119(26):6226-33.  

50.
Bin­dels EM, Haver­mans M, Lugt­hart S, Erpe­linck C, Woc­jto­wicz E, Krivt­sov AV, Rom­bouts E, Arm­strong SA, Tas­ke­sen E, Haan­s­tra JR, Bever­loo HB, Döh­ner H, Hud­son WA, Ker­sey JH, Del­wel R, Kumar AR.  EVI1 is cri­ti­cal for the patho­ge­nesis of a sub­set of MLL-​AF9 rear­ran­ged AMLs.  Blood. 2012 Jun 14;119(24):5838-49.  

49.  Cwy­nar­ski K, van Bie­zen A, de Wreede L, Stil­gen­bauer S, Bun­jes D, Metz­ner B, Koza V, Mohty M, Remes K, Rus­sell N, Nag­ler A, Schol­ten M, de Witte T, Sureda A, Dre­ger P.  Auto­lo­gous and Allo­gen­eic Stem-​Cell Trans­plan­ta­tion for Trans­for­med Chro­nic Lym­pho­cy­tic Leuke­mia (Rich­ter's Syn­drome): A Retro­spec­tive Ana­ly­sis From the Chro­nic Lym­pho­cy­tic Leuke­mia Sub­com­mit­tee of the Chro­nic Leuke­mia Work­ing Party and Lym­phoma Work­ing Party of the European Group for Blood and Mar­row Trans­plan­ta­tion.  J Clin Oncol. 2012 Jun 20;30(18):2211-7.  

48.  Ger­ming U, Laus­eker M, Hil­de­brandt B, Symeo­ni­dis A, Cer­mak J, Fen­aux P, Kelaidi C, Pfeil­stö­cker M, Nöss­lin­ger T, Seke­res M, Macie­jew­ski J, Haase D, Schanz J, Sey­mour J, Kenealy M, Weide R, Lüb­bert M, Platz­be­cker U, Valent P, Götze K, Stau­der R, Blum S, Kreu­zer KA, Schlenk R, Gan­ser A, Hof­mann WK, Aul C, Krie­ger O, Künd­gen A, Haas R, Has­ford J and Gia­gouni­dis A.  Sur­vi­val, pro­gno­stic fac­tors and rates of leuke­mic trans­for­ma­tion in 381 untrea­ted pati­ents with MDS and del(5q): A mul­ti­cen­ter study.  Leuke­mia. 2012 Jun;26(6):1286-92.  

47.  Oehr­lein K, Lan­ger C, Sturm I, Pönisch W, Hahn-​Ast C, Kuhn S, Wei­sel KC.  Suc­cess­ful treat­ment of pati­ents with mul­ti­ple mye­loma and impai­red renal func­tion with lenali­do­mide: results of 4 ger­man cen­ters.  Clin Lym­phoma Mye­loma. Leuk. 2012 Jun;12(3):191-6.  

46.  Liu J, Mer­cher T, Scholl C, Brumme K, Gil­li­land DG, Zhu N.  A func­tio­nal role for the his­tone deme­thylase UTX in nor­mal and mali­gnant hema­to­poie­tic cells.  Exp Hema­tol. 2012 Jun;40(6):487-498.e3.  

45.  Mulaw MA, Krause A, Krause AJ, Desh­pande AJ, Krause LF, Rouhi A, La Starza R, Bork­hardt A, Buske C, Mecucci C, Lud­wig WD, Lot­taz C, Boh­l­an­der SK  CALM/AF10-​positive leuke­mias show upre­gu­la­tion of genes invol­ved in chro­ma­tin assem­bly and DNA repair proces­ses and of genes adja­cent to the break­point at 10p12.
Leuke­mia. 2012 May;26(5):1012-9.  

44.  Gale RP, Barosi G, Bar­bui T, Cer­van­tes F, Doh­ner K, Dupriez B, Gupta V, Har­ri­son C, Hoff­man R, Kilad­jian JJ, Mesa R, Mc Mul­lin MF, Pas­sa­monti F, Ribrag V, Roboz G, Saglio G, Van­nuc­chi A, Ver­stov­sek S  RBC-​transfusion gui­de­li­nes update.
Leuk Res. 2012 May;36(5):659-60.  

43.  Dre­ger P, Döh­ner H, McCla­na­han F, Busch R, Rit­gen M, Grei­nix H, Fink AM, Knauf W, Stad­ler M, Pfreund­schuh M, Dühr­sen U, Brit­tin­ger G, Hen­sel M, Sche­te­lig J, Wink­ler D, Büh­ler A, Kneba M, Schmitz N, Hal­lek M, and Stil­gen­bauer S.  Early auto­lo­gous stem cell trans­plan­ta­tion for chro­nic lym­pho­cy­tic leuke­mia: Long-​term follow-​up of the GCLLSG CLL3 trial.  Blood. 2012 May 24;119(21):4851-4859.  

42.  Nückel H, Lan­ger C, Herget-​Rosenthal S, Wichert M, Assert R, Döh­ner H, Dühr­sen U, Lie­bisch P.  Pro­gno­stic signi­ficance of serum cysta­tin C in mul­ti­ple mye­loma.  Int J Hema­tol. 2012 May;95(5):545-50.  

41.  Möl­ler P, Viar­dot A.  Anti­bio­tics as first-​line the­rapy for Hp-​associated gastric large B-​cell lym­phoma? Pro­bably yes.  Blood. 2012 May 24;119(21):4818-9. No abs­tract availa­ble.  

40.  Engert A, Haver­kamp H, Kobe C, Mar­kova J, Ren­ner C, Ho A, Zijl­s­tra J, Král Z, Fuchs M, Hal­lek M, Kanz L, Döh­ner H, Dör­ken B, Engel N, Topp M, Klut­mann S, Amt­hauer H, Bokisch A, Kluge R, Kra­toch­wil C, Scho­ber O, Greil R, Andree­sen R, Kneba M, Pfreund­schuh M, Stein H, Eich HT, Mül­ler RP, Diet­lein M, Borch­mann P, Diehl V; on behalf of the Ger­man Hodg­kin Study Group, the Swiss Group for Cli­ni­cal Can­cer Rese­arch, and the Öster­rei­chi­sche Arbeits­ge­mein­schaft für Kli­ni­sche Phar­ma­ko­lo­gie und The­ra­pie.  Reduced-​intensity che­mo­the­rapy and PET-​guided radio­the­rapy in pati­ents with advan­ced stage Hodg­kin's lym­phoma (HD15 trial): a ran­do­mi­sed, open-​label, phase 3 non-​inferiority trial.  Lan­cet. 2012 May 12;379(9828):1791-9. Erra­tum in: Lan­cet. 2012 May 12;379(9828):1790.  

39.  Schnei­der F, Hos­ter E, Unter­halt M, Schnei­der S, Dufour A, Bent­haus T, Mel­lert G, Zell­meier E, Kaka­dia PM, Boh­l­an­der SK, Feuring-​Buske M, Buske C, Braess J, Hein­ecke A, Sauer­land MC, Ber­del WE, Buech­ner T, Woer­mann BJ, Hid­de­mann W, Spie­ker­mann K.  The FLT3ITD mRNA level has a high pro­gno­stic impact in NPM1 muta­ted, but not in NPM1 unmuta­ted, AML with a nor­mal karyo­type.  Blood. 2012 May 10;119(19):4383-6.  

38.  Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Cata­lano J, Giss­lin­ger H, Wiktor-​Jedrzejczak W, Zode­lava M, Wei­sel K, Cas­ca­villa N, Iosava G, Cavo M, Kloczko J, Bladé J, Bek­sac M, Spi­cka I, Ples­ner T, Radke J, Lan­ger C, Ben Yehuda D, Corso A, Her­bein L, Yu Z, Mei J, Jac­ques C, Dimo­pou­los MA; MM-015 Inves­ti­ga­tors.  Con­ti­nuous lenali­do­mide treat­ment for newly dia­gno­sed mul­ti­ple mye­loma.  N Engl J Med. 2012 May 10;366(19):1759-69.  

37.  Zenz T, Grib­ben JG, Hal­lek M, Döh­ner H, Kea­ting MJ, Stil­gen­bauer S.  Risk cate­go­ries and refrac­tory CLL in the era of che­mo­im­mu­n­o­the­rapy.  Blood. 2012 May 3;119(18):4101-7.  

36.  Noor­der­meer SM, Mon­te­fer­ra­rio D, San­ders MA, Bul­lin­ger L, Jan­sen JH, van der Reij­den BA.  Impro­ved clas­si­fi­ca­tion of MLL-​AF9-​positive acute mye­loid leuke­mia pati­ents based on BRE and EVI1 expres­sion.  Blood. 2012 May 3;119(18):4335-7.  

35.  Czu­cz­man MS, Hess G, Gade­berg OV, Peder­sen LM, Gold­stein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Wind­feld K, Viar­dot A; for the 409 Study Inves­ti­ga­tors.  Che­mo­im­mu­n­o­the­rapy with ofa­tu­mu­mab in com­bi­na­tion with CHOP in pre­viously untrea­ted fol­li­cu­lar lym­phoma.  Br J Hae­ma­tol. 2012 May;157(4):438-445.  

34.  Pauls S, Fischer AC, Brambs HJ, Fet­scher S, Höche W, Bom­mer M.  Use of magne­tic reso­nance ima­ging to detect neo­plastic menin­gi­tis: limi­ted use in leuke­mia and lym­phoma but con­vin­cing results in solid tumors.  Eur J Radiol. 2012 May;81(5):974-8.  

33.  Gaspa­retto M, Seku­lo­vic S, Bro­cker C, Tang P, Zaka­ryan A, Xiang P, Kuchen­bauer F, Wen M, Kasaian K, Witty MF, Ros­ten P, Chen Y, Imren S, Dues­ter G, Thomp­son DC, Hum­phries RK, Vasi­liou V, Smith C  Alde­hyde dehy­dro­gena­ses are regu­la­tors of hema­to­poie­tic stem cell num­bers and B-​cell deve­lo­p­ment.
Exp Hema­tol. 2012 Apr;40(4):318-29.e2.  

32.  Här­ter G, Michel D  Anti­vi­ral treat­ment of cyto­me­ga­lo­vi­rus infec­tion: an update.  Expert Opin Phar­ma­co­ther. 2012 Apr;13(5):623-7.  

31.  Viar­dot A  [Mali­gnant lym­pho­mas: cli­ni­cal appearance, clas­si­fi­ca­tion, the­rapy and pro­gno­sis].  Radio­loge. 2012 Apr;52(4):321-9.  

30.  Kova­leva V, Mora R, Park YJ, Plass C, Chi­ra­mel A, Bar­ten­schla­ger R, Döh­ner H, Stil­gen­bauer S, Psche­rer A, Lich­ter P, Seif­fert M.  miRNA-​130a tar­gets ATG2B and DICER1 to inhi­bit auto­phagy and trig­ger kil­ling of chro­nic lym­pho­cy­tic leuke­mia cells.  Can­cer Res. 2012 Apr 1;72(7):1763-72.  

29.  Eis­feld AK, Mar­cucci G, Liya­na­rach­chi S, Döh­ner K, Schwind S, Maharry K, Lef­fel B, Döh­ner H, Rad­ma­cher MD, Bloom­field CD, Tan­ner SM and de la Cha­pelle A.  Heri­ta­ble poly­mor­phism pre­dis­po­ses to high BAALC expres­sion in acute mye­loid leuke­mia.  Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73.  

28.  de Wit TD, Bork­hardt A, Cho­mienne C, Döh­ner H, Fibbe WE, Foà R, Hagen­beek A, Skoda RC, Smand CR, Jäger U.  Rai­sing hema­to­logy's European voice: the impor­tance of cal­ling yours­elf a hema­to­lo­gist.  Hae­ma­to­lo­gica. 2012 Apr;97(4):476-8.  

27.  Gaid­zik VI, Paschka P, Späth D, Hab­dank M, Köhne C, Ger­ming U, von Lilienfeld-​Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döh­ner H, Schlenk RF, Bul­lin­ger L, Döh­ner K.  TET2 muta­ti­ons in acute mye­loid leuke­mia: Results from a com­pre­hen­sive gene­tic and cli­ni­cal ana­ly­sis of the AML Study Group (AMLSG).  J Clin Oncol. 2012 Apr 20;30(12):1350-7.  

26.  Azoi­tei N, Hoff­mann CM, Elleg­ast JM, Ball CR, Ober­mayer K, Gößele U, Koch B, Faber K, Genze F, Schra­der M, Kest­ler HA, Döh­ner H, Chio­sis G, Glimm H, Fröh­ling S,* Scholl C.*  Tar­ge­ting of KRAS mutant tumors by HSP90 inhi­bi­tors invol­ves degra­dation of STK33.  J Exp Med. 2012 Apr 9;209(4):697-711. *Equal con­tri­bu­tion.  

25.  Azim­za­deh O, Scherthan H, Yen­tra­palli R, Bar­jak­ta­ro­vic Z, Uef­fing M, Con­rad M, Neff F, Calzada-​Wack J, Aubele M, Buske C, Atkin­son MJ, Hauck SM, Tapio S.  Label-​free pro­tein pro­fi­ling of formalin-​fixed paraffin-​embedded (FFPE) heart tis­sue reveals imme­diate mito­chon­drial impair­ment after ionis­ing radia­tion.  J Pro­teo­mics. 2012 Apr 18;75(8):2384-95.  

24.  Hei­del FH, Bul­lin­ger L, Neff TA, Feng Z, Wang Z, Stein L, Kalaitzi­dis D, Lane SW, Arm­strong SA.  Gene­tic and Phar­ma­co­lo­gic Inhi­bi­tion of ß-​Catenin Tar­gets Ima­ti­nib Resistant Leuke­mia Stem Cells in CML.  Cell Stem Cell. 2012 Apr 6;10(4):412-24.  

23.  Xu C, Plat­tel W, van den Berg A, Rüt­her N, Huang X, Wang M, de Jong D, Vos H, Van Imhoff G, Viar­dot A, Möl­ler P, Pop­pema S, Diep­s­tra A, Vis­ser L.  Expres­sion of the c-Met onco­gene by tumor cells pre­dicts favorable out­come in clas­si­cal Hodg­kin lym­phoma.  Hae­ma­to­lo­gica. 2012 Apr;97(4):572-8.  

22.  Mer­tens D, Stil­gen­bauer S.  CLL and dele­tion 13q14: merely the miRs?  Blood. 2012 Mar 29;119(13):2974-5. No abs­tract availa­ble.  

21.  Bött­cher S, Rit­gen M, Fischer K, Stil­gen­bauer S, Busch RM, Fingerle-​Rowson G, Fink AM, Büh­ler A, Zenz T, Wen­ger MK, Men­dila M, Wendt­ner CM, Eich­horst BF, Döh­ner H, Hal­lek MJ, Kneba M.  Mini­mal Resi­dual Disease Quan­ti­fi­ca­tion Is an Inde­pen­dent Pre­dic­tor of Progression-​Free and Over­all Sur­vi­val in Chro­nic Lym­pho­cy­tic Leuke­mia: A Mul­ti­va­riate Ana­ly­sis From the Ran­do­mi­zed GCLLSG CLL8 Trial.  J Clin Oncol. 2012 Mar 20;30(9):980-8.  

20.  Li Z, Huang H, Li Y, Jiang X, Chen P, Arno­vitz S, Rad­ma­cher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Döh­ner K, Neilly MB, Price C, Lus­sier YA, Zhang Y, Lar­son RA, Le Beau MM, Cali­gi­uri MA, Bul­lin­ger L, Valk PJ, Del­wel R, Lowen­berg B, Liu PP, Mar­cucci G, Bloom­field CD, Row­ley JD, Chen J.  Up-​regulation of a HOXA-​PBX3 homeobox-​gene signa­ture fol­lo­wing down-​regulation of miR-181 is asso­cia­ted with adverse pro­gno­sis in pati­ents with cytogenetically-​abnormal AML.  Blood. 2012 Mar 8;119(10):2314-24.  

19.  Kühn MW*, Rad­tke I*, Bul­lin­ger L, Goorha S, Cheng J, Edel­mann J, Gohlke J, Su X, Paschka P, Pounds S, Krau­ter J, Gan­ser A, Ques­sar A, Ribeiro R, Gaid­zik VI, Shurtleff S, Krönke J, Holz­mann K, Ma J, Schlenk RF, Rub­nitz JE, Döh­ner K, Döh­ner H*, Dow­ning JR*.  Reso­lu­tion Geno­mic Pro­fi­ling of Adult and Ped­ia­tric Core-​Binding Fac­tor Acute Mye­loid Leuke­mia Reveals New Recur­rent Alte­ra­ti­ons.  Blood. 2012 Mar 8;119(10):e67-75.   *equal con­tri­bu­tion   18.  Bau­duer M, Grib­ben J, Herr­mann R, Thiel E, Rai K, Lar­son R, Fer­rara F, Bar­nard J, Pearce H, Tay­lor C, Bril­lant C, Steu­rer M, Wein­gart O, Flinn IW, Funk­houser A, Tall­man M, Sun Z, Jak­sic B, Suciu S, Che­v­ret S, Dighiero G, Lepor­rier M, Fran­kel SR, Sir­ard C, Hill­men P, Trehu B, Fel­der M, Busch R, Eich­horst B, Hal­lek M, Stil­gen­bauer S, Pan­ga­lis G, Beza­res R, van Oers MHJ, van Put­ten W, Gobbi M, Spriano M, Mabed M, Catovsky D, Richards S, Wade R, Abdel­ha­mid T, Dear­den C, Knauf W, Blon­ski J, Jam­ro­ziak K, Robak T, Mauro F, Hid­de­man W, John­son SA, Long­thorne G, Rum­mel MJ, Juli­us­son G, Pul­luqi P, Zin­zani PL, Poz­zato G, Rey­nolds C, Fur­man RR, Durrant J, Elphin­stone P, Evans V, Get­tins L, Hicks C, James S, Clarke M, MacKin­non L, McHugh TM, Mor­ris P, Read S, Gre­gory C, CLL Tria­lists Col­la­bo­ra­tive Grp  Sys­te­ma­tic review of purine ana­log treat­ment for chro­nic lym­pho­cy­tic leuke­mia: les­sons for future tri­als.  Hae­ma­to­lo­gica. 2012 Mar;97(3):428-36.  

17.  Lüb­bert M, Rüter B, Claus R, Schmoor C, Schmid M, Ger­ming U, Kuend­gen A, Rethwisch V, Gan­ser A, Platz­be­cker U, Galm O, Brug­ger W, Heil G, Hack­an­son B, Desch­ler B, Döh­ner K, Hage­mei­jer A, Wijer­mans P, Döh­ner H.
A mul­ti­cen­ter phase II trial of Deci­ta­bine as first-​line treat­ment of older AML pati­ents jud­ged unfit for induc­tion che­mo­the­rapy.
Hae­ma­to­lo­gica. 2012 Mar;97(3):393-401.  

16.  Rücker FG, Schlenk RF, Bul­lin­ger L, Kay­ser S, Teleanu V, Kett H, Hab­dank M, Kug­ler CM, Holz­mann K, Gaid­zik VI, Paschka P, Held G, von Lilienfeld-​Toal M, Lüb­bert M, Fröh­ling S, Zenz T, Krau­ter J, Schle­gel­ber­ger B, Gan­ser A, Lich­ter P, Döh­ner K, Döh­ner H.  TP53 alte­ra­ti­ons in acute mye­loid leuke­mia with com­plex karyo­type cor­re­late with spe­ci­fic copy num­ber alte­ra­ti­ons, mono­so­mal karyo­type, and dis­mal out­come.  Blood. 2012 Mar 1;119(9):2114-21.  

15.  Wendt­ner CM, Hill­men P, Maha­de­van D, Büh­ler A, Uha­rek L, Coutré S, Frank­furt O, Bloor A, Bosch F, Fur­man RR, Kimby E, Grib­ben JG, Gobbi M, Dreis­bach L, Hurd DD, Seke­res MA, Fer­ra­joli A, Shah S, Zhang J, Moutouh-​de Par­se­val L, Hal­lek M, Hee­rema NA, Stil­gen­bauer S, Chanan-​Khan AA.  Final results of a mul­ti­cen­ter phase 1 study of lenali­do­mide in pati­ents with relap­sed or refrac­tory chro­nic lym­pho­cy­tic leuke­mia.  Leuk Lym­phoma. 2012 Mar;53(3):417-23.  

14.  Score J, Hidalgo-​Curtis C, Jones AV, Win­kel­mann N, Skin­ner A, Ward D, Zoi K, Ernst T, Ste­gel­mann F, Döh­ner K, Chase A, Cross NC.
Inac­ti­va­tion of poly­comb repres­sive com­plex 2 com­po­n­ents in mye­lo­pro­li­fe­ra­tive and mye­lo­dys­plastic/mye­lo­pro­li­fe­ra­tive neo­plasms.  Blood. 2012 Feb 2;119(5):1208-13.  

13.  Damm F, Bunke T, Thol F, Mar­kus B, Wag­ner K, Göh­ring G, Schle­gel­ber­ger B, Heil G, Reu­ter CW, Püll­mann K, Schlenk RF, Döh­ner K, Heu­ser M, Krau­ter J, Döh­ner H, Gan­ser A, Mor­gan MA.  Pro­gno­stic impli­ca­ti­ons and mole­cu­lar asso­cia­ti­ons of NADH dehy­dro­genase sub­u­nit 4 (ND4) muta­ti­ons in acute mye­loid leuke­mia.  Leuke­mia. 2012 Feb;26(2):289-95.  

12  Bul­lin­ger L, Fröh­ling S.  Array-​based cyto­ge­ne­tic approa­ches in acute mye­loid leuke­mia: cli­ni­cal impact and bio­lo­gi­cal insights.  Semin Oncol. 2012 Feb;39(1):37-46.  

11.  Luo T, Mas­son K, Jaffe JD, Silk­worth W, Ross NT, Sche­rer CA, Scholl C, Fröh­ling S, Carr SA, Stern AM, Schrei­ber SL, Golub TR.
STK33 kinase inhi­bi­tor BRD-8899 has no effect on KRAS-​dependent can­cer cell via­bi­lity.
Proc Natl Acad Sci USA. 2012 Feb 21;109(8):2860-5.  

10.  Schroe­der T, Kuend­gen A, Kay­ser S, Kro­e­ger N, Braulke F, Platz­be­cker U, Klar­ner V, Zoh­ren F, Haase D, Stad­ler M, Schlenk RF, Czi­bere AG, Bruns I, Fenk R, Gat­ter­mann N, Haas R, Kobbe G, Ger­ming U.  Therapy-​related mye­loid neo­plasms fol­lo­wing treat­ment­with radio­i­odine.  Hae­ma­to­lo­gica. 2012 Feb;97(2):206-12.  

9.  Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Wal­ler EK, Lit­zow MR, Lies­veld JL, Laza­rus HM, Artz AS, Gupta V, Savani BN, McCar­thy PL, Cahn JY, Schou­ten HC, Finke J, Ball ED, Aljurf MD, Cut­ler CS, Rowe JM, Antin JH, Isola LM, Di Bar­to­lo­meo P, Camitta BM, Mil­ler AM, Cairo MS, Stockerl-​Goldstein K, Sierra J, Savoie ML, Hal­ter J, Stiff PJ, Nab­han C, Jaku­bow­ski AA, Bun­jes DW, Peters­dorf EW, Devine SM, Mazi­arz RT, Born­hau­ser M, Lewis VA, Marks DI, Bre­de­son CN, Soif­fer RJ, Weis­dorf DJ.  Clas­si­fy­ing Cyto­ge­ne­tics in Pati­ents with AML in Com­plete Remis­sion Under­go­ing Allo­gen­eic Trans­plan­ta­tion: A CIB­MTR Study.  Biol Blood Mar­row Trans­plant. 2012 Feb;18(2):280-8.  

8.  Kay­ser S, Schlenk RF.  Gene­tic and immu­no­phe­no­ty­pi­cal dia­gno­stics for acute mye­loid  leuke­mia and their impli­ca­tion on treat­ment stra­tegy  J Lab Med. 2012;36(1):37–45.  

7.  Klap­per W, Kreuz M, Koh­ler CW, Burk­hardt B, Szc­ze­panow­ski M, Sala­ver­ria I, Hum­mel M, Loeff­ler M, Pel­lis­sery S, Woess­mann W, Schwä­nen C, Trüm­per L, Wes­sen­dorf S, Spang R, Hasen­cle­ver D, Sie­bert R, Mole­cu­lar Mecha­nisms in Mali­gnant Lym­pho­mas Net­work Pro­ject of the Deut­sche Krebs­hilfe  Pati­ent age at dia­gno­sis is asso­cia­ted with the mole­cu­lar cha­rac­te­ristics of dif­fuse large B-​cell lym­phoma.  Blood. 2012 Feb 23;119(8):1882-7.  

6.  Jarius S, Ruprecht K, Wil­de­mann B, Kuempfel T, Rin­gel­stein M, Geis C, Klei­ter I, Klein­schnitz C, Bert­hele A, Brett­schnei­der J, Hell­wig K, Hem­mer B, Lin­ker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stan­gel M, Mar­zi­niak M, Hoff­mann F, Schipp­ling S, Faiss JH, Neu­haus O, Ettrich B, Zent­ner C, Guthke K, Hofstadt-​van Oy U, Reuss R, Pell­ko­fer H, Zie­mann U, Kern P, Wand­in­ger KP, Bergh FT, Boett­cher T, Lan­gel S, Lie­be­trau M, Rom­mer PS, Nie­haus S, Münch C, Win­kel­mann A, Zettl U UK, Metz I, Veau­t­hier C, Sieb JP, Wilke C, Har­tung HP, Aktas O, Paul F  Con­tras­ting disease pat­terns in sero­po­si­tive and sero­ne­ga­tive neu­ro­mye­li­tis optica: A mul­ti­centre study of 175 pati­ents.
J Neu­ro­in­flam­ma­tion.  2012 Jan 19;9: 14  

5.  Herold T, Sei­ler T, Egen­sper­ger R, Trumm C, Berg­mann M, Franke D, Mumm FF, Schin­wald N, Buske C, Drey­ling M.  Pro­gres­sive mul­ti­fo­cal leu­ko­en­ce­pha­lo­pa­thy after treat­ment with ritu­xi­mab, fludar­a­bine and cyclo­phos­pha­mide in a pati­ent with chro­nic lym­pho­cy­tic leuke­mia.  Leuk Lym­phoma. 2012 Jan;53(1):169-72. No abs­tract availa­ble.  

4.  Arnold F, Schnell J, Zirafi O, Stür­zel C, Meier C, Weil T, Ständ­ker L, Fors­smann WG, Roan NR, Greene WC, Kirch­hoff F, Münch J.  Natu­rally Occur­ring Frag­ments from Two Dis­tinct Regi­ons of the Pro­sta­tic Acid Phos­phatase Form Amy­lo­ido­ge­nic Enhan­cers of HIV Infec­tion.  J Virol. 2012 Jan;86(2):1244-9.  

3.  Rausch T, Jones DT, Zapatka M, Stütz AM, Zich­ner T, Wei­schen­feldt J, Jäger N, Remke M, Shih D, Nor­th­cott PA, Pfaff E, Tica J, Wang Q, Mas­simi L, Witt H, Ben­der S, Pleier S, Cin H, Hawkins C, Beck C, von Deim­ling A, Hans V, Brors B, Eils R, Scheur­len W, Blake J, Benes V, Kulo­zik AE, Witt O, Mar­tin D, Zhang C, Porat R, Merino DM, Was­ser­man J, Jabado N, Fon­te­basso A, Bul­lin­ger L, Rücker FG, Döh­ner K, Döh­ner H, Kos­ter J, Molen­aar JJ, Vers­teeg R, Kool M, Tabori U, Mal­kin D, Kors­hu­nov A, Tay­lor MD, Lich­ter P, Pfis­ter SM, Kor­bel JO.  Genome Sequen­cing of Ped­ia­tric Medul­lob­las­toma Links Cata­stro­phic DNA Rear­ran­ge­ments with TP53 Muta­ti­ons.  Cell. 2012 Jan 20;148(1-2):59-71.  

2.  Schnei­der F, Hos­ter E, Schnei­der S, Dufour A, Bent­haus T, Kaka­dia PM, Boh­l­an­der SK, Braess J, Hein­ecke A, Sauer­land MC, Ber­del WE, Buech­ner T, Woer­mann BJ, Feuring-​Buske M, Buske C, Creut­zig U, Thiede C, Zwaan MC, van den Heuvel-​Eibrink MM, Rein­hardt D, Hid­de­mann W, Spie­ker­mann K.  Age-​dependent fre­quen­cies of NPM1 muta­ti­ons and FLT3-ITD in pati­ents with nor­mal karyo­type AML (NK-​AML).  Ann Hema­tol. 2012 Jan;91(1):9-18.  

1.  Kay­ser S, Zuck­nick M, Döh­ner K, Krau­ter J, Köhne CH, Horst HA, Held G, von Lilienfeld-​Toal M, Wil­helm S, Rum­mel M, Ger­ming U, Götze K, Nach­baur D, Schle­gel­ber­ger B, Göh­ring G, Späth D, Mor­lok C, Teleanu V, Gan­ser A, Döh­ner H and Schlenk RF, for the German-​Austrian AMLSG:  Mono­so­mal karyo­type in adult acute mye­loid leuke­mia: pro­gno­stic impact and out­come after dif­fe­rent treat­ment stra­te­gies.  Blood. 2012 Jan 12;119(2):551-558.